

# Hepatocellular carcinoma

Lancet, The

362, 1907-1917

DOI: [10.1016/s0140-6736\(03\)14964-1](https://doi.org/10.1016/s0140-6736(03)14964-1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Percutaneous ethanol injection of hepatocellular carcinoma. , 0, , 108-126.		2
2	Hepatocellular carcinoma-related gene targeting using the large circular antisense library. <i>Oncology Reports</i> , 1994, 20, 905-11.	1.2	2
3	Survival advantages of multicellular spheroids vs. monolayers of HepG2 cells in vitro. <i>Oncology Reports</i> , 1994, 20, 1465.	1.2	32
4	Astragalus saponins induce apoptosis via an ERK-independent NF- $\kappa$ B signaling pathway in the human hepatocellular HepG2 cell line. <i>International Journal of Molecular Medicine</i> , 1998, 23, 189.	1.8	11
5	Evaluation of PRL-3 expression, and its correlation with angiogenesis and invasion in hepatocellular carcinoma. <i>International Journal of Molecular Medicine</i> , 1998, 22, 187.	1.8	13
6	Hepatocellular carcinoma - issues in imaging. <i>Cancer Imaging</i> , 2004, 4, 174-180.	1.2	2
7	Spontaneous Tumor-Specific Humoral and Cellular Immune Responses to NY-ESO-1 in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 4332-4341.	3.2	132
8	Increased Levels of Interleukin-10 in Serum from Patients with Hepatocellular Carcinoma Correlate with Profound Numerical Deficiencies and Immature Phenotype of Circulating Dendritic Cell Subsets. <i>Clinical Cancer Research</i> , 2004, 10, 7260-7269.	3.2	163
9	Management of hepatitis C. <i>British Medical Bulletin</i> , 2004, 70, 51-69.	2.7	17
10	Is transarterial chemoembolization an option for all patients with unresectable hepatocellular carcinoma?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2004, 1, 78-79.	1.7	3
11	Activation of Activator Protein 1 and Extracellular Signal-Regulated Kinases in Human Hepatocellular Transformation. <i>Tumor Biology</i> , 2004, 25, 313-320.	0.8	9
12	Genetic alterations in doxorubicin-resistant hepatocellular carcinoma cells: A combined study of spectral karyotyping, positional expression profiling and candidate genes. <i>International Journal of Oncology</i> , 2004, 25, 1357.	1.4	4
13	Hepatocellular carcinoma in HIV-infected patients. <i>Aids</i> , 2004, 18, 2285-2293.	1.0	213
14	Ectopic liver and hepatocarcinogenesis. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 727-729.	0.8	84
15	Superoxide generation from Kupffer cells contributes to hepatocarcinogenesis: studies on NADPH oxidase knockout mice. <i>Carcinogenesis</i> , 2004, 26, 319-329.	1.3	67
16	mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms. <i>Clinical Cancer Research</i> , 2004, 10, 8421-8425.	3.2	367
17	Rationale for clinical trials of coagulation: reactive drugs in hepatocellular carcinoma. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 777-784.	0.6	5
18	Ethanol Treatment of Hepatocellular Carcinoma: High Potentials of Low Concentrations. <i>Cancer Biology and Therapy</i> , 2004, 3, 430-433.	1.5	17

#	ARTICLE	IF	CITATIONS
19	Anti-Cancer and Pro-Apoptotic Effects of an Herbal Medicine and Saccharomyces Cerevisiae Product (CKBM) on Human Hepatocellular Carcinoma HepG2 Cells In Vitro and In Vivo. Immunopharmacology and Immunotoxicology, 2004, 26, 597-609.	1.1	20
20	The Orphan Nuclear Receptor Constitutive Active/Androstane Receptor Is Essential for Liver Tumor Promotion by Phenobarbital in Mice. Cancer Research, 2004, 64, 7197-7200.	0.4	324
21	Management of inoperable hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, S272-S278.	1.4	4
22	Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. Alimentary Pharmacology and Therapeutics, 2004, 19, 999-1007.	1.9	43
23	Spontaneous rupture of hepatocellular carcinoma: a case report and review of literature. International Journal of Clinical Practice, 2004, 59, 103-105.	0.8	3
24	Focus on hepatocellular carcinoma. Cancer Cell, 2004, 5, 215-219.	7.7	523
27	Treatment of hepatocellular carcinoma. Current Treatment Options in Gastroenterology, 2004, 7, 431-441.	0.3	44
28	Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology, 2004, 40, 667-676.	3.6	822
29	Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology, 2004, 40, 1352-1360.	3.6	409
30	Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score. Hepatology, 2004, 40, 1396-1405.	3.6	342
31	The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplantation, 2004, 10, S115-S120.	1.3	616
32	Glypican-3 and Alphafetoprotein as Diagnostic Tests for Hepatocellular Carcinoma. Molecular Diagnosis and Therapy, 2004, 8, 207-212.	1.3	81
33	Use of Yttrium-90 Glass Microspheres (TheraSphere) for the Treatment of Unresectable Hepatocellular Carcinoma in Patients with Portal Vein Thrombosis. Journal of Vascular and Interventional Radiology, 2004, 15, 335-345.	0.2	201
34	Diagnosis and staging of hepatocellular carcinoma. Gastroenterology, 2004, 127, S126-S132.	0.6	119
35	Chemoembolization for hepatocellular carcinoma. Gastroenterology, 2004, 127, S179-S188.	0.6	504
36	Hepatocellular carcinoma: Current management and future trends. Gastroenterology, 2004, 127, S218-S224.	0.6	220
37	International cancer patterns in men: geographical and temporal variations in cancer risk and the role of gender. The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender, 2004, 1, 38-46.	0.3	9
39	Hepatic tumors. , 2004, , 339-348.		2

#	ARTICLE	IF	CITATIONS
40	Hepatocellular carcinoma. <i>Disease-a-Month</i> , 2004, 50, 556-573.	0.4	27
41	Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. <i>European Journal of Cancer</i> , 2004, 40, 2439-2444.	1.3	79
42	Gene expression profiles in hepatocellular carcinoma: not yet there. <i>Journal of Hepatology</i> , 2004, 41, 336-339.	1.8	18
43	Out of control: hepatitis B reactivation by transarterial treatment of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2004, 41, 482-484.	1.8	4
44	Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2004, 41, 999-1007.	1.8	39
45	Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2004, 41, 1008-1016.	1.8	161
46	Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. <i>Lancet Oncology</i> , The, 2004, 5, 409-418.	5.1	143
47	Radiofrequency ablation of liver tumours: systematic review. <i>Lancet Oncology</i> , The, 2004, 5, 550-560.	5.1	168
48	Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. <i>Lancet</i> , The, 2004, 363, 757-767.	6.3	1,016
49	“Slow strangulation of a service” <i>Lancet</i> , The, 2004, 363, 767.	6.3	0
50	Hepatocellular carcinoma. <i>Lancet</i> , The, 2004, 363, 898-899.	6.3	2
51	Hepatocellular carcinoma. <i>Lancet</i> , The, 2004, 363, 899.	6.3	13
52	Predicting individual outcomes in hepatocellular carcinoma. <i>Lancet</i> , The, 2004, 364, 1837-1839.	6.3	28
54	Hepatocellular Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2004, 10, 67-73.	1.0	12
56	Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. , 2004, , CD003046.		31
57	Hepatocellular Carcinoma of Differential Viral Origin: Analysis by Oligonucleotide Microarray. <i>Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas</i> , 2005, 3, 269-276.	0.0	0
58	Percutaneous Ablation of Hepatocellular Carcinoma. <i>Medical Radiology</i> , 2005, , 329-336.	0.0	0
59	Different Model for End-Stage Liver Disease Score Block Distributions May Have a Variable Ability for Outcome Prediction. <i>Transplantation</i> , 2005, 80, 1414-1418.	0.5	21

#	ARTICLE	IF	CITATIONS
60	Retrospective Clinicopathologic Correlation of Gross Tumor Size of Hepatocellular Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 576-580.	0.6	20
61	Octreotide Therapy for Advanced Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2005, 39, 333-338.	1.1	35
62	Hepatocellular Carcinoma: Interventional Bridging to Liver Transplantation. Transplantation, 2005, 80, S113-S119.	0.5	41
63	Cerebral Lipiodol Embolism After Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma. Journal of Computer Assisted Tomography, 2005, 29, 680-682.	0.5	13
64	Mechanisms of Human Hepatocarcinogenesis: An Overview. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2005, , 153-170.	0.0	0
65	Interferons in the Treatment of Solid Tumors. , 2005, 126, 207-241.		26
66	Future therapies for hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2005, 17, 515-521.	0.8	9
67	Staging systems in hepatocellular carcinoma. Hpb, 2005, 7, 35-41.	0.1	230
68	Surgical treatment of hepatocellular carcinoma. Hpb, 2005, 7, 42-49.	0.1	126
69	Chinese Herbal Medicine and Chemotherapy in the Treatment of Hepatocellular Carcinoma: A Meta-analysis of Randomized Controlled Trials. Integrative Cancer Therapies, 2005, 4, 219-229.	0.8	71
70	Preneoplastic lesions in human hepatocarcinogenesis. Liver International, 2005, 25, 16-27.	1.9	161
71	Contrast-enhanced gray-scale harmonic ultrasound in the efficacy assessment of ablation treatments for hepatocellular carcinoma. Liver International, 2005, 25, 954-961.	1.9	33
72	Prediction of the ablated area by the spread of microbubbles during radiofrequency ablation of hepatocellular carcinoma. Liver International, 2005, 25, 967-972.	1.9	24
73	Enhanced uptake of lactosaminated human albumin by rat hepatocarcinomas: implications for an improved chemotherapy of primary liver tumors.. Liver International, 2005, 25, 854-860.	1.9	20
74	HDPR1, a novel inhibitor of the WNT/ $\beta$ 2-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing. Oncogene, 2005, 24, 1607-1614.	2.6	87
75	Morin inhibits 12-O-tetradecanoylphorbol-13-acetate-induced hepatocellular transformation via activator protein 1 signaling pathway and cell cycle progression. Biochemical Pharmacology, 2005, 69, 1603-1611.	2.0	70
76	EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochemical Pharmacology, 2005, 70, 1568-1578.	2.0	153
77	Treatment of small hepatocellular carcinoma with acetic acid percutaneous injection. Gastroenterologie Clinique Et Biologique, 2005, 29, 1213-1219.	0.9	14

#	ARTICLE	IF	CITATIONS
78	The Impact of Pre-Operative Loco-Regional Therapy on Outcome After Liver Transplantation for Hepatocellular Carcinoma. <i>American Journal of Transplantation</i> , 2005, 5, 795-804.	2.6	169
79	Microwave ablation with a triaxial antenna: results in ex vivo bovine liver. <i>IEEE Transactions on Microwave Theory and Techniques</i> , 2005, 53, 215-220.	2.9	109
80	Molecular genetic evidence supporting a novel human hepatocellular carcinoma tumor suppressor locus at 13q12.11. <i>Genes Chromosomes and Cancer</i> , 2005, 44, 320-328.	1.5	29
81	Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. <i>Hepatology</i> , 2005, 41, 307-314.	3.6	308
82	Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma. <i>Hepatology</i> , 2005, 41, 566-571.	3.6	32
83	Persistence of antibody after hepatitis B vaccine and the question of boosters. <i>Hepatology</i> , 2005, 41, 940-940.	3.6	0
84	Progression of liver fibrosis in women infected with hepatitis C: Long-term benefit of estrogen exposure. <i>Hepatology</i> , 2005, 41, 939-939.	3.6	5
85	Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. <i>Hepatology</i> , 2005, 41, 879-886.	3.6	48
86	More on the need for boosters 15 years after neonatal vaccination. <i>Hepatology</i> , 2005, 41, 940-941.	3.6	0
87	Percutaneous ablation for hepatocellular carcinoma. <i>Hepatology</i> , 2005, 41, 942-942.	3.6	0
88	Reply:. <i>Hepatology</i> , 2005, 41, 941-941.	3.6	0
89	Reply:. <i>Hepatology</i> , 2005, 41, 939-940.	3.6	5
90	Intermittent disconjugate gaze: A novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis. <i>Hepatology</i> , 2005, 41, 943-943.	3.6	14
92	Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. <i>Hepatology</i> , 2005, 42, 1127-1136.	3.6	140
93	Management of hepatocellular carcinoma. <i>Hepatology</i> , 2005, 42, 1208-1236.	3.6	5,426
94	Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver. <i>International Journal of Cancer</i> , 2005, 113, 670-677.	2.3	19
95	Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2005, 115, 231-240.	2.3	64
96	SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. <i>International Journal of Cancer</i> , 2005, 117, 506-509.	2.3	58

#	ARTICLE	IF	CITATIONS
97	Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. <i>Cancer</i> , 2005, 104, 794-801.	2.0	99
98	Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis. <i>British Journal of Surgery</i> , 2005, 92, 198-202.	0.1	107
99	Bone marrow embolism after bone marrow aspiration and biopsy. <i>American Journal of Hematology</i> , 2005, 78, 158-158.	2.0	8
100	Acute renal failure in a patient with paroxysmal nocturnal hemoglobinuria and autoimmune hemolytic anemia. <i>American Journal of Hematology</i> , 2005, 78, 159-159.	2.0	3
101	T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: Response to cyclosporin A and mycophenolate mofetil. <i>American Journal of Hematology</i> , 2005, 78, 161-163.	2.0	18
102	Echocardiographic abnormalities in Brazilian sickle cell patients. <i>American Journal of Hematology</i> , 2005, 78, 160-161.	2.0	6
103	Intracerebral hematoma following intrathecal administration of methotrexate in a patient with non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , 2005, 78, 159-160.	2.0	8
104	Acute hemolytic transfusion reaction by anti-P1 antibody in pregnancy. <i>American Journal of Hematology</i> , 2005, 78, 163-164.	2.0	5
105	Cough mixture abuse in pregnancy, folate deficiency, and neural tube defects?. <i>American Journal of Hematology</i> , 2005, 78, 163-163.	2.0	7
106	Can the <i>Helicobacter pylori</i> eradication regimen induce platelet recovery in <i>H. pylori</i> -negative patients with idiopathic thrombocytopenic purpura?. <i>American Journal of Hematology</i> , 2005, 78, 164-165.	2.0	9
107	Hepatocellular carcinoma on cirrhosis-free liver in a HCV-infected thalassemic. <i>American Journal of Hematology</i> , 2005, 78, 158-159.	2.0	31
108	Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. <i>Liver Transplantation</i> , 2005, 11, 1117-1126.	1.3	204
109	Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 980-989.	3.3	51
110	Percutaneous image-guided radiofrequency ablation in the therapeutic management of hepatocellular carcinoma. <i>Abdominal Imaging</i> , 2005, 30, 401-408.	2.0	59
111	Spontaneous regression of hepatocellular carcinoma with complete necrosis: case report. <i>Abdominal Imaging</i> , 2005, 30, 734-737.	2.0	37
114	Screening for hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2005, 19, 101-118.	1.0	31
115	Treatment of hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2005, 19, 129-145.	1.0	41
116	Updated treatment approach to hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2005, 40, 225-235.	2.3	466

#	ARTICLE	IF	CITATIONS
117	Transfection of thymidine phosphorylase cDNA to human hepatocellular carcinoma cells enhances sensitivity to fluoropyrimidine but augments endothelial cell migration. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 547-551.	1.2	2
118	Hepatocellular carcinoma: Current treatment strategies. <i>Current Treatment Options in Gastroenterology</i> , 2005, 8, 457-466.	0.3	11
119	Oxidation of specific methionine and tryptophan residues of apolipoprotein A-I in hepatocarcinogenesis. <i>Proteomics</i> , 2005, 5, 4964-4972.	1.3	30
120	Hepatocellular and Fibrolamellar Carcinoma. , 2005, , 209-217.		1
121	Fibroblast growth factor-4 and hepatocyte growth factor induce differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocytes. <i>World Journal of Gastroenterology</i> , 2005, 11, 7461.	1.4	214
122	Regression of hepatocellular carcinoma during vitamin K administration. <i>World Journal of Gastroenterology</i> , 2005, 11, 6722.	1.4	19
123	A Pilot Study of Trans-Arterial Injection of <sup>166</sup> Holmium-Chitosan Complex for Treatment of Small Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2005, 46, 799.	0.9	11
124	Clinico-Pathological Classification. <i>Medical Radiology</i> , 2005, , 203-207.	0.0	0
125	Complete Tumor Response Following Intratumoral <sup>32</sup> P BioSilicon on Human Hepatocellular and Pancreatic Carcinoma Xenografts in Nude Mice. <i>Clinical Cancer Research</i> , 2005, 11, 7532-7537.	3.2	78
126	Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. <i>Gut</i> , 2005, 54, 237-241.	6.1	597
127	Farnesyltransferase Inhibitor, ABT-100, Is a Potent Liver Cancer Chemopreventive Agent. <i>Clinical Cancer Research</i> , 2005, 11, 4266-4274.	3.2	22
128	Mutations in anionic trypsinogen gene are not associated with tropical calcific pancreatitis. <i>Gut</i> , 2005, 54, 728-729.	6.1	26
129	Elevated plasma protein C levels correlate with the presence of fatty liver (NASH and NAFLD). <i>Gut</i> , 2005, 54, 729-729.	6.1	10
131	Phase II Trial of High-Dose Conformal Radiation Therapy With Concurrent Hepatic Artery Floxuridine for Unresectable Intrahepatic Malignancies. <i>Journal of Clinical Oncology</i> , 2005, 23, 8739-8747.	0.8	308
132	Overexpression of Platelet-Derived Growth Factor Receptor $\alpha$ in Endothelial Cells of Hepatocellular Carcinoma Associated with High Metastatic Potential. <i>Clinical Cancer Research</i> , 2005, 11, 8557-8563.	3.2	90
133	Sonographic Characterisation of Hepatocellular Carcinoma at Time of Diagnosis. <i>Zeitschrift Fur Gastroenterologie</i> , 2005, 43, 289-294.	0.2	53
134	Resection and Liver Transplantation for Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2005, 25, 181-200.	1.8	1,043
135	Early-Stage Hepatocellular Carcinoma in Patients with Cirrhosis: Long-term Results of Percutaneous Image-guided Radiofrequency Ablation. <i>Radiology</i> , 2005, 234, 961-967.	3.6	790



#	ARTICLE	IF	CITATIONS
136	Prognostic Prediction in Patients with Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2005, 25, 171-180.	1.8	80
137	Hepatocellular Carcinoma: Molecular Pathways and New Therapeutic Targets. <i>Seminars in Liver Disease</i> , 2005, 25, 212-225.	1.8	261
138	Genetic Profiling of Human Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2005, 25, 125-132.	1.8	55
139	Risk of Hepatitis B Exacerbation is Low After Transcatheter Arterial Chemoembolization Therapy for Patients with HBV-related Hepatocellular Carcinoma: Report of a Prospective Study. <i>American Journal of Gastroenterology</i> , 2005, 100, 2194-2200.	0.2	73
140	Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. <i>British Journal of Cancer</i> , 2005, 92, 628-630.	2.9	22
141	A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. <i>British Journal of Cancer</i> , 2005, 92, 607-612.	2.9	175
142	TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2005, 93, 458-463.	2.9	55
143	Coexistent chronic idiopathic intestinal pseudo obstruction and inflammatory bowel disease. <i>Gut</i> , 2005, 54, 729-730.	6.1	13
144	Both Antiangiogenesis- and Angiogenesis-Independent Effects Are Responsible for Hepatocellular Carcinoma Growth Arrest by Tyrosine Kinase Inhibitor PTK787/ZK222584. <i>Cancer Research</i> , 2005, 65, 3691-3699.	0.4	103
145	Randomized Controlled Trial of Tamoxifen in Advanced Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 4338-4346.	0.8	127
147	Inflammatory bowel disease stimulates formation of carcinogenic N-nitroso compounds. <i>Gut</i> , 2005, 54, 731-731.	6.1	44
148	Natural Killer Cell-Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate. <i>Cancer Research</i> , 2005, 65, 6321-6329.	0.4	349
149	Hepatocellular carcinoma occurring after successful treatment of childhood cancer with high dose chemotherapy and radiation. <i>Gut</i> , 2005, 54, 732-732.	6.1	20
150	Genotypes 677TT and 677CT+1298AC of methylenetetrahydrofolate reductase are associated with the severity of ulcerative colitis in central China. <i>Gut</i> , 2005, 54, 733-734.	6.1	16
151	Non-parenchymal liver cells support the growth advantage in the first stages of hepatocarcinogenesis. <i>Carcinogenesis</i> , 2005, 27, 152-161.	1.3	31
152	Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma. <i>Cancer Research</i> , 2005, 65, 2457-2464.	0.4	561
153	Telomerase-Dependent Virotherapy Overcomes Resistance of Hepatocellular Carcinomas against Chemotherapy and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand by Elimination of Mcl-1. <i>Cancer Research</i> , 2005, 65, 7393-7402.	0.4	63
154	Expression of Id proteins in human hepatocellular carcinoma: Relevance to tumor dedifferentiation. <i>International Journal of Oncology</i> , 2005, 26, 319.	1.4	22

#	ARTICLE	IF	CITATIONS
155	Sex-based molecular profiling of hepatitis C virus-related hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2005, 26, 673.	1.4	8
156	Pharmacokinetic and Clinical Phase II Trial of Imatinib in Patients with Impaired Liver Function and Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2005, 69, 363-371.	0.9	53
157	Vaccination with dendritic cells pulsed with apoptotic cells elicits effective antitumor immunity in murine hepatoma models. <i>International Journal of Oncology</i> , 2005, 26, 1313.	1.4	2
158	A Critical Appraisal of the Literature on Local Ablative Therapies for Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2005, 9, 301-314.	1.0	61
159	Chemoembolization and Bland Embolization: A Critical Appraisal. <i>Clinics in Liver Disease</i> , 2005, 9, 287-300.	1.0	10
160	Detection and Characterization of Hepatocellular Carcinoma by Imaging. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, S136-S140.	2.4	38
161	Prevention of Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2005, 9, 329-346.	1.0	49
162	Liver Transplantation for Hepatocellular Carcinoma: Is Expansion of Criteria Justified?. <i>Clinics in Liver Disease</i> , 2005, 9, 315-328.	1.0	23
163	Radiolabeled Lipiodol Therapy for Hepatocellular Carcinoma in Patients Awaiting Liver Transplantation: Pathology of the Explant Livers and Clinical Outcome. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2005, 20, 209-214.	0.7	10
164	Treatment of hepatitis C: critical appraisal of the evidence. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 399-408.	0.9	18
165	Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2005, 42, 218-224.	1.8	461
166	Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. <i>Journal of Hepatology</i> , 2005, 42, 210-217.	1.8	90
167	Management of patients with hepatitis B virus-induced cirrhosis. <i>Journal of Hepatology</i> , 2005, 42, S54-S64.	1.8	28
168	Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. <i>Journal of Hepatology</i> , 2005, 42, 535-540.	1.8	101
169	Evaluation of the increase in model for end-stage liver disease (MELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. <i>Journal of Hepatology</i> , 2005, 42, 826-832.	1.8	135
170	MELD score and hepatocellular carcinoma identify patients at different risk of short-term mortality among cirrhotics bleeding from esophageal varices. <i>Journal of Hepatology</i> , 2005, 42, 820-825.	1.8	97
171	The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2005, 42, 760-777.	1.8	180
172	Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. <i>Journal of Hepatology</i> , 2005, 43, 661-669.	1.8	146

#	ARTICLE	IF	CITATIONS
173	Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine. <i>Journal of Hepatology</i> , 2005, 43, 645-652.	1.8	50
174	Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. <i>Journal of Hepatology</i> , 2005, 43, 808-816.	1.8	80
175	Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. <i>Journal of Hepatology</i> , 2005, 43, 1013-1020.	1.8	200
176	GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2005, 43, 1007-1012.	1.8	321
177	Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization: Identification of genetic indicators to predict patient outcome. <i>Journal of Hepatology</i> , 2005, 43, 863-874.	1.8	64
178	Percutaneous ethanol injection for hepatocellular carcinoma: Alive or dead?. <i>Journal of Hepatology</i> , 2005, 43, 377-380.	1.8	47
179	Should we biopsy each liver mass suspicious for hepatocellular carcinoma before liver transplantation?â€“Yes. <i>Journal of Hepatology</i> , 2005, 43, 558-562.	1.8	29
180	Should we biopsy each liver mass suspicious for HCC before liver transplantation?â€“No, please don't. <i>Journal of Hepatology</i> , 2005, 43, 563-568.	1.8	60
181	Should we expand the criteria for hepatocellular carcinoma with living-donor liver transplantation?â€“No, never. <i>Journal of Hepatology</i> , 2005, 43, 573-577.	1.8	48
182	Tumours and tumour-like lesions of the hepatic parenchyma. <i>Current Diagnostic Pathology</i> , 2005, 11, 19-33.	0.4	2
183	Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. <i>European Journal of Surgical Oncology</i> , 2005, 31, 331-347.	0.5	124
184	Absence of epidermal growth factor receptor exon 18â€“21 mutation in hepatocellular carcinoma. <i>Cancer Letters</i> , 2005, 224, 117-121.	3.2	50
185	A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. <i>Cancer Letters</i> , 2005, 229, 77-83.	3.2	35
186	Nuclear factor-Î² and liver carcinogenesis. <i>Cancer Letters</i> , 2005, 229, 157-169.	3.2	162
188	Self-organizing-map-based molecular signature representing the development of hepatocellular carcinoma. <i>FEBS Letters</i> , 2005, 579, 1089-1100.	1.3	27
189	Hepatocellular Carcinoma in Renal Transplant Patients. <i>Transplantation Proceedings</i> , 2005, 37, 2086-2088.	0.3	14
191	The continuing challenge of hepatic cancer in Asia. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2005, 3, 210-215.	0.8	129
192	A Randomized Controlled Trial of Radiofrequency Ablation With Ethanol Injection for Small Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2005, 129, 122-130.	0.6	831

#	ARTICLE	IF	CITATIONS
193	Screening for hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2005, 37, 260-268.	0.4	32
194	Impressive regression of primary liver cancer after treatment with sirolimus. <i>Acta Oncologica</i> , 2005, 44, 496-496.	0.8	14
195	<i>Molecular Biology of Human Cancers.</i> , 2005, , .		4
196	Molecular Profiling of Hepatocellular Carcinoma in Mice with a Chronic Deficiency of Hepatic S-Adenosylmethionine: Relevance in Human Liver Diseases. <i>Journal of Proteome Research</i> , 2006, 5, 944-953.	1.8	18
197	Hepatocellular Carcinoma: Patients With Increasing Alpha-Fetoprotein But No Mass on Ultrasound. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 29-35.	2.4	10
198	Hepatocellular Carcinoma: Overcoming Challenges in Disease Management. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 252-261.	2.4	57
199	Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. <i>Carcinogenesis</i> , 2006, 27, 748-757.	1.3	252
200	Multidisciplinary treatment of patients with hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1377-1384.	1.1	8
201	Telescreening System for the Early Detection of Hepatocellular Carcinoma., 2006, , .		0
202	Effect of the Etiology of Viral Cirrhosis on the Survival of Patients with Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2006, 101, 91-98.	0.2	81
203	A Prospective Study of Hepatocellular Carcinoma Incidence in Thalassemia. <i>Hemoglobin</i> , 2006, 30, 119-124.	0.4	66
204	Epigenetic Instability and Chromosomal Instability in Hepatocellular Carcinoma. <i>American Journal of Pathology</i> , 2006, 168, 1375-1384.	1.9	51
205	The Effects of a Novel MEK Inhibitor PD184161 on MEK-ERK Signaling and Growth in Human Liver Cancer. <i>Neoplasia</i> , 2006, 8, 1-8.	2.3	64
206	Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase I-II study. <i>Acta Oncologica</i> , 2006, 45, 831-837.	0.8	459
208	Cleavage of Endoplasmic Reticulum Proteins in Hepatocellular Carcinoma: Detection of Generated Fragments in Patient Sera. <i>Gastroenterology</i> , 2006, 130, 2010-2022.	0.6	70
209	S-Adenosylmethionine Regulates Cytoplasmic HuR Via AMP-Activated Kinase. <i>Gastroenterology</i> , 2006, 131, 223-232.	0.6	87
210	Genomic Decoding of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2006, 131, 1344-1346.	0.6	14
211	A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis. <i>Gastroenterology</i> , 2006, 131, 1758-1767.	0.6	379

#	ARTICLE	IF	CITATIONS
213	Postresectional Adjuvant Intraportal Chemotherapy in Patients with Hepatocellular Carcinoma: A Case-Control Study. <i>Annals of Surgical Oncology</i> , 2006, 13, 1329-1337.	0.7	26
214	Extra-hepatic hepatocellular carcinoma presenting as obstructive jaundice. <i>Digestive and Liver Disease</i> , 2006, 38, 768-771.	0.4	3
215	Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5. <i>Cancer Research</i> , 2006, 66, 11851-11858.	0.4	1,315
216	Caspase-8 acts as a key upstream executor of mitochondria during justicidin A-induced apoptosis in human hepatoma cells. <i>FEBS Letters</i> , 2006, 580, 3185-3191.	1.3	33
217	Correlation between genomic DNA copy number alterations and transcriptional expression in hepatitis B virus-associated hepatocellular carcinoma. <i>FEBS Letters</i> , 2006, 580, 3571-3581.	1.3	56
218	Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach. <i>Cell</i> , 2006, 125, 1253-1267.	13.5	989
219	Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. <i>Cancer Treatment Reviews</i> , 2006, 32, 594-606.	3.4	84
220	Glutathione S-transferase M1 and T1 genetic polymorphisms are not related to the risk of hepatocellular carcinoma: A study in the Spanish population. <i>European Journal of Cancer</i> , 2006, 42, 73-77.	1.3	22
221	Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy. <i>Journal of Hepatology</i> , 2006, 44, 151-157.	1.8	217
222	Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. <i>Journal of Hepatology</i> , 2006, 44, S146-S150.	1.8	33
223	Prospective validation of the Barcelona Clinic Liver Cancer staging system. <i>Journal of Hepatology</i> , 2006, 44, 723-731.	1.8	378
224	NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2006, 45, 81-89.	1.8	53
225	Molecular prognostication of liver cancer: End of the beginning. <i>Journal of Hepatology</i> , 2006, 44, 798-805.	1.8	69
226	Risk factors for hepatocellular carcinoma in HCV-cirrhosis: What we know and what is missing. <i>Journal of Hepatology</i> , 2006, 44, 1013-1016.	1.8	22
227	Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice. <i>Journal of Hepatology</i> , 2006, 45, 688-695.	1.8	31
228	Overexpression of Hepatitis C Virus NS5A Protein Induces Chromosome Instability via Mitotic Cell Cycle Dysregulation. <i>Journal of Molecular Biology</i> , 2006, 359, 22-34.	2.0	38
229	Molecular Pathogenesis of Hepatocellular Carcinoma. <i>Journal of Surgical Research</i> , 2006, 136, 125-135.	0.8	93
230	Is Post-Lipiodol CT Better Than IV Contrast CT Scan for Early Detection of HCC? A Single Liver Transplant Center Experience. <i>Transplantation Proceedings</i> , 2006, 38, 2993-2995.	0.3	11

#	ARTICLE	IF	CITATIONS
231	Cost Analysis of Tumor Downsizing for Hepatocellular Carcinoma Liver Transplant Candidates. <i>Transplantation Proceedings</i> , 2006, 38, 3561-3563.	0.3	6
232	An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. <i>Vaccine</i> , 2006, 24, 3477-3489.	1.7	49
233	Different molecular pathways determining extrahepatic and intrahepatic recurrences of hepatocellular carcinoma. <i>Oncology Reports</i> , 2006, 16, 1137.	1.2	7
234	Identification of ID2 associated with invasion of hepatitis C virus-related hepatocellular carcinoma by gene expression profile. <i>International Journal of Oncology</i> , 2006, 29, 1445.	1.4	7
235	Evidence for epithelial-mesenchymal transitions in adult liver cells. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, G575-G583.	1.6	104
236	Can Therapy of Hepatitis C Affect the Development of Hepatocellular Carcinoma?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 751-757.	2.3	8
237	Octreotide for Unresectable Hepatocellular Carcinoma: Beyond the First Sight. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 86-87.	1.1	7
238	Hemolytic Anemia During 24 Weeks of Ribavirin and Interferon- $\alpha$ 2b Combination Therapy Does Not Influence the Cardiac Function of Patients With Viral Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 88-89.	1.1	1
239	Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. <i>Oncology Reports</i> , 2006, 15, 227-30.	1.2	63
240	Neurofibroma in the Colon. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 85-86.	1.1	33
241	Liver Transplantation and Recurrent Hepatocellular Carcinoma: Predictive Value of Nodule Size in a Retrospective and Explant Study. <i>Transplantation</i> , 2006, 81, 1532-1541.	0.5	70
242	Bleeding Colonic Ulcer and Eosinophilic Colitis: A Rare Complication of Nonsteroidal Anti-Inflammatory Drugs. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 84-85.	1.1	56
243	The General Practitioner's Management of Patients With a New Diagnosis of Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 87.	1.1	2
244	Laparoscopic Liver Resection for Peripheral Hepatocellular Carcinoma in Patients With Chronic Liver Disease. <i>Annals of Surgery</i> , 2006, 243, 499-506.	2.1	282
245	Dysphagia in Aging. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 88.	1.1	3
246	Liver Allocation for Hepatocellular Carcinoma: A European Center Policy in the Pre-MELD Era. <i>Transplantation</i> , 2006, 81, 525-530.	0.5	20
247	TGF- $\beta$ 1-induced cell growth arrest and partial differentiation is related to the suppression of Id1 in human hepatoma cells. <i>Oncology Reports</i> , 2006, 15, 401.	1.2	6
249	PIN1 expression contributes to hepatic carcinogenesis. <i>Journal of Pathology</i> , 2006, 210, 19-25.	2.1	53

#	ARTICLE	IF	CITATIONS
250	Screening for hepatocellular carcinoma: Still in search for evidence based medicine?. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 1355-1356.	1.4	7
251	Re: Impact of screening on survival for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 1356-1356.	1.4	0
252	Endoscopic therapy for bleeding esophageal varices improves the outcome of Child C cirrhotic patients. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 1704-1709.	1.4	9
253	Hepatobiliary cystadenocarcinoma without mesenchymal stroma showing a good prognosis. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 1356-1358.	1.4	4
254	HEPATOCELLULAR CARCINOMA PRESENTING WITH OBSTRUCTIVE JAUNDICE. ANZ Journal of Surgery, 2006, 76, 631-636.	0.3	37
255	Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver International, 2006, 26, 680-687.	1.9	45
256	Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver International, 2006, 26, 673-679.	1.9	25
257	A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentiation grade. Liver International, 2006, 26, 726-733.	1.9	24
258	Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. Liver International, 2006, 26, 766-773.	1.9	65
259	Comparison of <sup>11</sup> C-acetate positron emission tomography and <sup>67</sup> Gallium citrate scintigraphy in patients with hepatocellular carcinoma. Liver International, 2006, 26, 920-927.	1.9	17
260	Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Alimentary Pharmacology and Therapeutics, 2006, 23, 1535-1547.	1.9	341
261	Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2006, 24, 1495-1501.	1.9	15
262	New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene, 2006, 25, 3848-3856.	2.6	143
263	New therapies for hepatocellular carcinoma. Oncogene, 2006, 25, 3866-3884.	2.6	362
264	Comparative and integrative functional genomics of HCC. Oncogene, 2006, 25, 3801-3809.	2.6	109
265	Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene, 2006, 25, 3834-3847.	2.6	361
266	Endemic hepatitis B virus infection and chronic liver disease mortality in the Republic of Palau, 1990-2002. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100, 1130-1134.	0.7	12
267	Impact of European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) guidelines on the use of contrast agents in liver ultrasound. European Radiology, 2006, 16, 1610-1613.	2.3	32

#	ARTICLE	IF	CITATIONS
268	Applicability of the Milan Criteria for Determining Liver Transplantation as a First-Line Treatment for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2006, 13, 1500-1510.	0.7	6
269	Aspects of Digestive Tract Tumors in Down Syndrome: A Literature Review. <i>Digestive Diseases and Sciences</i> , 2006, 51, 2053-2061.	1.1	14
270	Host factors are important in determining clinical outcomes of <i>Helicobacter pylori</i> infection. <i>Journal of Gastroenterology</i> , 2006, 41, 1-9.	2.3	47
271	Liver transplantation for hepatic malignancies. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2006, 38, 63-68.	0.3	1
272	Liver transplantation organ allocation between Child and MELD. <i>Wiener Medizinische Wochenschrift</i> , 2006, 156, 410-415.	0.5	7
273	p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis. <i>Medical Molecular Morphology</i> , 2006, 39, 169-175.	0.4	36
274	Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 473-481.	1.2	38
275	Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 699-708.	1.2	26
277	Quantitative Detection of Osteopontin High Expression in Human and Rat Hepatocellular Carcinoma. <i>Chinese-German Journal of Clinical Oncology</i> , 2006, 5, 78-81.	0.1	1
278	Experimental study on siRNA expressing vector-based RNA interference targeting c-Myc in human hepatocellular carcinoma cell line BEL-7402. <i>Chinese-German Journal of Clinical Oncology</i> , 2006, 5, 332-335.	0.1	2
280	Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 436-442.	1.1	19
281	Treatment of hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 89-98.	2.0	140
282	CF mediated G1 arrest is associated with induction of p27Kip1 and inhibition of cyclin D1 expression in human hepatoma HepG2 cells. <i>Hepatology Research</i> , 2006, 35, 88-95.	1.8	3
284	Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2006, 1765, 126-147.	3.3	49
286	Hepatocellular carcinoma (primary cancer of the liver). <i>Gastroenterologie Clinique Et Biologique</i> , 2006, 30, 57-61.	0.9	2
287	Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. <i>Surgery</i> , 2006, 139, 755-764.	1.0	84
288	Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. <i>BMC Cancer</i> , 2006, 6, 232.	1.1	92
289	Surgery for hepatocellular carcinoma in patients with chronic liver disease. <i>British Journal of Surgery</i> , 2006, 93, 1179-1181.	0.1	4



#	ARTICLE	IF	CITATIONS
290	Genetic inactivation of the APC gene contributes to the malignant progression of sporadic hepatocellular carcinoma: A case report. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 1050-1057.	1.5	19
291	Particle embolization of recurrent hepatocellular carcinoma after hepatectomy. <i>Cancer</i> , 2006, 106, 2181-2189.	2.0	55
292	Proton beam therapy for hepatocellular carcinoma with limited treatment options. <i>Cancer</i> , 2006, 107, 591-598.	2.0	74
293	HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. <i>Hepatology</i> , 2006, 43, 425-434.	3.6	111
294	Functional genomics of hepatocellular carcinoma. <i>Hepatology</i> , 2006, 43, S145-S150.	3.6	131
295	Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2006, 118, 1527-1538.	2.3	77
296	Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan. <i>International Journal of Cancer</i> , 2006, 119, 192-195.	2.3	32
297	Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2006, 119, 2851-2860.	2.3	25
298	Food groups and risk of hepatocellular carcinoma: A multicenter case-control study in Italy. <i>International Journal of Cancer</i> , 2006, 119, 2916-2921.	2.3	87
299	Expanding HCC criteria for liver transplant: The urgent need for prospective, robust data. <i>Liver Transplantation</i> , 2006, 12, 1741-1743.	1.3	14
300	Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: A critical appraisal. <i>Liver Transplantation</i> , 2006, 12, 1747-1754.	1.3	16
301	High volume hydrodynamic injection of plasmid DNA via the hepatic artery results in a high level of gene expression in rat hepatocellular carcinoma induced by diethylnitrosamine. <i>Journal of Gene Medicine</i> , 2006, 8, 1018-1026.	1.4	34
304	Molecular Diagnosis of Chronic Liver Disease and Hepatocellular Carcinoma: The Potential of Gene Expression Profiling. <i>Seminars in Liver Disease</i> , 2006, 26, 373-384.	1.8	48
305	Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma Before Liver Transplantation: A Prospective Study with Histopathologic Comparison. <i>American Journal of Roentgenology</i> , 2006, 186, S296-S305.	1.0	68
306	Hepatocellular Carcinoma Associated with Hereditary Hemochromatosis Occurring in Non-Cirrhotic Liver. <i>Zeitschrift Fur Gastroenterologie</i> , 2006, 44, 39-42.	0.2	17
307	Expanded Criteria for Hepatocellular Carcinoma Through Down-Staging Prior to Liver Transplantation: Not Yet There. <i>Seminars in Liver Disease</i> , 2006, 26, 248-253.	1.8	29
308	Technology Insight: image-guided therapies for hepatocellular carcinoma—“intra-arterial and ablative techniques. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 315-324.	4.3	54
310	Medical treatments for hepatocellular carcinoma (HCC): what’s next?. <i>Annals of Oncology</i> , 2006, 17, x308-x314.	0.6	26

#	ARTICLE	IF	CITATIONS
311	Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward. <i>Clinical Cancer Research</i> , 2006, 12, 3661-3697.	3.2	263
312	HBV, HCV, and TTV detection by in situ polymerase chain reaction could reveal occult infection in hepatocellular carcinoma: comparison with blood markers. <i>Journal of Clinical Pathology</i> , 2006, 59, 526-529.	1.0	37
313	Expression of E-cadherin in tumor cells influences invasive potential of human hepatocellular carcinoma. <i>FASEB Journal</i> , 2006, 20, 2291-2301.	0.2	52
314	PTEN/Akt Signaling through Epidermal Growth Factor Receptor Is Prerequisite for Angiogenesis by Hepatocellular Carcinoma Cells That Is Susceptible to Inhibition by Gefitinib. <i>Cancer Research</i> , 2006, 66, 5346-5353.	0.4	62
316	RFA for Liver Tumors: Does It Really Work?. <i>Oncologist</i> , 2006, 11, 801-808.	1.9	41
317	New Targets, New Agents, and the Evolving Phenomena of Drug Resistance in Cancer. <i>Current Cancer Therapy Reviews</i> , 2006, 2, 23-30.	0.2	1
318	Surgery for Hepatocellular Carcinoma Arising in Hereditary Hemochromatosis. <i>European Surgical Research</i> , 2006, 38, 371-376.	0.6	3
319	Spontaneous Rupture of Hepatocellular Carcinoma. <i>Archives of Surgery</i> , 2006, 141, 191.	2.3	199
320	Hepatocellular cancer in HIV-infected individuals: tomorrow's problem?. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1553-1558.	1.1	14
321	Liver Intestine-Cadherin (CDH17) Haplotype Is Associated with Increased Risk of Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 5248-5252.	3.2	34
322	Cyclooxygenase-2 Inhibition Induces Apoptosis Signaling via Death Receptors and Mitochondria in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2006, 66, 7059-7066.	0.4	151
323	Immunization with UV-Induced Apoptotic Cells Generates Monoclonal Antibodies Against Proteins Differentially Expressed in Hepatocellular Carcinoma Cell Lines. <i>Hybridoma</i> , 2007, 26, 55-61.	0.5	4
324	Transcatheter and Ablative Therapeutic Approaches for Solid Malignancies. <i>Journal of Clinical Oncology</i> , 2007, 25, 978-986.	0.8	168
325	Adenovirus-Mediated IL-24 Expression Suppresses Hepatocellular Carcinoma Growth via Induction of Cell Apoptosis and Cycling Arrest and Reduction of Angiogenesis. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 56-63.	0.7	15
326	Surveillance for Early Diagnosis of Hepatocellular Carcinoma: Is It Effective in Intermediate/Advanced Cirrhosis?. <i>American Journal of Gastroenterology</i> , 2007, 102, 2448-2457.	0.2	110
327	Image-guided thermal ablation of nonresectable hepatic tumors using the Cool-Tip <sup>®</sup> radiofrequency ablation system. <i>Expert Review of Medical Devices</i> , 2007, 4, 803-814.	1.4	7
328	S-adenosyl methionine protects ob/ob mice from CYP2E1-mediated liver injury. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, G91-G103.	1.6	14
329	Factors predicting early postoperative liver cirrhosis-related complications after lung cancer surgery in patients with liver cirrhosis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2007, 6, 720-730.	0.5	16

#	ARTICLE	IF	CITATIONS
330	The Development of Targeted Therapies for Hepatocellular Cancer. <i>Current Pharmaceutical Design</i> , 2007, 13, 3292-3300.	0.9	8
331	Liver Transplantation for Hepatocellular Carcinoma: Current Role and Future Opportunities. <i>Current Pharmaceutical Design</i> , 2007, 13, 3265-3273.	0.9	4
332	Hepatocellular Carcinoma with Indeterminate or False-Negative Findings at Initial MR Imaging: Effect on Eligibility for Curative Treatment—Initial Observations. <i>Radiology</i> , 2007, 244, 776-783.	3.6	30
333	Future of molecular profiling of human hepatocellular carcinoma. <i>Future Oncology</i> , 2007, 3, 429-439.	1.1	19
334	Evaluating Patients with Cirrhosis for Hepatocellular Carcinoma: Value of Clinical Symptomatology, Imaging and Alpha-Fetoprotein. <i>Oncology</i> , 2007, 72, 117-123.	0.9	52
335	Genomics and Signaling Pathways in Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2007, 27, 055-076.	1.8	491
337	Percutaneous and Intraoperative Ultrasound-Guided Radiofrequency Ablation of Hepatic Tumours. <i>Ultraschall in Der Medizin</i> , 2007, 28, 181-188.	0.8	12
338	Octreotide Alone or in Combination with Rofecoxib as Palliative Treatment for Advanced Hepatocellular Cancer. <i>Zeitschrift Fur Gastroenterologie</i> , 2007, 45, 369-377.	0.2	8
339	Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. <i>Cancer Biology and Therapy</i> , 2007, 6, 1900-1907.	1.5	57
341	Role of MDCT in the Diagnosis of Hepatocellular Carcinoma in Patients with Cirrhosis Undergoing Orthotopic Liver Transplantation. <i>American Journal of Roentgenology</i> , 2007, 189, 792-798.	1.0	49
342	Superselective transcatheter arterial chemoembolisation of an unresectable hepatocellular carcinoma using three-dimensional rotational angiography. <i>British Journal of Radiology</i> , 2007, 80, e85-e87.	1.0	3
344	Hepatocellular Carcinoma Treated with Radiofrequency Ablation with or without Ethanol Injection: A Prospective Randomized Trial. <i>Radiology</i> , 2007, 244, 599-607.	3.6	137
345	First International Symposium of Current Issues for Nationwide Survey of Primary Liver Cancer in Korea, Taiwan and Japan. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 233-240.	0.6	4
346	Liver Transplantation Criteria For Hepatocellular Carcinoma Should Be Expanded. <i>Annals of Surgery</i> , 2007, 246, 502-511.	2.1	404
347	Identification and Validation of a Novel Gene Signature Associated with the Recurrence of Human Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 6275-6283.	3.2	155
348	Liver Transplantation for Hepatocellular Carcinoma in Asia. <i>Oncologist</i> , 2007, 12, 1321-1331.	1.9	117
350	AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2468-2476.	1.9	42
351	FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis. <i>Clinical Cancer Research</i> , 2007, 13, 902-911.	3.2	385

#	ARTICLE	IF	CITATIONS
352	Liver Resection or Combined Chemoembolization and Radiofrequency Ablation Improve Survival in Patients with Hepatocellular Carcinoma. <i>Digestion</i> , 2007, 75, 104-112.	1.2	52
353	Peritoneal Dissemination of Hepatocellular Carcinoma Treated with a Combination Therapy of Interferon-alpha-2b and Oral Tegafur/Uracil. <i>Internal Medicine</i> , 2007, 46, 565-569.	0.3	6
354	Stronger growth-inhibitory effect of interferon (IFN)- $\beta$ compared to IFN- $\alpha$ is mediated by IFN signaling pathway in hepatocellular carcinoma cells. <i>International Journal of Oncology</i> , 2007, 30, 201.	1.4	15
355	Gene expression studies of hepatitis virus-induced woodchuck hepatocellular carcinoma in correlation with human results. <i>International Journal of Oncology</i> , 2007, 30, 33.	1.4	8
356	Interferon. <i>Annals of Surgery</i> , 2007, 245, 843-845.	2.1	36
357	Repeated courses of transarterial embolization with polyvinyl alcohol particles: long life elixir in a cirrhotic patient with unresectable hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 329-332.	0.8	4
358	Emerging Approaches in Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 839-854.	1.1	15
359	Peripheral Blood Lymphocyte Populations in End-stage Liver Diseases. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 713-721.	1.1	17
360	Genes Associated With Progression and Recurrence of Hepatocellular Carcinoma in Hepatitis C Patients Waiting and Undergoing Liver Transplantation: Preliminary Results. <i>Transplantation</i> , 2007, 83, 973-981.	0.5	24
361	Evaluation of a Novel Time-Efficient Protocol for Gadobenate Dimeglumine (Gd-BOPTA)-Enhanced Liver Magnetic Resonance Imaging. <i>Investigative Radiology</i> , 2007, 42, 105-115.	3.5	20
362	Predictors of Graft and Patient Survival in Hepatitis C Virus (HCV) Recipients: Model to Predict HCV Cirrhosis After Liver Transplantation. <i>Transplantation</i> , 2007, 84, 56-63.	0.5	39
363	Screening for Hepatocellular Carcinoma in Clinical Practice. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 729-730.	1.1	1
364	$\alpha$ -lipoic acid promotes the growth of rat hepatic pre-neoplastic lesions in the choline-deficient model. <i>Carcinogenesis</i> , 2007, 29, 161-168.	1.3	16
365	Regulation of the human cathepsin E gene by the constitutive androstane receptor. <i>Archives of Biochemistry and Biophysics</i> , 2007, 467, 132-138.	1.4	6
366	Nutrients intake and the risk of hepatocellular carcinoma in Italy. <i>European Journal of Cancer</i> , 2007, 43, 2381-2387.	1.3	55
367	Liver resections for hepatocellular carcinoma in chronic liver disease: Experience in an Italian centre. <i>European Journal of Surgical Oncology</i> , 2007, 33, 1014-1018.	0.5	23
368	Saxifragifolin B from <i>Androsace umbellata</i> induced apoptosis on human hepatoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2007, 362, 759-765.	1.0	23
369	Supernatant of bacterial fermented soybean induces apoptosis of human hepatocellular carcinoma Hep 3B cells via activation of caspase 8 and mitochondria. <i>Food and Chemical Toxicology</i> , 2007, 45, 303-314.	1.8	26

#	ARTICLE	IF	CITATIONS
370	Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. <i>Clinica Chimica Acta</i> , 2007, 383, 147-152.	0.5	89
371	Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome?. <i>Cancer Treatment Reviews</i> , 2007, 33, 437-447.	3.4	290
372	A novel peptide that selectively binds highly metastatic hepatocellular carcinoma cell surface is related to invasion and metastasis. <i>Cancer Letters</i> , 2007, 247, 234-242.	3.2	23
373	hF-LANA, a human homologue of Derlin family, regulating the expression of cancer-related genes promotes NIH3T3 cell transformation. <i>Cancer Letters</i> , 2007, 258, 171-180.	3.2	2
374	Hepatocellular Carcinoma: Trends of Incidence and Survival in Europe and the United States at the End of the 20th Century. <i>American Journal of Gastroenterology</i> , 2007, 102, 1661-1670.	0.2	121
375	Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.–Canadian multicenter study. <i>Journal of Hepatology</i> , 2007, 47, 527-537.	1.8	231
376	Hepatocellular carcinoma in human immunodeficiency virus (HIV)-infected patients: Is it really different, and if so, why?. <i>Journal of Hepatology</i> , 2007, 47, 447-450.	1.8	11
377	Clinicopathological significance of missing in metastasis B expression in hepatocellular carcinoma. <i>Human Pathology</i> , 2007, 38, 1201-1206.	1.1	43
378	Inverse expression of Jun activation domain binding protein 1 and cell cycle inhibitor p27Kip1: influence on proliferation in hepatocellular carcinoma. <i>Human Pathology</i> , 2007, 38, 1621-1627.	1.1	23
379	Radiofrequency Ablation of Liver Cancer. <i>Techniques in Vascular and Interventional Radiology</i> , 2007, 10, 38-46.	0.4	107
380	Transcatheter Arterial Chemoembolization: Current Technique and Future Promise. <i>Techniques in Vascular and Interventional Radiology</i> , 2007, 10, 2-11.	0.4	63
381	Atypical hepatic focal nodular hyperplasia presenting as acute abdomen and misdiagnosed as hepatocellular carcinoma. <i>Hepatology Research</i> , 2007, 37, 1100-1105.	1.8	19
382	Current management of liver cancer. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 444-446.	2.2	4
383	Liver-directed therapies for hepatocellular cancer. <i>Community Oncology</i> , 2007, 4, 571-575.	0.2	1
384	Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2007, 67, 6092-6099.	0.4	782
385	Transarterial Chemoembolization for Primary Hepatocellular Carcinoma in Patients at High Risk. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 1517-1526.	0.2	90
386	Surveillance for Hepatocellular Carcinoma and Early Diagnosis. <i>Clinics in Liver Disease</i> , 2007, 11, 817-837.	1.0	22
387	Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma in the United States: A Population-Based Case-Control Study. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1221-1228.	2.4	455

#	ARTICLE	IF	CITATIONS
388	Screening for Hepatocellular Carcinoma Among Veterans With Hepatitis C on Disease Stage, Treatment Received, and Survival. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 508-512.	2.4	67
389	Intraarterial Therapy with a New Potent Inhibitor of Tumor Metabolism (3-bromopyruvate): Identification of Therapeutic Dose and Method of Injection in an Animal Model of Liver Cancer. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 95-101.	0.2	44
390	Hepatitis B Virus Infection Predicts Extrahepatic Metastasis After Hepatic Resection in Patients With Large Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2007, 14, 3181-3187.	0.7	15
395	Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. <i>Journal of Translational Medicine</i> , 2007, 5, 3.	1.8	67
396	Pin1 Interacts With a Specific Serine-Proline Motif of Hepatitis B Virus X-Protein to Enhance Hepatocarcinogenesis. <i>Gastroenterology</i> , 2007, 132, 1088-1103.	0.6	121
397	Telomerase Deletion Limits Progression of p53-Mutant Hepatocellular Carcinoma With Short Telomeres in Chronic Liver Disease. <i>Gastroenterology</i> , 2007, 132, 1465-1475.	0.6	59
398	Hepatitis B Virus X Protein and Pin1 in Liver Cancer: "Les Liaisons Dangereuses". <i>Gastroenterology</i> , 2007, 132, 1180-1183.	0.6	12
399	Increased Regulatory T Cells Correlate With CD8 T-Cell Impairment and Poor Survival in Hepatocellular Carcinoma Patients. <i>Gastroenterology</i> , 2007, 132, 2328-2339.	0.6	743
400	Identification and Characterization of Tumorigenic Liver Cancer Stem/Progenitor Cells. <i>Gastroenterology</i> , 2007, 132, 2542-2556.	0.6	1,096
402	Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2007, 97, 1399-1403.	2.9	78
403	Management of Solitary 1â€cm to 2â€cm Liver Nodules in Patients with Compensated Cirrhosis: A Decision Analysis. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2007, 21, 491-500.	1.8	22
404	Tumor Response to Transcatheter Arterial Chemoembolization in Recurrent Hepatocellular Carcinoma after Living Donor Liver Transplantation. <i>Korean Journal of Radiology</i> , 2007, 8, 320.	1.5	42
405	Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2007, 13, 2952.	1.4	63
407	Subcellular Localization of APE1/Ref-1 in Human Hepatocellular Carcinoma: Possible Prognostic Significance. <i>Molecular Medicine</i> , 2007, 13, 89-96.	1.9	93
408	Hepatocellular carcinoma in patients with autoimmune liver diseases: Two case reports and literature review. <i>Annals of Hepatology</i> , 2007, 6, 122-126.	0.6	12
409	Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. <i>International Journal of Cancer</i> , 2007, 120, 1555-1559.	2.3	82
410	Identification of overexpressed genes in hepatocellular carcinoma, with special reference toubiquitin-conjugating enzyme E2Cgene expression. <i>International Journal of Cancer</i> , 2007, 121, 33-38.	2.3	98
411	Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: Analysis of 5,613 cases from a medical center in southern Taiwan. <i>International Journal of Cancer</i> , 2007, 120, 2650-2655.	2.3	95

#	ARTICLE	IF	CITATIONS
412	Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. <i>Hepatology</i> , 2007, 45, 938-947.	3.6	632
413	Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?. <i>Hepatology</i> , 2008, 47, 82-89.	3.6	950
414	Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. <i>Hepatology</i> , 2008, 47, 97-104.	3.6	884
415	Consequences of missed opportunities. <i>Journal of Hospital Medicine</i> , 2007, 2, 274-279.	0.7	1
416	Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. <i>Liver Transplantation</i> , 2007, 13, 807-813.	1.3	64
417	Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center. <i>Liver Transplantation</i> , 2007, 13, 896-903.	1.3	48
418	Surveillance and diagnosis for hepatocellular carcinoma. <i>Liver Transplantation</i> , 2007, 13, S2-S12.	1.3	10
419	Clinical and molecular classification of hepatocellular carcinoma. <i>Liver Transplantation</i> , 2007, 13, S13-S16.	1.3	19
420	Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2007, 95, 213-220.	0.8	28
421	CD117 (c-kit) Expression in Human Hepatocellular Carcinoma. <i>Clinical Oncology</i> , 2007, 19, 204-208.	0.6	37
422	Proton Beam Therapy for Aged Patients With Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 805-812.	0.4	56
423	Intra-Arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-Sponsored Multination Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1448-1455.	0.4	70
424	Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cells. <i>Laboratory Investigation</i> , 2007, 87, 582-590.	1.7	63
425	Neoplasms of the liver. <i>Modern Pathology</i> , 2007, 20, S49-S60.	2.9	123
427	Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. <i>Differentiation</i> , 2007, 75, 843-852.	1.0	37
428	Targeting chemokines as a therapeutic option for hepatocellular carcinoma: A reality or just a fantasy?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 611-612.	1.4	2
429	Oxidative stress induces p53-dependent apoptosis in hepatoblastoma cell through its nuclear translocation. <i>Genes To Cells</i> , 2007, 12, 461-471.	0.5	34
430	Development of a heterologous, multigenotype vaccine against hepatitis C virus infection. <i>European Journal of Clinical Investigation</i> , 2007, 37, 396-406.	1.7	12

#	ARTICLE	IF	CITATIONS
431	Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 383-391.	1.9	19
432	Toward the discovery of new biomarkers of hepatocellular carcinoma by proteomics. <i>Liver International</i> , 2007, 27, 163-173.	1.9	37
433	Expression of microsomal prostaglandin E synthase-1 in human hepatocellular carcinoma. <i>Liver International</i> , 2007, 27, 989-996.	1.9	20
434	Evolution of hepatitis C virus non-structural 5A gene in the progression of liver disease to hepatocellular carcinoma. <i>Liver International</i> , 2007, 27, 1126-1133.	1.9	8
435	Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. <i>Liver International</i> , 2008, 28, 393-401.	1.9	113
436	Antisense oligonucleotides targeting midkine inhibit tumor growth in an in situ human hepatocellular carcinoma model. <i>Acta Pharmacologica Sinica</i> , 2007, 28, 453-458.	2.8	15
437	Consensus and Controversy in the Management of Hepatocellular Carcinoma. <i>Journal of the American College of Surgeons</i> , 2007, 205, 108-123.	0.2	28
438	Screening for hepatocellular carcinoma. <i>Hepatology Research</i> , 2007, 37, S152-65.	1.8	16
439	Review of current staging systems for hepatocellular carcinoma. <i>Hepatology Research</i> , 2007, 37, S210-5.	1.8	7
440	Japanese experience in ablation therapies for hepatocellular carcinoma. <i>Hepatology Research</i> , 2007, 37, S223-S229.	1.8	6
441	Combined intra-arterial 5-fluorouracil and subcutaneous interferon-alpha therapy for highly advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2007, 37, S238-50.	1.8	10
442	Malignant tumours of the liver. <i>Surgery</i> , 2007, 25, 34-41.	0.1	1
443	Hepatocellular Carcinoma (HCC): An Update. <i>Seminars in Oncology</i> , 2007, 34, S12-S20.	0.8	57
444	Large-sized hepatocellular carcinoma (HCC): a neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser-induced thermotherapy (LITT). <i>European Radiology</i> , 2007, 17, 553-563.	2.3	39
445	Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. <i>European Radiology</i> , 2007, 17, 684-692.	2.3	310
446	Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. <i>European Radiology</i> , 2007, 17, 2519-2530.	2.3	96
447	Percutaneous Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma After Hepatectomy: Long-term Results and Prognostic Factors. <i>Annals of Surgical Oncology</i> , 2007, 14, 2319-2329.	0.7	125
448	Salvage Surgery Following Downstaging of Unresectable Hepatocellular Carcinoma—A Strategy to Increase Resectability. <i>Annals of Surgical Oncology</i> , 2007, 14, 3301-3309.	0.7	104



#	ARTICLE	IF	CITATIONS
449	Single hepatocellular carcinoma ranging from 3 to 5cm: radiofrequency ablation or resection?. <i>Hpb</i> , 2007, 9, 429-434.	0.1	84
452	Chronic Viral Hepatitis and Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2007, 31, 1245-1250.	0.8	85
453	Liver Resection for Hepatocellular Carcinoma in a Hepatitis B Endemic Area. <i>World Journal of Surgery</i> , 2007, 31, 1775-1781.	0.8	243
454	Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies. <i>CardioVascular and Interventional Radiology</i> , 2007, 30, 6-25.	0.9	698
455	Long-Term Outcome of a Hepatocellular Carcinoma 7½ Years After Surgery and Repeated Radiofrequency Ablation: Case Report and Review of the Literature. <i>CardioVascular and Interventional Radiology</i> , 2007, 30, 289-292.	0.9	5
457	Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. <i>Quality of Life Research</i> , 2007, 16, 389-397.	1.5	70
458	Causes of Death in Patients with Unresectable Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2007, 52, 3285-3289.	1.1	49
459	RECK" a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 675-683.	2.7	151
460	Clinical management of focal liver lesions: the key role of real-time contrast-enhanced US. <i>European Radiology, Supplement</i> , 2007, 17, 73-79.	1.8	40
461	Bioluminescent imaging of hepatocellular carcinoma in live mice. <i>Biotechnology Letters</i> , 2007, 29, 1665-1670.	1.1	14
462	Risk factors for fatal recurrence of liver transplant recipients with hepatocellular carcinoma in the first year. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2007, 19, 165-170.	0.7	0
463	Effects of paclitaxel and doxorubicin in histocultures of hepatocellular carcinomas. <i>Journal of Biomedical Science</i> , 2007, 14, 233-244.	2.6	27
466	Hepatocellular carcinoma in viral hepatitis: Improving standard therapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2008, 22, 1137-1151.	1.0	20
467	Image-guided thermal ablation of hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 200-207.	2.0	41
468	Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization. <i>Clinical and Experimental Metastasis</i> , 2008, 25, 811-817.	1.7	16
469	Anion exchanger inhibitor DIDS induces human poorly-differentiated malignant hepatocellular carcinoma HA22T cell apoptosis. <i>Molecular and Cellular Biochemistry</i> , 2008, 308, 117-125.	1.4	21
470	Synthesis and primary biological evaluation of 188ReN-NEMPTDD. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2008, 277, 365-369.	0.7	1
471	Mechanisms of Action and Resistance of Somatostatin Analogues for the Treatment of Hepatocellular Carcinoma: A Message Not Well Taken. <i>Digestive Diseases and Sciences</i> , 2008, 53, 2359-2365.	1.1	19

#	ARTICLE	IF	CITATIONS
472	Immunohistochemical Expression of Components of the Akt-mTORC1 Pathway is Associated with Hepatocellular Carcinoma in Patients with Chronic Liver Disease. <i>Digestive Diseases and Sciences</i> , 2008, 53, 844-849.	1.1	24
473	Efficacy of Loco-Regional Ablation Therapy of HCC in a Population of Liver Transplanted Patients. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1131-1137.	1.1	11
474	Pulmonary Resection for Non-small Cell Lung Cancer in Patients with Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2008, 32, 2204-2212.	0.8	8
475	Correlation of Multislice CT and Histomorphology in HCC Following TACE: Predictors of Outcome. <i>CardioVascular and Interventional Radiology</i> , 2008, 31, 768-777.	0.9	50
477	Carbon dioxide microbubbles-enhanced sonographically guided radiofrequency ablation: treatment of patients with local progression of hepatocellular carcinoma. <i>Radiation Medicine</i> , 2008, 26, 92-97.	0.8	10
478	Update on the treatment of hepatocellular carcinoma. <i>Memo - Magazine of European Medical Oncology</i> , 2008, 1, 111-115.	0.3	0
479	Systemic therapy of hepatocellular carcinoma: Are we making progress?. <i>Advances in Therapy</i> , 2008, 25, 1089-1104.	1.3	79
480	In Search of Liver Cancer Stem Cells. <i>Stem Cell Reviews and Reports</i> , 2008, 4, 179-192.	5.6	21
481	Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. <i>Medical Oncology</i> , 2008, 25, 201-206.	1.2	28
482	Unusual presentation of metastatic hepatocellular carcinoma in the nasal septum: a case report and review of the literature. <i>Medical Oncology</i> , 2008, 25, 264-268.	1.2	8
483	Economic evaluation of a surveillance program of hepatocellular carcinoma (HCC) in India. <i>Hepatology International</i> , 2008, 2, 231-236.	1.9	8
484	How to predict the development of hepatocellular carcinoma in cirrhotic patients. Despite recent advances, the search continues. <i>Oncology Reviews</i> , 2008, 1, 187-188.	0.8	0
485	Hepatitis b virus genotype and mutants and the risk of hepatocellular carcinoma. <i>Oncology Reviews</i> , 2008, 2, 129-130.	0.8	0
486	Laparoscopic liver resection for hepatocellular carcinoma. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2008, 22, 372-378.	1.3	109
487	Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model. <i>Langenbeck's Archives of Surgery</i> , 2008, 393, 333-341.	0.8	11
488	Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 535-541.	1.2	90
489	APC promoter methylation and protein expression in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 579-589.	1.2	47
490	2D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesis. <i>Proteomics</i> , 2008, 8, 5086-5096.	1.3	41

#	ARTICLE	IF	CITATIONS
491	Prediction of microvascular invasion before curative resection of hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2008, 97, 246-252.	0.8	104
492	Treatment and prognosis of hepatocellular carcinoma: A population based study in France. <i>Journal of Surgical Oncology</i> , 2008, 98, 505-509.	0.8	68
493	Hepatocellular carcinoma developed on compensated cirrhosis: Resection as a selection tool for liver transplantation. <i>Liver Transplantation</i> , 2008, 14, 779-788.	1.3	76
494	Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. <i>Liver Transplantation</i> , 2008, 14, 1449-1460.	1.3	101
495	Differential expression of Estrogen receptors in human hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2008, 122, 547-557.	2.3	22
496	Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. <i>International Journal of Cancer</i> , 2008, 123, 2808-2815.	2.3	88
497	Identification of local and circulating cancer stem cells in human liver cancer. <i>Hepatology</i> , 2008, 47, 919-928.	3.6	314
498	Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. <i>Hepatology</i> , 2008, 47, 1964-1973.	3.6	163
499	Transforming growth factor- $\beta$ gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. <i>Hepatology</i> , 2008, 47, 2059-2067.	3.6	302
500	Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase. <i>Hepatology</i> , 2008, 48, 519-530.	3.6	77
501	Molecular targeted therapies in hepatocellular carcinoma. <i>Hepatology</i> , 2008, 48, 1312-1327.	3.6	899
502	Comprehensive analysis of the $\alpha$ -fetoprotein-specific CD8 <sup>+</sup> T cell responses in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2008, 48, 1821-1833.	3.6	60
503	Hepatitis B virus X protein affects S phase progression leading to chromosome segregation defects by binding to damaged DNA binding protein 1. <i>Hepatology</i> , 2008, 48, 1467-1476.	3.6	95
504	Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. <i>Hepatology</i> , 2008, 48, 1864-1873.	3.6	38
505	Vascular Changes in Hepatocellular Carcinoma. <i>Anatomical Record</i> , 2008, 291, 721-734.	0.8	169
506	Prognostic Factors and Optimal Treatment Strategy for Intrahepatic Nodular Recurrence After Curative Resection of Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2008, 15, 618-629.	0.7	70
507	Early Hepatocellular Carcinoma: Pathology, Imaging, and Therapy. <i>Annals of Surgical Oncology</i> , 2008, 15, 972-978.	0.7	73
508	Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma: A Retrospective Study. <i>Annals of Surgical Oncology</i> , 2008, 15, 3484-3493.	0.7	112

#	ARTICLE	IF	CITATIONS
509	Surgical Treatment of Hepatocellular Carcinoma beyond Milan Criteria. Results of Liver Resection, Salvage Transplantation, and Primary Liver Transplantation. <i>Annals of Surgical Oncology</i> , 2008, 15, 1383-1391.	0.7	316
510	Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma. <i>Acta Pharmacologica Sinica</i> , 2008, 29, 1467-1477.	2.8	26
511	Management of combined hepatocellular and cholangiocarcinoma. <i>International Journal of Clinical Practice</i> , 2008, 62, 1271-1278.	0.8	130
512	Human hepatocellular carcinoma expresses specific PCNA isoforms: an in vivo and in vitro evaluation. <i>Laboratory Investigation</i> , 2008, 88, 995-1007.	1.7	21
513	Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. <i>British Journal of Cancer</i> , 2008, 98, 1161-1165.	2.9	50
514	Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2008, 99, 143-150.	2.9	183
515	New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis. <i>British Journal of Cancer</i> , 2008, 99, 151-159.	2.9	40
516	An enormous hepatitis B virus-related liver disease burden projected in Vietnam by 2025. <i>Liver International</i> , 2008, 28, 525-531.	1.9	65
517	Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation. <i>Liver International</i> , 2008, 28, 622-631.	1.9	22
518	British HIV Association guidelines for HIV-associated malignancies 2008. <i>HIV Medicine</i> , 2008, 9, 336-388.	1.0	158
519	Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 437-444.	1.4	48
520	Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 445-452.	1.4	47
521	Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 467-473.	1.4	109
522	Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 453-458.	1.4	29
523	Management and patient survival in hepatocellular carcinoma: Does the physician's level of experience matter?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, e179-88.	1.4	12
524	Huanghanjiedu tang, a traditional Chinese medicine prescription, induces cell cycle arrest and apoptosis in human liver cancer cells <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, e290-9.	1.4	47
525	Role of magnetic resonance cholangiopancreatography and other non-invasive imaging modalities in assessing bile duct stones. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 684-686.	1.4	1
526	Chemotherapy for advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 682-684.	1.4	14

#	ARTICLE	IF	CITATIONS
527	Genetic association between functional haplotype of collagen type III alpha 1 and chronic hepatitis B and cirrhosis in Koreans. <i>Tissue Antigens</i> , 2008, 72, 539-548.	1.0	5
528	Translational microarray systems for outcome prediction of hepatocellular carcinoma. <i>Cancer Science</i> , 2008, 99, 659-665.	1.7	20
529	Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by $\beta$ -catenin/TCF. <i>Cancer Science</i> , 2008, 99, 1139-1146.	1.7	47
530	Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics. <i>Cancer Science</i> , 2008, 99, 1685-1692.	1.7	21
531	RNA-electroporated CD40-activated B cells induce functional T-cell responses against HepG2 cells. <i>European Journal of Cancer Care</i> , 2008, 17, 404-411.	0.7	11
532	Laminin $\beta$ 5 mediates ectopic adhesion of hepatocellular carcinoma through integrins and/or Lutheran/basal cell adhesion molecule. <i>Experimental Cell Research</i> , 2008, 314, 2579-2590.	1.2	45
533	Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation â€œ HeiLivCa [ISRCTN24081794]. <i>BMC Cancer</i> , 2008, 8, 349.	1.1	89
534	Significance of CD90+ Cancer Stem Cells in Human Liver Cancer. <i>Cancer Cell</i> , 2008, 13, 153-166.	7.7	1,115
535	Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. <i>Clinical Immunology</i> , 2008, 129, 428-437.	1.4	259
536	Doxorubicin coupled to lactosaminated human albumin: a hepatocellular carcinoma targeted drug. <i>Drug Discovery Today</i> , 2008, 13, 1002-1009.	3.2	23
537	Liver Transplantation in a Large Pediatric Liver Tumor : A Case Report. <i>Apollo Medicine</i> , 2008, 5, 232-233.	0.0	0
538	Liver Transplantation for Recurrent Hepatocellular Carcinoma on Cirrhosis After Liver Resection: University of Bologna Experience. <i>American Journal of Transplantation</i> , 2008, 8, 1177-1185.	2.6	153
539	Risk factors of survival after percutaneous radiofrequency ablation of hepatocellular carcinoma. <i>Surgical Oncology</i> , 2008, 17, 23-31.	0.8	33
540	Sorafenib in Advanced Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 378-390.	13.9	12,004
541	Guidelines for imaging focal lesions in liver cirrhosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 697-703.	1.4	25
542	Hepatocellular Carcinoma Is Associated With an Increased Risk of Hepatitis B Virus Recurrence After Liver Transplantation. <i>Gastroenterology</i> , 2008, 134, 1890-1899.	0.6	155
543	Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 135, 1972-1983.e11.	0.6	644
544	Contrast-enhanced ultrasound assessment of arterial vascularization of small nodules arising in the cirrhotic liver. <i>Digestive and Liver Disease</i> , 2008, 40, 206-215.	0.4	18

#	ARTICLE	IF	CITATIONS
545	Efficacy of doxorubicin coupled to lactosaminated albumin on rat hepatocellular carcinomas evaluated by ultrasound imaging. <i>Digestive and Liver Disease</i> , 2008, 40, 278-284.	0.4	23
546	Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2008, 40, 446-452.	0.4	88
547	Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: A prospective study. <i>Digestive and Liver Disease</i> , 2008, 40, 684-689.	0.4	29
548	Guidelines for the use of contrast-enhanced ultrasound in hepatocellular carcinoma. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 1-8.	2.2	3
549	Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 6779-6788.	0.4	589
550	Hepatocellular carcinoma: Epidemiology and clinical aspects. <i>Molecular Aspects of Medicine</i> , 2008, 29, 130-143.	2.7	92
551	Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. <i>Journal of Hepatology</i> , 2008, 48, 83-90.	1.8	276
552	Novel advancements in the management of hepatocellular carcinoma in 2008. <i>Journal of Hepatology</i> , 2008, 48, S20-S37.	1.8	739
553	Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2008, 48, 848-857.	1.8	113
554	Liver transplantation for hepatocellular carcinoma: Extension of indications based on molecular markers. <i>Journal of Hepatology</i> , 2008, 49, 581-588.	1.8	80
555	Expression of multidrug resistance-associated protein 3 and cytotoxic T cell responses in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2008, 49, 946-954.	1.8	30
556	Gain of GRHL2 is associated with early recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2008, 49, 746-757.	1.8	57
557	siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. <i>Journal of Hepatology</i> , 2008, 49, 977-984.	1.8	75
558	Sorafenib in advanced hepatocellular carcinoma – “ We have won a battle not the war. <i>Journal of Hepatology</i> , 2008, 49, 871-873.	1.8	33
559	Hepatocellular Carcinoma: A Pledge for Evidence-based Medicine. <i>American Journal of Medicine</i> , 2008, 121, e7.	0.6	8
560	University of California at San Francisco Criteria Can Be Applied to Living Donor Liver Transplantation for Hepatocellular Carcinoma: Single-Center Preliminary Results in 27 Patients. <i>Transplantation Proceedings</i> , 2008, 40, 1476-1480.	0.3	3
561	Role of Osteopontin and CD44s Expression for Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation or Resection. <i>Transplantation Proceedings</i> , 2008, 40, 3182-3184.	0.3	15
562	Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. <i>Thrombosis Research</i> , 2008, 122, 299-306.	0.8	99

#	ARTICLE	IF	CITATIONS
563	Cyr61/CCN1 is a tumor suppressor in human hepatocellular carcinoma and involved in DNA damage response. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 98-109.	1.2	44
564	Imatinib for hepatocellular cancer – Focus on pharmacokinetic/pharmacodynamic modelling and liver function. <i>Cancer Letters</i> , 2008, 260, 146-154.	3.2	19
565	Decreased expression of ING2 gene and its clinicopathological significance in hepatocellular carcinoma. <i>Cancer Letters</i> , 2008, 261, 183-192.	3.2	54
566	Assessment of systemic inflammatory response (SIR) in patients undergoing radiofrequency ablation or partial liver resection for liver tumors. <i>European Journal of Surgical Oncology</i> , 2008, 34, 662-667.	0.5	35
567	Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid?. <i>European Journal of Surgical Oncology</i> , 2008, 34, 256-262.	0.5	51
568	Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous $\alpha$ -fetoprotein in mice. <i>Biochemical and Biophysical Research Communications</i> , 2008, 376, 10-14.	1.0	20
569	Development of high-performance magnetic chemiluminescence enzyme immunoassay for $\alpha$ -fetoprotein (AFP) in human serum. <i>Clinica Chimica Acta</i> , 2008, 393, 90-94.	0.5	69
570	Overview of Liver Pathology. <i>Disease-a-Month</i> , 2008, 54, 419-431.	0.4	1
571	Natural History of Hepatocellular Carcinoma and Current Treatment Options. <i>Seminars in Nuclear Medicine</i> , 2008, 38, S13-S18.	2.5	58
572	International Atomic Energy Agency-Sponsored Multination Study of Intra-Arterial Rhenium-188-Labeled Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results With Special Emphasis on Prognostic Value of Dosimetric Study. <i>Seminars in Nuclear Medicine</i> , 2008, 38, S40-S45.	2.5	34
573	Statins, Tregs and cancer. <i>Atherosclerosis</i> , 2008, 196, 483-484.	0.4	7
574	Manejo general y extrahospitalario del paciente con cirrosis. <i>Medicine</i> , 2008, 10, 726-731.	0.0	0
575	Carcinoma hepatocelular. <i>Medicine</i> , 2008, 10, 770-776.	0.0	0
576	Liver cirrhosis. <i>Lancet, The</i> , 2008, 371, 838-851.	6.3	1,745
577	Glypican-3 and MAGE-1 are predictors of tumor invasiveness of hepatocellular carcinoma. <i>Basic and Applied Pathology</i> , 2008, 1, 174-181.	0.2	1
578	Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies: Preliminary results for efficacy and toxicity. <i>Hepatology Research</i> , 2008, 38, 60-69.	1.8	59
579	Radiofrequency Ablation of Hepatocellular Carcinoma. <i>Journal of Medical Ultrasound</i> , 2008, 16, 272-284.	0.2	5
580	Dosimetry for <sup>125</sup> I radioactive seed implantation therapy for hepatocellular carcinoma. <i>Journal of Nanjing Medical University</i> , 2008, 22, 269-272.	0.1	0

#	ARTICLE	IF	CITATIONS
581	Liver Resection for Hepatocellular Carcinoma. <i>Surgical Oncology Clinics of North America</i> , 2008, 17, 607-633.	0.6	37
582	Cost Effectiveness of Alternative Surveillance Strategies for Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1418-1424.	2.4	225
583	Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. <i>Current Medical Research and Opinion</i> , 2008, 24, 3559-3569.	0.9	26
584	Ionic Versus Nonionic Contrast Media Solvents Used with an Epirubicin-based Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2008, 19, 342-350.	0.2	14
585	High-dimensional biology to comprehend hepatocellular carcinoma. <i>Expert Review of Proteomics</i> , 2008, 5, 45-60.	1.3	23
586	Hepatocellular Carcinoma Tele-screening System. , 2008, , .		2
587	MR Imaging of Hepatocellular Carcinoma in the Cirrhotic Liver: Challenges and Controversies. <i>Radiology</i> , 2008, 247, 311-330.	3.6	339
588	Urocortin's Inhibition of Tumor Growth and Angiogenesis in Hepatocellular Carcinoma via Corticotrophin-Releasing Factor Receptor 2. <i>Cancer Investigation</i> , 2008, 26, 359-368.	0.6	45
589	Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness. <i>American Journal of Gastroenterology</i> , 2008, 103, 914-921.	0.2	429
590	Complex Formation between Heat Shock Protein 72 and Hepatitis B Virus X Protein in Hepatocellular Carcinoma Tissues. <i>Journal of Proteome Research</i> , 2008, 7, 5133-5137.	1.8	7
591	Hepatitis B Virus Genotype and Mutants: Risk Factors for Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1121-1123.	3.0	16
592	Molecular Targeting in Hepatocellular Carcinoma. , 2008, , 165-210.		1
593	Chemoembolization Combined With Radiofrequency Ablation for Patients With Hepatocellular Carcinoma Larger Than 3 cm. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1669.	3.8	172
594	Interventional radiology in liver cancer. <i>Imaging</i> , 2008, 20, 185-193.	0.0	0
595	Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 3520-3528.	3.2	78
596	Efficacy and Safety of Percutaneous Transhepatic Portal Embolization before Right Liver Resection Using an Ethibloc/Lipiodol Mixture: A Single-Center Experience. <i>Digestive Surgery</i> , 2008, 25, 52-59.	0.6	15
597	Nine Months to Progression Using Fourth-Line Liposomally Encapsulated Paclitaxel against Hepatocellular Carcinoma. <i>Chemotherapy</i> , 2008, 54, 309-314.	0.8	12
598	Expanding the Treatment Options for Hepatocellular Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1716.	3.8	15



#	ARTICLE	IF	CITATIONS
599	MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. <i>Carcinogenesis</i> , 2008, 29, 1192-1196.	1.3	119
600	Gene Expression-Based Recurrence Prediction of Hepatitis B Virus-Related Human Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 2056-2064.	3.2	157
601	Chemoembolization Combined with Pravastatin Improves Survival in Patients with Hepatocellular Carcinoma. <i>Digestion</i> , 2008, 78, 34-38.	1.2	94
602	Tumor-initiating stem cells in liver cancer. <i>Cancer Biology and Therapy</i> , 2008, 7, 325-330.	1.5	22
603	Fighting Fire With Fire: Effects of Oncolytic Virotherapy on Underlying Viral Hepatitis in Hepatocellular Carcinoma. <i>Molecular Therapy</i> , 2008, 16, 1521-1523.	3.7	0
604	Acute Kidney Injury after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Retrospective Analysis. <i>Blood Purification</i> , 2008, 26, 454-459.	0.9	17
605	TACE versus TAE as therapy for hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1623-1641.	1.1	78
606	Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 761-784.	1.4	14
607	Advances in prevention and diagnosis of hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 425-433.	1.4	10
608	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3129-3140.	1.9	1,237
609	Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2008, 100, 698-711.	3.0	1,545
610	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 1995-2004.	13.9	1,148
611	Association of Mortalin (HSPA9) with Liver Cancer Metastasis and Prediction for Early Tumor Recurrence. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 315-325.	2.5	152
612	Mouse models in liver cancer research: A review of current literature. <i>World Journal of Gastroenterology</i> , 2008, 14, 6915.	1.4	70
613	Treatment of Hepatocellular Carcinoma Using Arterial Chemoembolization with Degradable Starch Microspheres and Continuous Arterial Infusion of 5-Fluorouracil. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 596-603.	0.6	14
614	High Expression of Macrophage Colony-Stimulating Factor in Peritumoral Liver Tissue Is Associated With Poor Survival After Curative Resection of Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 2707-2716.	0.8	503
615	Growth Rate of New Hepatocellular Carcinoma After Percutaneous Radiofrequency Ablation: Evaluation with Multiphase CT. <i>American Journal of Roentgenology</i> , 2008, 191, 215-220.	1.0	35
616	Pathogenesis and Clinical Practice in Gastroenterology. , 2008, , .		0

#	ARTICLE	IF	CITATIONS
617	Alcohol Drinking and Liver Cancer Risk: An Evaluation Based on a Systematic Review of Epidemiologic Evidence among the Japanese Population. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 816-838.	0.6	58
618	Epidermal Growth Factor Gene Functional Polymorphism and the Risk of Hepatocellular Carcinoma in Patients With Cirrhosis. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 53-60.	3.8	183
619	The Kringle 1 Domain of Hepatocyte Growth Factor Has Antiangiogenic and Antitumor Cell Effects on Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 404-414.	0.4	31
620	Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation. <i>Carcinogenesis</i> , 2008, 29, 2096-2105.	1.3	97
623	Transcatheter Arterial Embolization in the Emergency Department for Hemodynamic Instability Due to Ruptured Hepatocellular Carcinoma: Analysis of 167 Cases. <i>American Journal of Roentgenology</i> , 2008, 191, W231-W239.	1.0	45
624	Cirrhosis-associated Hepatocellular Nodules: Correlation of Histopathologic and MR Imaging Features. <i>Radiographics</i> , 2008, 28, 747-769.	1.4	176
625	Transarterial Chemoembolization in Patients Not Eligible for Liver Transplantation: Single-Center Results. <i>American Journal of Roentgenology</i> , 2008, 190, 1035-1042.	1.0	26
626	The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma. <i>Molecular Therapy</i> , 2008, 16, 1637-1642.	3.7	175
627	CD4 <sup>+</sup> CD25 <sup>+</sup> regulatory T cells: a therapeutic target for liver diseases. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 313-326.	1.5	6
628	In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249. <i>Carcinogenesis</i> , 2008, 29, 1428-1434.	1.3	28
629	Traditional Chinese Medicine Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma. <i>Journal of Alternative and Complementary Medicine</i> , 2008, 14, 1027-1042.	2.1	30
630	Selective or targeted gene/drug delivery for liver tumors: advantages and current status of local delivery. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 791-802.	1.4	7
631	Immunotherapy of Murine Hepatocellular Carcinoma by Î±-Fetoprotein DNA Vaccination Combined with Adenovirus-Mediated Chemokine and Cytokine Expression. <i>Human Gene Therapy</i> , 2008, 19, 753-759.	1.4	20
632	Effect of Acute Hepatic Failure on Epirubicin Pharmacokinetics after Intrahepatic Arterial Injection in Rats. <i>Biological and Pharmaceutical Bulletin</i> , 2008, 31, 493-496.	0.6	5
633	Adjuvant Intra-arterial Iodine-131-labeled Lipiodol for Resectable Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2008, 247, 43-48.	2.1	127
635	A three-gene predictor for early intrahepatic recurrence of hepatocellular carcinoma after curative hepatectomy. <i>Oncology Reports</i> , 2008, , .	1.2	13
636	Hepatocellular Carcinoma and Occupation in Men: A Case-Control Study. <i>Journal of Occupational and Environmental Medicine</i> , 2008, 50, 212-220.	0.9	7
637	High intensity focused ultrasound therapy resulted in a complete response in a patient with advanced gastric cancer with liver metastases: a case report. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 707-709.	0.8	5

#	ARTICLE	IF	CITATIONS
638	Minimal invasive Onkologie in der Therapie von Lebermetastasen. Chirurgische Gastroenterologie Interdisziplinär, 2008, 24, 207-215.	0.0	0
639	Transcatheter Arterial Chemoembolization: Technique and Future Potential. , 2008, , 192-201.		1
640	Image-guided Ablation of Hepatocellular Carcinoma. , 2008, , 145-159.		2
641	Image-guided radiofrequency ablation: techniques and results. , 0, , 148-166.		1
642	Medical Management of Colorectal Liver Metastasis. , 2008, , 222-242.		1
643	Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Current Opinion in Oncology, 2008, 20, 444-453.	1.1	60
644	Wnt Signaling in Liver Cancer. Current Drug Targets, 2008, 9, 1013-1024.	1.0	145
645	Hepatocellular carcinoma: latest developments. Current Opinion in Gastroenterology, 2008, 24, 312-319.	1.0	17
646	Extracapsular Penetration is a New Prognostic Factor in Human Hepatocellular Carcinoma. American Journal of Surgical Pathology, 2008, 32, 1675-1682.	2.1	30
647	Liver, gallbladder and biliary tract. , 0, , 141-150.		0
648	Evolving therapies in the treatment of hepatocellular carcinoma. Biologics: Targets and Therapy, 2008, Volume 2, 453-462.	3.0	17
649	The role of microRNAs in primary liver cancer. Annals of Hepatology, 2008, 7, 104-113.	0.6	48
650	Psychological intervention reduces postembolization pain during hepatic arterial chemoembolization therapy: A complementary approach to drug analgesia. World Journal of Gastroenterology, 2008, 14, 931.	1.4	14
652	1,2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP)-Formulated, Immune-Stimulatory Vascular Endothelial Growth Factor A Small Interfering RNA (siRNA) Increases Antitumoral Efficacy in Murine Orthotopic Hepatocellular Carcinoma with Liver Fibrosis. Molecular Medicine, 2008, 14, 365-373.	1.9	23
653	Thermal ablation of hepatocellular carcinoma. Cancer Imaging, 2008, 8, 19-26.	1.2	51
654	Validating a Markov Model of Treatment for Hepatitis C Virus-related Hepatocellular Carcinoma. Methods of Information in Medicine, 2008, 47, 529-540.	0.7	4
655	Unresectable Hepatocellular Carcinoma with a Solitary Metastasis to the Mandible. American Surgeon, 2008, 74, 346-349.	0.4	9
656	Surgical treatment of hepatocellular carcinoma: resection and transplantation. , 0, , 57-65.		0

#	ARTICLE	IF	CITATIONS
657	Regional therapies for treatment of intermediate-stage hepatocellular carcinoma. , 0, , 66-96.		0
658	Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2009, 2, 261.	1.0	7
659	TNF-based isolated hepatic perfusion. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 1771.	3.0	4
660	Genes Involved in Viral Carcinogenesis and Tumor Initiation in Hepatitis C Virus-Induced Hepatocellular Carcinoma. <i>Molecular Medicine</i> , 2009, 15, 85-94.	1.9	268
661	Modulation of TGF-beta signaling during progression of chronic liver diseases. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 2923.	3.0	61
663	The Antitumor Effect and Hepatotoxicity of a Hexokinase II Inhibitor 3-Bromopyruvate: In Vivo Investigation of Intraarterial Administration in a Rabbit VX2 Hepatoma Model. <i>Korean Journal of Radiology</i> , 2009, 10, 596.	1.5	31
664	A rare case of isolated duodenal metastases from hepatocellular carcinoma associated with p53 and ki-67 expression: a case report. <i>Cases Journal</i> , 2009, 2, 9344.	0.4	6
665	HCV Tumor Promoting Effect Is Dependent on Host Genetic Background. <i>PLoS ONE</i> , 2009, 4, e5025.	1.1	23
667	An overview of hepatocellular carcinoma study by omics-based methods. <i>Acta Biochimica Et Biophysica Sinica</i> , 2009, 41, 1-15.	0.9	51
668	Multimodal approaches to the treatment of hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 159-169.	8.2	66
669	Totally Laparoscopic Central Bisectionectomy for Hepatocellular Carcinoma. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2009, 19, 653-656.	0.5	29
670	Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 971-979.	3.2	725
671	Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The essential role of macrophages. <i>Cancer Biology and Therapy</i> , 2009, 8, 930-938.	1.5	23
672	Review: Current status of therapy for hepatocellular carcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2009, 2, 45-57.	1.4	15
673	The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. <i>Annals of Oncology</i> , 2009, 20, 353-357.	0.6	173
674	Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. <i>World Journal of Gastroenterology</i> , 2009, 15, 5080.	1.4	55
675	Mechanisms and Influence of Octreotide-Induced Regulation of Somatostatin Receptor 2 on Hepatocellular Carcinoma. <i>Chemotherapy</i> , 2009, 55, 312-320.	0.8	24
676	Treatment of Hepatocellular Carcinoma. <i>Oncology</i> , 2009, 77, 43-49.	0.9	6

#	ARTICLE	IF	CITATIONS
677	Treatment for the recurrence of hepatocellular carcinoma following liver transplantation: What is the best strategy?. <i>Cancer Biology and Therapy</i> , 2009, 8, 591-593.	1.5	2
678	Changing the clinical picture of challenging tumors: tales becoming reality?. <i>Future Oncology</i> , 2009, 5, 785-802.	1.1	1
679	Primary liver tumors: origin and target therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 957-965.	1.5	8
680	Interleukin-6 Polymorphisms and Gender: Relationship with the Occurrence of Hepatocellular Carcinoma in Patients with End-Stage Liver Disease. <i>Oncology</i> , 2009, 77, 304-313.	0.9	38
681	Clinical Staging of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2009, 27, 131-141.	0.8	20
682	Early development of sunitinib in hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 143-150.	1.1	28
683	Ethanol Ablation of Hepatocellular Carcinoma Up to 5.0 cm by Using a Multipronged Injection Needle with High-Dose Strategy. <i>Radiology</i> , 2009, 253, 552-561.	3.6	64
684	Hepatocarcinogenesis following pancreatic islet transplantation in streptozotocin- and autoimmune-diabetic rats. <i>Archives of Physiology and Biochemistry</i> , 2009, 115, 97-104.	1.0	1
685	Molecular Mechanisms Underlying Hepatocellular Carcinoma. <i>Viruses</i> , 2009, 1, 852-872.	1.5	35
686	New Utility of an Old Marker: Serial $\alpha$ -Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 446-452.	0.8	241
687	Role of hepatitis B virus X repression of C/EBP $\beta$ activity in the down-regulation of glutathioneS-transferase A2 gene: implications in other phase II detoxifying enzyme expression. <i>Xenobiotica</i> , 2009, 39, 182-192.	0.5	10
688	New kids on the block: Diagnostic and prognostic microRNAs in hepatocellular carcinoma. <i>Cancer Biology and Therapy</i> , 2009, 8, 1683-1690.	1.5	68
690	Dehydrocostuslactone, a Medicinal Plant-Derived Sesquiterpene Lactone, Induces Apoptosis Coupled to Endoplasmic Reticulum Stress in Liver Cancer Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 808-819.	1.3	67
691	Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. <i>Journal of Experimental Medicine</i> , 2009, 206, 1327-1337.	4.2	764
692	Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. <i>Carcinogenesis</i> , 2009, 30, 758-762.	1.3	56
693	Human Leukocyte Antigen-G Protein Expression Is an Unfavorable Prognostic Predictor of Hepatocellular Carcinoma following Curative Resection. <i>Clinical Cancer Research</i> , 2009, 15, 4686-4693.	3.2	86
694	Gadoxetic Acid-Enhanced MRI Versus Triple-Phase MDCT for the Preoperative Detection of Hepatocellular Carcinoma. <i>American Journal of Roentgenology</i> , 2009, 192, 1675-1681.	1.0	288
695	Transarterial Injection of <sup>131</sup> I-Lipiodol, Compared with Chemoembolization, in the Treatment of Unresectable Hepatocellular Cancer. <i>Journal of Nuclear Medicine</i> , 2009, 50, 871-877.	2.8	36

#	ARTICLE	IF	CITATIONS
696	Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. <i>Annals of Oncology</i> , 2009, 20, 1402-1407.	0.6	49
697	Cyclo-oxygenase-2 overexpression is a feature of early and well-differentiated hepatocellular carcinoma with a favourable prognosis. <i>Journal of Clinical Pathology</i> , 2009, 62, 690-693.	1.0	12
698	Resistance to Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors Correlates with Up-Regulation of the MEK/Extracellular Signal-Regulated Kinase Pathway in Hepatocellular Carcinoma Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 1063-1070.	1.3	34
699	Malignant tumours of the liver. <i>Surgery</i> , 2009, 27, 30-37.	0.1	14
700	Effect of local hyperthermia induced by nanometer magnetic fluid on the rabbit VX2 liver tumor model. <i>Progress in Natural Science: Materials International</i> , 2009, 19, 1705-1712.	1.8	20
701	Surgical management of hepatocellular carcinoma: Is the jury still out?. <i>Surgical Oncology</i> , 2009, 18, 298-321.	0.8	52
702	Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation. <i>BMC Cancer</i> , 2009, 9, 46.	1.1	14
703	Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. <i>BMC Medicine</i> , 2009, 7, 41.	2.3	127
704	Role of transarterial chemoembolization for hepatocellular carcinoma before liver transplantation with special consideration of tumor necrosis. <i>Clinical Transplantation</i> , 2009, 23, 61-67.	0.8	20
705	RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 1371-1380.	1.6	128
706	Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: Inhibition of cell proliferation and induction of apoptosis. <i>Chemico-Biological Interactions</i> , 2009, 179, 131-144.	1.7	151
707	Lymphotoxins: New Targets for Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2009, 16, 272-273.	7.7	17
708	Mst1 and Mst2 Maintain Hepatocyte Quiescence and Suppress Hepatocellular Carcinoma Development through Inactivation of the Yap1 Oncogene. <i>Cancer Cell</i> , 2009, 16, 425-438.	7.7	809
709	Safety of using iodized oil in chemoembolization for liver tumors in patients with previous adverse reactions to iodinated contrast media. <i>Clinical Imaging</i> , 2009, 33, 365-368.	0.8	2
711	Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. <i>Hepatology</i> , 2009, 49, 453-459.	3.6	403
712	Targeting transforming growth factor (TGF)- $\beta$ 2RI inhibits activation of $\beta$ 1 integrin and blocks vascular invasion in hepatocellular carcinoma. <i>Hepatology</i> , 2009, 49, 839-850.	3.6	127
713	Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)- $\beta$ 2 signaling from tumor suppression to oncogenesis in early chronic hepatitis B. <i>Hepatology</i> , 2009, 49, 1203-1217.	3.6	148
714	Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. <i>Hepatology</i> , 2009, 49, 1954-1961.	3.6	363

#	ARTICLE	IF	CITATIONS
715	Liver stiffness and hepatocellular carcinoma: Liaisons dangereuses?. <i>Hepatology</i> , 2009, 49, 1793-1794.	3.6	12
716	Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. <i>Hepatology</i> , 2009, 50, 1121-1129.	3.6	77
717	Overexpression of Tiam1 in hepatocellular carcinomas predicts poor prognosis of HCC patients. <i>International Journal of Cancer</i> , 2009, 124, 653-658.	2.3	57
718	Risk of liver cancer and exposure to organic solvents and gasoline vapors among Finnish workers. <i>International Journal of Cancer</i> , 2009, 124, 2954-2959.	2.3	14
719	Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: A meta-analysis of randomized controlled trials. <i>International Journal of Cancer</i> , 2009, 124, 2982-2988.	2.3	27
720	Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. <i>International Journal of Cancer</i> , 2009, 125, 1640-1648.	2.3	224
721	Cancer stem/progenitor cells are highly enriched in CD133 <sup>+</sup> CD44 <sup>+</sup> population in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2010, 126, 2067-2078.	2.3	348
722	Overexpression of SPARC obliterates the <i>in vivo</i> tumorigenicity of human hepatocellular carcinoma cells. <i>International Journal of Cancer</i> , 2010, 126, 2726-2740.	2.3	38
723	Real-time identification of liver cancers by using indocyanine green fluorescent imaging. <i>Cancer</i> , 2009, 115, 2491-2504.	2.0	706
724	The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula. <i>Cancer</i> , 2009, 115, 5132-5138.	2.0	42
725	RNAi-mediated silencing of insulin receptor substrate-4 enhances actinomycin D- and tumor necrosis factor- $\alpha$ -induced cell death in hepatocarcinoma cancer cell lines. <i>Journal of Cellular Biochemistry</i> , 2009, 108, 1292-1301.	1.2	18
726	Clinical evaluation of serum alpha-fetoprotein-IgM immune complexes on the diagnosis of primary hepatocellular carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2009, 23, 213-218.	0.9	10
727	Improved results of transplantation for hepatocellular carcinoma: A report from the international registry of hepatic tumors in liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 574-580.	1.3	66
728	Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre-model for end-stage liver disease eras and the independent impact of hepatitis C virus. <i>Liver Transplantation</i> , 2009, 15, 754-762.	1.3	24
729	Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. <i>Liver Transplantation</i> , 2009, 15, 1278-1287.	1.3	105
730	Contrast-enhanced sonography with abdominal virtual sonography in monitoring radiofrequency ablation of hepatocellular carcinoma. <i>Journal of Clinical Ultrasound</i> , 2010, 38, 138-144.	0.4	14
731	Preoperative prediction of poorly differentiated components in small-sized hepatocellular carcinoma for safe local ablation therapy. <i>Journal of Surgical Oncology</i> , 2009, 100, 121-126.	0.8	15
732	Liver tumor ablation: Percutaneous and open approaches. <i>Journal of Surgical Oncology</i> , 2009, 100, 619-634.	0.8	90

#	ARTICLE	IF	CITATIONS
733	Fascin expression in progression and prognosis of hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2009, 100, 575-579.	0.8	43
734	Liberal selection criteria for liver transplantation for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2009, 96, 785-791.	0.1	22
735	Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. <i>British Journal of Surgery</i> , 2009, 96, 975-981.	0.1	151
736	Inhibition of hepatitis B virus replication by small interference RNA induces expression of MICA in HepG2.2.15 cells. <i>Medical Microbiology and Immunology</i> , 2009, 198, 27-32.	2.6	19
737	Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 271-281.	1.2	14
738	Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 847-854.	1.2	33
739	A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 1437-1445.	1.2	122
740	The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. <i>Journal of Gastroenterology</i> , 2009, 44, 96-101.	2.3	195
741	Image-guided percutaneous ablation therapies for hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2009, 44, 122-131.	2.3	28
742	Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. <i>Journal of Gastroenterology</i> , 2009, 44, 483-491.	2.3	60
743	Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. <i>Journal of Gastroenterology</i> , 2009, 44, 635-642.	2.3	60
744	Brain metastases from hepatocellular carcinoma: prognostic factors and outcome. <i>Journal of Neuro-Oncology</i> , 2009, 91, 307-313.	1.4	103
745	Nanogram per milliliter-level immunologic detection of alpha-fetoprotein with integrated rotating-resonance microcantilevers for early-stage diagnosis of hepatocellular carcinoma. <i>Biomedical Microdevices</i> , 2009, 11, 183-191.	1.4	54
746	A Potential Targeting Gene Vector Based on Biotinylated Polyethyleneimine/Avidin Bioconjugates. <i>Pharmaceutical Research</i> , 2009, 26, 1931-1941.	1.7	15
747	Chemopreventive potential of Epoxy clerodane diterpene from <i>Tinospora cordifolia</i> against diethylnitrosamine-induced hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2009, 27, 347-355.	1.2	52
748	A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. <i>Hepatology International</i> , 2009, 3, 480-489.	1.9	22
749	Surgical treatment for hepatocellular carcinoma in cirrhotic patients. Guide to the selection and decision-making process in a context of multimodal strategy. <i>Clinical and Translational Oncology</i> , 2009, 11, 20-27.	1.2	3
750	Sonazoid-enhanced sonography for guiding radiofrequency ablation for hepatocellular carcinoma: better tumor visualization by Kupffer-phase imaging and vascular-phase imaging after reinjection. <i>Japanese Journal of Radiology</i> , 2009, 27, 185-193.	1.0	32



#	ARTICLE	IF	CITATIONS
751	Percutaneous Microwave Ablation of Liver Cancer Adjacent to the Gastrointestinal Tract. <i>Journal of Gastrointestinal Surgery</i> , 2009, 13, 318-324.	0.9	46
752	Prognostic Impact of Surgical Complications and Preoperative Serum Hepatocyte Growth Factor in Hepatocellular Carcinoma Patients After Initial Hepatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2009, 13, 325-333.	0.9	40
753	Hepatocellular Carcinoma: Resection or Transplantation. <i>Journal of Gastrointestinal Surgery</i> , 2009, 13, 1023-1025.	0.9	8
754	Is Liver Resection Justified in Advanced Hepatocellular Carcinoma? Results of an Observational Study in 464 Patients. <i>Journal of Gastrointestinal Surgery</i> , 2009, 13, 1313-1320.	0.9	69
755	Chromogenic In Situ Hybridization Analysis of Epidermal Growth Factor Receptor Gene/Chromosome 7 Numerical Aberrations in Hepatocellular Carcinoma Based on Tissue Microarrays. <i>Pathology and Oncology Research</i> , 2009, 15, 511-520.	0.9	8
756	Percutaneous image-guided radiofrequency ablation of liver tumors. <i>Abdominal Imaging</i> , 2009, 34, 547-556.	2.0	42
757	The immunosuppressive tumor microenvironment in hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 877-886.	2.0	50
758	Predicting Morbidity and Mortality After Hepatic Resection in Patients with Hepatocellular Carcinoma: The Role of Model for End-Stage Liver Disease Score. <i>World Journal of Surgery</i> , 2009, 33, 2412-2419.	0.8	68
759	Analysis of Nontarget Embolization Mechanisms During Embolization and Chemoembolization Procedures. <i>CardioVascular and Interventional Radiology</i> , 2009, 32, 615-622.	0.9	37
760	Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 473-483.	1.1	56
761	Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 497-507.	1.1	28
762	A copy number gain of the 6p arm is linked with advanced hepatocellular carcinoma: an array-based comparative genomic hybridization study. <i>Journal of Pathology</i> , 2009, 217, 677-684.	2.1	44
763	Immunotherapy for liver tumors: present status and future prospects. <i>Journal of Biomedical Science</i> , 2009, 16, 30.	2.6	23
764	Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats. <i>Cancer Science</i> , 2009, 100, 189-194.	1.7	33
765	Combination of peritumoral mast cells and T-regulatory cells predicts prognosis of hepatocellular carcinoma. <i>Cancer Science</i> , 2009, 100, 1267-1274.	1.7	68
766	Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. <i>Cancer Science</i> , 2009, 100, 2249-2254.	1.7	49
767	Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. <i>Journal of Viral Hepatitis</i> , 2009, 16, 453-463.	1.0	252
768	A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. <i>Nature Biotechnology</i> , 2009, 27, 264-274.	9.4	194

#	ARTICLE	IF	CITATIONS
769	Lin28 promotes transformation and is associated with advanced human malignancies. <i>Nature Genetics</i> , 2009, 41, 843-848.	9.4	742
770	Serum autoantibodies as biomarkers for early cancer detection. <i>FEBS Journal</i> , 2009, 276, 6880-6904.	2.2	272
771	Cross-species hybridization of woodchuck hepatitis viral infection-induced woodchuck hepatocellular carcinoma using human, rat and mouse oligonucleotide microarrays. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 605-617.	1.4	9
772	Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 800-805.	1.4	38
773	Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 815-820.	1.4	46
774	Combination therapy with transarterial chemoembolization and interferon- $\alpha$ compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1437-1444.	1.4	26
775	LAPAROSCOPIC RADIOFREQUENCY ABLATION FOR HEPATOCELLULAR CARCINOMA. <i>Digestive Endoscopy</i> , 2009, 21, 67-72.	1.3	27
776	Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and outwith Milan criteria. <i>Hpb</i> , 2009, 11, 398-404.	0.1	59
777	Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma. <i>Liver International</i> , 2009, 29, 203-207.	1.9	21
778	Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma. <i>Liver International</i> , 2010, 30, 1027-1032.	1.9	18
779	Hepatitis B and C virus-related carcinogenesis. <i>Clinical Microbiology and Infection</i> , 2009, 15, 964-970.	2.8	123
780	G-308A TNF- $\alpha$ polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: Case-control study. <i>Cancer Epidemiology</i> , 2009, 33, 261-264.	0.8	54
781	The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. <i>Biomaterials</i> , 2009, 30, 226-232.	5.7	262
782	Surgical aspects in management of hepato-pancreatico-biliary tumours in the elderly. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2009, 23, 919-923.	1.0	13
783	Preparation and Identification of Monoclonal Antibody Against Human Hepatocellular Carcinoma with a Novel Immunization. <i>Hybridoma</i> , 2009, 28, 43-50.	0.5	0
784	Comparison of Recurrence of Hepatocellular Carcinoma After Resection in Patients with Cirrhosis to Its Occurrence in a Surveilled Cirrhotic Population. <i>Annals of Surgical Oncology</i> , 2009, 16, 413-422.	0.7	178
785	Management of Early Hepatocellular Carcinoma in Patients with Well-Compensated Cirrhosis. <i>Annals of Surgical Oncology</i> , 2009, 16, 1820-1831.	0.7	48
786	Both Fibrous Capsule Formation and Extracapsular Penetration Are Powerful Predictors of Poor Survival in Human Hepatocellular Carcinoma: A Histological Assessment of 365 Patients in Japan. <i>Annals of Surgical Oncology</i> , 2009, 16, 2539-2546.	0.7	62

#	ARTICLE	IF	CITATIONS
787	Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 333-343.	0.9	165
789	Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005. <i>Journal of Clinical Oncology</i> , 2009, 27, 1485-1491.	0.8	1,489
790	High intensity focused ultrasound (HIFU) therapy for local treatment of hepatocellular carcinoma: Role of partial rib resection. <i>European Journal of Radiology</i> , 2009, 72, 160-166.	1.2	76
791	Epidermal growth factor receptor viii enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma. <i>Cancer Letters</i> , 2009, 279, 30-38.	3.2	42
792	Molecular pathogenesis and early detection of hepatocellular carcinoma – Perspectives from West Africa. <i>Cancer Letters</i> , 2009, 286, 44-51.	3.2	8
793	Ablation of phosphoinositide-3-kinase class II alpha suppresses hepatoma cell proliferation. <i>Biochemical and Biophysical Research Communications</i> , 2009, 387, 310-315.	1.0	19
794	Hepatic Resection for Hepatocellular Carcinoma Meeting Milan Criteria in Child-Turcotte-Pugh Class A Patients With Cirrhosis. <i>Transplantation Proceedings</i> , 2009, 41, 1691-1697.	0.3	35
795	Milan Criteria Versus San Francisco Criteria in Hepatocellular Carcinoma: Our Center's Experience. <i>Transplantation Proceedings</i> , 2009, 41, 1012-1013.	0.3	8
796	Predictive Factors of Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Multivariate Analysis. <i>Transplantation Proceedings</i> , 2009, 41, 1306-1309.	0.3	23
797	Liver Function as Assessed by Breath Tests in Patients With Hepatocellular Carcinoma. <i>Journal of Surgical Research</i> , 2009, 157, 199-207.	0.8	23
798	High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. <i>Human Pathology</i> , 2009, 40, 381-389.	1.1	191
799	Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. <i>Human Pathology</i> , 2009, 40, 834-842.	1.1	44
801	Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. <i>Journal of Hepatology</i> , 2009, 50, 388-393.	1.8	72
802	LIM and SH3 protein 1 (Lasp1) is a novel p53 transcriptional target involved in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2009, 50, 528-537.	1.8	55
803	Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo. <i>Journal of Hepatology</i> , 2009, 50, 1112-1121.	1.8	32
804	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. <i>Journal of Hepatology</i> , 2009, 51, 725-733.	1.8	206
805	Risk of recurrence in hepatitis B-related hepatocellular carcinoma: Impact of viral load in late recurrence. <i>Journal of Hepatology</i> , 2009, 51, 842-844.	1.8	33
806	Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. <i>Molecular Immunology</i> , 2009, 46, 1654-1662.	1.0	47

#	ARTICLE	IF	CITATIONS
807	Role of $\alpha$ -fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both?. <i>Future Oncology</i> , 2009, 5, 889-899.	1.1	30
808	Inhibition of matrix metalloproteinase expression by menatetrenone, a vitamin K2 analogue. <i>Oncology Reports</i> , 2009, 22, 599-604.	1.2	12
810	Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2009, 137, 682-690.	0.6	152
811	In Vitro Recapitulating of TP53 Mutagenesis in Hepatocellular Carcinoma Associated With Dietary Aflatoxin B1 Exposure. <i>Gastroenterology</i> , 2009, 137, 1127-1137.e5.	0.6	69
812	Phase II Study of Transarterial Holmium-166-Chitosan Complex Treatment in Patients with a Single, Large Hepatocellular Carcinoma. <i>Oncology</i> , 2009, 76, 1-9.	0.9	41
813	Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. <i>Molecular Cancer</i> , 2009, 8, 76.	7.9	87
814	Mitomycin C induces bystander killing in homogeneous and heterogeneous hepatoma cellular models. <i>Molecular Cancer</i> , 2009, 8, 87.	7.9	25
815	Role of hepatitis B surface antigen in the development of hepatocellular carcinoma: regulation of lymphoid enhancer-binding factor 1. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 58.	3.5	30
816	Leptomeningeal Dissemination. , 2008, , 1648-1651.		0
817	Preoperative Combined with Postoperative Chemoembolization Can Improve Survival in Patients with Hepatocellular Carcinoma: A Single-center Study. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 472-483.	0.2	9
818	Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional activation of hTERT. <i>Gut</i> , 2009, 58, 1528-1537.	6.1	51
819	Molecular markers and hepatocellular carcinoma: lending a helping hand in liver transplantation?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 211-213.	1.4	2
820	Molecular profiling to predict hepatocellular carcinoma outcome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 101-103.	1.4	37
821	Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 861-866.	0.6	35
822	Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2009, 92, 184-194.	0.3	132
823	Management of hepatocellular carcinoma in the age of liver transplantation. <i>International Journal of Surgery</i> , 2009, 7, 324-329.	1.1	3
824	Hypervascular Liver Lesions. <i>Seminars in Ultrasound, CT and MRI</i> , 2009, 30, 387-407.	0.7	57
825	Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2009, 10, 25-34.	5.1	5,104

#	ARTICLE	IF	CITATIONS
826	Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. <i>Lancet Oncology</i> , The, 2009, 10, 794-800.	5.1	287
827	Major achievements in hepatocellular carcinoma. <i>Lancet</i> , The, 2009, 373, 614-616.	6.3	275
828	Multicentric occurrence and spread of hepatocellular carcinoma in whole explanted end-stage liver. <i>Hepatology Research</i> , 2009, 39, 143-148.	1.8	11
829	Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. <i>Hepatology Research</i> , 2009, 39, 177-186.	1.8	308
830	Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma. <i>Hepatology Research</i> , 2009, 39, 553-562.	1.8	37
831	Clinical application of an enzyme-linked immunosorbent assay detecting hepatoma-specific $\gamma$ -glutamyltransferase. <i>Hepatology Research</i> , 2009, 39, 979-987.	1.8	10
832	Biotinylated disulfide containing PEI/avidin bioconjugate shows specific enhanced transfection efficiency in HepG2 cells. <i>Organic and Biomolecular Chemistry</i> , 2009, 7, 4201.	1.5	24
833	mTOR inhibitors for hepatocellular cancer: a forward-moving target. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 247-261.	1.1	74
834	<i>Interventional Oncology</i> , 2009, , 159-264.		1
835	Does Postembolization Fever after Chemoembolization Have Prognostic Significance for Survival in Patients with Unresectable Hepatocellular Carcinoma?. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 209-216.	0.2	36
836	The Role of Minimally Invasive Treatments in Surgical Oncology. <i>Surgical Clinics of North America</i> , 2009, 89, 53-77.	0.5	28
837	Selecting a Short-term Prognostic Model for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 773-781.	1.1	21
838	Development of Sunitinib in Hepatocellular Carcinoma: Rationale, Early Clinical Experience, and Correlative Studies. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 263-268.	1.0	33
839	Gingival Tumor as the First Sign of Advanced Hepatocellular Carcinoma on FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2009, 34, 72-73.	0.7	1
840	Pathogenesis of hepatocellular carcinoma and molecular therapies. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 186-194.	1.0	118
841	SELDI Protein Chip Technology for the Detection of Serum Biomarkers for Liver Disease. <i>Protein and Peptide Letters</i> , 2009, 16, 467-472.	0.4	15
842	Additional Value of SPIO-Enhanced MR Imaging for the Noninvasive Imaging Diagnosis of Hepatocellular Carcinoma in Cirrhotic Liver. <i>Investigative Radiology</i> , 2009, 44, 800-807.	3.5	20
843	A Somatostatin Analogue, Octreotide, Inhibits the Occurrence of Second Primary Tumors and Lung Metastasis after Resection of Hepatocellular Carcinoma in Mice. <i>Tohoku Journal of Experimental Medicine</i> , 2009, 218, 155-160.	0.5	15

#	ARTICLE	IF	CITATIONS
844	Nucleotide Analogs for Patients with HBV-Related Hepatocellular Carcinoma Increase the Survival Rate through Improved Liver Function. <i>Internal Medicine</i> , 2009, 48, 11-17.	0.3	43
845	Radiological diagnosis of hepatocellular carcinoma. , 0, , 33-50.		0
846	Diagnosis of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2009, 15, 1301.	1.4	140
847	Induction of apoptosis in human liver carcinoma HepG2 cell line by 5-allyl-7-gen-difluoromethylenechrysin. <i>World Journal of Gastroenterology</i> , 2009, 15, 2234.	1.4	24
848	Cryotherapy for hepatocellular carcinoma. <i>The Cochrane Library</i> , 2009, , CD007611.	1.5	8
849	Amperometric immunosensor for $\alpha$ -fetoprotein antigen in human serum based on co-immobilizing dinuclear copper complex and gold nanoparticle doped chitosan film. <i>Journal of Physics: Conference Series</i> , 2009, 188, 012047.	0.3	1
851	Modulation of the transforming growth factor- $\beta$ 1-induced Smad phosphorylation by the extracellular matrix receptor $\beta$ 1-integrin. <i>International Journal of Oncology</i> , 2009, 35, 1441-7.	1.4	8
852	Liver Resection for Transplantable Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2009, 250, 738-746.	2.1	247
853	Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 489-495.	1.1	146
854	Is Portal Hypertension a Contraindication to Hepatic Resection?. <i>Annals of Surgery</i> , 2009, 250, 922-928.	2.1	202
855	Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 391-398.	0.8	60
856	Consensus Report of the Third International Forum for Liver Magnetic Resonance Imaging. <i>Investigative Radiology</i> , 2010, 45, S1-S10.	3.5	4
858	Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. <i>Anti-Cancer Drugs</i> , 2010, 21, 326-332.	0.7	48
859	Chemoembolization for Primary and Metastatic Liver Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2010, 16, 156-162.	1.0	33
860	Transcatheter Arterial Chemoembolization of the Liver. <i>Contemporary Diagnostic Radiology</i> , 2010, 33, 1-5.	0.1	1
862	Meta-analysis of the Therapeutic Effect of Hepatectomy Versus Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2010, 20, 130-140.	0.4	40
863	Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro. <i>International Journal of Oncology</i> , 2010, 36, 841-8.	1.4	35
864	Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2010, 16, 3521.	1.4	32

#	ARTICLE	IF	CITATIONS
865	Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization. <i>World Journal of Gastroenterology</i> , 2010, 16, 3161.	1.4	44
866	HSG provides antitumor efficacy on hepatocellular carcinoma both in vitro and in vivo. <i>Oncology Reports</i> , 2010, 24, .	1.2	10
867	Sorafenib in hepatocellular carcinoma. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2010, 71, 451-456.	0.2	14
868	Diagnostic value of serum haptoglobin protein as hepatocellular carcinoma candidate marker complementary to Î± fetoprotein. <i>Oncology Reports</i> , 2010, 24, 1271-6.	1.2	28
869	Antibody Therapies for Liver Malignancy and Transplantation. , 2010, , 13-30.		0
870	The Genotypes of IL-1 beta and MMP-3 are Associated with the Prognosis of HCV-related Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2010, 49, 887-895.	0.3	54
871	Effect of acute hepatic failure on the hepatic first-pass effect of 5-fluorouracil in rats. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 598-603.	1.2	6
872	Intra-Arterial Therapies for Hepatocellular Carcinoma: Where Do We Stand?. <i>Annals of Surgical Oncology</i> , 2010, 17, 1234-1246.	0.7	80
873	Health Insurance Status Affects Staging and Influences Treatment Strategies in Patients with Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2010, 17, 3104-3111.	0.7	38
874	Recurrence and Treatment Pattern in Long-Term Survivors with Hepatocellular Carcinoma: A Comparison between Radiofrequency Ablation and Surgery as a First-Line Treatment. <i>World Journal of Surgery</i> , 2010, 34, 1881-1886.	0.8	11
875	Prognostic Impact of Underlying Liver Fibrosis and Cirrhosis After Curative Resection of Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2010, 34, 2442-2451.	0.8	31
876	Prognostic Factors and Outcome of 438 Chinese Patients with Hepatocellular Carcinoma Underwent Partial Hepatectomy in a Single Center. <i>World Journal of Surgery</i> , 2010, 34, 2434-2441.	0.8	24
877	Bland Embolization in Patients with Unresectable Hepatocellular Carcinoma Using Precise, Tightly Size-Calibrated, Anti-Inflammatory Microparticles: First Clinical Experience and One-Year Follow-Up. <i>CardioVascular and Interventional Radiology</i> , 2010, 33, 552-559.	0.9	90
878	A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 373-382.	1.1	55
879	Î²-catenin signaling involves HGF-enhanced HepG2 scattering through activating MMP-7 transcription. <i>Histochemistry and Cell Biology</i> , 2010, 134, 285-295.	0.8	12
880	Prognostic factors affecting survival and recurrence after hepatic resection for hepatocellular carcinoma in cirrhotic liver. <i>Langenbeck's Archives of Surgery</i> , 2010, 395, 625-632.	0.8	56
881	Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 267-274.	1.2	50
882	LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 275-281.	1.2	61

#	ARTICLE	IF	CITATIONS
883	Long-term interferon- $\alpha$ treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1891-1900.	1.2	12
884	Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. <i>International Journal of Clinical Oncology</i> , 2010, 15, 544-551.	1.0	54
885	Efficacy and safety of viscum fraxini-2 in advanced hepatocellular carcinoma: a phase II study. <i>Chinese-German Journal of Clinical Oncology</i> , 2010, 9, 452-458.	0.1	1
886	Laparoscopic resection for hepatocellular carcinoma: a matched-pair comparative study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2010, 24, 1170-1176.	1.3	245
887	Liver transplantation for hepatocellular carcinoma: the Baylor experience. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010, 17, 559-566.	1.4	14
888	Medical treatments: in association or alone, their roles and their future perspectives. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010, 17, 420-421.	1.4	1
889	Perioperative change in white blood cell count predicts outcome of hepatic resection for hepatocellular carcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010, 17, 892-897.	1.4	8
890	Transcatheter arterial infusion chemotherapy with cisplatin $\alpha$ lipiodol suspension in patients with hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2010, 45, 60-67.	2.3	23
891	Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2010, 45, 146-152.	2.3	74
892	Novel combinational treatment of cisplatin with cyclophilin a inhibitors in human hepatocellular carcinomas. <i>Archives of Pharmacal Research</i> , 2010, 33, 1401-1409.	2.7	22
893	The Prevalence of the Mutation in Codon 249 of the P53 Gene in Patients with Hepatocellular Carcinoma (HCC) in Turkey. <i>Journal of Gastrointestinal Cancer</i> , 2010, 41, 185-189.	0.6	10
894	Sequential Therapy of Transarterial Chemoembolisation and Sorafenib in Intermediate Stage Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2010, 41, 149-152.	0.6	4
895	GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. <i>Medical Oncology</i> , 2010, 27, 339-345.	1.2	66
896	Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. <i>Hepatology International</i> , 2010, 4, 439-474.	1.9	944
897	Effect of surveillance for hepatocellular carcinoma on tumor staging and treatment decisions in Egyptian patients. <i>Hepatology International</i> , 2010, 4, 500-506.	1.9	29
898	Current Management of Hepatocellular Cancer. <i>Current Oncology Reports</i> , 2010, 12, 186-192.	1.8	42
899	High Hepatitis B Viral Load Predicts Recurrence of Small Hepatocellular Carcinoma after Curative Resection. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 1111-1120.	0.9	67
900	FAK is involved in invasion and metastasis of hepatocellular carcinoma. <i>Clinical and Experimental Metastasis</i> , 2010, 27, 71-82.	1.7	103



#	ARTICLE	IF	CITATIONS
901	Delisheng, a Chinese medicinal compound, exerts anti-proliferative and pro-apoptotic effects on HepG2 cells through extrinsic and intrinsic pathways. <i>Molecular Biology Reports</i> , 2010, 37, 3407-3412.	1.0	18
902	Suppression of the Inflammatory Cascade is Implicated in Resveratrol Chemoprevention of Experimental Hepatocarcinogenesis. <i>Pharmaceutical Research</i> , 2010, 27, 1080-1091.	1.7	74
903	Hepatocellular Carcinoma Immunopathogenesis: Clinical Evidence for Global T Cell Defects and an Immunomodulatory Role for Soluble CD25 (sCD25). <i>Digestive Diseases and Sciences</i> , 2010, 55, 484-495.	1.1	34
904	Ultrasound-Guided Percutaneous Microwave Coagulation Therapy with a "Cooled-tip Needle" for the Treatment of Hepatocellular Carcinoma Adjacent to the Gallbladder. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2664-2669.	1.1	8
905	Hepatocellular Carcinoma: Current Management. <i>Current Problems in Surgery</i> , 2010, 47, 10-67.	0.6	65
906	Cryoablation induces greater inflammatory and coagulative responses than radiofrequency ablation or laser induced thermotherapy in a rat liver model. <i>Surgery</i> , 2010, 147, 686-695.	1.0	97
907	Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2010, 10, 317.	1.1	39
908	Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. <i>Stereotactic radiotherapy for liver cancer</i> . <i>BMC Cancer</i> , 2010, 10, 475.	1.1	219
909	Repeat hepatectomy for recurrent hepatocellular carcinoma: a local experience and a systematic review. <i>World Journal of Surgical Oncology</i> , 2010, 8, 55.	0.8	97
910	Lactosaminated human albumin, a hepatotropic carrier of drugs. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 40, 253-262.	1.9	31
911	Expression of Sonic Hedgehog Signaling Components in Hepatocellular Carcinoma and Cyclopamine-induced Apoptosis Through Bcl-2 Downregulation In Vitro. <i>Archives of Medical Research</i> , 2010, 41, 315-323.	1.5	42
912	Molecularly targeted therapy in hepatocellular carcinoma. <i>Biochemical Pharmacology</i> , 2010, 80, 550-560.	2.0	110
913	Obesity, Inflammatory Signaling, and Hepatocellular Carcinoma—An Enlarging Link. <i>Cancer Cell</i> , 2010, 17, 115-117.	7.7	47
914	Kinases as targets in the treatment of solid tumors. <i>Cellular Signalling</i> , 2010, 22, 984-1002.	1.7	88
915	Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma. <i>Cancer</i> , 2010, 116, 4069-4077.	2.0	24
916	Progenitor-derived hepatocellular carcinoma model in the rat. <i>Hepatology</i> , 2010, 51, 1401-1409.	3.6	118
917	Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. <i>Hepatology</i> , 2010, 52, 142-154.	3.6	69
918	Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. <i>Hepatology</i> , 2010, 52, 518-527.	3.6	265

#	ARTICLE	IF	CITATIONS
919	Small molecule antagonists of Tcf4/ $\beta$ -catenin complex inhibit the growth of HCC cells <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2010, 126, 2426-2436.	2.3	113
920	Soluble glypican 3 inhibits the growth of hepatocellular carcinoma <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2010, 126, 1291-1301.	2.3	87
921	LAPTM4B $\beta$ 35 is a novel prognostic factor of hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2010, 101, 363-369.	0.8	49
922	Recent advances in the management of primary hepatic tumors refinement of surgical techniques and effect on outcome. <i>Journal of Surgical Oncology</i> , 2010, 101, 745-754.	0.8	14
923	Is it time to reconsider the BCLC/AASLD therapeutic flowchart?. <i>Journal of Surgical Oncology</i> , 2010, 102, 868-876.	0.8	24
924	Interferon $\alpha$ 1 therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2010, 102, 796-801.	0.8	34
925	Contrast-enhanced sonography-guided radiofrequency ablation for the local recurrence of previously treated hepatocellular carcinoma undetected by $\beta$ -mode sonography. <i>Journal of Clinical Ultrasound</i> , 2010, 38, 339-345.	0.4	17
926	Prevention of intrahepatic metastasis of liver cancer by suicide gene therapy and chemokine ligand 2/monocyte chemoattractant protein $\beta$ 1 delivery in mice. <i>Journal of Gene Medicine</i> , 2010, 12, 1002-1013.	1.4	25
927	Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. <i>Liver Transplantation</i> , 2010, 16, 1186-1194.	1.3	52
928	Polyethylene sebacate-doxorubicin nanoparticles for hepatic targeting. <i>International Journal of Pharmaceutics</i> , 2010, 401, 113-122.	2.6	67
929	The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model. <i>Biomaterials</i> , 2010, 31, 916-922.	5.7	73
930	Stereotactic Body Radiotherapy: A Review. <i>Clinical Oncology</i> , 2010, 22, 157-172.	0.6	128
931	Inherited hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 725-734.	1.0	28
932	Emerging role of small ribonucleic acids in gastrointestinal tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 76, 173-185.	2.0	0
933	Is Local Radiotherapy Still Valuable for Patients With Multiple Intrahepatic Hepatocellular Carcinomas?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1433-1440.	0.4	18
934	Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2010, 10, 78.	0.8	158
935	Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4. <i>Comparative Hepatology</i> , 2010, 9, 1.	0.9	31
936	Prospective evaluation of microscopic extension using whole-mount preparation in patients with hepatocellular carcinoma: Definition of clinical target volume for radiotherapy. <i>Radiation Oncology</i> , 2010, 5, 73.	1.2	31

#	ARTICLE	IF	CITATIONS
937	The loss of phenol sulfotransferase 1 in hepatocellular carcinogenesis. <i>Proteomics</i> , 2010, 10, 266-276.	1.3	15
938	Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. <i>Hpb</i> , 2010, 12, 313-320.	0.1	68
939	Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre. <i>Hpb</i> , 2010, 12, 637-643.	0.1	8
940	HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. <i>Liver International</i> , 2010, 30, 1461-1470.	1.9	67
941	Proteomic mining in the dysplastic liver of WHV/c-myc mice – insights and indicators for early hepatocarcinogenesis. <i>FEBS Journal</i> , 2010, 277, 4039-4053.	2.2	23
942	Influence of hepatic artery occlusion on tumor growth and metastatic potential in a human orthotopic hepatoma nude mouse model: Relevance of epithelial-mesenchymal transition. <i>Cancer Science</i> , 2010, 101, 120-128.	1.7	46
943	Epithelial-mesenchymal transition gene signature to predict clinical outcome of hepatocellular carcinoma. <i>Cancer Science</i> , 2010, 101, 1521-1528.	1.7	45
944	Review article: the management of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 461-476.	1.9	174
945	Systematic review: the association between obesity and hepatocellular carcinoma – epidemiological evidence. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1051-1063.	1.9	95
946	Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 543-550.	1.9	37
947	The unexpected role of lymphotoxin $\beta_2$ receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development. <i>Oncogene</i> , 2010, 29, 5006-5018.	2.6	86
948	Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma. <i>Gene Therapy</i> , 2010, 17, 692-708.	2.3	69
949	Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 129-137.	1.4	99
950	Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: Results and prognostic factors on long-term follow up. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 597-604.	1.4	72
951	Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 951-956.	1.4	28
952	Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1435-1442.	1.4	25
953	Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1426-1434.	1.4	28
954	Optimal management of hepatocellular carcinoma: Challenges and opportunities. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1336-1338.	1.4	10

#	ARTICLE	IF	CITATIONS
955	Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis. <i>Transplant International</i> , 2010, 23, 662-667.	0.8	27
956	Transarterial embolization ablation of hepatocellular carcinoma with a lipiodol-ethanol mixture. <i>World Journal of Gastroenterology</i> , 2010, 16, 5766.	1.4	14
957	System biology analysis of cell cycle pathway involved in hepatocellular carcinoma. <i>Frontiers in Bioscience - Scholar</i> , 2010, S2, 1127-1144.	0.8	8
958	Multimodal therapy for hepatocellular carcinoma: A complementary approach to liver transplantation. <i>Annals of Hepatology</i> , 2010, 9, 23-32.	0.6	12
960	Diagnosis and Management of Hepatocellular Carcinoma: Results of a Consensus Meeting of The Ottawa Hospital Cancer Centre. <i>Current Oncology</i> , 2010, 17, 6-12.	0.9	6
961	Transarterial Radioembolization with Yttrium-90 for Regional Management of Hepatocellular Cancer: The Early Results of a Nontransplant Center. <i>American Surgeon</i> , 2010, 76, 1079-1083.	0.4	1
962	Does Surgical Resection Have a Role in the Treatment of Large or Multinodular Hepatocellular Carcinoma?. <i>American Surgeon</i> , 2010, 76, 1189-1197.	0.4	18
963	Hepatocellular carcinoma " diagnostic dilemmas. <i>Przeład Gastroenterologiczny</i> , 2010, 2, 61-67.	0.3	0
964	&lt;i>Chlorella vulgaris&lt;/i> modulates hydrogen peroxide-induced dna damage and telomere shortening of human fibroblasts derived from different aged individuals. <i>Tropical Journal of Obstetrics and Gynaecology</i> , 2010, 6, 560-72.	0.3	8
965	Overexpression of Cyclooxygenase-2 in Noncancerous Liver Tissue Increases the Postoperative Recurrence of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Related Cirrhosis. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2010, 24, 435-440.	1.8	12
966	Male-biased genes of <i>Drosophila melanogaster</i> that are conserved in mammalian testis. <i>Frontiers in Bioscience - Elite</i> , 2010, E2, 668.	0.9	0
967	Tratamiento quir&#225;rgico en hepatocarcinoma: Experiencia preliminar. <i>Revista Chilena De Cirugia</i> , 2010, 62, .	0.1	0
968	Management of ruptured hepatocellular carcinoma: Implications for therapy. <i>World Journal of Gastroenterology</i> , 2010, 16, 1221.	1.4	56
969	Long-lasting Response with Metronomic Capecitabine in Advanced Hepatocellular Carcinoma. <i>Tumori</i> , 2010, 96, 768-770.	0.6	11
970	Hepatocellular carcinoma in thalassemia: A critical review. <i>World Journal of Hepatology</i> , 2010, 2, 171.	0.8	51
971	Antitumor effect of matrine in human hepatoma G2 cells by inducing apoptosis and autophagy. <i>World Journal of Gastroenterology</i> , 2010, 16, 4281.	1.4	120
972	Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis. <i>Brazilian Journal of Infectious Diseases</i> , 2010, 14, 457-461.	0.3	7
973	Sigmoid colon metastasis from hepatocellular carcinoma. <i>The Korean Journal of Hepatology</i> , 2010, 16, 397.	1.5	13

#	ARTICLE	IF	CITATIONS
974	Sorafenib for the treatment of advanced hepatocellular carcinoma. Health Technology Assessment, 2010, 14, 17-21.	1.3	29
975	Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Experimental Biology and Medicine, 2010, 235, 32-39.	1.1	32
976	The Challenge of Prognosis and Staging for Hepatocellular Carcinoma. Oncologist, 2010, 15, 23-33.	1.9	121
977	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers. Clinical Chemistry, 2010, 56, e1-e48.	1.5	184
978	High Expression of Macrophage Colony-Stimulating Factor-1 Receptor in Peritumoral Liver Tissue Is Associated with Poor Outcome in Hepatocellular Carcinoma After Curative Resection. Oncologist, 2010, 15, 732-743.	1.9	50
979	Irreversible Electroporation Therapy in the Liver: Longitudinal Efficacy Studies in a Rat Model of Hepatocellular Carcinoma. Cancer Research, 2010, 70, 1555-1563.	0.4	165
980	Activation of $\beta$ -Catenin by Hypoxia in Hepatocellular Carcinoma Contributes to Enhanced Metastatic Potential and Poor Prognosis. Clinical Cancer Research, 2010, 16, 2740-2750.	3.2	161
981	Over-Expression of the <i>Endocan</i> Gene in Endothelial Cells from Hepatocellular Carcinoma is Associated with Angiogenesis and Tumour Invasion. Journal of International Medical Research, 2010, 38, 498-510.	0.4	71
982	A Seven-Gene Set Associated with Chronic Hypoxia of Prognostic Importance in Hepatocellular Carcinoma. Clinical Cancer Research, 2010, 16, 4278-4288.	3.2	56
983	The Screening of Volatile Markers for Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2247-2253.	1.1	71
984	The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. Oncologist, 2010, 15, 5-13.	1.9	817
985	Stereotactic Radiotherapy of Hepatocellular Carcinoma: Preliminary Results. Technology in Cancer Research and Treatment, 2010, 9, 479-487.	0.8	107
986	New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers. Clinical Cancer Research, 2010, 16, 4688-4694.	3.2	114
987	A comparison of the cytotoxic potential of standardized aqueous and ethanolic extracts of a polyherbal mixture comprised of <i>Nigella sativa</i> (seeds), <i>Hemidesmus indicus</i> (roots) and <i>Smilax glabra</i> (rhizome). Pharmacognosy Research (discontinued), 2010, 2, 335.	0.3	48
988	Transarterial embolisation of hepatocellular carcinoma with doxorubicin-eluting beads: single centre early experience. Biomedical Imaging and Intervention Journal, 2010, 6, e7.	0.5	16
989	The Significance of Fibroblast Growth Factor Receptor 2 Expression in Differentiation of Hepatocellular Carcinoma. Oncology, 2010, 78, 361-368.	0.9	41
990	Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements. Seminars in Liver Disease, 2010, 30, 035-051.	1.8	267
991	G $\beta$ 12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation. Carcinogenesis, 2010, 31, 1230-1237.	1.3	21

#	ARTICLE	IF	CITATIONS
992	Current Approaches to the Treatment of Early Hepatocellular Carcinoma. <i>Oncologist</i> , 2010, 15, 34-41.	1.9	50
993	Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection. <i>Gut</i> , 2010, 59, 1699-1708.	6.1	48
994	Integrative and Functional Genomics of HCC. , 2010, , 221-240.		0
995	<i>Nf2</i> /Merlin controls progenitor homeostasis and tumorigenesis in the liver. <i>Genes and Development</i> , 2010, 24, 1718-1730.	2.7	233
996	CT and MRI of hepatocellular carcinoma: an update. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 507-519.	1.1	31
997	Glutamine Synthetase Immunostaining Correlates with Pathologic Features of Hepatocellular Carcinoma and Better Survival after Radiofrequency Thermal Ablation. <i>Clinical Cancer Research</i> , 2010, 16, 2157-2166.	3.2	67
998	An Integrated Genomic and Epigenomic Approach Predicts Therapeutic Response to Zebularine in Human Liver Cancer. <i>Science Translational Medicine</i> , 2010, 2, 54ra77.	5.8	92
999	Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 41-49.	8.2	47
1000	Safety and Feasibility of Using Sorafenib in Recurrent Hepatocellular Carcinoma after Orthotopic Liver Transplantation. <i>Oncology</i> , 2010, 79, 62-66.	0.9	48
1001	Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. <i>Journal of Clinical Oncology</i> , 2010, 28, 1660-1665.	0.8	424
1002	Hypofractionated Stereotactic Body Radiotherapy for Primary and Metastatic Liver Tumors Using the Novalis Image-Guided System: Preliminary Results regarding Efficacy and Toxicity. <i>Technology in Cancer Research and Treatment</i> , 2010, 9, 619-627.	0.8	29
1003	A Hypoxia- and $\text{HIF-1}\alpha$ -Fetoprotein-Dependent Oncolytic Adenovirus Exhibits Specific Killing of Hepatocellular Carcinomas. <i>Clinical Cancer Research</i> , 2010, 16, 6071-6082.	3.2	45
1004	Contrast-Enhanced Ultrasound Techniques for Guiding and Assessing Response to Locoregional Treatments for Hepatocellular Carcinoma. <i>Oncology</i> , 2010, 78, 68-77.	0.9	11
1005	Chemoembolization for Unresectable Hepatocellular Carcinoma in Japan. <i>Oncology</i> , 2010, 78, 135-141.	0.9	12
1006	Treatment of Advanced Hepatocellular Carcinoma: Intraarterial Infusion Chemotherapy Combined with Interferon. <i>Oncology</i> , 2010, 78, 142-147.	0.9	34
1007	Positioning and Indication of Sorafenib in the Treatment Algorithm and Real Practice Setting: Western and Eastern Approach – Asian Perspective. <i>Oncology</i> , 2010, 78, 167-171.	0.9	12
1008	Rapid Regression of Advanced Hepatocellular Carcinoma Associated with Elevation of Des-Gamma-Carboxy Prothrombin after Short-Term Treatment with Sorafenib – A Report of Two Cases. <i>Case Reports in Oncology</i> , 2010, 3, 298-303.	0.3	18
1009	Platelet count less than SHARP: what does a case series reveal?. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 1-8.	1.0	5

#	ARTICLE	IF	CITATIONS
1010	Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. <i>Acta Pharmacologica Sinica</i> , 2010, 31, 1643-1648.	2.8	40
1011	Automated Retrieval of CT Images of Liver Lesions on the Basis of Image Similarity: Method and Preliminary Results. <i>Radiology</i> , 2010, 256, 243-252.	3.6	92
1012	Overexpression of High-Mobility Group Box 2 Is Associated with Tumor Aggressiveness and Prognosis of Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2010, 16, 5511-5521.	3.2	63
1013	Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. <i>International Journal of Molecular Medicine</i> , 2010, 26, 735-41.	1.8	91
1015	Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2010, 30, 052-060.	1.8	3,250
1016	Networks Inferred from Biochemical Data Reveal Profound Differences in Toll-like Receptor and Inflammatory Signaling between Normal and Transformed Hepatocytes. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 1849-1865.	2.5	95
1017	Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies. <i>Epigenomics</i> , 2010, 2, 233-243.	1.0	23
1018	Hepatocyte Nuclear Factor 4 $\beta$ Suppresses the Development of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2010, 70, 7640-7651.	0.4	205
1020	Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma. <i>Acta Pharmacologica Sinica</i> , 2010, 31, 1165-1171.	2.8	45
1021	Tumors of the Liver and Intrahepatic Bile Ducts: Radiologic Pathologic Correlation. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2010, 18, 587-609.	0.6	13
1022	Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis. <i>Brazilian Journal of Infectious Diseases</i> , 2010, 14, 457-461.	0.3	12
1023	Recurrent hepatocellular carcinoma cells with stem cell-like properties: possible targets for immunotherapy. <i>Cytotherapy</i> , 2010, 12, 190-200.	0.3	14
1024	Arterial Patency after Repeated Hepatic Artery Bland Particle Embolization. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 522-526.	0.2	34
1025	Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. <i>Acta Pharmacologica Sinica</i> , 2010, 31, 1409-1420.	2.8	150
1026	Tyrosine kinase inhibitors to treat liver cancer. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 13-26.	1.0	20
1027	Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: Survival rate and prognostic factors. <i>Digestive and Liver Disease</i> , 2010, 42, 515-519.	0.4	17
1028	Engineered Newcastle Disease Virus as an Improved Oncolytic Agent Against Hepatocellular Carcinoma. <i>Molecular Therapy</i> , 2010, 18, 275-284.	3.7	78
1029	Hepatic Tumor Ablation. <i>Surgical Clinics of North America</i> , 2010, 90, 863-876.	0.5	25

#	ARTICLE	IF	CITATIONS
1030	Current Approach to Hepatocellular Carcinoma. <i>Surgical Clinics of North America</i> , 2010, 90, 803-816.	0.5	55
1031	Exploration of Potential Genomic Portraits Associated with Intrahepatic Recurrence in Human Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2010, 17, 3145-3154.	0.7	3
1032	Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. <i>Molecular Cancer</i> , 2010, 9, 74.	7.9	70
1033	Differentiating the impact of anatomic and non-anatomic liver resection on early recurrence in patients with Hepatocellular Carcinoma. <i>World Journal of Surgical Oncology</i> , 2010, 8, 43.	0.8	25
1034	Surveillance and early diagnosis of hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2010, 42, S223-S227.	0.4	25
1035	Treatment of early hepatocellular carcinoma: How to predict and prevent recurrence. <i>Digestive and Liver Disease</i> , 2010, 42, S249-S257.	0.4	24
1036	Molecular approaches to treatment of hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2010, 42, S264-S272.	0.4	75
1037	Does chemotherapy prevent HCV-related hepatocellular carcinoma? <i>Cons. Digestive and Liver Disease</i> , 2010, 42, S287-S292.	0.4	4
1038	Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. <i>Gastroenterology</i> , 2010, 138, 52-64.	0.6	925
1039	Preparation of <sup>177</sup> Lu-Labeled Oxine in Lipiodol as a Possible Agent for Therapy of Hepatocellular Carcinoma: A Preliminary Animal Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 539-543.	0.7	17
1040	Tricetin, a Dietary Flavonoid, Induces Apoptosis through the Reactive Oxygen Species/c-Jun NH <sub>2</sub> -Terminal Kinase Pathway in Human Liver Cancer Cells. <i>Journal of Agricultural and Food Chemistry</i> , 2010, 58, 12547-12556.	2.4	30
1041	Increased liver-infiltrating CD8 <sup>+</sup> FoxP3 <sup>+</sup> regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients. <i>Human Immunology</i> , 2010, 71, 1180-1186.	1.2	54
1042	The fusion protein of HSP65 with tandem repeats of $\hat{I}^2$ -hCG acting as a potent tumor vaccine in suppressing hepatocarcinoma. <i>International Immunopharmacology</i> , 2010, 10, 230-238.	1.7	11
1043	The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2010, 52, 63-71.	1.8	70
1044	Risk of HCC: Genetic heterogeneity and complex genetics. <i>Journal of Hepatology</i> , 2010, 52, 252-257.	1.8	194
1045	Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: A meta-analysis. <i>Journal of Hepatology</i> , 2010, 52, 380-388.	1.8	264
1046	Cancer gene discovery in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2010, 52, 921-929.	1.8	173
1047	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. <i>Journal of Hepatology</i> , 2010, 52, 550-559.	1.8	211



#	ARTICLE	IF	CITATIONS
1048	A new prognostic model for hepatocellular carcinoma based on total tumor volume: The Taipei Integrated Scoring system. <i>Journal of Hepatology</i> , 2010, 53, 108-117.	1.8	157
1049	Risk assessment for the development of hepatocellular carcinoma: According to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. <i>Journal of Hepatology</i> , 2010, 53, 118-125.	1.8	114
1050	Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. <i>Journal of Hepatology</i> , 2010, 53, 291-297.	1.8	281
1051	Genomic tracing of the elusive liver cancer ancestor. <i>Journal of Hepatology</i> , 2010, 53, 578-579.	1.8	1
1052	Epigenetic regulation of cancer stem cells in liver cancer: Current concepts and clinical implications. <i>Journal of Hepatology</i> , 2010, 53, 568-577.	1.8	96
1054	The adenovirus-mediated linamarase/linamarin suicide system: A potential strategy for the treatment of hepatocellular carcinoma. <i>Cancer Letters</i> , 2010, 289, 217-227.	3.2	16
1055	Interferon alpha inhibits hepatocellular carcinoma growth through inducing apoptosis and interfering with adhesion of tumor endothelial cells. <i>Cancer Letters</i> , 2010, 290, 204-210.	3.2	25
1056	Overexpression of LPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. <i>Cancer Letters</i> , 2010, 294, 236-244.	3.2	69
1057	Icariin, a natural flavonol glycoside, induces apoptosis in human hepatoma SMMC-7721 cells via a ROS/JNK-dependent mitochondrial pathway. <i>Cancer Letters</i> , 2010, 298, 222-230.	3.2	134
1059	Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. <i>Cancer Treatment Reviews</i> , 2010, 36, 43-53.	3.4	175
1060	Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. <i>European Journal of Cancer</i> , 2010, 46, 744-751.	1.3	91
1061	The efficacy of intraperitoneal saline infusion for percutaneous radiofrequency ablation for hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2010, 74, 536-540.	1.2	16
1062	A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. <i>European Journal of Surgical Oncology</i> , 2010, 36, 257-263.	0.5	56
1063	Radiofrequency ablation as first-line treatment for small solitary hepatocellular carcinoma: Long-term results. <i>European Journal of Surgical Oncology</i> , 2010, 36, 1054-1060.	0.5	50
1064	Reexpression of ARHI inhibits tumor growth and angiogenesis and impairs the mTOR/VEGF pathway in hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2010, 403, 417-421.	1.0	27
1065	Methylated cyclin D2 gene circulating in the blood as a prognosis predictor of hepatocellular carcinoma. <i>Clinica Chimica Acta</i> , 2010, 411, 516-520.	0.5	28
1066	Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. <i>Pathologie Et Biologie</i> , 2010, 58, 273-277.	2.2	233
1067	Bridge Therapy in Hepatocellular Carcinoma Before Liver Transplantation: The Experience of Two Chilean Centers. <i>Transplantation Proceedings</i> , 2010, 42, 296-298.	0.3	1

#	ARTICLE	IF	CITATIONS
1068	Patients With Unresectable Hepatocellular Carcinoma Beyond Milan Criteria: Should We Perform Transarterial Chemoembolization or Liver Transplantation?. <i>Transplantation Proceedings</i> , 2010, 42, 821-824.	0.3	14
1069	Apurinic Apyrimidinic Endonuclease/Redox Effector Factor 1 Immunoreactivity and Grading in Hepatocellular Carcinoma Risk of Relapse After Liver Transplantation. <i>Transplantation Proceedings</i> , 2010, 42, 1204-1208.	0.3	9
1070	Hepatocellular Carcinoma in Unrelated Viral Cirrhosis: Long-Term Results After Liver Transplantation. <i>Transplantation Proceedings</i> , 2010, 42, 1212-1215.	0.3	4
1071	Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy. <i>Annual Review of Medicine</i> , 2010, 61, 317-328.	5.0	229
1072	Expansion of CD4 <sup>+</sup> CD25 <sup>+</sup> FoxP3 <sup>+</sup> regulatory T cells in hepatitis C virus-related chronic hepatitis, cirrhosis and hepatocellular carcinoma. <i>Hepatology Research</i> , 2010, 40, 179-187.	1.8	31
1073	Combination of transarterial chemoembolization and percutaneous local ablation therapy for hepatocellular carcinoma. <i>Hepatology Research</i> , 2010, 40, 105-107.	1.8	1
1074	Chemokine CCL3 facilitates the migration of hepatoma cells by changing the concentration intracellular Ca <sup>2+</sup> . <i>Hepatology Research</i> , 2010, 40, 424-431.	1.8	10
1075	Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice. <i>Hepatology Research</i> , 2010, 40, 540-549.	1.8	19
1076	Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). <i>Hepatology Research</i> , 2010, 40, 667-685.	1.8	154
1077	Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis. <i>Hepatology Research</i> , 2010, 40, 943-953.	1.8	94
1078	Oleanolic Acid and Ursolic Acid Induce Apoptosis in HuH7 Human Hepatocellular Carcinoma Cells through a Mitochondrial-Dependent Pathway and Downregulation of XIAP. <i>Journal of Agricultural and Food Chemistry</i> , 2010, 58, 6110-6118.	2.4	162
1079	Neuroradiologie et radiologie digestive interventionnelles. <i>Actualites Pharmaceutiques Hospitalieres</i> , 2010, 6, 47-50.	0.1	0
1080	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2010, 53, 126-131.	1.8	124
1081	Comparison of efficacy and toxicity of short-course carbon ion radiotherapy for hepatocellular carcinoma depending on their proximity to the porta hepatis. <i>Radiotherapy and Oncology</i> , 2010, 96, 231-235.	0.3	73
1082	Chemoembolization Follow-up of Hepatocellular Carcinoma with MR Imaging: Usefulness of Evaluating Enhancement Features on One-month Posttherapy MR Imaging for Predicting Residual Disease. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1396-1404.	0.2	14
1083	The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2010, 298, R459-R466.	0.9	35
1084	Transcription factor c-Myb promotes the invasion of hepatocellular carcinoma cells via increasing osteopontin expression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 172.	3.5	21
1085	Coronin-1C is a novel biomarker for hepatocellular carcinoma invasive progression identified by proteomics analysis and clinical validation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 17.	3.5	41

#	ARTICLE	IF	CITATIONS
1086	Tumor doubling time after initial response to transarterial chemoembolization in patients with hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 332-339.	0.6	20
1087	Hepatocellular Carcinoma: CT for Tumor Response after Transarterial Chemoembolization in Patients Exceeding Milan Criteriaâ€”Selection Parameter for Liver Transplantation. <i>Radiology</i> , 2010, 255, 289-300.	3.6	62
1088	Application of Quantum Dots-Based Biotechnology in Cancer Diagnosis: Current Status and Future Perspectives. <i>Journal of Nanomaterials</i> , 2010, 2010, 1-11.	1.5	366
1089	A study on the thermochemotherapy effect of nanosized As <sub>2</sub> O <sub>3</sub> /MZF thermosensitive magnetoliposomes on experimental hepatoma <i>in vitro</i> and <i>in vivo</i> . <i>Nanotechnology</i> , 2011, 22, 315102.	1.3	22
1090	Evaluating tumors in transcatheter arterial chemoembolization (TACE) using dual-phase cone-beam CT. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2011, 20, 276-281.	0.6	25
1091	Hepatic Tumor Ablation: Application in a Community Hospital Setting. <i>Surgical Oncology Clinics of North America</i> , 2011, 20, 455-466.	0.6	1
1092	Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. <i>British Journal of Cancer</i> , 2011, 105, 640-648.	2.9	71
1093	Blood Neutrophil-to-lymphocyte Ratio Predicts Survival in Patients with Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 702-709.	0.2	106
1094	Hepatocellular carcinoma: Resection versus transplantation. <i>Indian Journal of Transplantation</i> , 2011, 5, 102-103.	0.0	0
1095	Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 140, 1501-1512.e2.	0.6	389
1096	MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. <i>Gastroenterology</i> , 2011, 140, 1618-1628.e16.	0.6	205
1097	Type 2 Diabetes does not worsen prognosis in hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 214-220.	0.7	8
1098	Preserved liver function, portal thrombosis and absence of oesophageal varices are risk factors for metastasis of hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2011, 43, 319-324.	0.4	21
1099	Functional significance of the ATPâ€binding cassette transporter B6 in hepatocellular carcinoma. <i>Molecular Oncology</i> , 2011, 5, 410-425.	2.1	30
1100	Primary Hepatocellular Carcinoma. <i>Molecular Pathology Library</i> , 2011, , 831-848.	0.1	0
1101	Upregulated and Downregulated Proteins in Hepatocellular Carcinoma: A Systematic Review of Proteomic Profiling Studies. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 61-71.	1.0	33
1102	Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Plasma Metabolomics and Lipid Profiling. <i>Cancer Research</i> , 2011, 71, 6590-6600.	0.4	243
1103	Targeted Therapies for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 140, 1410-1426.	0.6	408

#	ARTICLE	IF	CITATIONS
1104	Occult HBV infection among Egyptian hepatocellular carcinoma patients. <i>Virology Journal</i> , 2011, 8, 90.	1.4	37
1105	Lung Cancer Epidemiology. , 2011, , 2100-2104.		6
1106	Leukemia Diagnostics. , 2011, , 2005-2025.		0
1107	Focal liver lesions/echo enhancing agents and the liver. , 2011, , 138-166.		2
1108	Hepatocellular Carcinoma:. , 2011, , .		4
1109	Laparoscopic Liver Resection in the Treatment of Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2011, 15, 371-384.	1.0	12
1111	Imaging of Hepatocellular Carcinoma: Practical Guide to Differential Diagnosis. <i>Clinics in Liver Disease</i> , 2011, 15, 335-352.	1.0	15
1112	Percutaneous radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma: retrospective randomized control study. <i>Journal of Medical Colleges of PLA</i> , 2011, 26, 316-323.	0.1	3
1113	Molecular mechanism for the involvement of nuclear receptor FXR in HBV-associated hepatocellular carcinoma. <i>Acta Pharmaceutica Sinica B</i> , 2011, 1, 73-79.	5.7	4
1114	Promotion of Liver and Lung Tumorigenesis in DEN-Treated Cytoglobin-Deficient Mice. <i>American Journal of Pathology</i> , 2011, 179, 1050-1060.	1.9	81
1115	Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers. <i>Clinica Chimica Acta</i> , 2011, 412, 152-158.	0.5	27
1116	An insertion/deletion polymorphism in the 3' untranslated region of type I collagen $\alpha 2$ (COL1A2) is associated with susceptibility for hepatocellular carcinoma in a Chinese population. <i>Cancer Genetics</i> , 2011, 204, 265-269.	0.2	12
1117	Role of a novel CAR-induced gene, TUBA8, in hepatocellular carcinoma cell lines. <i>Cancer Genetics</i> , 2011, 204, 382-391.	0.2	10
1123	NF- $\kappa$ B, JNK and p53 pathways are involved in tubeimoside-1-induced apoptosis in HepG2 cells with oxidative stress and G2/M cell cycle arrest. <i>Food and Chemical Toxicology</i> , 2011, 49, 3046-3054.	1.8	44
1124	Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 2117-2127.	1.3	496
1125	High-intensity focused ultrasound combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: Long-term follow-up and clinical analysis. <i>European Journal of Radiology</i> , 2011, 80, 662-669.	1.2	32
1126	Regulation of human hepatocellular carcinoma cells by Spred2 and correlative studies on its mechanism. <i>Biochemical and Biophysical Research Communications</i> , 2011, 410, 803-808.	1.0	25
1127	Signaling Pathways in Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 18-23.	0.9	39

#	ARTICLE	IF	CITATIONS
1128	Transcatheter Arterial Infusion Chemotherapy with a Fine-powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. Japanese Journal of Clinical Oncology, 2011, 41, 770-775.	0.6	28
1129	Role of stress-induced NKG2D ligands in liver diseases. Liver International, 2012, 32, 370-382.	1.9	17
1130	Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma. Journal of Clinical Oncology, 2011, 29, 3960-3967.	0.8	279
1131	Mammalian target of rapamycin regulates expression of $\beta$ -catenin in hepatocellular carcinoma. Human Pathology, 2011, 42, 659-668.	1.1	13
1132	Down-regulation of formin-like 2 predicts poor prognosis in hepatocellular carcinoma. Human Pathology, 2011, 42, 1603-1612.	1.1	28
1133	Histologic classification of microscopic portal venous invasion to predict prognosis in hepatocellular carcinoma. Human Pathology, 2011, 42, 1531-1538.	1.1	39
1134	Hepatocellular Carcinoma Survival in Uninsured and Underinsured Patients. Journal of Surgical Research, 2011, 166, 189-193.	0.8	10
1135	Predicting the Prognosis of Hepatocellular Carcinoma Using Gene Expression. Journal of Surgical Research, 2011, 171, 524-531.	0.8	6
1136	Progallin A isolated from the acetic ether part of the leaves of <i>Phyllanthus emblica</i> L. induces apoptosis of human hepatocellular carcinoma BEL-7404 cells by up-regulation of Bax expression and down-regulation of Bcl-2 expression. Journal of Ethnopharmacology, 2011, 133, 765-772.	2.0	24
1137	<i>Agrimonia pilosa</i> ethanol extract induces apoptotic cell death in HepG2 cells. Journal of Ethnopharmacology, 2011, 138, 358-363.	2.0	25
1138	Potential of immunotherapy for hepatocellular carcinoma. Journal of Hepatology, 2011, 54, 830-834.	1.8	109
1139	Methylation profile as a new tool for classification of hepatocellular carcinoma. Journal of Hepatology, 2011, 54, 602-603.	1.8	7
1140	Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. Journal of Hepatology, 2011, 55, 103-110.	1.8	183
1141	Augmentation of DHCR24 expression by hepatitis C virus infection facilitates viral replication in hepatocytes. Journal of Hepatology, 2011, 55, 512-521.	1.8	54
1142	Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. Journal of Hepatology, 2011, 55, 846-857.	1.8	117
1143	Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization. Journal of Hepatology, 2011, 55, 1034-1040.	1.8	37
1144	Gene-expression signature of vascular invasion in hepatocellular carcinoma. Journal of Hepatology, 2011, 55, 1325-1331.	1.8	133
1145	EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. Journal of Hepatology, 2011, 55, 1309-1316.	1.8	286

#	ARTICLE	IF	CITATIONS
1146	Embolization of hepatocellular carcinoma with drug-eluting beads: Doxorubicin tissue concentration and distribution in patient liver explants. <i>Journal of Hepatology</i> , 2011, 55, 1332-1338.	1.8	150
1147	Vascular invasion leaves its mark in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011, 55, 1174-1175.	1.8	7
1148	Criteria for liver transplantation for HCC: What should the limits be?. <i>Journal of Hepatology</i> , 2011, 55, 1137-1147.	1.8	66
1149	19-Nor-21-(3-hydroxypropyl)-1 $\alpha$ ,25-dihydroxyvitamin D3 (MART-10) is a potent cell growth regulator with enhanced chemotherapeutic potency in liver cancer cells. <i>Steroids</i> , 2011, 76, 1513-1519.	0.8	33
1150	Radiochemotherapy of hepatocarcinoma via lentivirus-mediated transfer of human sodium iodide symporter gene and herpes simplex virus thymidine kinase gene. <i>Nuclear Medicine and Biology</i> , 2011, 38, 757-763.	0.3	7
1151	Percutaneous radiofrequency ablation for liver tumors: Is it safer and more effective in low-risk areas than in high-risk areas?. <i>Hepatology Research</i> , 2011, 41, 635-640.	1.8	9
1152	Molecular characteristics of non-cancerous liver tissue in non-B non-C hepatocellular carcinoma. <i>Hepatology Research</i> , 2011, 41, 711-721.	1.8	25
1153	Shear Wave Velocity Imaging Using Transient Electrode Perturbation: Phantom and ex vivo Validation. <i>IEEE Transactions on Medical Imaging</i> , 2011, 30, 666-678.	5.4	32
1154	Combining sorafenib with chemoembolization for hepatocellular cancer. <i>Community Oncology</i> , 2011, 8, 216-219.	0.2	0
1155	Carcinoma hepatocelular. <i>EMC - Tratado De Medicina</i> , 2011, 15, 1-9.	0.0	0
1156	Gastrointestinal Complications After Concurrent Chemoradiation Therapy in Patients With Hepatocellular Carcinoma: Endoscopic Findings and Risk Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1343-1351.	0.4	42
1157	Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB) Tj ETQq1 1 0.784314 rgBT /Over	0.5	68
1159	What we learned from difficult hepatectomies in patients with advanced hepatic malignancy. <i>Korean Journal of Hepato-biliary-pancreatic Surgery</i> , 2011, 15, 218.	1.0	0
1160	Identifying serum biomarkers for TACE therapy efficiency of hepatocellular carcinoma. <i>Frontiers in Bioscience - Elite</i> , 2011, E3, 212-220.	0.9	4
1161	Role of High-Intensity Focused Ultrasound in Treatment of Hepatocellular Carcinoma. <i>American Surgeon</i> , 2011, 77, 1496-1501.	0.4	22
1162	Correlação do nível de alfa-feto proteína, Índice de sobrevida e recidiva tumoral em pacientes submetidos a transplante hepático. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2011, 24, 43-47.	0.5	3
1163	Advanced hepatocellular carcinoma. Review of targeted molecular drugs. <i>Annals of Hepatology</i> , 2011, 10, 21-27.	0.6	94
1164	The Use of Flow Cytometric DNA Ploidy Analysis of Liver Biopsies in Liver Cirrhosis and Hepatocellular Carcinoma. , 0, , .		4

#	ARTICLE	IF	CITATIONS
1165	36 Hoch-intensiver fokussierter Ultraschall. , 2011, , .		0
1166	Vitamin C and diallyl sulfide as chemosensitizers to cisplatin in treating hepatocellular carcinoma. Journal of Solid Tumors, 2011, 1, .	0.1	7
1167	Hepatic Regeneration after Sublethal Partial Liver Irradiation in Cirrhotic Rats. Journal of Radiation Research, 2011, 52, 582-591.	0.8	12
1168	MRI-Guided Laser Ablation in the Liver. Medical Radiology, 2011, , 289-302.	0.0	1
1169	Terpenoids as potential chemopreventive and therapeutic agents in liver cancer. World Journal of Hepatology, 2011, 3, 228.	0.8	249
1170	Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. Hepatic Medicine: Evidence and Research, 2011, 3, 21.	0.9	6
1171	Could HBx Protein Expression Affect Signal Pathway Inhibition by Gefitinib or Selumetinib, a MEK Inhibitor, in Hepatocellular Carcinoma Cell Lines?. Journal of Korean Medical Science, 2011, 26, 214.	1.1	3
1172	Diagnostic and Prognostic Molecular Markers in Hepatocellular Carcinoma. Disease Markers, 2011, 31, 181-190.	0.6	67
1173	Hepatitis B Learning Needs Assessment of Family Medicine Trainees in Canada: Results of a Nationwide Survey. Canadian Journal of Gastroenterology & Hepatology, 2011, 25, 127-134.	1.8	9
1174	Early Experience of Helical Tomotherapy for Hepatobiliary Radiotherapy. Case Reports in Hepatology, 2011, 2011, 1-8.	0.4	0
1175	Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Predictors of Survival. Canadian Journal of Gastroenterology & Hepatology, 2011, 25, 426-432.	1.8	10
1176	Regulation of TGF- $\beta$ 1-Induced Pro-Apoptotic Signaling by Growth Factor Receptors and Extracellular Matrix Receptor Integrins in the Liver. Frontiers in Physiology, 2011, 2, 78.	1.3	40
1177	Sequencing and Bioinformatics-Based Analyses of the microRNA Transcriptome in Hepatitis B-Related Hepatocellular Carcinoma. PLoS ONE, 2011, 6, e15304.	1.1	69
1178	A Comprehensive Analysis of the Dynamic Biological Networks in HCV Induced Hepatocarcinogenesis. PLoS ONE, 2011, 6, e18516.	1.1	24
1179	Efficient Colonization and Therapy of Human Hepatocellular Carcinoma (HCC) Using the Oncolytic Vaccinia Virus Strain GLV-1h68. PLoS ONE, 2011, 6, e22069.	1.1	36
1180	RNA interference against granulin-epithelin precursor prevents hepatocellular carcinoma growth: Its application as a therapeutic agent. International Journal of Oncology, 2011, 39, 853-61.	1.4	9
1181	Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid-Enhanced Magnetic Resonance Imaging Findings of Borderline Lesions at High Risk for Progression to Hypervascular Classic Hepatocellular Carcinoma. Journal of Computer Assisted Tomography, 2011, 35, 181-186.	0.5	33
1182	Liver Transplantation for Advanced Hepatocellular Carcinoma Using Poor Tumor Differentiation on Biopsy as an Exclusion Criterion. Annals of Surgery, 2011, 253, 166-172.	2.1	245

#	ARTICLE	IF	CITATIONS
1183	Living Donor Liver Transplantation in Patients Who Have Received Pretransplant Treatment for Hepatocellular Carcinoma. <i>Transplantation</i> , 2011, 91, e61-e62.	0.5	6
1184	Laparoscopic Anatomic S4 Segmentectomy for Hepatocellular Carcinoma. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2011, 21, e183-e186.	0.4	13
1185	Analysis of Factors Affecting Recurrence of Hepatocellular Carcinoma After Liver Transplantation With a Special Focus on Inflammation Markers. <i>Transplantation</i> , 2011, 91, 1279-1285.	0.5	102
1186	Selective Targeting of Genetically Engineered Mesenchymal Stem Cells to Tumor Stroma Microenvironments Using Tissue-Specific Suicide Gene Expression Suppresses Growth of Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2011, 254, 767-775.	2.1	104
1187	Metastatic Hepatocellular Carcinoma With Associated Spinal Cord Compression. <i>American Journal of the Medical Sciences</i> , 2011, 341, 148-152.	0.4	11
1188	Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. <i>The Cochrane Library</i> , 2011, , CD004787.	1.5	173
1189	Subcutaneous Metastases After Laparoscopic-assisted Partial Hepatectomy for Hepatocellular Carcinoma. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2011, 21, e41-e43.	0.4	5
1190	Microvascular Invasion Is a Better Predictor of Tumor Recurrence and Overall Survival Following Surgical Resection for Hepatocellular Carcinoma Compared to the Milan Criteria. <i>Annals of Surgery</i> , 2011, 254, 108-113.	2.1	402
1191	Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. <i>International Journal of Oncology</i> , 2012, 40, 63-70.	1.4	54
1192	5-Lipoxygenase contributes to the progression of hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2011, 4, 1195-200.	1.1	24
1194	Suppression of microRNA-96 expression inhibits the invasion of hepatocellular carcinoma cells. <i>Molecular Medicine Reports</i> , 2011, 5, 800-4.	1.1	30
1195	Emodin inhibits the differentiation and maturation of dendritic cells and increases the production of regulatory T cells. <i>International Journal of Molecular Medicine</i> , 2011, 29, 159-64.	1.8	17
1196	Predictors of Surgical Intervention for Hepatocellular Carcinoma. <i>Archives of Surgery</i> , 2011, 146, 778.	2.3	77
1197	One-Stage Emergency Right Hemihepatectomy Due to Spontaneous Rupture of Hepatocellular Carcinoma - Case Report. <i>Polski Przegląd Chirurgiczny</i> , 2011, 83, 339-42.	0.2	2
1198	Cisplatin sensitizes human hepatocellular carcinoma cells, but not hepatocytes and mesenchymal stem cells, to TRAIL within a therapeutic window partially depending on the upregulation of DR5. <i>Oncology Reports</i> , 2011, 25, 461-8.	1.2	12
1199	Diluted povidone-iodine inhibits tumor growth through apoptosis-induction and suppression of SOD activity. <i>Oncology Reports</i> , 2012, 27, 383-8.	1.2	13
1200	Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysis. <i>Clinical Transplantation</i> , 2011, 25, E541-51.	0.8	20
1201	MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 <i>in vitro</i> . <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 371-377.	1.4	39



#	ARTICLE	IF	CITATIONS
1202	Diagnostic sensitivity of hepatocellular carcinoma imaging and its application to non-cirrhotic patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 745-750.	1.4	14
1203	Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1638-1645.	1.4	17
1204	Portal venous invasion: The single most independent risk factor for immediate postoperative recurrence of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1646-1651.	1.4	42
1205	Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1604-1611.	1.4	85
1206	Hepatocellular carcinoma and vitamin D: A review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1597-1603.	1.4	60
1207	Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer. <i>Cancer Science</i> , 2011, 102, 2214-2220.	1.7	30
1208	Liver stiffness measurement by magnetic resonance elastography is not associated with developing hepatocellular carcinoma in subjects with compensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 83-91.	1.9	21
1209	The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 205-213.	1.9	88
1210	Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden. <i>Journal of Internal Medicine</i> , 2011, 269, 538-545.	2.7	61
1212	International multicentre prospective study on microwave ablation of liver tumours: preliminary results. <i>Hpb</i> , 2011, 13, 579-585.	0.1	45
1213	Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. <i>Liver International</i> , 2011, 31, 120-131.	1.9	51
1214	Early $\alpha$ -fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Liver International</i> , 2011, 31, 369-376.	1.9	55
1215	Criteria for liver transplantation for hepatocellular carcinoma: what is an acceptable outcome?. <i>Liver International</i> , 2011, 31, 161-163.	1.9	13
1216	Role of angiotensin-1 receptor blockade in cirrhotic liver resection. <i>Liver International</i> , 2011, 31, 642-655.	1.9	6
1217	AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases. <i>Liver International</i> , 2011, 31, 810-816.	1.9	47
1218	PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. <i>Liver International</i> , 2011, 31, 1137-1143.	1.9	102
1219	Prognostic value of $^{18}$ F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. <i>Liver International</i> , 2011, 31, 1144-1149.	1.9	56
1220	Molecular Pathogenesis of Hepatocellular Carcinoma. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 821-825.	1.4	47

#	ARTICLE	IF	CITATIONS
1221	Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies. <i>International Journal of Clinical Practice</i> , 2011, 65, 182-188.	0.8	23
1222	Targeted hepatocellular carcinoma proapoptotic BikDD gene therapy. <i>Oncogene</i> , 2011, 30, 1773-1783.	2.6	25
1223	Inhibin/activin expression in human and rodent liver: subunits $\alpha$ and $\beta$ as new players in human hepatocellular carcinoma?. <i>British Journal of Cancer</i> , 2011, 104, 1303-1312.	2.9	6
1224	In vitro and in vivo studies of adenovirus-mediated human norepinephrine transporter gene transduction to hepatocellular carcinoma. <i>Cancer Gene Therapy</i> , 2011, 18, 196-205.	2.2	12
1225	The tumor suppressor function of LECT2 in human hepatocellular carcinoma makes it a potential therapeutic target. <i>Cancer Gene Therapy</i> , 2011, 18, 399-406.	2.2	44
1226	Rate of Tumor Growth Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation in Patients Beyond Milan or UCSF Criteria. <i>Transplantation Proceedings</i> , 2011, 43, 3813-3818.	0.3	24
1227	MicroRNA response to environmental mutagens in liver. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2011, 717, 67-76.	0.4	24
1228	Lutetium-177 and iodine-131 loaded chelating polymer microparticles intended for radioembolization of liver malignancies. <i>Reactive and Functional Polymers</i> , 2011, 71, 1155-1159.	2.0	8
1229	Gene signatures in hepatocellular carcinoma (HCC). <i>Seminars in Cancer Biology</i> , 2011, 21, 4-9.	4.3	47
1230	Chemoembolization for Hepatocellular Carcinoma. <i>Seminars in Roentgenology</i> , 2011, 46, 105-114.	0.2	4
1231	Decreased lactate dehydrogenase B expression enhances claudin 1-mediated hepatoma cell invasiveness via mitochondrial defects. <i>Experimental Cell Research</i> , 2011, 317, 1108-1118.	1.2	42
1232	Tissue expression of squamous cellular carcinoma antigen and Ki67 in hepatocellular carcinoma-correlation with prognosis: A historical prospective study. <i>Diagnostic Pathology</i> , 2011, 6, 121.	0.9	47
1233	Acute heart failure caused by a giant hepatocellular metastatic tumor of the right atrium. <i>Journal of Cardiothoracic Surgery</i> , 2011, 6, 102.	0.4	7
1234	Clinical response to Auron Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 478.	0.4	1
1235	Shikonin, a Chinese plant-derived naphthoquinone, induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species: A potential new treatment for hepatocellular carcinoma. <i>Free Radical Biology and Medicine</i> , 2011, 51, 2259-2271.	1.3	129
1236	Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. <i>European Radiology</i> , 2011, 21, 1719-1726.	2.3	49
1237	Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. <i>Medical Molecular Morphology</i> , 2011, 44, 183-189.	0.4	29
1238	Continuous Occlusion of Hepatic Artery Proper for Prevention of Blood Loss in Partial Hepatectomy for Ruptured Hepatocellular Carcinoma: A Case-Matched Comparative Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 1638-1643.	0.7	16

#	ARTICLE	IF	CITATIONS
1239	Expression of apolipoprotein M in human hepatocellular carcinoma tissues. <i>Acta Histochemica</i> , 2011, 113, 53-57.	0.9	17
1240	Clinicopathological Characteristics of 20 Cases of Hepatocellular Carcinoma with Bile Duct Tumor Thrombi. <i>Digestive Diseases and Sciences</i> , 2011, 56, 252-259.	1.1	60
1241	Meta-Analysis of Laparoscopic Versus Open Resection for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1937-1943.	1.1	108
1242	Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2011, 29, 380-391.	1.2	35
1243	A novel tripeptide, tyrosilerleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude mice. <i>Investigational New Drugs</i> , 2011, 29, 861-872.	1.2	25
1244	Clinical Presentation of Hepatocellular Carcinoma (HCC) in Asian-Americans Versus Non-Asian-Americans. <i>Journal of Immigrant and Minority Health</i> , 2011, 13, 842-848.	0.8	26
1245	Kinase Gene Expression and Subcellular Protein Expression Pattern of Protein Kinase C Isoforms in Curcumin-treated Human Hepatocellular Carcinoma Hep 3B Cells. <i>Plant Foods for Human Nutrition</i> , 2011, 66, 136-142.	1.4	15
1246	Expression of cytokeratin 19 and matrix metalloproteinase 2 predicts lymph node metastasis in hepatocellular carcinoma. <i>Molecular Biology Reports</i> , 2011, 38, 3531-3539.	1.0	27
1247	Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression. <i>Molecular Biology Reports</i> , 2011, 38, 3671-3677.	1.0	33
1248	Laparoscopic resection vs. open liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: a case-matched study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2011, 25, 3668-3677.	1.3	124
1249	Clinical characteristics of patients with hepatocellular carcinoma in Austria – is there a need for a structured screening program?. <i>Wiener Klinische Wochenschrift</i> , 2011, 123, 542-551.	1.0	51
1250	Hepatocellular carcinoma during pregnancy: is hepatocellular carcinoma more aggressive in pregnant patients?. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2011, 18, 422-431.	1.4	27
1251	Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. <i>Journal of Gastroenterology</i> , 2011, 46, 799-808.	2.3	24
1252	The effectiveness of particle radiotherapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. <i>Journal of Gastroenterology</i> , 2011, 46, 913-920.	2.3	30
1253	Meta-analysis of anatomic resection versus nonanatomic resection for hepatocellular carcinoma. <i>Langenbeck's Archives of Surgery</i> , 2011, 396, 1109-1117.	0.8	100
1254	Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 129-139.	1.4	105
1255	Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 659-667.	1.2	57
1256	Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. <i>Medical Molecular Morphology</i> , 2011, 44, 117-124.	0.4	19

#	ARTICLE	IF	CITATIONS
1257	A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma. <i>Functional and Integrative Genomics</i> , 2011, 11, 419-429.	1.4	19
1258	Prospective comparative study of cool-tip radiofrequency ablation and surgical resection for hepatocellular carcinoma. <i>Chinese-German Journal of Clinical Oncology</i> , 2011, 10, 399-405.	0.1	5
1259	The potential use of 2-[18F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1723-1731.	3.3	35
1260	The current role of minimally invasive therapies in the management of liver tumors. <i>Abdominal Imaging</i> , 2011, 36, 635-647.	2.0	23
1261	Current concepts in transarterial chemoembolization of hepatocellular carcinoma. <i>Abdominal Imaging</i> , 2011, 36, 677-683.	2.0	22
1262	A Prognostic Model and Treatment Strategy for Intrahepatic Recurrence of Hepatocellular Carcinoma after Curative Resection. <i>World Journal of Surgery</i> , 2011, 35, 170-177.	0.8	50
1263	Resection of a Transplantable Single Nodule Hepatocellular Carcinoma in Child-Pugh Class A Cirrhosis: Factors Affecting Survival and Recurrence. <i>World Journal of Surgery</i> , 2011, 35, 1055-1062.	0.8	16
1264	CEACAM1 Cytoplasmic Expression is Closely Related to Tumor Angiogenesis and Poorer Relapse-free Survival After Curative Resection of Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2011, 35, 2259-2265.	0.8	13
1265	Kinase activation profile associated with TGF- $\beta$ -dependent migration of HCC cells: a preclinical study. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 79-86.	1.1	42
1266	High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 239-245.	1.1	34
1267	Increased Frequency of CD4 <sup>+</sup> CD25 <sup>high</sup> FoxP3 <sup>+</sup> Regulatory T Cells in Patients with Hepatocellular Carcinoma. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2011, 59, 309-314.	1.0	20
1268	TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis. <i>Medical Oncology</i> , 2011, 28, 1038-1043.	1.2	23
1269	Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection. <i>Medical Oncology</i> , 2011, 28, 1044-1047.	1.2	11
1270	Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. <i>Hepatology International</i> , 2011, 5, 850-856.	1.9	40
1271	Prognosis of patients with spontaneous rupture of hepatocellular carcinoma in cirrhosis. <i>Updates in Surgery</i> , 2011, 63, 25-30.	0.9	41
1272	Pharmacokinetics of miriplatin in experimental dog models of hepatic or renal impairment. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2011, 36, 213-222.	0.6	1
1273	Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified?. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2011, 31, 637-641.	1.0	8
1274	Radiofrequency Ablation Versus Surgical Resection for Hepatocellular Carcinoma in Childs A Cirrhosis—a Retrospective Study of 1,061 Cases. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 311-320.	0.9	74

#	ARTICLE	IF	CITATIONS
1275	Prognostic Factors and 10-Year Survival in Patients with Hepatocellular Carcinoma After Curative Hepatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 598-607.	0.9	28
1276	Significance of Platelet Count in the Outcomes of Hepatectomized Patients with Hepatocellular Carcinoma Exceeding the Milan Criteria. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 1173-1181.	0.9	25
1277	Prognostic Impact of Preoperative the Branched-Chain Amino Acid to the Tyrosine Ratio in Hepatocellular Carcinoma Patients after Initial Hepatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 1433-1439.	0.9	14
1278	Infiltrating Hepatocellular Carcinoma: Seeing the Tree through the Forest. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 2089-2097.	0.9	63
1279	Silencing of the HCCR2 Gene Induces Apoptosis and Suppresses the Aggressive Phenotype of Hepatocellular Carcinoma Cells in Culture. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 1807-1813.	0.9	5
1280	Long-Term Outcome of Percutaneous Ablation in Very Early-Stage Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 2165-2171.	0.9	46
1281	Fuzheng Yiliu Granule (æ%ŃæŠç~éç—ç²') inhibits the growth of hepatocellular cancer by regulating immune function and inducing apoptosis in vivo and in vitro. <i>Chinese Journal of Integrative Medicine</i> , 2011, 17, 691-697.	0.7	21
1282	Towards the optimization of management of hepatocellular carcinoma. <i>Frontiers of Medicine</i> , 2011, 5, 271-276.	1.5	3
1283	Hepatocellular Carcinoma Surveillance in a Western Population with Hepatitis B. <i>Current Hepatitis Reports</i> , 2011, 10, 147-152.	0.3	0
1284	The comparison of grey-scale ultrasonic and clinical features of hepatoblastoma and hepatocellular carcinoma in children: a retrospective study for ten years. <i>BMC Gastroenterology</i> , 2011, 11, 78.	0.8	5
1285	Isomalto oligosaccharide sulfate inhibits tumor growth and metastasis of hepatocellular carcinoma in nude mice. <i>BMC Cancer</i> , 2011, 11, 150.	1.1	15
1286	Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: The PROMETHEUS-01 trial. <i>BMC Cancer</i> , 2011, 11, 67.	1.1	37
1287	Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro. <i>Cancer Cell International</i> , 2011, 11, 40.	1.8	20
1288	Role of bile salt in regulating Mcl-1 phosphorylation and chemoresistance in hepatocellular carcinoma cells. <i>Molecular Cancer</i> , 2011, 10, 44.	7.9	43
1289	Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies. <i>World Journal of Surgical Oncology</i> , 2011, 9, 108.	0.8	36
1290	Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. <i>Journal of Translational Medicine</i> , 2011, 9, 166.	1.8	74
1291	Detection of HBV Genotypes of Tumor Tissues and Serum by A Fluorescence Polarization Assay in North-Western China's Hepatocellular Carcinoma Patients. <i>Virology Journal</i> , 2011, 8, 362.	1.4	3
1292	A ŃRaf1â€“ERâ€“inducible oncogenic zebrafish liver cell model identifies hepatocellular carcinoma signatures. <i>Journal of Pathology</i> , 2011, 225, 19-28.	2.1	18

#	ARTICLE	IF	CITATIONS
1293	Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: A propensity score analysis. <i>Liver Transplantation</i> , 2011, 17, 556-566.	1.3	63
1294	Growth of hepatocellular carcinoma in the regenerating liver. <i>Liver Transplantation</i> , 2011, 17, 866-874.	1.3	51
1295	Usefulness of a modified inflammation-based prognostic system for predicting postoperative mortality of patients undergoing surgery for primary hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2011, 103, 801-806.	0.8	41
1296	Prognostic significance of postoperative complications after hepatectomy for hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2011, 104, 814-821.	0.8	50
1297	Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. <i>Hepatology</i> , 2011, 53, 483-492.	3.6	97
1298	Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). <i>Hepatology</i> , 2011, 53, 885-894.	3.6	329
1299	Evolution of genomic instability in diethylnitrosamine-induced hepatocarcinogenesis in mice. <i>Hepatology</i> , 2011, 53, 895-904.	3.6	47
1300	Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma. <i>Hepatology</i> , 2011, 53, 1538-1548.	3.6	148
1301	Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. <i>Hepatology</i> , 2011, 53, 2086-2096.	3.6	71
1302	c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. <i>Hepatology</i> , 2011, 54, 879-889.	3.6	165
1303	Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy. <i>Hepatology</i> , 2011, 54, 1199-1207.	3.6	58
1304	Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells. <i>Hepatology</i> , 2011, 54, 1259-1272.	3.6	53
1305	Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans. <i>Hepatology</i> , 2011, 54, 1661-1678.	3.6	49
1306	Recombinant adenovirus carrying the hepatocyte nuclear factor-1alpha gene inhibits hepatocellular carcinoma xenograft growth in mice. <i>Hepatology</i> , 2011, 54, 2036-2047.	3.6	73
1307	Magnetic resonance imaging of focal liver lesions: Approach to imaging diagnosis. <i>Hepatology</i> , 2011, 54, 2227-2237.	3.6	90
1308	The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. <i>Cancer</i> , 2011, 117, 3053-3059.	2.0	162
1309	Hepatocellular carcinoma with extrahepatic metastasis. <i>Cancer</i> , 2011, 117, 4475-4483.	2.0	350
1310	<sup>18</sup> F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. <i>Cancer</i> , 2011, 117, 4779-4787.	2.0	47

#	ARTICLE	IF	CITATIONS
1311	Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. <i>Cancer</i> , 2011, 117, 4890-4904.	2.0	139
1312	dbHCCvar: A comprehensive database of human genetic variations in hepatocellular carcinoma. <i>Human Mutation</i> , 2011, 32, E2308-E2316.	1.1	11
1313	Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue. <i>International Journal of Cancer</i> , 2011, 128, 1559-1569.	2.3	26
1314	Neighbor of pinc E11, a novel oncofetal marker for hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2011, 128, 2353-2363.	2.3	15
1315	Tetrandrine induces apoptosis by activating reactive oxygen species and repressing Akt activity in human hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2011, 129, 1519-1531.	2.3	123
1316	Upregulation of LPTM4B Promotes Malignant Transformation and Tumorigenesis in L02 Human Liver Cell Line. <i>Anatomical Record</i> , 2011, 294, 1135-1142.	0.8	23
1317	Hepatic fibrosis does not affect the pharmacokinetics of 5-fluorouracil in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 126-130.	1.1	1
1318	N,N,N-Trimethyl chitosan nanoparticles for the delivery of monoclonal antibodies against hepatocellular carcinoma cells. <i>Carbohydrate Polymers</i> , 2011, 85, 215-220.	5.1	41
1319	Contrast-Enhanced Ultrasound With Perflubutane Microbubble Agent: Evaluation of Differentiation of Hepatocellular Carcinoma. <i>American Journal of Roentgenology</i> , 2011, 196, W123-W131.	1.0	49
1320	Role of Class II Nuclear Receptors in Liver Carcinogenesis. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2011, 11, 529-542.	0.9	10
1322	The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1535-1546.	1.5	7
1323	A Randomized Phase II Study of Drug-Eluting Beads versus Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. <i>Onkologie</i> , 2011, 34, 368-376.	1.1	116
1324	IL-6 $\gamma$ 174G/C Polymorphism and IL-6 Serum Levels in Patients with Liver Cirrhosis and Hepatocellular Carcinoma. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 183-186.	1.0	50
1325	Radiofrequency Ablation Combined With Chemoembolization: Treatment of Recurrent Hepatocellular Carcinomas After Hepatectomy. <i>American Journal of Roentgenology</i> , 2011, 197, 488-494.	1.0	11
1326	Upregulation of Rac GTPase-Activating Protein 1 Is Significantly Associated with the Early Recurrence of Human Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 6040-6051.	3.2	122
1327	Ectopic hepatocellular carcinomas developed in the chest wall and skull. <i>Asian Cardiovascular and Thoracic Annals</i> , 2011, 19, 360-362.	0.2	4
1328	Surgical Treatment for Hepatocellular Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 447-454.	0.6	58
1329	Overexpression of Forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinoma. <i>Oncology Reports</i> , 2011, 25, 1533-9.	1.2	55

#	ARTICLE	IF	CITATIONS
1330	The Golden State of Healthcare Reform. Archives of Surgery, 2011, 146, 784.	2.3	0
1331	Prediction of Hepatocellular Carcinoma Development by Plasma ADAMTS13 in Chronic Hepatitis B and C. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2204-2211.	1.1	17
1332	An overview of evidence-based management of hepatocellular carcinoma: A meta-analysis. Journal of Cancer Research and Therapeutics, 2011, 7, 463.	0.3	98
1333	Mobile right atrial thrombus with pulmonary thromboembolism in a patient with advanced hepatocellular carcinoma and disseminated tumor thrombosis. Heart Views, 2011, 12, 173.	0.1	7
1334	Targeted Therapy in Hepatocellular Carcinoma. International Journal of Hepatology, 2011, 2011, 1-11.	0.4	23
1335	Thyroid Hormone Receptor Mutations in Cancer and Resistance to Thyroid Hormone: Perspective and Prognosis. Journal of Thyroid Research, 2011, 2011, 1-20.	0.5	23
1336	The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma. International Journal of Hepatology, 2011, 2011, 1-8.	0.4	9
1337	Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians. International Journal of Hepatology, 2011, 2011, 1-13.	0.4	34
1338	Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in India. Indian Journal of Radiology and Imaging, 2011, 21, 113-120.	0.3	31
1339	Treatment of Advanced Hepatocellular Carcinoma: Sorafenib and Beyond. Clinical Medicine Reviews in Oncology, 2011, 3, 39-47.	0.0	0
1340	Sorafenib Therapy in Patients with Advanced Hepatocellular Carcinoma in Advanced Liver Cirrhosis. Digestion, 2011, 83, 275-282.	1.2	17
1341	Tumeurs solides. , 2011, , 542-798.		0
1342	Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma. Indian Journal of Medical and Paediatric Oncology, 2011, 32, 71-75.	0.1	23
1343	FLNA and PGK1 are Two Potential Markers for Progression in Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2011, 27, 207-216.	1.1	80
1344	Nuclear receptor CAR-regulated expression of the FAM84A gene during the development of mouse liver tumors. International Journal of Oncology, 2011, 38, 1511-20.	1.4	11
1345	Prevention of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection. Oncology, 2011, 81, 41-49.	0.9	42
1346	Living Donor Liver Transplantation for Hepatocellular Carcinoma: The Japanese Experience. Oncology, 2011, 81, 111-115.	0.9	17
1347	Current Situation of Hepatocellular Carcinoma in Mongolia. Oncology, 2011, 81, 148-151.	0.9	25



#	ARTICLE	IF	CITATIONS
1348	Adjuvant Hepatic Arterial Infusional Chemotherapy with 5-Fluorouracil and Cisplatin after Curative Resection of Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 184-191.	0.9	20
1349	Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma. <i>The Cochrane Library</i> , 2011, , CD008713.	1.5	8
1350	Golgi protein 73(GP73), a useful serum marker in liver diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1311-1316.	1.4	53
1351	Growth Suppression of Human Hepatocellular Carcinoma Xenografts by a Monoclonal Antibody CH12 Directed to Epidermal Growth Factor Receptor Variant III. <i>Journal of Biological Chemistry</i> , 2011, 286, 5913-5920.	1.6	41
1352	Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2011, 105, 945-952.	2.9	39
1353	Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1807-1816.	1.1	22
1354	Drug delivery embolization systems: a physician's perspective. <i>Expert Opinion on Drug Delivery</i> , 2011, 8, 1071-1084.	2.4	15
1355	Tumor Necrosis Factor Alpha 308 G/A Polymorphism and Hepatocellular Carcinoma Risk in a Chinese Population. <i>Genetic Testing and Molecular Biomarkers</i> , 2011, 15, 569-572.	0.3	12
1356	Treatment of liver tumours adjacent to hepatic hilum with percutaneous microwave ablation combined with ethanol injection: A pilot study. <i>International Journal of Hyperthermia</i> , 2011, 27, 249-254.	1.1	28
1357	ShRNA-Targeted MAP4K4 Inhibits Hepatocellular Carcinoma Growth. <i>Clinical Cancer Research</i> , 2011, 17, 710-720.	3.2	86
1358	Clinical MRI of the Abdomen. , 2011, , .		12
1359	Clinical course of sorafenib treatment in patients with hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 809-819.	0.6	15
1360	CYP2E1 potentiates toxicity in obesity and after chronic ethanol treatment. <i>Drug Metabolism and Drug Interactions</i> , 2012, 27, 125-44.	0.3	22
1361	Hepatocellular Carcinoma: Focus on Different Aspects of Management. <i>ISRN Oncology</i> , 2012, 2012, 1-12.	2.1	84
1362	Epidemiological Pattern of Hepatitis B and Hepatitis C as Etiological Agents for Hepatocellular Carcinoma in Iran and Worldwide. <i>Hepatitis Monthly</i> , 2012, 12, e6894.	0.1	61
1363	Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway. <i>Carcinogenesis</i> , 2012, 33, 538-547.	1.3	34
1364	Angiotensin II Induces Angiogenic Factors Production Partly Via AT1/JAK2/STAT3/SOCS3 Signaling Pathway in MHCC97H Cells. <i>Cellular Physiology and Biochemistry</i> , 2012, 29, 863-874.	1.1	40
1365	Small (â‰‰2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multislice detector CT. <i>British Journal of Radiology</i> , 2012, 85, e314-e322.	1.0	63

#	ARTICLE	IF	CITATIONS
1366	Gemcitabine and cisplatin-based combination chemotherapy in advanced hepatocellular carcinoma: An Indian experience. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2012, 33, 42.	0.1	9
1367	The Silencing of Pokemon Attenuates the Proliferation of Hepatocellular Carcinoma Cells In Vitro and In Vivo by Inhibiting the PI3K/Akt Pathway. <i>PLoS ONE</i> , 2012, 7, e51916.	1.1	35
1368	Reduced Expression of Argininosuccinate Lyase is Closely Associated With Postresectional Survival in Hepatocellular Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2012, 20, 602-606.	0.6	3
1369	Cediranib (AZD2171) in Patients With Advanced Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 329-333.	0.6	59
1370	Autophagy-related Gene 7 (ATG7) and Reactive Oxygen Species/Extracellular Signal-regulated Kinase Regulate Tetrandrine-induced Autophagy in Human Hepatocellular Carcinoma. <i>Journal of Biological Chemistry</i> , 2012, 287, 35576-35588.	1.6	119
1371	TGF-Beta Inhibitor-loaded Polyelectrolyte Multilayers Capsules for Sustained Targeting of Hepatocarcinoma Cells. <i>Current Pharmaceutical Design</i> , 2012, 18, 4155-4164.	0.9	16
1372	The Activation of MEK/ERK Signaling Pathway by Bone Morphogenetic Protein 4 to Increase Hepatocellular Carcinoma Cell Proliferation and Migration. <i>Molecular Cancer Research</i> , 2012, 10, 415-427.	1.5	67
1373	Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. <i>Gut</i> , 2012, 61, 427-438.	6.1	307
1374	TP53 Codon 72 Polymorphism with Hepatocellular Carcinoma: A Meta-Analysis. <i>Journal of International Medical Research</i> , 2012, 40, 446-454.	0.4	11
1375	miRNAs in Gastrointestinal and Liver Cancers: Their Perspectives and Clinical Applications. <i>Current Pharmaceutical Design</i> , 2012, 19, 1301-1310.	0.9	4
1376	Metabolomics: A Revolution for Novel Cancer Marker Identification. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2012, 15, 266-275.	0.6	30
1377	Curcumin and Liver Cancer: A Review. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 218-228.	0.9	218
1378	The Impact of CT Follow-Up Interval on Stages of Hepatocellular Carcinomas Detected During the Surveillance of Patients With Liver Cirrhosis. <i>American Journal of Roentgenology</i> , 2012, 199, 816-821.	1.0	6
1379	Recurrent Hepatocellular Carcinoma Treated with Sequential Transcatheter Arterial Chemoembolization and RF Ablation versus RF Ablation Alone: A Prospective Randomized Trial. <i>Radiology</i> , 2012, 262, 689-700.	3.6	183
1380	Radiofrequency Ablation versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas 2 cm or Smaller: A Retrospective Comparative Study. <i>Radiology</i> , 2012, 262, 1022-1033.	3.6	203
1381	MR Imaging of Hypervascular Lesions in the Cirrhotic Liver: A Diagnostic Dilemma. <i>Radiographics</i> , 2012, 32, 767-787.	1.4	37
1382	Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1283-1288.	1.1	8
1383	Enhancement patterns of hepatocellular carcinomas on multiphasic multidetector row CT: comparison with pathological differentiation. <i>British Journal of Radiology</i> , 2012, 85, e573-e583.	1.0	88

#	ARTICLE	IF	CITATIONS
1384	Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development. <i>Current Medicinal Chemistry</i> , 2012, 19, 938-944.	1.2	72
1385	Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. <i>Laboratory Investigation</i> , 2012, 92, 952-966.	1.7	65
1386	Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma. <i>Journal of Liposome Research</i> , 2012, 22, 224-236.	1.5	40
1387	Percutaneous microwave ablation for liver cancer adjacent to the diaphragm. <i>International Journal of Hyperthermia</i> , 2012, 28, 218-226.	1.1	37
1388	Tumours and tumour-like lesions of the liver. , 2012, , 761-851.		22
1389	Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 173-185.	1.4	57
1390	Totally Anatomic Laparoscopic Right Anterior Sectionectomy. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2012, 22, 913-916.	0.5	11
1391	Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors. <i>American Journal of Gastroenterology</i> , 2012, 107, 569-577.	0.2	604
1392	Long Term Survival of Mice with Hepatocellular Carcinoma after Pulse Power Ablation with Nanosecond Pulsed Electric Fields. <i>Technology in Cancer Research and Treatment</i> , 2012, 11, 83-93.	0.8	70
1393	Enhancement of Hepatitis B Virus Replication by Androgen and Its Receptor in Mice. <i>Journal of Virology</i> , 2012, 86, 1904-1910.	1.5	48
1394	Toll-Like Receptor 3 Expressing Tumor Parenchyma and Infiltrating Natural Killer Cells in Hepatocellular Carcinoma Patients. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1796-1807.	3.0	77
1395	Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2284-2293.	1.9	168
1396	Tumor-Infiltrating FoxP3+ Tregs and CD8+ T Cells Affect the Prognosis of Hepatocellular Carcinoma Patients. <i>Digestion</i> , 2012, 86, 329-337.	1.2	96
1397	Expression and prognostic value of ING3 in human primary hepatocellular carcinoma. <i>Experimental Biology and Medicine</i> , 2012, 237, 352-361.	1.1	25
1398	Pathogenetic and Prognostic Significance of Inactivation of RASSF Proteins in Human Hepatocellular Carcinoma. <i>Molecular Biology International</i> , 2012, 2012, 1-8.	1.7	14
1399	Selective doxorubicin drug eluting beads chemoembolization of hypovascular hepatocellular carcinoma using cone beam computed tomography. <i>Indian Journal of Radiology and Imaging</i> , 2012, 22, 254-256.	0.3	1
1400	The Effects of Anesthetic Technique on Cancer Recurrence in Percutaneous Radiofrequency Ablation of Small Hepatocellular Carcinoma. <i>Anesthesia and Analgesia</i> , 2012, 114, 290-296.	1.1	82
1401	TGF- $\beta$ 2 in Epithelial to Mesenchymal Transition and Metastasis of Liver Carcinoma. <i>Current Pharmaceutical Design</i> , 2012, 18, 4135-4147.	0.9	95

#	ARTICLE	IF	CITATIONS
1402	Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2012, 82, 119-125.	0.9	26
1403	Application of Radiotherapeutic Strategies in the BCLC-defined Stages of Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2012, 1, 216-225.	4.2	35
1404	Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. <i>International Journal of Oncology</i> , 2012, 41, 903-909.	1.4	21
1405	mTOR as a Potential Target for the Prevention and Treatment of Hepatocellular Carcinoma. <i>Current Cancer Drug Targets</i> , 2012, 12, 1045-1061.	0.8	22
1406	Role of Acyclic Retinoid in the Chemoprevention of Hepatocellular Carcinoma: Basic Aspects, Clinical Applications, and Future Prospects. <i>Current Cancer Drug Targets</i> , 2012, 12, 1119-1128.	0.8	5
1407	Hepatocellular Carcinoma Diagnostics, Treatments and Potential Theragnostics in the Asia-Pacific. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2012, 10, 159-169.	0.2	0
1408	Chemoprevention of Hepatocarcinogenesis with Dietary Isoprenic Derivatives: Cellular and Molecular Aspects. <i>Current Cancer Drug Targets</i> , 2012, 12, 1173-1190.	0.8	9
1409	Transcatheter arterial chemoembolization confers survival benefit in patients with a spontaneously ruptured hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 640-645.	0.8	52
1411	Degradable starch microspheres transarterial chemoembolisation (DSM-TACE) of HCC: Dynamic Contrast-Enhanced Ultrasonography (DCE-US) based evaluation of therapeutic efficacy using a novel perfusion software. <i>Clinical Hemorheology and Microcirculation</i> , 2012, 52, 123-129.	0.9	12
1412	Cancer Stem Cell as a Potential Therapeutic Target in Hepatocellular Carcinoma. <i>Current Cancer Drug Targets</i> , 2012, 12, 1081-1094.	0.8	34
1413	Relationship of HLA-DRB1 Alleles With Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 420-426.	1.1	10
1414	A transcatheter arterial chemotherapy using a novel lipophilic platinum derivative (miriplatin) for patients with small and multiple hepatocellular carcinomas. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 583-588.	0.8	4
1415	Role of NF- $\kappa$ B in Hepatocarcinogenesis and Its Potential Inhibition by Dietary Antioxidants. <i>Current Cancer Drug Targets</i> , 2012, 12, 1160-1172.	0.8	7
1416	High HBV-DNA Titer in Surrounding Liver Rather Than in Hepatocellular Carcinoma Tissue Predisposes to Recurrence After Curative Surgical Resection. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 413-419.	1.1	5
1417	Magnetic Resonance-guided Laser-induced Thermoablation in Patients With Oligonodular Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 796-801.	1.1	22
1418	Hepatitis B virus X protein promotes the growth of hepatocellular carcinoma by modulation of the Notch signaling pathway. <i>Oncology Reports</i> , 2012, 27, 1170-1176.	1.2	37
1419	14-kDa Phosphohistidine phosphatase plays an important role in hepatocellular carcinoma cell proliferation. <i>Oncology Letters</i> , 2012, 4, 658-664.	0.8	17
1420	Long-term survival of patients with hepatocellular carcinoma with pulmonary and adrenal metastasis: A case report. <i>Experimental and Therapeutic Medicine</i> , 2012, 3, 699-702.	0.8	5

#	ARTICLE	IF	CITATIONS
1421	Diabetes Worsens the Surgical Outcomes in Cirrhotic Patients with Hepatocellular Carcinoma. <i>Tohoku Journal of Experimental Medicine</i> , 2012, 227, 73-81.	0.5	25
1422	Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells. <i>Oncology Reports</i> , 2012, 28, 867-873.	1.2	71
1423	Overexpression of the RD RNA binding protein in hepatitis C virus-related hepatocellular carcinoma. <i>Oncology Reports</i> , 2012, 28, 728-734.	1.2	11
1424	Autoantibodies against glucose-regulated protein 78 as serological diagnostic biomarkers in hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2012, 41, 1061-1067.	1.4	33
1425	C9orf100, a new member of the Dbl-family guanine nucleotide exchange factors, promotes cell proliferation and migration in hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2012, 5, 1169-74.	1.1	15
1426	Water extract of <i>Hedyotis Diffusa</i> Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway. <i>Oncology Reports</i> , 2012, 28, 742-748.	1.2	46
1427	Anti-proliferative effects of anandamide in human hepatocellular carcinoma cells. <i>Oncology Letters</i> , 2012, 4, 403-407.	0.8	12
1428	Efficacy of Contrast-Enhanced Ultrasonography in Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2012, 51, 1-7.	0.3	32
1429	Hepatocellular carcinoma. <i>Lancet</i> , The, 2012, 379, 1245-1255.	6.3	3,897
1430	LI-RADS: A Case-based Review of the New Categorization of Liver Findings in Patients with End-Stage Liver Disease. <i>Radiographics</i> , 2012, 32, 1977-1995.	1.4	87
1431	Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2012, 11, 458-466.	0.6	37
1432	Update on yttrium-90 based radioembolization for treatment of hepatocellular carcinoma. <i>ANZ Journal of Surgery</i> , 2012, 82, 505-509.	0.3	5
1433	Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. <i>British Journal of Surgery</i> , 2012, 99, 1622-1629.	0.1	178
1434	Natural killer cells in hepatitis C virus infection. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 775-788.	1.3	9
1435	Hepatocellular Carcinoma Serum Markers. <i>Seminars in Oncology</i> , 2012, 39, 410-433.	0.8	147
1436	Emerging roles for biomaterials in the treatment of liver disease. <i>Expert Review of Medical Devices</i> , 2012, 9, 181-188.	1.4	0
1437	TNF-Dependent Signaling Pathways in Liver Cancer: Promising Targets for Therapeutic Strategies?. <i>Digestive Diseases</i> , 2012, 30, 500-507.	0.8	16
1438	Liver resection for hepatocellular carcinoma in patients without cirrhosis. <i>British Journal of Surgery</i> , 2012, 100, 130-137.	0.1	37

#	ARTICLE	IF	CITATIONS
1439	Natural history and staging for hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2012, 1, 183-185.	1.0	6
1440	Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation. <i>Hepatology</i> , 2012, 56, 1760-1769.	3.6	48
1441	Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: experimental and clinical studies. <i>European Radiology</i> , 2012, 22, 1983-1990.	2.3	153
1442	Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1879-1890.	1.2	16
1443	Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2012, 47, 1152-1159.	2.3	11
1444	A Simple and Sensitive LC-MS/MS Method for Simultaneous Determination of Temsirolimus and Its Major Metabolite in Human Whole Blood. <i>Chromatographia</i> , 2012, 75, 1405-1413.	0.7	3
1445	CD4+CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity. <i>Immunology Letters</i> , 2012, 148, 83-89.	1.1	26
1446	Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats. <i>Saudi Pharmaceutical Journal</i> , 2012, 20, 365-370.	1.2	39
1447	PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation. <i>Journal of Surgical Research</i> , 2012, 176, 542-548.	0.8	79
1448	The effect of overweight status on the short-term and 20-y outcomes after hepatic resection in patients with hepatocellular carcinoma. <i>Journal of Surgical Research</i> , 2012, 178, 640-645.	0.8	27
1449	Current opinion on the role of resection and liver transplantation for hepatocellular cancer. <i>Indian Journal of Gastroenterology</i> , 2012, 31, 89-99.	0.7	6
1451	Hepatitis C Virus Infection and the Rising Incidence of Hepatocellular Carcinoma. <i>Mayo Clinic Proceedings</i> , 2012, 87, 7-8.	1.4	14
1452	Characterizing hepatocellular carcinoma using multi-breath-hold two-dimensional susceptibility-weighted imaging: Comparison to conventional liver MRI. <i>Clinical Radiology</i> , 2012, 67, e91-e97.	0.5	5
1453	Retrospective Study on the Use of Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients with Hepatocellular Carcinoma. <i>Academic Radiology</i> , 2012, 19, 434-439.	1.3	9
1454	Planning Ultrasound for Percutaneous Radiofrequency Ablation to Treat Small (<math>\leq 3\text{ cm}</math>) Hepatocellular Carcinomas Detected on Computed Tomography or Magnetic Resonance Imaging: A Multicenter Prospective Study to Assess Factors Affecting Ultrasound Visibility. <i>Journal of Vascular and Interventional Radiology</i> , 2012, 23, 627-634.	0.2	73
1455	From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms. <i>Genome Medicine</i> , 2012, 4, 8.	3.6	39
1456	The IL-8 Gene Polymorphisms and the Risk of the Hepatitis B Virus/Infected Patients. <i>DNA and Cell Biology</i> , 2012, 31, 1125-1130.	0.9	12
1457	Modelling survival in hepatocellular carcinoma. <i>Current Medical Research and Opinion</i> , 2012, 28, 1141-1153.	0.9	7

#	ARTICLE	IF	CITATIONS
1459	Role of the Hypoxia-Related Gene, JMJD1A, in Hepatocellular Carcinoma: Clinical Impact on Recurrence after Hepatic Resection. <i>Annals of Surgical Oncology</i> , 2012, 19, 355-364.	0.7	78
1460	An ensemble feature extraction classifier for the analysis of integrated data of HCV-HCC related DNA microarray. , 2012, , .		0
1461	Knockdown Survivin Expression Reduces the Efficacy of Curcumin Treatment in Hepatocellular Carcinoma Cells. <i>Annals of Surgical Oncology</i> , 2012, 19, 3547-3555.	0.7	15
1462	Prediction of Recurrence after Curative Resection of Hepatocellular Carcinoma using Liver Stiffness Measurement (FibroScan®). <i>Annals of Surgical Oncology</i> , 2012, 19, 4278-4286.	0.7	70
1463	Impact of restricting access to high-cost medications for hepatocellular carcinoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 465-473.	0.7	6
1464	Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. <i>Hpb</i> , 2012, 14, 285-290.	0.1	86
1465	Does transient elastography (FibroScan®) have a role in decision making in hepatocellular carcinoma?. <i>Hpb</i> , 2012, 14, 403-408.	0.1	16
1466	Applicability of <sc>BCLC</sc> stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1120-1127.	1.9	91
1467	<sc>MCM</sc>7 expression predicts postoperative prognosis for hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1505-1509.	1.9	44
1468	Expression of chondroitin-6-glucuronate C5-epimerase and cellular immune responses in patients with hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1516-1526.	1.9	14
1469	Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients. <i>American Journal of Surgery</i> , 2012, 203, 101-106.	0.9	83
1470	A randomized controlled trial of emergency treatment of bleeding esophageal varices in cirrhosis for hepatocellular carcinoma. <i>American Journal of Surgery</i> , 2012, 203, 182-190.	0.9	7
1471	Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China. <i>American Journal of Surgery</i> , 2012, 203, 741-750.	0.9	39
1472	Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence. <i>Journal of Hepatology</i> , 2012, 56, 381-388.	1.8	99
1473	Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?. <i>Journal of Hepatology</i> , 2012, 56, 686-695.	1.8	161
1474	Cell population genetics and deep sequencing: A novel approach for drivers discovery in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 1198-1200.	1.8	3
1475	EASL/EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 908-943.	1.8	5,214
1476	Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. <i>Journal of Hepatology</i> , 2012, 56, 1343-1350.	1.8	181

#	ARTICLE	IF	CITATIONS
1477	Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. <i>Journal of Hepatology</i> , 2012, 57, 330-336.	1.8	17
1478	Liver transplantation for unresectable hepatocellular carcinoma in normal livers. <i>Journal of Hepatology</i> , 2012, 57, 297-305.	1.8	49
1479	Polymorphisms of DNA repair genes in Korean hepatocellular carcinoma patients with chronic hepatitis B: Possible implications on survival. <i>Journal of Hepatology</i> , 2012, 57, 621-627.	1.8	46
1480	A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI). <i>Journal of Hepatology</i> , 2012, 57, 1013-1020.	1.8	164
1481	Hepatitis C viral protein NS5A induces EMT and participates in oncogenic transformation of primary hepatocyte precursors. <i>Journal of Hepatology</i> , 2012, 57, 1021-1028.	1.8	67
1482	Clinicopathologic Characteristics and Surgical Outcomes of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. <i>Journal of Surgical Research</i> , 2012, 175, 243-250.	0.8	35
1483	Comparison of chemiluminescence enzyme immunoassay based on magnetic microparticles with traditional colorimetric ELISA for the detection of serum $\alpha$ -fetoprotein. <i>Journal of Pharmaceutical Analysis</i> , 2012, 2, 130-135.	2.4	36
1484	Combined anti-tumor effects of IFN- $\beta$ and sorafenib on hepatocellular carcinoma in vitro and in vivo. <i>Biochemical and Biophysical Research Communications</i> , 2012, 422, 687-692.	1.0	25
1485	Silencing cathepsin S gene expression inhibits growth, invasion and angiogenesis of human hepatocellular carcinoma in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2012, 425, 703-710.	1.0	32
1486	Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. <i>Cancer Letters</i> , 2012, 319, 98-108.	3.2	30
1487	The MAP30 protein from bitter melon ( <i>Momordica charantia</i> ) seeds promotes apoptosis in liver cancer cells in vitro and in vivo. <i>Cancer Letters</i> , 2012, 324, 66-74.	3.2	92
1489	Hepatocellular carcinoma in patients with chronic liver disease: A comparison of gadoxetic acid-enhanced MRI and multiphase MDCT. <i>Clinical Radiology</i> , 2012, 67, 148-156.	0.5	60
1490	Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. <i>Digestive and Liver Disease</i> , 2012, 44, 788-792.	0.4	30
1491	Autotaxin in liver fibrosis. <i>Clinica Chimica Acta</i> , 2012, 413, 1817-1821.	0.5	51
1492	EASL and EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2012, 48, 599-641.	1.3	406
1493	Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection. <i>European Journal of Cancer</i> , 2012, 48, 1014-1022.	1.3	52
1494	Development of hepatocellular carcinomas in patients with absence of tumors on a prior ultrasound examination. <i>European Journal of Radiology</i> , 2012, 81, 1450-1454.	1.2	10
1495	CT-guided single high-dose percutaneous acetic acid injection for small hepatocellular carcinoma: A long-term follow-up study. <i>European Journal of Radiology</i> , 2012, 81, 1184-1186.	1.2	2



#	ARTICLE	IF	CITATIONS
1496	Selective and sequential transarterial chemoembolization: Survival in patients with hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2012, 81, 2290-2297.	1.2	13
1497	Adjuvant therapy options following curative treatment of hepatocellular carcinoma: A systematic review of randomized trials. <i>European Journal of Surgical Oncology</i> , 2012, 38, 286-295.	0.5	71
1498	Clinical and biological significance of Cdk10 in hepatocellular carcinoma. <i>Gene</i> , 2012, 498, 68-74.	1.0	29
1499	Association study of microRNA polymorphisms with hepatocellular carcinoma in Korean population. <i>Gene</i> , 2012, 504, 92-97.	1.0	105
1500	Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. <i>Hepatology</i> , 2012, 56, 1342-1351.	3.6	388
1501	Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. <i>Hepatology</i> , 2012, 56, 1371-1379.	3.6	130
1502	<i>In vivo</i> bioluminescent imaging of $\alpha$ -fetoprotein-producing hepatocellular carcinoma in the diethylnitrosamine-treated mouse using recombinant adenoviral vector. <i>Journal of Gene Medicine</i> , 2012, 14, 513-520.	1.4	12
1503	Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2012, 12, 127.	0.8	9
1504	Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: A long-term follow-up study. <i>BMC Cancer</i> , 2012, 12, 148.	1.1	18
1505	The efficacy of TACE combined sorafenib in advanced stages hepatocellular carcinoma. <i>BMC Cancer</i> , 2012, 12, 263.	1.1	78
1506	Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation. <i>BMC Cancer</i> , 2012, 12, 584.	1.1	50
1507	Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2012, 10, 163.	0.8	45
1508	Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study. <i>World Journal of Surgical Oncology</i> , 2012, 10, 41.	0.8	33
1509	Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early Hepatocellular carcinoma in patients with cirrhosis. <i>Journal of Hematology and Oncology</i> , 2012, 5, 37.	6.9	30
1511	The significance of serum levels of adiponectin, leptin, and hyaluronic acid in hepatocellular carcinoma of cirrhotic and noncirrhotic patients. <i>Human and Experimental Toxicology</i> , 2012, 31, 311-321.	1.1	47
1512	Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. <i>The Cochrane Library</i> , 2012, , CD002799.	1.5	61
1513	Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice. <i>Gastroenterology</i> , 2012, 143, 1660-1669.e7.	0.6	262
1514	Alpha-L-fucosidase as a tumour marker of hepatocellular carcinoma. <i>Arab Journal of Gastroenterology</i> , 2012, 13, 9-13.	0.4	36

#	ARTICLE	IF	CITATIONS
1515	Therapeutic efficacy of kaempferol against AFB1 induced experimental hepatocarcinogenesis with reference to lipid peroxidation, antioxidants and biotransformation enzymes. <i>Biomedicine and Preventive Nutrition</i> , 2012, 2, 252-259.	0.9	14
1516	Diverse roles of hepatitis B virus in liver cancer. <i>Current Opinion in Virology</i> , 2012, 2, 467-473.	2.6	46
1517	Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 216-224.	2.0	42
1518	Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: Trans-arterial radio-embolisation of HCC. <i>Cancer Treatment Reviews</i> , 2012, 38, 641-649.	3.4	38
1519	Bufotalin from <i>Venenum Bufonis</i> inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis. <i>European Journal of Pharmacology</i> , 2012, 692, 19-28.	1.7	98
1520	Predicting Survival After Liver Transplantation Using Up-to-Seven Criteria in Patients With Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2012, 44, 2438-2440.	0.3	22
1521	Sorafenib Treatment for Recurrent Hepatocellular Carcinoma After Liver Transplantation. <i>Transplantation Proceedings</i> , 2012, 44, 2754-2756.	0.3	31
1522	The influence on liver function after transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation in patients with hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2012, 111, 510-515.	0.8	22
1523	Role of glypican-3 in the early diagnosis of hepatocellular carcinoma among Egyptian patients. <i>Journal of Genetic Engineering and Biotechnology</i> , 2012, 10, 73-79.	1.5	8
1524	Brain metastases from hepatocellular carcinoma in two Caucasian Australian patients. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 1442-1445.	0.8	0
1525	Activation of sonic hedgehog signaling pathway is an independent potential prognosis predictor in human hepatocellular carcinoma patients. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2012, 24, 323-331.	0.7	34
1526	Evaluation of the effect of sorafenib using serum NX-des- $\beta$ -carboxyprothrombin in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2012, 43, n/a-n/a.	1.8	15
1527	Hepatocellular carcinoma with blood supply from parasitized omental artery: Angiographic appearance and chemoembolization. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2012, 24, 207-212.	0.7	3
1528	miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. <i>Medical Oncology</i> , 2012, 29, 1859-1865.	1.2	52
1529	Correlation of LPTM4B polymorphisms with hepatocellular carcinoma in Chinese patients. <i>Medical Oncology</i> , 2012, 29, 2744-2749.	1.2	19
1530	High co-expression of vascular endothelial growth factor receptor-1 and Snail is associated with poor prognosis after curative resection of hepatocellular carcinoma. <i>Medical Oncology</i> , 2012, 29, 2750-2761.	1.2	12
1531	Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. <i>Medical Oncology</i> , 2012, 29, 2793-2799.	1.2	40
1532	Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis. <i>Hepatology International</i> , 2012, 6, 753-762.	1.9	20

#	ARTICLE	IF	CITATIONS
1533	Dynamic Education of Macrophages in Different Areas of Human Tumors. <i>Cancer Microenvironment</i> , 2012, 5, 195-201.	3.1	36
1534	Biliary drainage for obstructive jaundice caused by unresectable hepatocellular carcinoma: the endoscopic versus percutaneous approach. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2012, 11, 636-642.	0.6	28
1535	Human Cell Culture Protocols. <i>Methods in Molecular Biology</i> , 2012, , .	0.4	11
1536	Immunoassay for serum alpha-fetoprotein using silver nanoparticles and detection via resonance light scattering. <i>Mikrochimica Acta</i> , 2012, 179, 241-248.	2.5	14
1537	Proton therapy for hepatocellular carcinoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2012, 24, 361-367.	0.7	18
1538	Quality-Improvement Guidelines for Hepatic Transarterial Chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 2012, 35, 765-774.	0.9	69
1539	A national registry of haemoglobinopathies in Greece: Deducted demographics, trends in mortality and affected births. <i>Annals of Hematology</i> , 2012, 91, 1451-1458.	0.8	72
1540	Effects of over-expression of ANXA10 gene on proliferation and apoptosis of hepatocellular carcinoma cell line HepG2. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2012, 32, 669-674.	1.0	12
1541	Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis?. <i>Japanese Journal of Radiology</i> , 2012, 30, 560-566.	1.0	65
1542	Current Status of Hepatocellular Carcinoma Treatment in Japan. <i>Clinical Drug Investigation</i> , 2012, 32, 15-23.	1.1	9
1543	Circulating Tumor Cells in Hepatocellular Carcinoma: Detection Techniques, Clinical Implications, and Future Perspectives. <i>Seminars in Oncology</i> , 2012, 39, 449-460.	0.8	70
1545	Chimioembolisations et chimiothérapies intra-artérielles hépatiques. <i>Collection De La Société Française D'imagerie Cardiaque Et Vasculaire</i> , 2012, , 119-136.	0.0	0
1547	Circulating Cell-Free Nucleic Acids: Promising Biomarkers of Hepatocellular Carcinoma. <i>Seminars in Oncology</i> , 2012, 39, 440-448.	0.8	32
1548	Liver Resection and Transplantation in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2012, 1, 71-82.	4.2	113
1549	Chronic HCV infection: epidemiological and clinical relevance. <i>BMC Infectious Diseases</i> , 2012, 12, S2.	1.3	97
1550	Elevated serum levels of Chromogranin A in hepatocellular carcinoma. <i>BMC Surgery</i> , 2012, 12, S7.	0.6	32
1551	Embolisation. <i>Collection De La Société Française D'imagerie Cardiaque Et Vasculaire</i> , 2012, , .	0.0	4
1552	Validation of the Japanese version of the EORTC hepatocellular carcinoma-specific quality of life questionnaire module (QLQ-HCC18). <i>Health and Quality of Life Outcomes</i> , 2012, 10, 58.	1.0	9

#	ARTICLE	IF	CITATIONS
1553	Epidermal Growth Factor Gene Polymorphism and Risk of Hepatocellular Carcinoma: A Meta-Analysis. PLoS ONE, 2012, 7, e32159.	1.1	47
1554	LAPTM4B Allele *2 Is a Marker of Poor Prognosis Following Hepatic Tumor Resection for Hepatocellular Carcinoma. PLoS ONE, 2012, 7, e34984.	1.1	18
1555	Regulation of Amphiregulin Gene Expression by $\beta$ -Catenin Signaling in Human Hepatocellular Carcinoma Cells: A Novel Crosstalk between FGF19 and the EGFR System. PLoS ONE, 2012, 7, e52711.	1.1	45
1556	Ultrasound Imaging of Liver Tumors – Current Clinical Applications. , 2012, , .		10
1557	Embolization of liver tumors: Past, present and future. World Journal of Radiology, 2012, 4, 405.	0.5	68
1558	An immunosuppressive subtype of neutrophils identified in patients with hepatocellular carcinoma. Journal of Clinical Biochemistry and Nutrition, 2012, 51, 204-12.	0.6	36
1559	Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Experimental and Therapeutic Medicine, 2012, 3, 171-180.	0.8	8
1560	Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World Journal of Gastroenterology, 2012, 18, 2995.	1.4	35
1561	Effect of Ultrasound-Guided Radiofrequency Ablation in Incompletely Treated Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization. Korean Journal of Radiology, 2012, 13, S104.	1.5	9
1562	Comparison of Epirubicin-Iodized Oil Suspension and Emulsion for Transcatheter Arterial Chemoembolization in VX2 Tumor. Scientific World Journal, The, 2012, 2012, 1-7.	0.8	8
1563	Hepatic tumors. , 2012, , 352-362.		0
1564	Transplante de fígado de acordo com os critérios de Milão: revisão dos últimos 10 anos. , 2012, 91, 120.	0.0	2
1565	Factors related to survival in hepatocellular carcinoma in the geographic area of Sabadell (Catalonia, Spain). Revista Espanola De Enfermedades Digestivas, 2012, 104, 242-247.	0.1	5
1566	Hepatocellular carcinoma stem cells origins and roles in hepatocarcinogenesis and disease progression. Frontiers in Bioscience - Elite, 2012, E4, 1157-1169.	0.9	27
1567	Radiographic characteristics of bone metastases from hepatocellular carcinoma. Wspolczesna Onkologia, 2012, 5, 424-431.	0.7	8
1568	Bif-1 is overexpressed in hepatocellular carcinoma and correlates with shortened patient survival. Oncology Letters, 2012, 3, 851-854.	0.8	7
1569	Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Experimental and Therapeutic Medicine, 2012, 4, 188-196.	0.8	6
1570	Embelin-induced apoptosis of HepG2 human hepatocellular carcinoma cells and blockade of HepG2 cells in the G2/M phase via the mitochondrial pathway. Experimental and Therapeutic Medicine, 2012, 4, 649-654.	0.8	12

#	ARTICLE	IF	CITATIONS
1571	Interventional therapies for hepatocellular carcinoma. <i>Cancer Imaging</i> , 2012, 12, 79-88.	1.2	26
1572	Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. <i>Oncotarget</i> , 2012, 3, 236-260.	0.8	152
1573	Suppression of Hepatocyte Proliferation by Hepatocyte Nuclear Factor 4 $\beta$ in Adult Mice. <i>Journal of Biological Chemistry</i> , 2012, 287, 7345-7356.	1.6	173
1574	Polymeric Nanoparticle-Encapsulated Hedgehog Pathway Inhibitor HPI-1 (NanoHHI) Inhibits Systemic Metastases in an Orthotopic Model of Human Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 1291-1302.	3.2	69
1575	Hepatobiliary MR imaging with gadolinium-based contrast agents. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 492-511.	1.9	121
1576	Histological differentiation grade and microvascular invasion of hepatocellular carcinoma predicted by dynamic contrast-enhanced MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 36, 641-647.	1.9	76
1577	Polyelectrolyte Capsules as Carriers for Growth Factor Inhibitor Delivery to Hepatocellular Carcinoma. <i>Macromolecular Bioscience</i> , 2012, 12, 656-665.	2.1	24
1578	Tg737 inhibition results in malignant transformation in fetal liver stem/progenitor cells by promoting cell cycle progression and differentiation arrest. <i>Molecular Carcinogenesis</i> , 2012, 51, 659-673.	1.3	13
1579	Family history of liver cancer and hepatocellular carcinoma. <i>Hepatology</i> , 2012, 55, 1416-1425.	3.6	92
1580	Notch1 and Snail in E-cadherin pathway in metastatic hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2012, 131, E163-72.	2.3	78
1581	Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. <i>Cancer</i> , 2012, 118, 4725-4736.	2.0	139
1582	A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. <i>Cancer</i> , 2012, 118, 3984-3992.	2.0	53
1583	Functional Genomic Studies: Insights into the Pathogenesis of Liver Cancer. <i>Annual Review of Genomics and Human Genetics</i> , 2012, 13, 171-205.	2.5	86
1584	Hepatic artery embolization and chemoembolization of liver tumors. , 2012, , 1344-1361.e3.		0
1585	Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. <i>Investigational New Drugs</i> , 2012, 30, 1150-1157.	1.2	10
1586	High Expression of CCL20 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma after Curative Resection. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 828-836.	0.9	38
1587	Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2012, 24, 36-43.	0.7	27
1588	Cryotherapy is Associated with Improved Clinical Outcomes of Sorafenib Therapy for Advanced Hepatocellular Carcinoma. <i>Cell Biochemistry and Biophysics</i> , 2012, 63, 159-169.	0.9	20

#	ARTICLE	IF	CITATIONS
1589	Clinical and Biological Significance of Never in Mitosis Gene A-Related Kinase 6 (NEK6) Expression in Hepatic Cell Cancer. <i>Pathology and Oncology Research</i> , 2012, 18, 201-207.	0.9	24
1590	Functional imaging techniques in hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1070-1079.	3.3	16
1591	Imaging of HCC. <i>Abdominal Imaging</i> , 2012, 37, 215-230.	2.0	67
1592	Impact of Preoperative $\alpha$ -Fetoprotein Level on Disease-Free Survival After Liver Transplantation for Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2012, 36, 1824-1831.	0.8	15
1593	HCC: current surgical treatment concepts. <i>Langenbeck's Archives of Surgery</i> , 2012, 397, 681-695.	0.8	50
1594	Resection and radiofrequency ablation in the treatment of hepatocellular carcinoma: a single-center experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 990-997.	1.3	26
1595	Austrian Joint $\alpha$ -GGH- $\alpha$ -GIR- $\alpha$ -GHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 104-110.	1.0	14
1596	Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2012, 47, 477-485.	2.3	46
1597	Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. <i>Surgery Today</i> , 2012, 42, 1-7.	0.7	145
1600	Should cirrhosis change our attitude towards treating non- $\alpha$ -hepatic cancer?. <i>Liver International</i> , 2012, 32, 21-27.	1.9	21
1601	Reduced N-cadherin expression is associated with metastatic potential and poor surgical outcomes of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 173-180.	1.4	24
1602	Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 158-164.	1.4	40
1603	Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: A meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 51-58.	1.4	91
1604	HCV-related liver cancer in people with haemophilia. <i>Haemophilia</i> , 2012, 18, 17-24.	1.0	13
1605	Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. <i>International Journal of Clinical Practice</i> , 2012, 66, 21-27.	0.8	36
1606	The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 164-171.	0.7	35
1607	Recent trend of clinical features in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2012, 42, 368-375.	1.8	82
1608	Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography. <i>Hepatology Research</i> , 2012, 42, 376-384.	1.8	51

#	ARTICLE	IF	CITATIONS
1609	Effects of interferon therapy on development of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis: A meta-analysis of randomized controlled trials. <i>Hepatology Research</i> , 2012, 42, 782-789.	1.8	11
1610	A Rare Occurrence of Hepatocellular Carcinoma Metastasis to the Mandible: Report of a Case and Review of the Literature. <i>Journal of Oral and Maxillofacial Surgery</i> , 2012, 70, 1219-1223.	0.5	14
1611	Early cancer-related death after resection of hepatocellular carcinoma. <i>Surgery</i> , 2012, 151, 232-237.	1.0	18
1612	Potentially curative treatment in patients with hepatocellular cancer—results from the liver cancer research network. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 257-265.	1.9	35
1613	Increased serum activin A differentiates alcoholic from cirrhosis of other aetiologies. <i>European Journal of Clinical Investigation</i> , 2012, 42, 815-822.	1.7	18
1614	Liver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined selection criteria. <i>Transplant International</i> , 2012, 25, 867-875.	0.8	54
1615	Resection for hepatocellular carcinoma: Is it justifiable to restrict this to the American Association for the Study of the Liver/Barcelona Clinic for Liver Cancer criteria?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 452-457.	1.4	19
1616	Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models. <i>Cancer Cell International</i> , 2012, 12, 5.	1.8	9
1617	Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: An intention-to-treat analysis. <i>Hepatology</i> , 2012, 55, 132-140.	3.6	235
1618	CD133+ liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. <i>Hepatology</i> , 2012, 55, 807-820.	3.6	206
1619	Excessive activity of apolipoprotein B mRNA editing enzyme catalytic polypeptide 2 (APOBEC2) contributes to liver and lung tumorigenesis. <i>International Journal of Cancer</i> , 2012, 130, 1294-1301.	2.3	37
1620	Proteomic research progress in lymphatic metastases of cancers. <i>Clinical and Translational Oncology</i> , 2012, 14, 21-30.	1.2	22
1621	AIB1 as an Independent Prognostic Marker in Hepatocellular Carcinoma After Hepatic Resection. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 356-360.	0.9	5
1623	Reduced High-Mobility Group Box 1 Expression Induced by RNA Interference Inhibits the Bioactivity of Hepatocellular Carcinoma Cell Line HCCLM3. <i>Digestive Diseases and Sciences</i> , 2012, 57, 92-98.	1.1	16
1624	Igf2-derived intronic miR-483 promotes mouse hepatocellular carcinoma cell proliferation. <i>Molecular and Cellular Biochemistry</i> , 2012, 361, 337-343.	1.4	19
1625	Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. <i>Molecular Biology Reports</i> , 2012, 39, 1683-1689.	1.0	29
1626	Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. <i>Angiogenesis</i> , 2012, 15, 59-70.	3.7	53
1627	Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells. <i>Cell and Tissue Research</i> , 2012, 347, 225-243.	1.5	74

#	ARTICLE	IF	CITATIONS
1628	Expression of FOXJ1 in hepatocellular carcinoma: Correlation with patients' prognosis and tumor cell proliferation. <i>Molecular Carcinogenesis</i> , 2013, 52, 647-659.	1.3	43
1629	Development of a dual-label time-resolved fluoroimmunoassay for the detection of $\alpha$ -fetoprotein and hepatitis B virus surface antigen. <i>Luminescence</i> , 2013, 28, 401-406.	1.5	22
1630	C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion. <i>World Journal of Surgical Oncology</i> , 2013, 11, 92.	0.8	22
1631	Expression of glioma-associated oncogene 2 (Gli 2) is correlated with poor prognosis in patients with hepatocellular carcinoma undergoing hepatectomy. <i>World Journal of Surgical Oncology</i> , 2013, 11, 25.	0.8	29
1632	Tumor-Associated Macrophage Promotes Tumor Progression via STAT3 Signaling in Hepatocellular Carcinoma. <i>Pathobiology</i> , 2013, 80, 146-154.	1.9	91
1634	Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2013, 12, 251-255.	0.6	10
1635	Primary Malignant Neoplasms of the Liver. , 2013, , 1089-1114.		0
1636	MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells. <i>Tumor Biology</i> , 2013, 34, 3209-3218.	0.8	49
1637	Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis. <i>BMC Gastroenterology</i> , 2013, 13, 34.	0.8	89
1638	Connexin-43 can delay early recurrence and metastasis in patients with hepatitis B-related hepatocellular carcinoma and low serum alpha-fetoprotein after radical hepatectomy. <i>BMC Cancer</i> , 2013, 13, 306.	1.1	19
1639	Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells. <i>BMC Cancer</i> , 2013, 13, 267.	1.1	49
1640	Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. <i>BMC Cancer</i> , 2013, 13, 191.	1.1	28
1641	Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2013, 13, 78.	1.1	95
1642	Operative Microwave Ablation for Hepatocellular Carcinoma: Complications, Recurrence, and Long-Term Outcomes. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 719-729.	0.9	75
1643	AEG-1/MTDH/LYRIC in Liver Cancer. <i>Advances in Cancer Research</i> , 2013, 120, 193-221.	1.9	51
1644	Hepatitis B virus X protein co-activates pregnane X receptor to induce the cytochrome P450 3A4 enzyme, a potential implication in hepatocarcinogenesis. <i>Digestive and Liver Disease</i> , 2013, 45, 1041-1048.	0.4	24
1645	Multimodal Treatment Strategies in Patients Undergoing Surgery for Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2013, 31, 112-117.	0.8	12
1646	Single-step multimodal locoregional treatment for unresectable hepatocellular carcinoma: balloon-occluded percutaneous radiofrequency thermal ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE). <i>Radiologia Medica</i> , 2013, 118, 555-569.	4.7	24



#	ARTICLE	IF	CITATIONS
1647	Living Donor Liver Transplantation for Hepatocellular Carcinoma. <i>Recent Results in Cancer Research</i> , 2013, 190, 165-179.	1.8	12
1648	Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma. <i>Molecular and Cellular Biochemistry</i> , 2013, 383, 103-112.	1.4	16
1649	Protein expression profiling of nuclear membrane protein reveals potential biomarker of human hepatocellular carcinoma. <i>Clinical Proteomics</i> , 2013, 10, 6.	1.1	16
1650	Sustained Complete Remission of Metastatic Hepatocellular Carcinoma with Single Agent Sorafenib. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 98-101.	0.6	6
1651	High SKIP expression is correlated with poor prognosis and cell proliferation of hepatocellular carcinoma. <i>Medical Oncology</i> , 2013, 30, 537.	1.2	10
1652	Staging laparoscopy in patients with hepatocellular carcinoma: is it useful?. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 826-831.	1.3	5
1653	Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2013, 48, 1249-1258.	2.3	78
1654	Inhibition of hepatocellular carcinoma by PegIFN $\alpha$ -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. <i>Journal of Gastroenterology</i> , 2013, 48, 382-390.	2.3	21
1655	Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib. <i>World Journal of Surgical Oncology</i> , 2013, 11, 171.	0.8	32
1656	The Noncytotoxic Dose of Sorafenib Sensitizes Bel-7402/5-FU Cells to 5-FU by Down-Regulating 5-FU-Induced Nrf2 Expression. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1615-1626.	1.1	17
1657	Is Liver-Specific Gadoxetic Acid-Enhanced Magnetic Resonance Imaging a Reliable Tool for Detection of Hepatocellular Carcinoma in Patients with Chronic Liver Disease?. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3313-3325.	1.1	25
1658	Presence of EpCAM $\alpha$ -positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2013, 133, 2165-2171.	2.3	200
1659	$^{18}\text{F}$ -Fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 865-873.	3.3	49
1660	Defining vascular signatures of malignant hepatic masses: role of MDCT with 3D rendering. <i>Abdominal Imaging</i> , 2013, 38, 763-773.	2.0	6
1661	Increase in CD14 $^{+}$ HLA-DR $^{+}$ /low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1421-1430.	2.0	231
1662	Hepatic Resection for Hepatocellular Carcinoma Patients on Hemodialysis for Uremia: A Nationwide Cohort Study. <i>World Journal of Surgery</i> , 2013, 37, 2402-2409.	0.8	17
1663	Total Tumor Volume Is a Better Marker of Tumor Burden in Hepatocellular Carcinoma Defined by the Milan Criteria. <i>World Journal of Surgery</i> , 2013, 37, 1348-1355.	0.8	26
1664	Does Hepatic Ischemia $\rightarrow$ Reperfusion Injury Induced by Hepatic Pedicle Clamping Affect Survival after Partial Hepatectomy for Hepatocellular Carcinoma?. <i>World Journal of Surgery</i> , 2013, 37, 192-201.	0.8	21

#	ARTICLE	IF	CITATIONS
1665	Iodine-125 Seeds Strand for Treatment of Tumor Thrombus in Inferior Vena Cava: An Experimental Study in a Rabbit Model. CardioVascular and Interventional Radiology, 2013, 36, 1371-1382.	0.9	11
1666	Predictive Factors of Downstaging of Hepatocellular Carcinoma Beyond the Milan Criteria Treated with Intra-arterial Therapies. CardioVascular and Interventional Radiology, 2013, 36, 433-439.	0.9	33
1667	Novel Percutaneous Radiofrequency Ablation of Portal Vein Tumor Thrombus: Safety and Feasibility. CardioVascular and Interventional Radiology, 2013, 36, 245-248.	0.9	11
1668	Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma. Annals of Medicine, 2013, 45, 482-487.	1.5	30
1669	Clinical significance of cell cycle inhibitors in hepatocellular carcinoma. Medical Molecular Morphology, 2013, 46, 185-192.	0.4	28
1670	Individual Profiling of Circulating Tumor Cell Composition and Therapeutic Outcome in Patients with Hepatocellular Carcinoma. Translational Oncology, 2013, 6, 420-428.	1.7	52
1671	Hepatocellular Carcinoma Likelihood on MRI Exams. Academic Radiology, 2013, 20, 694-698.	1.3	25
1672	N-WASP is highly expressed in hepatocellular carcinoma and associated with poor prognosis. Surgery, 2013, 153, 518-525.	1.0	23
1673	Detection of primary YMDD mutations in HBV-related hepatocellular carcinoma using hybridization-fluorescence polarization. Journal of Virological Methods, 2013, 187, 259-263.	1.0	3
1674	The Size of the Problem: Clinical Algorithms. Digestive Diseases, 2013, 31, 95-103.	0.8	5
1675	Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (<scp>EPOIHCC</scp>). Liver International, 2013, 33, 327-337.	1.9	70
1676	Comparison Between Resection and Transplantation in Combined Hepatocellular and Cholangiocarcinoma. Transplantation Proceedings, 2013, 45, 3041-3046.	0.3	27
1677	TMT-HCC: A tool for text mining the biomedical literature for hepatocellular carcinoma (HCC) biomarkers identification. Computer Methods and Programs in Biomedicine, 2013, 112, 640-648.	2.6	9
1678	An anthraquinone derivative, emodin sensitizes hepatocellular carcinoma cells to TRAIL induced apoptosis through the induction of death receptors and downregulation of cell survival proteins. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1175-1187.	2.2	36
1679	Is bone scintigraphy indicated in surgical work-up for hepatocellular carcinoma patients?. Journal of Surgical Research, 2013, 181, 256-261.	0.8	9
1680	Hepatocellular Carcinoma: Illustrated Guide to Systematic Radiologic Diagnosis and Staging According to Guidelines of the American Association for the Study of Liver Diseases. Radiographics, 2013, 33, 1653-1668.	1.4	81
1681	Failure of Fibrotic Liver Regeneration in Mice Is Linked to a Severe Fibrogenic Response Driven by Hepatic Progenitor Cell Activation. American Journal of Pathology, 2013, 183, 182-194.	1.9	99
1682	Prognostic Gene Expression Signature for Patients With Hepatitis C-Related Early-Stage Cirrhosis. Gastroenterology, 2013, 144, 1024-1030.	0.6	195

#	ARTICLE	IF	CITATIONS
1683	Chemical composition of total flavonoids from <i>Salvia chinensis</i> Benth and their pro-apoptotic effect on hepatocellular carcinoma cells: Potential roles of suppressing cellular NF- $\kappa$ B signaling. <i>Food and Chemical Toxicology</i> , 2013, 62, 420-426.	1.8	17
1684	DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques. <i>Cancer Gene Therapy</i> , 2013, 20, 652-662.	2.2	32
1685	Inflammatory Markers are Associated with Outcome in Patients with Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Annals of Surgical Oncology</i> , 2013, 20, 923-928.	0.7	61
1686	Microvascular Invasion Does Not Predict Long-Term Survival in Hepatocellular Carcinoma up to 2 $\hat{A}$ cm: Reappraisal of the Staging System for Solitary Tumors. <i>Annals of Surgical Oncology</i> , 2013, 20, 1223-1229.	0.7	121
1687	Short- and Long-term Outcomes after Laparoscopic and Open Hepatectomy for Hepatocellular Carcinoma: A Global Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2013, 20, 1203-1215.	0.7	174
1688	Performance Status Enhances the Selection of Treatment for Patients with Hepatocellular Carcinoma Within the Milan Criteria. <i>Annals of Surgical Oncology</i> , 2013, 20, 2035-2042.	0.7	17
1689	Liver Intervention: Angiography. , 2013, , 969-982.		0
1690	Transarterial Embolization with Sorafenib in Animal Livers: A Pharmacokinetics Study. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1657-1663.e1.	0.2	12
1691	Safety and Efficacy of Doxorubicin Drug-eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 307-315.	0.2	68
1692	Two-step Selection Criteria for Living Donor Liver Transplantation in Patients With Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2013, 45, 3310-3313.	0.3	9
1693	Antitumor and immunomodulatory activity of <i>Astragalus membranaceus</i> polysaccharides in H22 tumor-bearing mice. <i>International Journal of Biological Macromolecules</i> , 2013, 62, 287-290.	3.6	174
1694	PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. <i>Journal of Surgical Research</i> , 2013, 185, 225-230.	0.8	27
1695	Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study. <i>Journal of Hepatology</i> , 2013, 58, 495-501.	1.8	126
1696	Management of Hepatocellular Carcinoma. <i>Surgical Clinics of North America</i> , 2013, 93, 1423-1450.	0.5	34
1698	Percutaneous Ethanol Injection Injectables in the Treatment of Primary Liver Cancers. , 2013, , 317-326.		0
1699	Enhanced tumorigenesis and lymphatic metastasis of CD133+ hepatocarcinoma ascites syngeneic cell lines mediated by JNK signaling pathway in vitro and in vivo. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 337-345.	2.5	15
1700	Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases. <i>Liver International</i> , 2013, 33, 1601-1606.	1.9	60
1701	Liver Cancer and Metastases. <i>Medical Radiology</i> , 2013, , 151-166.	0.0	0

#	ARTICLE	IF	CITATIONS
1702	Advances in adenovirus-mediated p53 cancer gene therapy. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1569-1583.	1.4	50
1703	TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. <i>Hepatology</i> , 2013, 57, 1416-1425.	3.6	115
1704	Angiogenic and anti-angiogenic factor gene transcript level quantitation by quantitative real time PCR in patients with hepatocellular carcinoma. <i>Molecular Biology Reports</i> , 2013, 40, 5843-5852.	1.0	10
1705	A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2013, 11, 240.	0.8	18
1706	Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2013, 11, 190.	0.8	60
1707	A new type of protein chip to detect hepatocellular carcinoma-related autoimmune antibodies in the sera of hepatitis C virus-positive patients. <i>Proteome Science</i> , 2013, 11, 33.	0.7	14
1708	Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 65.	3.5	16
1709	Bufalin, a component in Chansu, inhibits proliferation and invasion of hepatocellular carcinoma cells. <i>BMC Complementary and Alternative Medicine</i> , 2013, 13, 185.	3.7	72
1710	Tackling hepatitis B virus-associated hepatocellular carcinoma—the future is now. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 229-268.	2.7	19
1711	Synchronous development of intrahepatic cholangiocarcinoma and hepatocellular carcinoma in different sites of the liver with chronic B-viral hepatitis: two case reports. <i>BMC Research Notes</i> , 2013, 6, 520.	0.6	10
1712	MicroRNA-200a and -200b Mediated Hepatocellular Carcinoma Cell Migration Through the Epithelial to Mesenchymal Transition Markers. <i>Annals of Surgical Oncology</i> , 2013, 20, 360-368.	0.7	42
1714	Evaluation of safety parameters and changes in serum concentration in liver transplant recipients treated with doxorubicin during the anhepatic period. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1325-1333.	1.1	2
1715	Gene expression signature of human HepG2 cell line. <i>Gene</i> , 2013, 518, 335-345.	1.0	77
1716	Evaluation of MAGE-D4 expression in hepatocellular carcinoma in Japanese patients. <i>Journal of Surgical Oncology</i> , 2013, 108, 557-562.	0.8	22
1718	Association analysis between MDR1 gene polymorphisms and risk of hepatocellular carcinoma in Chinese population. <i>Biomarkers</i> , 2013, 18, 236-241.	0.9	8
1719	Inhibitory role of Smad7 in hepatocarcinogenesis in mice and in vitro. <i>Journal of Pathology</i> , 2013, 230, 441-452.	2.1	38
1720	Interventional Radiology Techniques in Ablation. , 2013, , .		5
1721	Rhenium-188 Lipiodol for the Treatment of Hepatocellular Carcinoma (HCC). <i>Medical Radiology</i> , 2013, , 393-404.	0.0	3

#	ARTICLE	IF	CITATIONS
1722	Antitumor efficacy of CXCL12 motif chemokine ligand 14 in hepatocellular carcinoma <i>in vitro</i> and <i>in vivo</i> . <i>Cancer Science</i> , 2013, 104, 1523-1531.	1.7	42
1723	Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 2161-2181.	1.1	143
1724	CD147/EMMPRIN: an effective therapeutic target for hepatocellular carcinoma. <i>Journal of Drug Targeting</i> , 2013, 21, 224-231.	2.1	19
1725	Can methanolic extract of <i>Nigella sativa</i> seed affect glyco-regulatory enzymes in experimental hepatocellular carcinoma?. <i>Environmental Health and Preventive Medicine</i> , 2013, 18, 49-56.	1.4	19
1726	Use of Acid Sphingomyelinase for Cancer Therapy. <i>Advances in Cancer Research</i> , 2013, 117, 91-115.	1.9	23
1727	Risk factors of postoperative recurrence and adequate surgical approach to improve long-term outcomes of hepatocellular carcinoma. <i>Hpb</i> , 2013, 15, 31-39.	0.1	97
1728	Effects of hepatitis B e antigen on recurrence of hepatitis B-related hepatocellular carcinoma after curative resection: A meta-analysis. <i>Hepatology Research</i> , 2013, 43, 347-354.	1.8	8
1729	IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma. <i>Cancer Letters</i> , 2013, 329, 99-108.	3.2	11
1730	Notch1 signaling contributes to the oncogenic effect of HBx on human hepatic cells. <i>Biotechnology Letters</i> , 2013, 35, 29-37.	1.1	12
1731	Next generation sequencing reveals genetic landscape of hepatocellular carcinomas. <i>Cancer Letters</i> , 2013, 340, 247-253.	3.2	59
1732	Receptor for activated C kinase 1 promotes hepatocellular carcinoma growth by enhancing mitogen-activated protein kinase kinase 7 activity. <i>Hepatology</i> , 2013, 57, 140-151.	3.6	55
1733	Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. <i>Hepatology</i> , 2013, 57, 120-130.	3.6	52
1734	p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release. <i>Journal of Hepatology</i> , 2013, 59, 762-768.	1.8	54
1735	Safety and effectiveness of repeat arterial closure using the StarClose vascular closure device in patients with hepatic malignancy. <i>Clinical Radiology</i> , 2013, 68, e498-e501.	0.5	2
1736	Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma. <i>Translational Oncology</i> , 2013, 6, 511-519.	1.7	42
1737	Indocyanine green clearance in evaluating the recovery of liver reserve function after superselective transarterial chemoembolization. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2013, 12, 656-660.	0.6	8
1738	RIP3 Inhibits Inflammatory Hepatocarcinogenesis but Promotes Cholestasis by Controlling Caspase-8- and JNK-Dependent Compensatory Cell Proliferation. <i>Cell Reports</i> , 2013, 4, 776-790.	2.9	124
1739	Clinical Characteristics of Hepatocellular Carcinoma in Elderly Patients. <i>International Journal of Gerontology</i> , 2013, 7, 85-89.	0.7	3

#	ARTICLE	IF	CITATIONS
1740	Prediction of postoperative complications in elderly patients with hepatocellular carcinoma. <i>Journal of Surgical Research</i> , 2013, 185, 614-619.	0.8	33
1741	Transarterial Chemoembolization Treatment: Association between Multiple Treatments, Cumulative Expenditures, and Survival. <i>Value in Health</i> , 2013, 16, 760-768.	0.1	16
1742	THU-09 Hepatocellular carcinoma downstaging to transplantation. <i>Digestive and Liver Disease</i> , 2013, 45, S237.	0.4	0
1743	Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification. <i>Cancer Letters</i> , 2013, 339, 60-69.	3.2	73
1744	Factors Associated With Outcomes and Response to Therapy in Patients With Infiltrative Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 572-578.	2.4	30
1745	Ubiquitin C-terminal Hydrolase 37, a novel predictor for hepatocellular carcinoma recurrence, promotes cell migration and invasion via interacting and deubiquitinating PRP19. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013, 1833, 559-572.	1.9	56
1746	THU-10 Hepatocellular carcinoma: Resection or ablation. <i>Digestive and Liver Disease</i> , 2013, 45, S237-S238.	0.4	0
1748	15-Lipoxygenase-1/15-hydroxyeicosatetraenoic acid promotes hepatocellular cancer cells growth through protein kinase B and heat shock protein 90 complex activation. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 1031-1041.	1.2	27
1749	Knockdown of TIGAR by RNA interference induces apoptosis and autophagy in HepG2 hepatocellular carcinoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2013, 437, 300-306.	1.0	43
1750	Synergistic Effects of Family History of Hepatocellular Carcinoma and Hepatitis B Virus Infection on Risk for Incident Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1636-1645.e3.	2.4	84
1751	Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2013, 49, 3442-3449.	1.3	176
1752	Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. <i>Cancer Letters</i> , 2013, 329, 74-83.	3.2	154
1753	Bile Acids Activate YAP to Promote Liver Carcinogenesis. <i>Cell Reports</i> , 2013, 5, 1060-1069.	2.9	159
1754	Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2013, 82, 1471-1480.	1.2	31
1755	HBV Infection and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2013, 17, 375-397.	1.0	34
1757	Laparoscopic radiofrequency ablation of solitary small hepatocellular carcinoma in the caudate lobe. <i>European Journal of Surgical Oncology</i> , 2013, 39, 1236-1242.	0.5	20
1758	THU-08 Molecular signature of prognosis and outcomes in hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2013, 45, S236-S237.	0.4	1
1759	High tumor necrosis factor- $\alpha$ /interleukin-10 ratio is associated with hepatocellular carcinoma in patients with chronic hepatitis C. <i>Cytokine</i> , 2013, 62, 421-425.	1.4	47

#	ARTICLE	IF	CITATIONS
1760	Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function. <i>Clinical and Translational Oncology</i> , 2013, 15, 146-153.	1.2	14
1761	Performance of Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 243-251.	1.9	14
1762	Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 411-419.	1.9	122
1763	Time series analysis of oxidative stress response patterns in HepG2: A toxicogenomics approach. <i>Toxicology</i> , 2013, 306, 24-34.	2.0	37
1764	ACTB in cancer. <i>Clinica Chimica Acta</i> , 2013, 417, 39-44.	0.5	137
1765	Novel insight into the role of GAPDH playing in tumor. <i>Clinical and Translational Oncology</i> , 2013, 15, 167-172.	1.2	105
1766	Dramatic increase in hepatic and biliary curcumin exposure by modulation of its elimination pathway in rats. <i>Journal of Pharmacy and Pharmacology</i> , 2013, 65, 423-429.	1.2	1
1767	Liver resection and transplantation offer similar 5-year survival for Child-Pugh-Turcotte A HCC-patients with a single nodule up to 5Åcm: A multicenter, exploratory analysis. <i>European Journal of Surgical Oncology</i> , 2013, 39, 386-395.	0.5	33
1768	Wogonin induced cytotoxicity in human hepatocellular carcinoma cells by activation of unfolded protein response and inactivation of <scp>AKT</scp>. <i>Hepatology Research</i> , 2013, 43, 890-905.	1.8	34
1769	Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 730-735.	1.8	131
1770	MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor Î² receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. <i>Hepatology</i> , 2013, 58, 205-217.	3.6	233
1771	Treatment of hepatocellular carcinoma: present and future. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 469-479.	1.1	23
1772	Composite fatty acid ether amides suppress growth of liver cancer cells in vitro and in an in vivo allograft mouse model. <i>Cellular Oncology (Dordrecht)</i> , 2013, 36, 247-257.	2.1	3
1773	Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2. <i>Cancer Science</i> , 2013, 104, 750-759.	1.7	24
1774	Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2013, 144, 512-527.	0.6	600
1775	Circulating markers for prognosis of hepatocellular carcinoma. <i>Expert Opinion on Medical Diagnostics</i> , 2013, 7, 319-329.	1.6	22
1776	Control of mitogenic and motogenic pathways by miR-198, diminishing hepatoma cell growth and migration. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013, 1833, 1190-1198.	1.9	33
1777	Adipose tissue-derived stem cells as a regenerative therapy for a mouse steatohepatitis-induced cirrhosis model. <i>Hepatology</i> , 2013, 58, 1133-1142.	3.6	96

#	ARTICLE	IF	CITATIONS
1778	Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice. <i>Hepatology</i> , 2013, 58, 1021-1030.	3.6	65
1779	Chemopreventive and Therapeutic Potential of Tea Polyphenols in Hepatocellular Cancer. <i>Nutrition and Cancer</i> , 2013, 65, 329-344.	0.9	88
1780	Aberrant upregulation of LRRC1 contributes to human hepatocellular carcinoma. <i>Molecular Biology Reports</i> , 2013, 40, 4543-4551.	1.0	22
1782	Gastrodin stimulates anticancer immune response and represses transplanted H22 hepatic ascitic tumor cell growth: Involvement of NF- $\kappa$ B signaling activation in CD4+ T cells. <i>Toxicology and Applied Pharmacology</i> , 2013, 269, 270-279.	1.3	61
1783	SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt. <i>Molecular and Cellular Biochemistry</i> , 2013, 379, 191-199.	1.4	40
1784	Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor. <i>Cancer Letters</i> , 2013, 328, 176-187.	3.2	15
1785	Surgical resection versus liver transplant for patients with hepatocellular carcinoma. <i>The Cochrane Library</i> , 2013, , CD006935.	1.5	19
1786	Resection of hepatocellular cancer $\geq$ 2 cm: Results from two Western centers. <i>Hepatology</i> , 2013, 57, 1426-1435.	3.6	326
1787	Hepatic arterial phase and portal venous phase computed tomography for dose calculation of stereotactic body radiation therapy plans in liver cancer: a dosimetric comparison study. <i>Radiation Oncology</i> , 2013, 8, 264.	1.2	6
1788	PTK787/ZK222584 Combined with Interferon Alpha and 5-Fluorouracil Synergistically Inhibits VEGF Signaling Pathway in Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 517-526.	0.7	5
1789	Dynamic evaluation and quantification of microvascularization during degradable starch microspheres transarterial chemoembolisation (DSM-TACE) of HCC lesions using contrast enhanced ultrasound (CEUS): A feasibility study. <i>Clinical Hemorheology and Microcirculation</i> , 2013, 53, 337-348.	0.9	25
1790	Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis. <i>Clinical Transplantation</i> , 2013, 27, 140-147.	0.8	76
1791	Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C. <i>Digestive and Liver Disease</i> , 2013, 45, 510-515.	0.4	24
1792	Prediction of Disease-free Survival in Hepatocellular Carcinoma by Gene Expression Profiling. <i>Annals of Surgical Oncology</i> , 2013, 20, 3747-3753.	0.7	130
1793	HSP72 and gp96 in gastroenterological cancers. <i>Clinica Chimica Acta</i> , 2013, 417, 73-79.	0.5	20
1794	Small hepatocellular carcinoma: current and future approaches. <i>Hepatology International</i> , 2013, 7, 805-812.	1.9	13
1795	Synthesis of metal(II) [M=Cu, Mn, Zn] Schiff base complexes and their Pro-apoptotic activity in liver tumor cells via caspase activation. <i>Medicinal Chemistry Research</i> , 2013, 22, 4727-4736.	1.1	16
1796	Coagulation Areas Produced by Cool-Tip Radiofrequency Ablation and Microwave Ablation Using a Device to Decrease Back-Heating Effects: A Prospective Pilot Study. <i>CardioVascular and Interventional Radiology</i> , 2013, 37, 723-9.	0.9	26



#	ARTICLE	IF	CITATIONS
1797	Impairment of CD4 <sup>+</sup> cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 58, 139-149.	3.6	163
1798	Diarrhea Is a Positive Outcome Predictor for Sorafenib Treatment of Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2013, 84, 6-13.	0.9	54
1799	Biomarkers: Evaluation of Screening for and Early Diagnosis of Hepatocellular Carcinoma in Japan and China. <i>Liver Cancer</i> , 2013, 2, 31-39.	4.2	90
1800	Surgical Strategy for Liver Cancers in the Era of Effective Chemotherapy. <i>Liver Cancer</i> , 2013, 2, 47-54.	4.2	24
1801	Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK $\epsilon$ p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis. <i>Carcinogenesis</i> , 2013, 34, 1323-1330.	1.3	141
1804	Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma. <i>Oncology</i> , 2013, 84, 40-43.	0.9	22
1806	Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit. <i>Future Oncology</i> , 2013, 9, 485-491.	1.1	11
1807	Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. <i>Seminars in Liver Disease</i> , 2013, 32, 348-359.	1.8	508
1808	Fermented Wheat Germ Extract Induced Cell Death and Enhanced Cytotoxicity of Cisplatin and 5-Fluorouracil on Human Hepatocellular Carcinoma Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-9.	0.5	12
1809	Association Study of Single Nucleotide Polymorphisms in <i>XRCC1</i> Gene with Risk of Hepatocellular Carcinoma in Chinese Han Population. <i>BioMed Research International</i> , 2013, 2013, 1-6.	0.9	11
1810	Radiographic Parameters in Predicting Outcome of Patients with Hepatocellular Carcinoma Treated with Yttrium-90 Microsphere Radioembolization. <i>ISRN Oncology</i> , 2013, 2013, 1-8.	2.1	8
1811	Molecular Imaging of Hepatocellular Carcinoma Xenografts with Epidermal Growth Factor Receptor Targeted Affibody Probes. <i>BioMed Research International</i> , 2013, 2013, 1-11.	0.9	21
1812	Safety and efficacy of a peripheral intravenous bolus of Licartin for the treatment of advanced hepatocellular carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2013, 6, 1417-1422.	0.8	4
1813	Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. <i>Future Oncology</i> , 2013, 9, 403-410.	1.1	22
1814	N-acetylglucosaminyltransferase V confers hepatoma cells with resistance to anoikis through EGFR/PAK1 activation. <i>Glycobiology</i> , 2013, 23, 1097-1109.	1.3	32
1815	Surgical Management of HCC. , 2013, , .		1
1816	Aggregated time intensity curves after transarterial chemoembolization with degradable starch microspheres: A feasibility study. <i>Clinical Hemorheology and Microcirculation</i> , 2013, 55, 417-421.	0.9	3
1817	A brief comment on liver resection for hepatocellular carcinoma. <i>Gastroenterology Report</i> , 2013, 1, 184-185.	0.6	2

#	ARTICLE	IF	CITATIONS
1818	Immunohistochemical characteristics of hepatocellular carcinoma in non-cirrhotic livers. <i>Journal of Clinical Pathology</i> , 2013, 66, 687-691.	1.0	20
1819	Hepatitis B Virus-Encoded X Protein Downregulates EGFR Expression via Inducing MicroRNA-7 in Hepatocellular Carcinoma Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-10.	0.5	30
1820	Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin- $\beta^2$ (hCG $\beta^2$ ) in patients with hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 1066-1073.	0.6	17
1821	Differential Expression of Wnt Pathway Genes in Sporadic Hepatocellular Carcinomas Infected With Hepatitis B Virus Identified With OligoGE Arrays. <i>Hepatitis Monthly</i> , 2013, 13, e6192.	0.1	4
1822	Safety and Efficacy of Transcatheter Arterial Chemoembolization in the Real-Life Management of Unresectable Hepatocellular Carcinoma. <i>Hepatitis Monthly</i> , 2013, 13, e7070.	0.1	8
1823	Sonic hedgehog signaling pathway induces cell migration and invasion through focal adhesion kinase/AKT signaling-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9 in liver cancer. <i>Carcinogenesis</i> , 2013, 34, 10-19.	1.3	144
1824	The biological implication of cancer stem cells in hepatocellular carcinoma: a possible target for future therapy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 749-757.	1.4	7
1825	Multidisciplinary approach for HCC patients: hepatology for the oncologists. <i>Annals of Oncology</i> , 2013, 24, 15-23.	0.6	31
1826	Ruralâ€“urban, sex variations, and time trend of primary liver cancer incidence in China, 1988â€“2005. <i>European Journal of Cancer Prevention</i> , 2013, 22, 448-454.	0.6	15
1827	The Efficacy of High-dose 3-Dimensional Conformal Radiation Therapy in Patients With Small Hepatocellular Carcinoma Not Eligible for Other Local Modalities. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 162-166.	0.6	17
1828	Surgical Therapy for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, S30-S36.	1.1	9
1829	Laparoscopic Ultrasound for Hepatocellular Carcinoma and Colorectal Liver Metastasis. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2013, 23, 135-144.	0.4	19
1830	Retinoic Acid Decorated Albumin-Chitosan Nanoparticles for Targeted Delivery of Doxorubicin Hydrochloride in Hepatocellular Carcinoma. <i>Journal of Nanomaterials</i> , 2013, 2013, 1-12.	1.5	13
1831	Enhancement of Antitumor Activity of Low-Dose 5-Fluorouracil by Combination With Fuzheng-Yiliu Granules in Hepatoma 22 Tumor-Bearing Mice. <i>Integrative Cancer Therapies</i> , 2013, 12, 174-181.	0.8	13
1832	Increasing Incidence of Hepatocellular Carcinoma in HIV-Infected Patients in Spain. <i>Clinical Infectious Diseases</i> , 2013, 56, 143-150.	2.9	62
1833	Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia. <i>Journal of Clinical Oncology</i> , 2013, 31, 3501-3508.	0.8	396
1834	Enhancement of invasion of hepatocellular carcinoma cells through lysophosphatidic acid receptor. <i>Journal of International Medical Research</i> , 2013, 41, 55-63.	0.4	11
1835	High-Intensity Focused Ultrasound Ablation for Treatment of Hepatocellular Carcinoma and Hypersplenism. <i>Journal of Ultrasound in Medicine</i> , 2013, 32, 1855-1862.	0.8	14

#	ARTICLE	IF	CITATIONS
1836	Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 426-432.	0.8	433
1837	Novel Mouse Models of Hepatocarcinogenesis with Stepwise Accumulation of Genetic Alterations. <i>Digestive Diseases</i> , 2013, 31, 454-458.	0.8	3
1838	Recurrences of hepatocellular carcinoma following complete remission by transarterial chemoembolization or radiofrequency therapy: Focused on the recurrence patterns. <i>Hepatology Research</i> , 2013, 43, 1304-1312.	1.8	35
1839	Antiangiogenic Therapies for Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2013, 18, 430-438.	1.9	43
1840	Clinical Characteristics and Time Trends in Etiology of Hepatocellular Cancer in Germany. <i>Digestion</i> , 2013, 87, 147-159.	1.2	34
1841	Methylation Profile Analysis of DNA Repair Genes in Hepatocellular Carcinoma With MS-MLPA. <i>Diagnostic Molecular Pathology</i> , 2013, 22, 222-227.	2.1	3
1842	Comparison of the antitumor efficacy of transcatheter arterial chemoembolization with a miriplatinâ€odized oil suspension and a cisplatinâ€odized oil suspension for hepatocellular carcinoma. <i>Hepatology Research</i> , 2013, 43, 1071-1077.	1.8	9
1843	Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. <i>Hepatology Research</i> , 2013, 43, 147-154.	1.8	173
1844	Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 530-536.	1.4	82
1845	Resveratrol Downregulates Cyp2e1 and Attenuates Chemically Induced Hepatocarcinogenesis in SD Rats. <i>Journal of Toxicologic Pathology</i> , 2013, 26, 385-392.	0.3	18
1846	Depressive symptoms after treatment in hepatocellular carcinoma survivors: prevalence, determinants, and impact on healthâ€related quality of life. <i>Psycho-Oncology</i> , 2013, 22, 2347-2353.	1.0	19
1847	Optimisation of hepatocellular carcinoma surveillance in patients with viral hepatitis: a quality improvement study. <i>Internal Medicine Journal</i> , 2013, 43, 772-777.	0.5	26
1848	Tumor biology and preâ€transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation. <i>Clinical Transplantation</i> , 2013, 27, 311-318.	0.8	15
1849	Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2013, 100, 1523-1530.	0.1	425
1850	Predicting clinical outcome in a patient with chronic hepatitis B virus infection. <i>Clinical Liver Disease</i> , 2013, 2, 5-7.	1.0	0
1851	Vitamin D in chronic liver disease. <i>Liver International</i> , 2013, 33, 338-352.	1.9	138
1852	A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e114.	2.3	79
1853	Palliative Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice Using Biliary Drainage with Subsequent Transarterial Chemoembolization. <i>Journal of Palliative Medicine</i> , 2013, 16, 1026-1033.	0.6	12

#	ARTICLE	IF	CITATIONS
1854	Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients. <i>Liver International</i> , 2013, 33, 756-761.	1.9	53
1855	Improved survival trend of patients with hepatocellular carcinoma at an Australian tertiary hospital between 1995–2009. <i>Internal Medicine Journal</i> , 2013, 43, 197-203.	0.5	9
1856	Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma. <i>Liver International</i> , 2013, 33, 1441-1448.	1.9	4
1857	Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. <i>International Journal of Cancer</i> , 2013, 133, 2895-2902.	2.3	49
1858	Hepatitis B virus-induced hepatocellular carcinoma: functional roles of MICA variants. <i>Journal of Viral Hepatitis</i> , 2013, 20, 687-698.	1.0	61
1859	Evolución natural y estratificación del carcinoma hepatocelular. <i>Clinical Liver Disease</i> , 2013, 2, S33–S36.	1.0	0
1860	Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2013, 84, 108-114.	0.9	31
1861	Effect of Mst1 overexpression on the growth of human hepatocellular carcinoma HepG2 cells and the sensitivity to cisplatin in vitro. <i>Acta Biochimica Et Biophysica Sinica</i> , 2013, 45, 268-279.	0.9	13
1862	RASSF1A-Mediated Regulation of AREG via the Hippo Pathway in Hepatocellular Carcinoma. <i>Molecular Cancer Research</i> , 2013, 11, 748-758.	1.5	33
1863	Metabolic syndrome and hepatocellular carcinoma risk. <i>British Journal of Cancer</i> , 2013, 108, 222-228.	2.9	137
1864	Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2013, 109, 2072-2078.	2.9	30
1865	HBxAP1/Rsf-1-mediated HBx-hBubR1 interactions regulate the mitotic spindle checkpoint and chromosome instability. <i>Carcinogenesis</i> , 2013, 34, 1680-1688.	1.3	18
1866	A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2013, 52, 1589-1592.	0.3	12
1867	ANT2 suppression by shRNA may be able to exert anticancer effects in HCC further by restoring SOCS1 expression. <i>International Journal of Oncology</i> , 2013, 42, 574-582.	1.4	11
1868	Hepatobiliary Malignancies: Lessons from Asia. <i>Digestive Diseases</i> , 2013, 31, 130-137.	0.8	10
1869	Induction of apoptosis and suppression of angiogenesis of hepatocellular carcinoma by HS-159, a novel phosphatidylinositol 3-kinase inhibitor. <i>International Journal of Oncology</i> , 2013, 43, 201-209.	1.4	4
1870	The Notch1/cyclooxygenase-2/Snail/E-cadherin pathway is associated with hypoxia-induced hepatocellular carcinoma cell invasion and migration. <i>Oncology Reports</i> , 2013, 29, 362-370.	1.2	8
1871	Inhibitory effect of dsRNA TLR3 agonist in a rat hepatocellular carcinoma model. <i>Molecular Medicine Reports</i> , 2013, 8, 1037-1042.	1.1	16

#	ARTICLE	IF	CITATIONS
1872	Ethyl acetate extraction from a Chinese herbal formula, Jiedu Xiaozheng Yin, inhibits the proliferation of hepatocellular carcinoma cells via induction of G0/G1 phase arrest in vivo and in vitro. <i>International Journal of Oncology</i> , 2013, 42, 202-210.	1.4	37
1873	The Anticancer Properties and Apoptosis-inducing Mechanisms of Cinnamaldehyde and the Herbal Prescription Huang-Lian-Jie-Du-Tang (é»f é€€£è§£æ¹ˆ HuĀĭng LiĀĭn JiĀĎ DĀĕ Tang) in Human Hepatoma Cells. <i>Journal of Traditional and Complementary Medicine</i> , 2013, 3, 227-233.		26
1874	Icaritin reverses multidrug resistance of HepG2/ADR human hepatoma cells via downregulation of MDR1 and P-glycoprotein expression. <i>Molecular Medicine Reports</i> , 2013, 8, 1883-1887.	1.1	68
1875	Anterior approach versus conventional liver resection for hepatocellular carcinoma. <i>The Cochrane Library</i> , 0, , .	1.5	1
1877	Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention. <i>Oncology Letters</i> , 2013, 5, 1087-1092.	0.8	222
1878	Treatment of 131I-labeled anti-CD147 monoclonal antibody in VX2 carcinoma-induced liver tumors. <i>Oncology Reports</i> , 2013, 30, 246-252.	1.2	9
1879	Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. <i>The Cochrane Library</i> , 2013, , CD003046.	1.5	73
1880	Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: Effect of patient and nonpatient factors. <i>Hepatology</i> , 2013, 57, 1858-1868.	3.6	49
1881	Î±-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. <i>Hepatology</i> , 2013, 58, 1253-1262.	3.6	227
1882	Posthepatectomy HBV Reactivation in Hepatitis Bâ€“Related Hepatocellular Carcinoma Influences Postoperative Survival in Patients With Preoperative Low HBV-DNA Levels. <i>Annals of Surgery</i> , 2013, 257, 490-505.	2.1	104
1883	Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma. <i>Nuclear Medicine Communications</i> , 2013, 34, 674-681.	0.5	18
1884	Prognostic Factors Affecting Survival at Recurrence of Hepatocellular Carcinoma After Living-Donor Liver Transplantation. <i>Transplantation</i> , 2013, 96, 1008-1012.	0.5	56
1885	Suicide gene therapy for hepatocellular carcinoma cells by survivin promoter-driven expression of the herpes simplex virus thymidine kinase gene. <i>Oncology Reports</i> , 2013, 29, 1435-1440.	1.2	25
1886	Antiproliferative effects of sorafenib and pegylated IFN-Î±2b on human liver cancer cells in vitro and in vivo. <i>International Journal of Oncology</i> , 2013, 42, 1897-1903.	1.4	14
1887	Mycotoxins are conventional and novel risk biomarkers for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2013, 19, 2587.	1.4	20
1888	Total alkaloids of <i>Rubus alaeifolius</i> Poir. inhibit the STAT3 signaling pathway leading to suppression of proliferation and cell cycle arrest in a mouse model of hepatocellular carcinoma. <i>Oncology Reports</i> , 2013, 30, 1309-1314.	1.2	12
1889	Small Liver Nodule Detection With a High-Frequency Transducer in Patients With Chronic Liver Disease. <i>Journal of Ultrasound in Medicine</i> , 2013, 32, 355-359.	0.8	7
1890	Multiple Hypervascular FNH-like Lesions in a Patient with No History of Alcohol Abuse or Chronic Liver Disease. <i>Internal Medicine</i> , 2013, 52, 2225-2230.	0.3	1

#	ARTICLE	IF	CITATIONS
1891	The fibroblast growth factor receptor 2-mediated extracellular signal-regulated kinase 1/2 signaling pathway plays is important in regulating excision repair cross-complementary gene 1 expression in hepatocellular carcinoma. <i>Biomedical Reports</i> , 2013, 1, 604-608.	0.9	11
1892	Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. <i>Cancer Management and Research</i> , 2013, 5, 337.	0.9	16
1893	Suppression of hepatoma tumor growth by systemic administration of the phytotoxin gelonin driven by the survivin promoter. <i>Neoplasma</i> , 2013, 60, 469-479.	0.7	9
1894	Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report. <i>World Journal of Gastrointestinal Oncology</i> , 2013, 5, 38.	0.8	15
1895	Dickkopf-1: As a Diagnostic and Prognostic Serum Marker for Early Hepatocellular Carcinoma. <i>International Journal of Biological Markers</i> , 2013, 28, 286-297.	0.7	39
1896	The Clinical Significance of the CD163+ and CD68+ Macrophages in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e59771.	1.1	89
1897	Decrease of 5-Hydroxymethylcytosine Is Associated with Progression of Hepatocellular Carcinoma through Downregulation of TET1. <i>PLoS ONE</i> , 2013, 8, e62828.	1.1	136
1898	Prognostic Roles of Cross-Talk between Peritumoral Hepatocytes and Stromal Cells in Hepatocellular Carcinoma Involving Peritumoral VEGF-C, VEGFR-1 and VEGFR-3. <i>PLoS ONE</i> , 2013, 8, e64598.	1.1	19
1899	An RGD-Modified MRI-Visible Polymeric Vector for Targeted siRNA Delivery to Hepatocellular Carcinoma in Nude Mice. <i>PLoS ONE</i> , 2013, 8, e66416.	1.1	39
1900	Identification of Serum Monocyte Chemoattractant Protein-1 and Prolactin as Potential Tumor Markers in Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e68904.	1.1	36
1901	Therapeutic Efficacy of Percutaneous Radiofrequency Ablation versus Microwave Ablation for Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e76119.	1.1	124
1902	The Expression of CD90/Thy-1 in Hepatocellular Carcinoma: An In Vivo and In Vitro Study. <i>PLoS ONE</i> , 2013, 8, e76830.	1.1	70
1903	Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e77240.	1.1	20
1904	Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. <i>PLoS ONE</i> , 2013, 8, e82918.	1.1	13
1905	Practical Effect of Sorafenib Monotherapy on Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis. <i>Gut and Liver</i> , 2013, 7, 696-703.	1.4	68
1906	Post-Therapeutic Follow-Up and Early Detection of Recurrence in Hepatocellular Carcinoma. , 0, , .		1
1907	Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Perspectives. , 2013, , .		2
1908	Association between the C.1161G>A and C.1779C>G Genetic Variants of <i>XRCC1</i> Gene and Hepatocellular Carcinoma Risk in Chinese Population. <i>International Journal of Biological Sciences</i> , 2013, 9, 289-294.	2.6	8

#	ARTICLE	IF	CITATIONS
1909	Cellular basis of hepatic fibrosis and its role in inflammation and cancer. <i>Frontiers in Bioscience - Scholar</i> , 2013, S5, 217-230.	0.8	89
1910	Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma. <i>Scientific World Journal, The</i> , 2013, 2013, 1-8.	0.8	21
1911	Molecular Signatures of Recurrent Hepatocellular Carcinoma Secondary to Hepatitis C Virus following Liver Transplantation. <i>Journal of Transplantation</i> , 2013, 2013, 1-14.	0.3	9
1912	Treatment for Hepatocellular Carcinoma in Elderly Patients: A Literature Review. <i>Journal of Cancer</i> , 2013, 4, 635-643.	1.2	90
1913	Surgical Treatment Strategies and Prognosis of Hepatocellular Carcinoma. , 0, , .		1
1914	Interventional radiology in liver cancer. <i>Imaging</i> , 2013, 22, 20120010.	0.0	0
1915	Management of Hepatocellular Carcinoma in Homozygous $\beta^2$ -Thalassemia Cirrhotic Patients. <i>American Surgeon</i> , 2013, 79, 111-113.	0.4	3
1916	Cecal Diverticulitis after Laparoscopic Resection of Appendiceal Diverticulitis with Perforation. <i>American Surgeon</i> , 2013, 79, 114-116.	0.4	2
1917	Diagnosis and Management of Diverticula in the Jejunum and Ileum. <i>American Surgeon</i> , 2013, 79, 108-110.	0.4	7
1918	Saving Time on Morning Rounds: The Application of the Traveling Salesman Problem to Surgical Team Movement Patterns. <i>American Surgeon</i> , 2013, 79, 110-111.	0.4	1
1919	When Dabigatran and Trauma Collide. <i>American Surgeon</i> , 2013, 79, 113-114.	0.4	5
1920	Is the Research of Extracapsular Lymph Nodal Invasion Mandatory in Histological Examination of Gastric Carcinoma?. <i>American Surgeon</i> , 2013, 79, 116-117.	0.4	1
1921	The Role of Surgery in the Treatment of Hepatocellular Carcinoma. , 2013, , .		0
1922	Neoadjuvant Chemotherapy for Hepatocellular Carcinoma. , 2013, , .		3
1923	Sorafenib in the Continuum of Care for Hepatocellular Carcinoma: Challenges in Defining Optimal Practice. , 0, , .		0
1924	Management of hepatocellular carcinoma: international guidelines. <i>Italian Journal of Medicine</i> , 2013, , 136-147.	0.2	0
1925	Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2014, 1, 43.	1.8	7
1926	Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2014, 1, 35.	1.8	17

#	ARTICLE	IF	CITATIONS
1927	Hepatocellular carcinoma: epidemiology and risk factors. <i>Journal of Hepatocellular Carcinoma</i> , 2014, 1, 115.	1.8	88
1928	The Association of HMGB1 Gene with the Prognosis of HCC. <i>PLoS ONE</i> , 2014, 9, e89097.	1.1	45
1929	Comparing Staging Systems for Predicting Prognosis and Survival in Patients with Hepatocellular Carcinoma in Egypt. <i>PLoS ONE</i> , 2014, 9, e90929.	1.1	61
1930	Association of Hepatitis B Virus Pre-S Deletions with the Development of Hepatocellular Carcinoma in Qidong, China. <i>PLoS ONE</i> , 2014, 9, e98257.	1.1	38
1931	Targeting the Wnt/ $\beta$ -Catenin Signaling Pathway in Liver Cancer Stem Cells and Hepatocellular Carcinoma Cell Lines with FH535. <i>PLoS ONE</i> , 2014, 9, e99272.	1.1	93
1932	An Updated Meta-Analysis of Randomized Controlled Trials Assessing the Effect of Sorafenib in Advanced Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e112530.	1.1	24
1933	Abieslactone Induces Cell Cycle Arrest and Apoptosis in Human Hepatocellular Carcinomas through the Mitochondrial Pathway and the Generation of Reactive Oxygen Species. <i>PLoS ONE</i> , 2014, 9, e115151.	1.1	20
1934	Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. <i>Nuklearmedizin - NuclearMedicine</i> , 2014, 53, 39-45.	0.3	28
1935	Elemene Injection Induced Autophagy Protects Human Hepatoma Cancer Cells from Starvation and Undergoing Apoptosis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-8.	0.5	16
1936	Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma. <i>Scientific World Journal, The</i> , 2014, 2014, 1-8.	0.8	15
1937	A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors. <i>Journal of Hepatocellular Carcinoma</i> , 2014, 1, 1.	1.8	9
1938	The effect of using different embolic agents on survival in transarterial chemoembolization of hepatocellular carcinoma: gelfoam versus polyvinyl alcohol. <i>Diagnostic and Interventional Radiology</i> , 2014, 20, 323-329.	0.7	15
1939	Recent Advances in Liver Resection for Hepatocellular Carcinoma. <i>Frontiers in Surgery</i> , 2014, 1, 21.	0.6	35
1940	The Impact of Liver Transplantation after Surgical Treatment of Hepatocellular Carcinoma. <i>Frontiers in Surgery</i> , 2014, 1, 29.	0.6	0
1941	Effect of liver regeneration on malignant hepatic tumors. <i>World Journal of Gastroenterology</i> , 2014, 20, 16167.	1.4	51
1942	Tumor-Associated Macrophages, Inflammation and Pathogenesis of Hepatocellular Carcinoma. <i>Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research</i> , 2014, 08, .	0.1	3
1943	Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling. <i>Oncotarget</i> , 2014, 5, 2853-2863.	0.8	78
1944	Effect of Previous Interferon-based Therapy on Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. <i>International Journal of Medical Sciences</i> , 2014, 11, 707-712.	1.1	21



#	ARTICLE	IF	CITATIONS
1945	Radiological diagnosis of hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2014, 1, 137.	1.8	14
1946	TAT-LHRH conjugated low molecular weight chitosan as a gene carrier specific for hepatocellular carcinoma cells. <i>International Journal of Nanomedicine</i> , 2014, 9, 2879.	3.3	21
1947	Association study of c.910A>G and c.1686C>G polymorphisms in XRCC1 gene with risk of hepatocellular carcinoma in the Chinese population. <i>Genetics and Molecular Research</i> , 2014, 13, 1314-1322.	0.3	4
1948	Metabolic Syndrome-Related Hepatocellular Carcinoma Treated by Volumetric Modulated Arc Therapy. <i>Current Oncology</i> , 2014, 21, 340-344.	0.9	4
1949	The risk factors of early recurrence after hepatectomy in hepatocellular carcinoma. <i>Annals of Surgical Treatment and Research</i> , 2014, 86, 283.	0.4	19
1950	Role of hepatitis B virus DNA integration in human hepatocarcinogenesis. <i>World Journal of Gastroenterology</i> , 2014, 20, 6236.	1.4	75
1951	The Diagnosis and Treatment of Hepatocellular Carcinoma. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2014, 111, 101-6.	0.6	66
1952	Interventional treatment for unresectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 13453.	1.4	39
1953	Incidence of hepatocellular carcinoma in hepatitis C cirrhotic patients with and without HIV infection: a cohort study, 1999-2011. <i>Annals of Hepatology</i> , 2014, 13, 38-44.	0.6	8
1954	Stem cell and hepatocyte proliferation in hepatitis C cirrhosis and hepatocellular carcinoma: transplant implications. <i>Annals of Hepatology</i> , 2014, 13, 45-53.	0.6	12
1955	Latin American Association for the Study of the Liver (LAASL) Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. <i>Annals of Hepatology</i> , 2014, 13, S4-S40.	0.6	34
1956	Resveratrol and cancer: focus on in vivo evidence. <i>Endocrine-Related Cancer</i> , 2014, 21, R209-R225.	1.6	409
1957	MRI of the Liver. , 2014, , 139-154.		0
1958	Dysregulated expression of dickkopfs for potential detection of hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 535-548.	1.5	16
1959	Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. <i>Tumor Biology</i> , 2014, 35, 8451-8459.	0.8	25
1960	MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule. <i>Translational Oncology</i> , 2014, 7, 672-680.	1.7	11
1961	Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. <i>Tumor Biology</i> , 2014, 35, 10905-10910.	0.8	15
1962	Standardizing MELD Exceptions: Current Challenges and Future Directions. <i>Current Transplantation Reports</i> , 2014, 1, 232-237.	0.9	37

#	ARTICLE	IF	CITATIONS
1963	Integrated analyses of DNA methylation and hydroxymethylation reveal tumor suppressive roles of ECM1, ATF5, and EOMESin human hepatocellular carcinoma. <i>Genome Biology</i> , 2014, 15, 533.	3.8	57
1964	Postoperative therapy options for hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 649-661.	0.6	53
1965	The aPKC <sup>1</sup> blocking agent ATM negatively regulates EMT and invasion of hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2014, 5, e1129-e1129.	2.7	23
1966	Risk factors for early intrahepatic distant recurrence after radiofrequency ablation for hepatocellular carcinoma in Egyptian patients. <i>Journal of Digestive Diseases</i> , 2014, 15, 676-683.	0.7	7
1967	Embolization. , 2014, , .		4
1968	IGFBP1 in epithelial circulating tumor cells as a potential response marker to selective internal radiation therapy in hepatocellular carcinoma. <i>Biomarkers in Medicine</i> , 2014, 8, 687-698.	0.6	11
1969	Tivantinib: critical review with a focus on hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1563-1574.	1.9	18
1971	Rho GDP Dissociation Inhibitor Beta Promotes Cell Proliferation and Invasion by Modulating the AKT Pathway in Hepatocellular Carcinoma. <i>DNA and Cell Biology</i> , 2014, 33, 781-786.	0.9	13
1972	Novel Aspects of the Liver Microenvironment in Hepatocellular Carcinoma Pathogenesis and Development. <i>International Journal of Molecular Sciences</i> , 2014, 15, 9422-9458.	1.8	73
1973	Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome. <i>ISRN Hepatology</i> , 2014, 2014, 1-25.	0.9	18
1974	Predictive value of indocyanine green retention rate with respect to complications of radiofrequency ablation in 878 patients with hepatocellular carcinoma. <i>International Journal of Hyperthermia</i> , 2014, 30, 402-407.	1.1	7
1975	Effects of cordycepin on HepG2 and EA.hy926 cells: Potential antiproliferative, antimetastatic and anti-angiogenic effects on hepatocellular carcinoma. <i>Oncology Letters</i> , 2014, 7, 1556-1562.	0.8	42
1976	Incidence, risk factors, and prognosis of acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma: A prospective cohort study. <i>Indian Journal of Cancer</i> , 2014, 51, 3.	0.2	9
1977	Association of Upregulated HMGB1 and c-IAP2 Proteins With Hepatocellular Carcinoma Development and Progression. <i>Hepatitis Monthly</i> , 2014, 14, e23552.	0.1	3
1978	Hepatitis B Virus X Upregulates HuR Protein Level to Stabilize HER2 Expression in Hepatocellular Carcinoma Cells. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	27
1979	Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma. <i>Clinical Science</i> , 2014, 126, 243-252.	1.8	23
1980	Hepatocellular Carcinoma Presenting with Obstructive Jaundice during Pregnancy. <i>Case Reports in Surgery</i> , 2014, 2014, 1-4.	0.2	3
1981	WNT/β-catenin pathway activation in hepatocellular carcinoma: a clinical perspective. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 0, , 49.	5.5	5

#	ARTICLE	IF	CITATIONS
1982	Plasmid Transfer of Plasminogen K1-5 Reduces Subcutaneous Hepatoma Growth by Affecting Inflammatory Factors. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	0
1983	Clinical utility of simultaneous measurement of alpha-fetoprotein and des-Î³-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects. <i>BioScience Trends</i> , 2014, 8, 266-273.	1.1	40
1984	Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis. <i>Molecular and Clinical Oncology</i> , 2014, 2, 1125-1134.	0.4	33
1985	Liquiritigenin Induces Tumor Cell Death through Mitogen-Activated Protein Kinase- (MPAKs-) Mediated Pathway in Hepatocellular Carcinoma Cells. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	25
1986	Control of the Inflammatory Response Mechanisms Mediated by Natural and Induced Regulatory T-Cells in HCV-, HTLV-1-, and EBV-Associated Cancers. <i>Mediators of Inflammation</i> , 2014, 2014, 1-15.	1.4	27
1987	Nucleolin identified by comparative mass-spectra analysis is a potential marker for invasive progression of hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2014, 10, 1489-1494.	1.1	4
1988	Non-Hypervascular Hypointense Nodules ≥1 cm on the Hepatobiliary Phase of Gadoteric Acid-Enhanced Magnetic Resonance Imaging in Cirrhotic Livers. <i>Digestive Diseases</i> , 2014, 32, 678-689.	0.8	26
1989	Prevalence of Risk Factors for Liver Disease in a Random Population Sample in Southern Germany. <i>Zeitschrift Fur Gastroenterologie</i> , 2014, 52, 558-563.	0.2	3
1991	Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization. <i>Hpb</i> , 2014, 16, 327-335.	0.1	19
1992	Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1056-1064.	1.4	41
1993	The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1305-1313.	1.5	22
1994	The role of <i>Foxp7</i> expression in hepatocellular carcinoma and adjacent non-tumor liver tissue. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1822-1829.	1.4	23
1995	miR-141 targets ZEB2 to suppress HCC progression. <i>Tumor Biology</i> , 2014, 35, 9993-9997.	0.8	35
1996	Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 942-952.	1.9	27
1997	Specific molecular signatures of non-tumor liver tissue may predict a risk of hepatocarcinogenesis. <i>Cancer Science</i> , 2014, 105, 749-754.	1.7	23
1998	Microsphere priming facilitates induction of potent therapeutic T-cell immune responses against autochthonous liver cancers. <i>European Journal of Immunology</i> , 2014, 44, 1213-1224.	1.6	17
1999	Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1463-1469.	1.4	26
2000	Waiting Time and Explant Pathology in Transplant Recipients With Hepatocellular Carcinoma: A Novel Study Using National Data. <i>American Journal of Transplantation</i> , 2014, 14, 1657-1663.	2.6	23

#	ARTICLE	IF	CITATIONS
2001	Specific miRNA expression profiles of non-tumor liver tissue predict a risk for recurrence of hepatocellular carcinoma. <i>Hepatology Research</i> , 2014, 44, 631-638.	1.8	20
2002	Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway – A population-based cohort study. <i>Cancer Epidemiology</i> , 2014, 38, 741-747.	0.8	14
2003	JNK signalling in cancer: in need of new, smarter therapeutic targets. <i>British Journal of Pharmacology</i> , 2014, 171, 24-37.	2.7	292
2004	Chaperoned function of HSP72 in hepatocellular carcinomas. , 2014, , .		0
2005	Post-therapeutic needle biopsy in patients with hepatocellular carcinoma is a useful tool to evaluate response to proton irradiation. <i>Hepatology Research</i> , 2014, 44, 403-409.	1.8	3
2006	Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 305-312.	1.9	28
2007	Comparison of inflammation-based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2014, 21, 682-688.	1.4	72
2008	Ionizable Amphiphilic Dendrimer-Based Nanomaterials with Alkyl-Substituted Amines for Tunable siRNA Delivery to the Liver Endothelium In Vivo. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 14397-14401.	7.2	80
2009	Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma. <i>Hepatology Research</i> , 2014, 44, 149-158.	1.8	34
2010	Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma. <i>Cancer Science</i> , 2014, 105, 354-358.	1.7	9
2011	Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials. <i>Hepatology Research</i> , 2014, 44, 259-269.	1.8	23
2012	Hypomethylation of long interspersed nuclear element 1 promoter is associated with poor outcomes for curative resected hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 136-146.	1.9	40
2013	Predicting recurrence patterns after resection of hepatocellular cancer. <i>Hpb</i> , 2014, 16, 943-953.	0.1	54
2014	Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. <i>Journal of Surgical Oncology</i> , 2014, 109, 533-541.	0.8	22
2015	Combined hepatocellular-cholangiocarcinoma: A population-level analysis of an uncommon primary liver tumor. <i>Liver Transplantation</i> , 2014, 20, 952-959.	1.3	122
2016	Increased serum mitochondrial creatine kinase activity as a risk for hepatocarcinogenesis in chronic hepatitis C patients. <i>International Journal of Cancer</i> , 2014, 135, 871-879.	2.3	6
2017	Laparoscopic Resection of Hepatocellular Carcinoma: When, Why, and How? A Single-Center Experience. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2014, 24, 223-228.	0.5	13
2018	Treatment Strategies of Intermediate-Stage Hepatocellular Carcinomas in Japan (Barcelona Clinic Liver) Tj ETQq1 1 0,784314.rgBT /Over 14	0,9	14

#	ARTICLE	IF	CITATIONS
2019	The Pathogenesis of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2014, 32, 545-553.	0.8	45
2020	The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 144-153.	1.1	217
2021	Advancing the High Throughput Identification of Liver Fibrosis Protein Signatures Using Multiplexed Ion Mobility Spectrometry. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1119-1127.	2.5	51
2022	Intent-to-Treat Analysis of Liver Transplant for Hepatocellular Carcinoma in the MELD Era: Impact of Hepatitis C and Advanced Status. <i>Digestive Diseases and Sciences</i> , 2014, 59, 3062-3072.	1.1	2
2023	Tumor vascular homing endoglin-targeted radioimmunotherapy in hepatocellular carcinoma. <i>Tumor Biology</i> , 2014, 35, 12205-12215.	0.8	6
2024	Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. <i>Current Pathobiology Reports</i> , 2014, 2, 245-256.	1.6	30
2025	Liver resection and radiofrequency ablation of very early hepatocellular carcinoma cases (single) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 50	0.8	37
2026	Hangzhou criteria for liver transplantation in hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 200-204.	0.8	18
2027	Trends in Epidemiology, Treatment, and Survival of Hepatocellular Carcinoma Patients Between 1998 and 2009. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 279-289.	1.1	80
2028	The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma. <i>Gut Microbes</i> , 2014, 5, 441-445.	4.3	66
2029	Correlation Between Biological Marker Expression and Fluorine-18 Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma. <i>American Journal of Clinical Pathology</i> , 2014, 142, 391-397.	0.4	24
2030	The use of cryoablation in treating liver tumors. <i>Expert Review of Medical Devices</i> , 2014, 11, 41-52.	1.4	11
2031	Treatment of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2014, 32, 554-563.	0.8	33
2032	Clinical prognostic value of CD4+CD25+FOXP3+regulatory T cells in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 1357-65.	1.4	26
2033	Prediction of Hepatocellular Carcinoma Recurrence in Patients With Low Hepatitis B Virus DNA Levels and High Preoperative Hepatitis B Surface Antigen Levels. <i>JAMA Surgery</i> , 2014, 149, 519.	2.2	43
2034	Aberrant DNA Methylation of G-protein-coupled Bile Acid Receptor Gpbar1 ( <i>TGR5</i> ) is a Potential Biomarker for Hepatitis B Virus Associated Hepatocellular Carcinoma. <i>International Journal of Medical Sciences</i> , 2014, 11, 164-171.	1.1	56
2035	Molecular Profiling of Liver Tumors: Classification and Clinical Translation for Decision Making. <i>Seminars in Liver Disease</i> , 2014, 34, 363-375.	1.8	47
2036	HIF-1a Plays a Role in the Chemotactic Migration of Hepatocarcinoma Cells Through the Modulation of CXCL6 Expression. <i>Cellular Physiology and Biochemistry</i> , 2014, 34, 1536-1546.	1.1	46

#	ARTICLE	IF	CITATIONS
2037	Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study. <i>Molecular and Clinical Oncology</i> , 2014, 2, 1047-1054.	0.4	18
2038	Transarterial therapy: An evolving treatment modality of hepatocellular carcinoma. <i>Saudi Journal of Gastroenterology</i> , 2014, 20, 333.	0.5	6
2039	Autoantibody Response to Murine Double Minute 2 Protein in Immunodiagnosis of Hepatocellular Carcinoma. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	0.9	8
2040	Perspectives on a combined test of multi serum biomarkers in China: Towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. <i>Drug Discoveries and Therapeutics</i> , 2014, 8, 102-109.	0.6	27
2041	VEGFA Genomic Amplification Tailors Treatment of HCCs with Sorafenib. <i>Cancer Discovery</i> , 2014, 4, 640-641.	7.7	10
2042	Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	10
2043	Radiofrequency Ablation Versus Surgical Resection for Small Unifocal Hepatocellular Carcinomas. <i>Medicine (United States)</i> , 2014, 93, e271.	0.4	32
2044	Tissue Biomarkers of Prognostic Significance in Hepatocellular Carcinoma. <i>Advances in Anatomic Pathology</i> , 2014, 21, 270-284.	2.4	21
2045	SALL4 Immunoreactivity Predicts Prognosis in Western Hepatocellular Carcinoma Patients but Is a Rare Event. <i>American Journal of Surgical Pathology</i> , 2014, 38, 966-972.	2.1	35
2046	Preserving hepatic artery flow during portal triad blood inflow occlusion reduces the outgrowth of hepatocarcinoma in mice after ischemia-reperfusion. <i>Hepatology Research</i> , 2014, 44, 1224-1233.	1.8	1
2047	Effect of combined mutations in the enhancer and basal core promoter of hepatitis B virus on development of hepatocellular carcinoma in China. <i>Hepatology Research</i> , 2014, 44, 1186-1195.	1.8	13
2048	Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib. <i>Hepatology Research</i> , 2014, 44, 1268-1276.	1.8	24
2049	Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis. <i>Modern Pathology</i> , 2014, 27, 420-432.	2.9	33
2050	Decorin deficiency promotes hepatic carcinogenesis. <i>Matrix Biology</i> , 2014, 35, 194-205.	1.5	71
2051	Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2014, 146, 1691-1700.e3.	0.6	576
2052	Expression and prognostic significance of p21-activated kinase 6 in hepatocellular carcinoma. <i>Journal of Surgical Research</i> , 2014, 189, 81-88.	0.8	37
2053	Postoperative but not preoperative treatment with sorafenib inhibits liver regeneration in rats. <i>Journal of Surgical Research</i> , 2014, 191, 331-338.	0.8	1
2054	Hepatic RIG-I Predicts Survival and Interferon- $\gamma$ Therapeutic Response in Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2014, 25, 49-63.	7.7	182

#	ARTICLE	IF	CITATIONS
2055	Percutaneous treatment of hepatocellular carcinoma in patients with cirrhosis: A comparison of the safety of cryoablation and radiofrequency ablation. <i>European Journal of Radiology</i> , 2014, 83, 632-638.	1.2	40
2056	Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC. <i>Journal of Hepatology</i> , 2014, 61, 589-593.	1.8	28
2057	Laparoscopic resection of hepatocellular carcinoma: a French survey in 351 patients. <i>Hpb</i> , 2014, 16, 357-365.	0.1	104
2058	The role of Aurora B expression in non-tumor liver tissues of patients with hepatocellular carcinoma. <i>International Journal of Clinical Oncology</i> , 2014, 19, 622-628.	1.0	10
2059	Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. <i>Journal of Gastroenterology</i> , 2014, 49, 117-125.	2.3	51
2060	Paclitaxel-loaded nanoparticles decorated with anti-CD133 antibody: a targeted therapy for liver cancer stem cells. <i>Journal of Nanoparticle Research</i> , 2014, 16, 1.	0.8	17
2061	Role of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis. <i>Alexandria Journal of Medicine</i> , 2014, 50, 221-226.	0.4	18
2062	Molecular Therapies in Hepatocellular Carcinoma: What Can We Target?. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1688-1697.	1.1	39
2063	Genetic polymorphisms of XRCC1 gene and susceptibility to hepatocellular carcinoma in Chinese population. <i>Medical Oncology</i> , 2014, 31, 887.	1.2	1
2064	Does Anti-HBV Therapy Benefit the Prognosis of HBV-Related Hepatocellular Carcinoma Following Hepatectomy?. <i>Annals of Surgical Oncology</i> , 2014, 21, 1010-1015.	0.7	15
2065	Surgery Versus Transarterial Chemoembolization for Solitary Large Hepatocellular Carcinoma of BCLC Stage A. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 555-561.	0.9	37
2066	Treatment Options and Surveillance Strategies After Therapy for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 758-766.	0.7	51
2067	Association analysis between the c.1804C>A genetic polymorphism of XRCC1 gene and risk of hepatocellular carcinoma in Chinese population. <i>Medical Oncology</i> , 2014, 31, 854.	1.2	4
2068	Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. <i>Medical Oncology</i> , 2014, 31, 843.	1.2	12
2069	An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 121-132.	2.0	39
2070	Icariin Synergizes with Arsenic Trioxide to Suppress Human Hepatocellular Carcinoma. <i>Cell Biochemistry and Biophysics</i> , 2014, 68, 427-436.	0.9	35
2071	Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-1R/PI3K/Akt signaling pathway activation. <i>Tumor Biology</i> , 2014, 35, 303-313.	0.8	14
2072	Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma. <i>Tumor Biology</i> , 2014, 35, 2327-2333.	0.8	15

#	ARTICLE	IF	CITATIONS
2073	MicroRNAs and liver disease: viral hepatitis, liver fibrosis and hepatocellular carcinoma. <i>Postgraduate Medical Journal</i> , 2014, 90, 106-112.	0.9	18
2074	Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies. <i>Seminars in Cell and Developmental Biology</i> , 2014, 27, 86-95.	2.3	22
2075	UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2014, 25, 196-209.	7.7	261
2076	Microfluidic fabrication of 6-methoxyethylamino numonafide-eluting magnetic microspheres. <i>Acta Biomaterialia</i> , 2014, 10, 742-750.	4.1	19
2077	Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis. <i>Tumor Biology</i> , 2014, 35, 7407-7413.	0.8	45
2078	Genomic portrait of resectable hepatocellular carcinomas: Implications of <i>RB1</i> and <i>FGF19</i> aberrations for patient stratification. <i>Hepatology</i> , 2014, 60, 1972-1982.	3.6	345
2079	Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. <i>Hepatology</i> , 2014, 59, 1577-1590.	3.6	290
2080	Haplotype-based case-control study of DNA repair gene <i>XRCC3</i> and hepatocellular carcinoma risk in a Chinese population. <i>Tumor Biology</i> , 2014, 35, 3415-3419.	0.8	9
2081	Anticancer effects of deproteinized asparagus polysaccharide on hepatocellular carcinoma in vitro and in vivo. <i>Tumor Biology</i> , 2014, 35, 3517-3524.	0.8	27
2082	<i>SERPINB3</i> is associated with <i>TGF-<math>\beta</math>1</i> and cytoplasmic $\beta$ -catenin expression in hepatocellular carcinomas with poor prognosis. <i>British Journal of Cancer</i> , 2014, 110, 2708-2715.	2.9	57
2083	Dairy products and risk of hepatocellular carcinoma: The European Prospective Investigation into Cancer and Nutrition. <i>International Journal of Cancer</i> , 2014, 135, 1662-1672.	2.3	58
2084	Comparison of microwave ablation and surgical resection for treatment of hepatocellular carcinomas conforming to Milan criteria. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1500-1507.	1.4	64
2085	Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2014, 134, 342-351.	2.3	97
2086	HCC therapies—lessons learned. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 447-452.	8.2	128
2087	Effect of N-acetylcysteine on $\beta$ -radiation-induced cytotoxicity in human hepatocellular carcinoma cells. <i>Biomedicine and Aging Pathology</i> , 2014, 4, 317-321.	0.8	1
2088	Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design. <i>Clinical Cancer Research</i> , 2014, 20, 2072-2079.	3.2	341
2089	British HIV Association guidelines for HIV-associated malignancies 2014. <i>HIV Medicine</i> , 2014, 15, 1-92.	1.0	67
2090	Bone Marrow-Derived Stromal Cell Therapy in Cirrhosis: Clinical Evidence, Cellular Mechanisms, and Implications for the Treatment of Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 786-803.	0.4	22



#	ARTICLE	IF	CITATIONS
2091	Hepatitis C Virus: Epidemiology and Clinical Features of Related Cancer. , 2014, , 87-112.		0
2092	Survival Benefit of Transplantation for Recurrence of Hepatocellular Carcinoma After Liver Resection. Transplantation Proceedings, 2014, 46, 2287-2289.	0.3	5
2093	<sc>GIDEON</sc> (Global Investigation of therapeutic <sc>DE</sc> cisions in hepatocellular) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Clinical Practice, 2014, 68, 609-617.	0.8	215
2094	Changes in glucose-6-phosphate dehydrogenase expression results in altered behavior of HBV-associated liver cancer cells. American Journal of Physiology - Renal Physiology, 2014, 307, G611-G622.	1.6	36
2095	Three-Dimensional Personalized Monte Carlo Dosimetry in <sup>90</sup>Y Resin Microspheres Therapy of Hepatic Metastases: Nontumoral Liver and Lungs Radiation Protection Considerations and Treatment Planning Optimization. Journal of Nuclear Medicine, 2014, 55, 405-413.	2.8	31
2098	Quality of life after surgical resection compared with radiofrequency ablation for small hepatocellular carcinomas. British Journal of Surgery, 2014, 101, 1006-1015.	0.1	41
2099	Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET. Clinical Cancer Research, 2014, 20, 2959-2970.	3.2	186
2100	Advances in preoperative assessment of liver function. Hepatobiliary and Pancreatic Diseases International, 2014, 13, 361-370.	0.6	60
2101	Effect of bone marrowâ€derived mesenchymal stromal cells on hepatoma. Cytotherapy, 2014, 16, 1197-1206.	0.3	25
2102	Transarterial Chemoembolization vs. Radiofrequency Ablation for the Treatment of Single Hepatocellular Carcinoma 2â€cm or Smaller. American Journal of Gastroenterology, 2014, 109, 1234-1240.	0.2	65
2103	Stem cell-mediated delivery of SPIO-loaded gold nanoparticles for the theranosis of liver injury and hepatocellular carcinoma. Nanotechnology, 2014, 25, 405101.	1.3	43
2104	Prognosis prediction and staging. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 855-865.	1.0	20
2105	Chemoembolization of intermediate stage hepatocellular carcinomas: Results from a Nordic tertiary liver cancer center. Indian Journal of Gastroenterology, 2014, 33, 322-329.	0.7	6
2106	Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma. Journal of Zhejiang University: Science B, 2014, 15, 713-719.	1.3	9
2107	Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage B). Japanese Journal of Radiology, 2014, 32, 644-649.	1.0	42
2108	Diagnostic Imaging of Hepatic Lesions in Adults. Surgical Oncology Clinics of North America, 2014, 23, 789-820.	0.6	20
2110	Integration of genomic information in the clinical management of HCC. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 831-842.	1.0	19
2111	Radiofrequency ablation guided by contrast-enhanced ultrasound for hepatic malignancies: Preliminary results. Clinical Radiology, 2014, 69, 1129-1135.	0.5	21

#	ARTICLE	IF	CITATIONS
2112	Genetic insights on host and hepatitis B virus in liver diseases. <i>Mutation Research - Reviews in Mutation Research</i> , 2014, 762, 65-75.	2.4	18
2113	Prognostic Significance of Preoperative Peripheral Blood Monocyte Ratio in Patients with Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2014, 38, 2377-2385.	0.8	9
2114	Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1 $\alpha$ pathway in patients with hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1507-1515.	1.2	27
2115	Association of variants in HLA-DP on chromosome 6 with chronic hepatitis B virus infection and related phenotypes. <i>Amino Acids</i> , 2014, 46, 1819-1826.	1.2	9
2116	Down-regulation of Gli-1 inhibits hepatocellular carcinoma cell migration and invasion. <i>Molecular and Cellular Biochemistry</i> , 2014, 393, 283-291.	1.4	43
2117	Reprogramming Using microRNA-302 Improves Drug Sensitivity in Hepatocellular Carcinoma Cells. <i>Annals of Surgical Oncology</i> , 2014, 21, 591-600.	0.7	29
2118	Is Resection or Transplantation the ideal Treatment in Patients with Hepatocellular Carcinoma in Cirrhosis if Both Are Possible? A Systematic Review and Metaanalysis. <i>Annals of Surgical Oncology</i> , 2014, 21, 3096-3107.	0.7	57
2119	Prognostic impact of telomere maintenance gene polymorphisms on hepatocellular carcinoma patients with chronic hepatitis B. <i>Hepatology</i> , 2014, 59, 1912-1920.	3.6	29
2120	BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 2410-2423.	3.2	18
2121	Autotaxin in the crosshairs: Taking aim at cancer and other inflammatory conditions. <i>FEBS Letters</i> , 2014, 588, 2712-2727.	1.3	102
2122	Hepatic venous congestion in living donor grafts in liver transplantation: Is there an effect on hepatocellular carcinoma recurrence?. <i>Liver Transplantation</i> , 2014, 20, 784-790.	1.3	17
2123	Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. <i>Japanese Journal of Radiology</i> , 2014, 32, 260-265.	1.0	82
2124	Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. <i>Medical Oncology</i> , 2014, 31, 969.	1.2	34
2125	Association of IL-6 polymorphisms with hepatocellular carcinoma risk: evidences from a meta-analysis. <i>Tumor Biology</i> , 2014, 35, 3551-3561.	0.8	15
2126	High expression of Golgi phosphoprotein-3 is associated with poor survival in patients with hepatocellular carcinoma. <i>Tumor Biology</i> , 2014, 35, 8625-8632.	0.8	16
2128	Mass-Selected Site-Specific Core-Fucosylation of Ceruloplasmin in Alcohol-Related Hepatocellular Carcinoma. <i>Journal of Proteome Research</i> , 2014, 13, 2887-2896.	1.8	48
2129	OATP1B3 expression is strongly associated with Wnt/ $\beta$ -catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 1080-1087.	1.8	101
2130	Adjuvant interferon therapy after surgical treatment for hepatitis B virus-related hepatocellular carcinoma: A meta-analysis. <i>Hepatology Research</i> , 2014, 44, 209-217.	1.8	13

#	ARTICLE	IF	CITATIONS
2131	Staphylococcal nuclease domain containing $\alpha$ 1 (SND1) promotes migration and invasion via angiotensin II type 1 receptor (AT1R) and TGF $\beta$ 2 signaling. <i>FEBS Open Bio</i> , 2014, 4, 353-361.	1.0	41
2132	Prediction of aggressiveness in early-stage hepatocellular carcinoma for selection of surgical resection. <i>Journal of Hepatology</i> , 2014, 60, 1219-1224.	1.8	39
2133	Efficacy and Nontarget Effects of Transarterial Chemoembolization in Bridging of Hepatocellular Carcinoma Patients to Liver Transplantation: A Histopathologic Study. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1018-1026.e4.	0.2	17
2134	Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization. <i>Clinical Biochemistry</i> , 2014, 47, 184-190.	0.8	22
2135	Surveillance for Hepatocellular Carcinoma. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, S50-S56.	0.4	4
2136	ZPDC glycoprotein (24kDa) induces apoptosis and enhances activity of NK cells in N-nitrosodiethylamine-injected Balb/c. <i>Cellular Immunology</i> , 2014, 289, 1-6.	1.4	21
2137	Percutaneous microwave ablation for hepatocellular carcinoma adjacent to large vessels: A long-term follow-up. <i>European Journal of Radiology</i> , 2014, 83, 552-558.	1.2	83
2138	O impacto da hepatite C em Portugal. <i>GE Jornal Português De Gastreenterologia</i> , 2014, 21, 44-54.	0.0	13
2139	Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach. <i>Hepatology</i> , 2014, 59, 1471-1481.	3.6	52
2140	Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, S112-S121.	0.4	24
2141	Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma. <i>Biomaterials</i> , 2014, 35, 7479-7487.	5.7	10
2142	Characteristics of combined hepatocellular-cholangiocarcinoma and comparison with intrahepatic cholangiocarcinoma. <i>European Journal of Surgical Oncology</i> , 2014, 40, 976-981.	0.5	53
2143	The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The APuri Recommendations. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, S3-S26.	0.4	50
2144	Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma. <i>Oncology Reports</i> , 2014, 31, 1305-1313.	1.2	19
2145	Aberrant Regulation of Alternative Pre-mRNA Splicing in Hepatocellular Carcinoma. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2014, 24, 133-149.	0.4	12
2146	Role of mitochondria in alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 2136.	1.4	107
2147	Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2014, 44, 44-52.	1.4	41
2148	Role of tumor-associated macrophages in the angiogenesis of well-differentiated hepatocellular carcinoma: Pathological-radiological correlation. <i>Oncology Reports</i> , 2014, 31, 2499-2505.	1.2	17

#	ARTICLE	IF	CITATIONS
2149	Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (â‰¥10 cm) hepatocellular carcinomas: A clinical study. <i>Molecular and Clinical Oncology</i> , 2014, 2, 839-844.	0.4	28
2150	Mitogen-activated protein kinase pathway is pivotal for anoikis resistance in metastatic hepatoma cells. <i>Molecular Medicine Reports</i> , 2014, 9, 1121-1127.	1.1	10
2151	Upregulation of microRNA-25 associates with prognosis in hepatocellular carcinoma. <i>Diagnostic Pathology</i> , 2014, 9, 47.	0.9	47
2152	Reduced Organic Anion Transporter Expression Is a Risk Factor for Hepatocellular Carcinoma in Chronic Hepatitis C Patients: A Propensity Score Matching Study. <i>Oncology</i> , 2014, 86, 53-62.	0.9	18
2153	Liver transplantation for hepatocellular carcinoma: how far have we come and what is the future?. <i>Hepatic Oncology</i> , 2014, 1, 309-321.	4.2	1
2154	Latexin exhibits tumor suppressor potential in hepatocellular carcinoma. <i>Oncology Reports</i> , 2014, 31, 1364-1372.	1.2	17
2155	Nationwide Study of 4741 Patients With Non-B Non-C Hepatocellular Carcinoma With Special Reference to the Therapeutic Impact. <i>Annals of Surgery</i> , 2014, 259, 336-345.	2.1	62
2156	Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H22 murine hepatocarcinoma model. <i>Oncology Reports</i> , 2014, 31, 2252-2260.	1.2	38
2157	Tumor Lysis Syndrome Occurring After Transarterial Embolization in a 70-year-old Man with a Hepatocellular Carcinoma Ruptured in a Motor Vehicle Accident. <i>International Journal of Gerontology</i> , 2014, 8, 100-102.	0.7	1
2158	Clinical utility of PDSS2 expression to stratify patients at risk for recurrence of hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2014, 45, 2005-2012.	1.4	17
2159	Association between ephrin-A1 mRNA expression and poor prognosis after hepatectomy to treat hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2014, 45, 1051-1058.	1.4	22
2160	Purified vitexin compound 1 inhibits growth and angiogenesis through activation of FOXO3a by inactivation of Akt in hepatocellular carcinoma. <i>International Journal of Molecular Medicine</i> , 2014, 33, 441-448.	1.8	36
2161	Puerarin inhibits growth and induces apoptosis in SMMC-7721 hepatocellular carcinoma cells. <i>Molecular Medicine Reports</i> , 2014, 10, 2752-2758.	1.1	26
2162	Second Hepatectomy Improves Survival in Patients With Microvascular Invasive Hepatocellular Carcinoma Meeting the Milan Criteria. <i>Medicine (United States)</i> , 2015, 94, e2070.	0.4	17
2163	Anticancer agent icaritin induces apoptosis through caspase-dependent pathways in human hepatocellular carcinoma cells. <i>Molecular Medicine Reports</i> , 2015, 11, 3094-3100.	1.1	33
2164	Establishment of monoclonal HCC cell lines with organ site-specific tropisms. <i>BMC Cancer</i> , 2015, 15, 678.	1.1	14
2165	Hiwi downregulation, mediated by shRNA, reduces the proliferation and migration of human hepatocellular carcinoma cells. <i>Molecular Medicine Reports</i> , 2015, 11, 1455-1461.	1.1	40
2166	Biology of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2015, 33, 635-641.	0.8	16

#	ARTICLE	IF	CITATIONS
2167	Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. <i>Cancer Medicine</i> , 2015, 4, 1836-1843.	1.3	54
2168	Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study. <i>Liver International</i> , 2015, 35, 2155-2166.	1.9	813
2169	Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience Second Analysis. <i>Digestive Diseases</i> , 2015, 33, 728-734.	0.8	10
2170	Oleuropein induces apoptosis via activation of caspases and suppression of phosphatidylinositol 3-kinase/protein kinase B pathway in HepG2 human hepatoma cell line. <i>Molecular Medicine Reports</i> , 2015, 11, 4617-4624.	1.1	66
2171	MicroRNA-215 is upregulated by treatment with Adriamycin and leads to the chemoresistance of hepatocellular carcinoma cells and tissues. <i>Molecular Medicine Reports</i> , 2015, 12, 5274-5280.	1.1	24
2172	Targeted sequencing of cancer-associated genes in hepatocellular carcinoma using next generation sequencing. <i>Molecular Medicine Reports</i> , 2015, 12, 4678-4682.	1.1	11
2173	Splicing factor 2/alternative splicing factor contributes to extracellular signal-regulated kinase activation in hepatocellular carcinoma cells. <i>Molecular Medicine Reports</i> , 2015, 12, 3890-3894.	1.1	3
2174	CXC195 induces apoptosis and endoplasmic reticulum stress in human hepatocellular carcinoma cells by inhibiting the PI3K/Akt/mTOR signaling pathway. <i>Molecular Medicine Reports</i> , 2015, 12, 8229-8236.	1.1	20
2175	A novel in situ permeation system and its utility in cancer tissue ablation. <i>International Journal of Oncology</i> , 2015, 47, 875-883.	1.4	3
2177	Inhibition of protein kinase C by isojacareubin suppresses hepatocellular carcinoma metastasis and induces apoptosis in vitro and in vivo. <i>Scientific Reports</i> , 2015, 5, 12889.	1.6	19
2178	Cidan inhibits liver cancer cell growth by reducing COX-2 and VEGF expression and cell cycle arrest. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 1709-1718.	0.8	14
2179	Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model. <i>Scientific Reports</i> , 2015, 4, 4324.	1.6	4
2180	Glycogen synthase kinase-3 $\beta$ regulates tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis via the NF- $\kappa$ B pathway in hepatocellular carcinoma. <i>Oncology Letters</i> , 2015, 10, 3557-3564.	0.8	4
2181	The <em>In Ovo</em> Chick Chorioallantoic Membrane (CAM) Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma. <i>Journal of Visualized Experiments</i> , 2015, , .	0.2	43
2183	Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1073-1079.	1.1	31
2184	New Pathologic Stratification of Microvascular Invasion in Hepatocellular Carcinoma. <i>Transplantation</i> , 2015, 99, 1236-1242.	0.5	104
2185	Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort. <i>BMC Medicine</i> , 2015, 13, 242.	2.3	93
2186	The Relationship Between Serum Interleukin-6 and the Recurrence of Hepatitis B Virus Related Hepatocellular Carcinoma after Curative Resection. <i>Medicine (United States)</i> , 2015, 94, e941.	0.4	33

#	ARTICLE	IF	CITATIONS
2187	Lack of evidence that adherence to standard of care therapy improves survival in subjects with hepatocellular carcinoma in clinical practice. <i>Journal of Medical Virology</i> , 2015, 87, 1368-1376.	2.5	2
2188	Hepatocellular carcinoma: Advances in diagnostic imaging. <i>Drug Discoveries and Therapeutics</i> , 2015, 9, 310-318.	0.6	20
2189	The pan- $\epsilon$ -acetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. <i>Molecular Carcinogenesis</i> , 2015, 54, 585-597.	1.3	26
2190	Sequential Use of Transhepatic Arterial Chemoembolization and Bipolar Radiofrequency Ablation in the Clinical Therapy of Hepatocellular Carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 427-432.	0.7	9
2191	Reply to Letter. <i>Annals of Surgery</i> , 2015, 262, e18-e19.	2.1	13
2192	DJ-1 knockdown inhibits growth and xenograft-induced tumor generation of human hepatocellular carcinoma cells. <i>Oncology Reports</i> , 2015, 33, 201-206.	1.2	12
2193	The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application. <i>Liver International</i> , 2015, 35, 2458-2465.	1.9	5
2194	Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. <i>Cancer</i> , 2015, 121, 2164-2174.	2.0	51
2195	The role of AEG-1 in the development of liver cancer. <i>Hepatic Oncology</i> , 2015, 2, 303-312.	4.2	20
2196	Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation. <i>Journal of Surgical Oncology</i> , 2015, 111, 1007-1015.	0.8	15
2197	Natural history and treatment trends in hepatocellular carcinoma subtypes: Insights from a national cancer registry. <i>Journal of Surgical Oncology</i> , 2015, 112, 872-876.	0.8	21
2198	Expression quantitative trait loci in long non-coding RNA ZNRD1AS1 influence both HBV infection and hepatocellular carcinoma development. <i>Molecular Carcinogenesis</i> , 2015, 54, 1275-1282.	1.3	42
2199	Transcatheter Arterial Chemoembolization With Gelatin Sponge Microparticles Treated for BCLC Stage B Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e2154.	0.4	13
2200	Hepatic Resection as a Safe and Effective Treatment for Hepatocellular Carcinoma Involving a Single Large Tumor, Multiple Tumors, or Macrovascular Invasion. <i>Medicine (United States)</i> , 2015, 94, e396.	0.4	110
2201	Dissecting EASL/AASLD Recommendations With a More Careful Knife. <i>Annals of Surgery</i> , 2015, 262, e17-e18.	2.1	16
2202	Reduced ubiquitin-specific protease 9X expression induced by RNA interference inhibits the bioactivity of hepatocellular carcinoma cells. <i>Oncology Letters</i> , 2015, 10, 268-272.	0.8	5
2203	Anti-Viral Therapy can Prevent Recurrent Hepatocellular Carcinoma Associated with Hepatitis B: Recent Development. <i>Journal of Antivirals &amp; Antiretrovirals</i> , 2015, 07, .	0.1	0
2204	Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. <i>World Journal of Hepatology</i> , 2015, 7, 787.	0.8	140

#	ARTICLE	IF	CITATIONS
2205	Transarterial Chemoembolization Using Gelatin Sponges or Microspheres Plus Lipiodol-Doxorubicin versus Doxorubicin-Loaded Beads for the Treatment of Hepatocellular Carcinoma. Korean Journal of Radiology, 2015, 16, 125.	1.5	37
2206	Estradiol induces apoptosis via activation of miRNA-23a and p53: implication for gender difference in liver cancer development. Oncotarget, 2015, 6, 34941-34952.	0.8	52
2207	Impact of more detailed categorization of shrinkage or progression ratio at initial imaging response after sorafenib treatment in advanced hepatocellular carcinoma patients. OncoTargets and Therapy, 2015, 8, 3193.	1.0	1
2208	A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases (Basel, Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	1.0	3
2209	Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 1054.	0.8	258
2210	Sorafenib in the Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Report of Four Cases. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2015, 65, 246.	0.2	1
2211	Liver Cell Carcinoma in Poland: Data Reported to the National Health Fund in the Years 2008-2012. Journal of Liver, 2015, 04, .	0.3	2
2212	From minimal to maximal surgery in the treatment of hepatocarcinoma: A review. World Journal of Hepatology, 2015, 7, 93.	0.8	12
2213	Fulminant Hepatitis in a Patient with Hepatocellular Carcinoma Related to Nonalcoholic Steatohepatitis Treated with Sorafenib. Tumori, 2015, 101, e46-e48.	0.6	7
2214	Impact of age on the prognosis after liver transplantation for patients with hepatocellular carcinoma: a single-center experience. OncoTargets and Therapy, 2015, 8, 3775.	1.0	5
2215	Combined Therapy for Gastrointestinal Carcinomas: Exploiting Synergies Between Gene Therapy and Classical Chemo-Radiotherapy. Current Gene Therapy, 2015, 15, 151-160.	0.9	8
2216	Percutaneous hepatic radiofrequency for hepatocellular carcinoma: results and outcome of 46 patients. Hepatic Medicine: Evidence and Research, 2015, 7, 21.	0.9	8
2217	Early &alpha;-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Journal of Hepatocellular Carcinoma, 2015, 2, 39.	1.8	24
2218	Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 13101.	1.4	15
2219	Current status and future of radiofrequency ablation for hepatocellular carcinoma. Journal of the Korean Medical Association, 2015, 58, 542.	0.1	2
2220	Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization. World Journal of Gastroenterology, 2015, 21, 5582.	1.4	25
2221	Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. Oncotarget, 2015, 6, 12340-12356.	0.8	28
2222	Early Detection of Hepatocellular Carcinoma: How to Screen and Follow up Patients with Liver Cirrhosis According to the GERMAN S3 Guideline?. Diagnostics, 2015, 5, 497-503.	1.3	11

#	ARTICLE	IF	CITATIONS
2223	Outcomes and Predictors of Toxicity after Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres for Unresectable Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2015, 5, 292.	1.3	10
2224	Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy. <i>World Journal of Gastroenterology</i> , 2015, 21, 1207.	1.4	83
2225	Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. <i>World Journal of Hepatology</i> , 2015, 7, 1041.	0.8	42
2226	Mouse models of liver cancer: Progress and recommendations. <i>Oncotarget</i> , 2015, 6, 23306-23322.	0.8	93
2227	Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2015, 16, 29-37.	0.9	16
2228	Astrocyte elevated gene-1 overexpression in hepatocellular carcinoma: an independent prognostic factor. <i>Annals of Surgical Treatment and Research</i> , 2015, 88, 77.	0.4	15
2229	Staging systems for hepatocellular carcinoma: Current status and future perspectives. <i>World Journal of Hepatology</i> , 2015, 7, 406.	0.8	109
2230	Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Survival and Metastasis for Recurrent Hepatocellular Carcinoma after Transarterial Chemoembolization. <i>PLoS ONE</i> , 2015, 10, e0119312.	1.1	77
2231	The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0128159.	1.1	31
2232	Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma. <i>International Journal of Nanomedicine</i> , 2015, 10, 5123.	3.3	57
2233	Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. <i>Arquivos De Gastroenterologia</i> , 2015, 52, 2-14.	0.3	12
2234	Emerging role of microRNAs in the treatment of hepatocellular carcinoma. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2015, , 89.	5.5	0
2235	TLR3 Plays Significant Roles against HBV-Associated HCC. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-9.	0.7	10
2236	The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies. <i>BioMed Research International</i> , 2015, 2015, 1-12.	0.9	25
2237	Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-9.	0.6	44
2238	Transarterial chemoembolisation in intermediate-stage hepatocellular carcinoma. Survey on clinical practice in hospitals in the Madrid Region. <i>Annals of Hepatology</i> , 2015, 14, 207-217.	0.6	1
2239	Extragastric manifestations of <i>Helicobacter pylori</i> infection: Possible role of bacterium in liver and pancreas diseases. <i>World Journal of Hepatology</i> , 2015, 7, 2968.	0.8	53
2240	Hepatocellular carcinoma in Asia: Prevention strategy and planning. <i>World Journal of Hepatology</i> , 2015, 7, 1708.	0.8	91



#	ARTICLE	IF	CITATIONS
2241	Current and future treatments for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 8478.	1.4	140
2242	Successful Generation of Hepatitis B virus (HBV) Pseudotype Particle; A Versatile Tool for Identification of the HBV Receptor and Investigation of HBV Infectivity. <i>Journal of Liver</i> , 2015, 04, .	0.3	0
2243	Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 12022.	1.4	62
2244	Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma. <i>Oncoscience</i> , 2015, 2, 443-456.	0.9	38
2245	Steroid Receptor-Associated Immunophilins: Candidates for Diverse Drug-Targeting Approaches in Disease. <i>Current Molecular Pharmacology</i> , 2015, 9, 66-95.	0.7	15
2246	Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines. <i>BMB Reports</i> , 2015, 48, 565-570.	1.1	18
2247	Experiences of 30 Years in Right Trisectionectomy for Huge Liver Tumor. , 0, , .		0
2248	Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors. <i>Nuclear Medicine Communications</i> , 2015, 36, 319-327.	0.5	20
2249	Identification of Cancer Stem Cell Subpopulations of CD34 <sup>+</sup> PLC/PRF/5 That Result in Three Types of Human Liver Carcinomas. <i>Stem Cells and Development</i> , 2015, 24, 1008-1021.	1.1	30
2250	Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. <i>World Journal of Surgical Oncology</i> , 2015, 13, 96.	0.8	41
2251	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 408-424.	12.5	456
2252	Long non-coding RNA PANDAR correlates with poor prognosis and promotes tumorigenesis in hepatocellular carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2015, 72, 113-118.	2.5	76
2253	Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging. <i>World Journal of Gastroenterology</i> , 2015, 21, 5654.	1.4	9
2254	Dendritic cells transfected with heat-shock protein 70 messenger RNA for patients with hepatitis C virus-related hepatocellular carcinoma: a phase 1 dose escalation clinical trial. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1047-1056.	2.0	48
2255	Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. <i>BMC Cancer</i> , 2015, 15, 236.	1.1	16
2256	Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature. <i>World Journal of Surgical Oncology</i> , 2015, 13, 144.	0.8	12
2257	The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment. <i>Medicine (United States)</i> , 2015, 94, e1659.	0.4	8
2258	Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil. <i>Liver Cancer</i> , 2015, 4, 263-273.	4.2	26

#	ARTICLE	IF	CITATIONS
2259	RACK1 expression contributes to JNK activity, but JNK activity does not enhance RACK1 expression in hepatocellular carcinoma SMMC-7721 cells. <i>Oncology Letters</i> , 2015, 9, 2767-2770.	0.8	6
2260	Study progression MRI findings with pathologic correlation in hepatitis B virus-associated multistage hepatocellular carcinoma. <i>Radiology of Infectious Diseases</i> , 2015, 2, 94-108.	2.4	0
2261	Neuropilin-2 induced by transforming growth factor- $\beta^2$ augments migration of hepatocellular carcinoma cells. <i>BMC Cancer</i> , 2015, 15, 909.	1.1	30
2262	Comparison of Two Types of Liquid Biopsies in Patients With Hepatocellular Carcinoma Awaiting Orthotopic Liver Transplantation. <i>Transplantation Proceedings</i> , 2015, 47, 2639-2642.	0.3	25
2263	Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma. <i>Hpb</i> , 2015, 17, 1137-1144.	0.1	44
2264	Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 756-762.	2.9	49
2265	Yttrium-90 Radioembolization of Hepatocellular Carcinoma—Performance, Technical Advances, and Future Concepts. <i>Seminars in Interventional Radiology</i> , 2015, 32, 388-397.	0.3	7
2266	Enoyl-coenzyme A hydratase short chain 1 silencing attenuates the proliferation of hepatocellular carcinoma by inhibiting epidermal growth factor signaling in vitro and in vivo. <i>Molecular Medicine Reports</i> , 2015, 12, 1421-1428.	1.1	9
2267	B-cell translocation gene 1 serves as a novel prognostic indicator of hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2015, 46, 641-648.	1.4	39
2268	Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. <i>Journal of Gastroenterology</i> , 2015, 50, 590-600.	2.3	31
2269	Identification of Hepatocellular Carcinoma-Related Genes with a Machine Learning and Network Analysis. <i>Journal of Computational Biology</i> , 2015, 22, 63-71.	0.8	53
2270	Preparation and structure of drug-carrying biodegradable microspheres designed for transarterial chemoembolization therapy. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2015, 26, 77-91.	1.9	19
2271	Hepatitis B Virus Regulates Apoptosis and Tumorigenesis through the MicroRNA-15a-Smad7-Transforming Growth Factor Beta Pathway. <i>Journal of Virology</i> , 2015, 89, 2739-2749.	1.5	43
2272	Annexin A11 knockdown inhibits in vitro proliferation and enhances survival of Hca-F cell via Akt2/FoxO1 pathway and MMP-9 expression. <i>Biomedicine and Pharmacotherapy</i> , 2015, 70, 58-63.	2.5	15
2273	How I Do It: Cone-Beam CT during Transarterial Chemoembolization for Liver Cancer. <i>Radiology</i> , 2015, 274, 320-334.	3.6	140
2274	HIF-2 $\alpha$ -dependent PAI-1 induction contributes to angiogenesis in hepatocellular carcinoma. <i>Experimental Cell Research</i> , 2015, 331, 46-57.	1.2	36
2275	Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2015, 47, 242-248.	0.4	53
2276	Cell Microenvironment-Controlled Antitumor Drug Releasing-Nanomicelles for GLUT1-Targeting Hepatocellular Carcinoma Therapy. <i>ACS Applied Materials &amp; Interfaces</i> , 2015, 7, 5444-5453.	4.0	60

#	ARTICLE	IF	CITATIONS
2277	Perioperative antiviral therapy improves safety in patients with hepatitis B related HCC following hepatectomy. <i>International Journal of Surgery</i> , 2015, 15, 1-5.	1.1	15
2278	Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 479-484.	0.6	41
2279	Surgical Outcomes in Patients with Hepatocellular Carcinoma Associated with Metabolic Syndrome. <i>World Journal of Surgery</i> , 2015, 39, 471-477.	0.8	19
2280	Correlation between the promoter basal core and precore mutations and HBsAg quantification in French blood donors infected with hepatitis B virus. <i>Journal of Medical Virology</i> , 2015, 87, 529-535.	2.5	14
2281	Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. <i>Journal of Hepatology</i> , 2015, 62, 848-854.	1.8	228
2282	Hepatocellular Carcinoma: Diagnostic Performance of Multidetector CT and MR Imaging—A Systematic Review and Meta-Analysis. <i>Radiology</i> , 2015, 275, 97-109.	3.6	393
2283	RNA over-editing of BLCAP contributes to hepatocarcinogenesis identified by whole-genome and transcriptome sequencing. <i>Cancer Letters</i> , 2015, 357, 510-519.	3.2	41
2284	Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1167-1174.	1.4	18
2285	Laparoscopic surgery minimizes the release of circulating tumor cells compared to open surgery for hepatocellular carcinoma. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 3146-3153.	1.3	38
2286	Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 403-413.	1.4	17
2287	Comparison of the Effectiveness and Safety of Ultrasound- and CT-Guided Percutaneous Radiofrequency Ablation of Non-Operation Hepatocellular Carcinoma. <i>Pathology and Oncology Research</i> , 2015, 21, 637-642.	0.9	10
2288	Prevention of Hepatocellular Carcinoma: Beyond Hepatitis B Vaccination. <i>Seminars in Oncology</i> , 2015, 42, 316-328.	0.8	16
2289	Impact of Hepatic Steatosis on Disease-Free Survival in Patients with Non-B Non-C Hepatocellular Carcinoma Undergoing Hepatic Resection. <i>Annals of Surgical Oncology</i> , 2015, 22, 2226-2234.	0.7	19
2290	Prognostic value of purinergic P2X7 receptor expression in patients with hepatocellular carcinoma after curative resection. <i>Tumor Biology</i> , 2015, 36, 5039-5049.	0.8	14
2291	Evidence for Heightened Hexokinase II Immunoexpression in Hepatocyte Dysplasia and Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2015, 60, 420-426.	1.1	43
2292	A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2015, 33, 128-137.	1.2	40
2293	RNAi Knockdown of Hypoxia-Inducible Factor-1 $\alpha$ Decreased the Proliferation, Migration, and Invasion of Hypoxic Hepatocellular Carcinoma Cells. <i>Cell Biochemistry and Biophysics</i> , 2015, 71, 1677-1684.	0.9	8
2294	Surveillance, Diagnosis, Treatment, and Outcome of Liver Cancer in Japan. <i>Liver Cancer</i> , 2015, 4, 39-50.	4.2	175

#	ARTICLE	IF	CITATIONS
2295	Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma. <i>Chinese Journal of Integrative Medicine</i> , 2015, 21, 49-57.	0.7	11
2296	Celastrol Induces Mitochondria-Mediated Apoptosis in Hepatocellular Carcinoma Bel-7402 Cells. <i>The American Journal of Chinese Medicine</i> , 2015, 43, 137-148.	1.5	38
2297	DNA-PKcs deficiency sensitizes the human hepatoma HepG2 cells to cisplatin and 5-fluorouracil through suppression of the PI3K/Akt/NF- $\kappa$ B pathway. <i>Molecular and Cellular Biochemistry</i> , 2015, 399, 269-278.	1.4	16
2298	Cases of Spontaneous Tumor Regression in Hepatobiliary Cancers: Implications for Immunotherapy?. <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 161-165.	0.6	13
2299	mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?. <i>Transplantation Reviews</i> , 2015, 29, 168-174.	1.2	56
2300	New molecular therapies for hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, S80-S85.	0.7	30
2301	PKC $\delta$ promotes generation of reactive oxygen species via DUOX2 in hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 839-845.	1.0	15
2302	MiR-17-92 cluster promotes hepatocarcinogenesis. <i>Carcinogenesis</i> , 2015, 36, 1213-1222.	1.3	78
2303	Effect of alcohol on diethylnitrosamine-induced hepatic toxicity: Critical role of ROS, lipid accumulation, and mitochondrial dysfunction. <i>Experimental and Toxicologic Pathology</i> , 2015, 67, 491-498.	2.1	10
2304	Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl- $\beta$ -cyclodextrin: Involvement of p53 and Fas receptor ligand complex. <i>Scientific Reports</i> , 2015, 5, 11853.	1.6	95
2305	Combination of Nanoparticle-Delivered siRNA for Astrocyte Elevated Gene-1 (AEG-1) and All-trans Retinoic Acid (ATRA): An Effective Therapeutic Strategy for Hepatocellular Carcinoma (HCC). <i>Bioconjugate Chemistry</i> , 2015, 26, 1651-1661.	1.8	44
2306	Liver Cancer (Hepatocellular Carcinoma)., 2015, , 269-288.		2
2307	Downregulation of FOXP2 promoter human hepatocellular carcinoma cell invasion. <i>Tumor Biology</i> , 2015, 36, 9611-9619.	0.8	32
2308	Synthesis and characterization of image-able polyvinyl alcohol microspheres for image-guided chemoembolization. <i>Journal of Materials Science: Materials in Medicine</i> , 2015, 26, 198.	1.7	37
2309	Glypican-3 Targeted Human Heavy Chain Antibody as a Drug Carrier for Hepatocellular Carcinoma Therapy. <i>Molecular Pharmaceutics</i> , 2015, 12, 2151-2157.	2.3	59
2310	Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: An autopsy case report. <i>Oncology Letters</i> , 2015, 9, 1633-1636.	0.8	9
2311	Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib. <i>Clinical Science</i> , 2015, 128, 29-37.	1.8	10
2312	Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation. <i>Laboratory Investigation</i> , 2015, 95, 1145-1156.	1.7	39

#	ARTICLE	IF	CITATIONS
2313	Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. <i>Journal of Hepatology</i> , 2015, 63, 1190-1197.	1.8	83
2314	Magnetic resonance elastography (MRE) in cancer: Technique, analysis, and applications. <i>Progress in Nuclear Magnetic Resonance Spectroscopy</i> , 2015, 90-91, 32-48.	3.9	69
2315	Reduced Expression of Adherens Junctions Associated Protein 1 Predicts Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. <i>Annals of Surgical Oncology</i> , 2015, 22, 1499-1507.	0.7	25
2316	Efficacy of antiviral therapy with nucleotide/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 458-468.	0.7	24
2317	Optimal Cut Points for Quality of Life Questionnaire-Core 30 (QLQ-C30) Scales: Utility for Clinical Trials and Updates of Prognostic Systems in Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2015, 20, 62-71.	1.9	13
2318	Glycopentalone, a novel compound from <i>Glycosmis pentaphylla</i> (Retz.) Correa with potent anti-hepatocellular carcinoma activity. <i>Journal of Ethnopharmacology</i> , 2015, 172, 38-43.	2.0	14
2319	Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 567-576.	0.6	29
2320	Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy. <i>Oncology Letters</i> , 2015, 9, 1201-1206.	0.8	18
2321	Oncogenic Viruses and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2015, 19, 341-360.	1.0	16
2322	Locoregional Therapy of Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2015, 19, 401-420.	1.0	28
2323	Management and diagnosis of fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 671-683.	1.4	11
2324	Antitumor immunostimulatory activity of polysaccharides from <i>Salvia chinensis</i> Benth. <i>Journal of Ethnopharmacology</i> , 2015, 168, 237-247.	2.0	28
2325	Chemical composition of total flavonoids from <i>Polygonum amplexicaule</i> and their pro-apoptotic effect on hepatocellular carcinoma cells: Potential roles of suppressing STAT3 signaling. <i>Food and Chemical Toxicology</i> , 2015, 80, 62-71.	1.8	14
2326	Cell line-specific oxidative stress in cellular toxicity: A toxicogenomics-based comparison between liver and colon cell models. <i>Toxicology in Vitro</i> , 2015, 29, 845-855.	1.1	15
2327	Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2015, 114, 289-295.	0.3	109
2328	Tetramethylpyrazine (TMP) exerts antitumor effects by inducing apoptosis and autophagy in hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2015, 26, 212-220.	1.7	44
2329	Siglec-10 is associated with survival and natural killer cell dysfunction in hepatocellular carcinoma. <i>Journal of Surgical Research</i> , 2015, 194, 107-113.	0.8	54
2330	Transplantation for Primary Hepatic Malignancy. , 2015, , 189-204.		1

#	ARTICLE	IF	CITATIONS
2331	Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoteric acid-enhanced MR imaging. <i>European Radiology</i> , 2015, 25, 211-220.	2.3	23
2332	Clinicopathological features of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Langenbeck's Archives of Surgery</i> , 2015, 400, 471-476.	0.8	8
2333	Trend of Improving Prognosis of Hepatocellular Carcinoma in Clinical Practice: An Italian In-Field Experience. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1465-1473.	1.1	10
2334	A polysaccharide from mushroom <i>Huaier</i> retards human hepatocellular carcinoma growth, angiogenesis, and metastasis in nude mice. <i>Tumor Biology</i> , 2015, 36, 2929-2936.	0.8	38
2335	A <i>Aconitum coreanum</i> polysaccharide fraction induces apoptosis of hepatocellular carcinoma (HCC) cells via pituitary tumor transforming gene 1 (PTTG1)-mediated suppression of the P13K/Akt and activation of p38 MAPK signaling pathway and displays antitumor activity in vivo. <i>Tumor Biology</i> , 2015, 36, 7085-7091.	0.8	26
2336	Soluble MICB protein levels and platelet counts during hepatitis B virus infection and response to hepatocellular carcinoma treatment. <i>BMC Infectious Diseases</i> , 2015, 15, 25.	1.3	8
2337	The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis. <i>BMC Cancer</i> , 2015, 15, 263.	1.1	25
2338	Suppression of SAMS1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 1453-1460.	0.7	17
2339	Imaging of Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2015, 19, 325-340.	1.0	11
2340	Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1399-1407.	3.3	33
2341	Notch signaling in hepatocellular carcinoma: molecular targeting in an advanced disease. <i>Hepatoma Research</i> , 2015, 1, 11.	0.6	10
2342	Perfusion computed tomography for detection of hepatocellular carcinoma in patients with liver cirrhosis. <i>European Radiology</i> , 2015, 25, 3123-3132.	2.3	43
2343	Milan Criteria, University of California, San Francisco, Criteria, and Model for End-Stage Liver Disease Score as Predictors of Salvage Liver Transplantation. <i>Transplantation Proceedings</i> , 2015, 47, 438-444.	0.3	9
2344	MALDI imaging-based classification of hepatocellular carcinoma and non-malignant lesions in fibrotic liver tissue. <i>Zeitschrift Fur Gastroenterologie</i> , 2015, 53, 33-39.	0.2	18
2345	SC-III3, a novel scopoletin derivative, induces autophagy of human hepatoma HepG2 cells through AMPK/mTOR signaling pathway by acting on mitochondria. <i>FÃ-toterapÃ</i> , 2015, 104, 31-40.	1.1	17
2346	Rab17 inhibits the tumorigenic properties of hepatocellular carcinomas via the Erk pathway. <i>Tumor Biology</i> , 2015, 36, 5815-5824.	0.8	18
2347	Addressing the Interplay of Liver Disease and Hepatocellular Carcinoma on Patient Survival: The ALBI Scoring Model. <i>Journal of Clinical Oncology</i> , 2015, 33, 529-531.	0.8	21
2348	Smac mimetic and oleanolic acid synergize to induce cell death in human hepatocellular carcinoma cells. <i>Cancer Letters</i> , 2015, 365, 47-56.	3.2	32

#	ARTICLE	IF	CITATIONS
2349	Genetic polymorphisms in antioxidant enzyme genes and susceptibility to hepatocellular carcinoma in Chinese population: a case-control study. <i>Tumor Biology</i> , 2015, 36, 4627-4632.	0.8	15
2350	Serosal Invasion Strongly Associated With Recurrence After Curative Hepatic Resection of Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e602.	0.4	11
2351	Generation of improved mouse models for the study of hepatitis C virus. <i>European Journal of Pharmacology</i> , 2015, 759, 313-325.	1.7	14
2352	The ageing patient with haemophilia. <i>European Journal of Haematology</i> , 2015, 94, 17-22.	1.1	27
2353	Antiviral Therapy Improves Postoperative Survival in Patients With Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2015, 261, 56-66.	2.1	178
2354	Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 149, 119-129.	0.6	94
2355	Identification and Optimization of Combinatorial Glucose Metabolism Inhibitors in Hepatocellular Carcinomas. <i>Journal of the Association for Laboratory Automation</i> , 2015, 20, 423-437.	2.8	35
2356	Mass-Selected Site-Specific Core-Fucosylation of Serum Proteins in Hepatocellular Carcinoma. <i>Journal of Proteome Research</i> , 2015, 14, 4876-4884.	1.8	37
2357	A Chimeric Cetuximab-Functionalized Corona as a Potent Delivery System for Microtubule-Destabilizing Nanocomplexes to Hepatocellular Carcinoma Cells: A Focus on EGFR and Tubulin Intracellular Dynamics. <i>Molecular Pharmaceutics</i> , 2015, 12, 3908-3923.	2.3	10
2358	Cancer initiating properties of erythrosine supplemented with sub necrotic dose of diethyl nitrosamine: potential effects on biochemical parameters of liver, Vitamin C and E. <i>Molecular and Cellular Toxicology</i> , 2015, 11, 357-366.	0.8	2
2359	Niche Mimicking for Selection and Enrichment of Liver Cancer Stem Cells by Hyaluronic Acid-Based Multilayer Films. <i>ACS Applied Materials &amp; Interfaces</i> , 2015, 7, 22188-22195.	4.0	17
2360	The advances in applying inorganic fluorescent nanomaterials for the detection of hepatocellular carcinoma and other cancers. <i>RSC Advances</i> , 2015, 5, 79572-79584.	1.7	10
2361	Pregnane X Receptor Represses <i>HNF4<math>\alpha</math></i> Gene to Induce Insulin-Like Growth Factor- $\alpha$ Binding Protein IGFBP1 that Alters Morphology of and Migrates HepG2 Cells. <i>Molecular Pharmacology</i> , 2015, 88, 746-757.	1.0	22
2362	Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis. <i>BMC Gastroenterology</i> , 2015, 15, 96.	0.8	24
2363	Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. <i>BMC Cancer</i> , 2015, 15, 392.	1.1	61
2364	Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3142-3148.	1.1	92
2365	miR-26a Promoted by Interferon-Alpha Inhibits Hepatocellular Carcinoma Proliferation and Migration by Blocking EZH2. <i>Genetic Testing and Molecular Biomarkers</i> , 2015, 19, 30-36.	0.3	18
2366	Downregulation of <i>VANGL1</i> Inhibits Cellular Invasion Rather than Cell Motility in Hepatocellular Carcinoma Cells Without Stimulation. <i>Genetic Testing and Molecular Biomarkers</i> , 2015, 19, 283-287.	0.3	9

#	ARTICLE	IF	CITATIONS
2367	N-Aryl benzenesulfonamide inhibitors of [3H]-thymidine incorporation and $\beta$ -catenin signaling in human hepatocyte-derived Huh-7 carcinoma cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3897-3899.	1.0	10
2368	Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1093-1101.e1.	0.2	4
2369	Dietary fat, fat subtypes and hepatocellular carcinoma in a large European cohort. <i>International Journal of Cancer</i> , 2015, 137, 2715-2728.	2.3	38
2370	Transarterial Therapy for Primary Liver Carcinomas: A Crack in the Armor?. <i>Annals of Surgical Oncology</i> , 2015, 22, 4111-4112.	0.7	0
2371	Hepatocellular Carcinoma in the Setting of Chronic Hepatitis B Virus Infection: Tumor Recurrence and Survival Rates After Liver Transplantation. <i>Transplantation Proceedings</i> , 2015, 47, 1939-1944.	0.3	7
2372	Prognostic significance of Nemo-like kinase expression in patients with hepatocellular carcinoma. <i>Tumor Biology</i> , 2015, 36, 8447-8453.	0.8	10
2373	BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma. <i>International Journal of Immunopathology and Pharmacology</i> , 2015, 28, 36-44.	1.0	49
2374	Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. <i>Radiology</i> , 2015, 277, 903-912.	3.6	60
2375	Contrast-enhanced ultrasound for the differentiation of small atypical hepatocellular carcinomas from dysplastic nodules in cirrhosis. <i>Digestive and Liver Disease</i> , 2015, 47, 775-782.	0.4	20
2376	Adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma: a systematic review and a meta-analysis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2015, 14, 236-245.	0.6	12
2377	Mesenchymal stem cell-conditioned medium prevents radiation-induced liver injury by inhibiting inflammation and protecting sinusoidal endothelial cells. <i>Journal of Radiation Research</i> , 2015, 56, 700-708.	0.8	58
2378	CEUS: An essential component in a multimodality approach to small nodules in patients at high-risk for hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2015, 84, 1623-1635.	1.2	58
2379	Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel. <i>Nanomedicine</i> , 2015, 10, 1139-1147.	1.7	53
2380	Postoperative complications are predictive of poor prognosis in hepatocellular carcinoma. <i>Journal of Surgical Research</i> , 2015, 199, 470-477.	0.8	50
2381	Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis. <i>Clinical Drug Investigation</i> , 2015, 35, 751-759.	1.1	26
2382	Occurrence of Malignant Tumours in the Acute Hepatic Porphyrrias. <i>JIMD Reports</i> , 2015, 22, 17-22.	0.7	13
2383	4-Acetylanthroquinol B Suppresses Tumor Growth and Metastasis of Hepatoma Cells via Blockade of Translation-Dependent Signaling Pathway and VEGF Production. <i>Journal of Agricultural and Food Chemistry</i> , 2015, 63, 208-215.	2.4	13
2384	Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 305-314.	1.9	42



#	ARTICLE	IF	CITATIONS
2385	HBCD and PCBs enhance the cell migration and invasion of HepG2 via the PI3 K/Akt pathway. <i>Toxicology Research</i> , 2015, 4, 677-685.	0.9	2
2386	Analytical validation of a Biochip prototype for integrated analysis of AFP-IgM and SCCA-IgM serum biomarkers in patients with liver cirrhosis and hepatocellular carcinoma. <i>Analytical Methods</i> , 2015, 7, 629-637.	1.3	5
2387	Impact of occult hepatitis B virus infection on outcome after resection for non-B non-C hepatocellular carcinoma. <i>Journal of Surgical Research</i> , 2015, 193, 153-160.	0.8	13
2388	Microwave Ablation Treatment of Solid Tumors. , 2015, , .		6
2389	Transarterial Chemoembolization for Primary Liver Malignancies and Colorectal Liver Metastasis. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 149-166.	0.6	15
2390	Efficacy and safety of cisplatin versus miriplatin in transcatheter arterial chemoembolization and transarterial infusion chemotherapy for hepatocellular carcinoma: A randomized controlled trial. <i>Hepatology Research</i> , 2015, 45, 514-522.	1.8	18
2391	Intracellular Osteopontin Inhibits Toll-like Receptor Signaling and Impedes Liver Carcinogenesis. <i>Cancer Research</i> , 2015, 75, 86-97.	0.4	39
2392	Costâ€effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. <i>Hepatology</i> , 2015, 61, 227-237.	3.6	68
2393	Impact of Vitamin D Supplementation on Sustained Virological Response in Chronic Hepatitis C Genotype 4 Patients Treated by Pegylated Interferon/Ribavirin. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 49-54.	0.5	37
2394	Epigenetic therapy as a novel approach in hepatocellular carcinoma. , 2015, 145, 103-119.		59
2395	Differentiation of lipid poor angiomyolipoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging. <i>Abdominal Imaging</i> , 2015, 40, 531-541.	2.0	27
2396	Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1-9.	1.2	74
2397	Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. <i>Journal of Gastroenterology</i> , 2015, 50, 191-202.	2.3	76
2398	Conventional chemoembolization and chemoembolization with drug-eluting beads: Technique and future potential. , 0, , 120-127.		0
2399	Potential Susceptibility Mutations in C Gene for Hepatitis B-Related Hepatocellular Carcinoma Identified by a Two-Stage Study in Qidong, China. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1708.	1.8	1
2400	Role of FLT3 in the proliferation and aggressiveness of hepatocellular carcinoma. <i>Turkish Journal of Medical Sciences</i> , 2016, 46, 572-581.	0.4	5
2401	Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2016, 3, 1.	1.8	15
2402	Agitated saline sonography: a simple technique for intraprocedural feeder identification during transcatheter arterial chemoembolization of hepatocellular carcinoma. <i>Diagnostic and Interventional Radiology</i> , 2016, 22, 269-272.	0.7	0

#	ARTICLE	IF	CITATIONS
2403	Inhibition of Regulatory Volume Decrease Enhances the Cytocidal Effect of Hypotonic Shock in Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2016, 7, 1524-1533.	1.2	8
2404	( $\alpha$ )-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 43475-43491.	0.8	60
2405	Targeting Wnt/ $\beta$ 2-catenin pathway in hepatocellular carcinoma treatment. <i>World Journal of Gastroenterology</i> , 2016, 22, 823.	1.4	246
2406	Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 160-167.	4.5	86
2407	OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway. <i>Journal of Korean Medical Science</i> , 2016, 31, 1215.	1.1	27
2408	Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 2016, 7, 428.	1.6	63
2409	Fish, Fish Oil, and Liver Cancer. , 2016, , 249-262.		0
2410	Effective Personalized Treatment of Advanced Hepatic Carcinoma based on Sorafenib. <i>Journal of Integrative Oncology</i> , 2016, 5, .	0.3	1
2411	IS RESECTION OF HEPATOCELLULAR CARCINOMA IN THE ERA OF LIVER TRANSPLANTATION WORTHWILE? A single center experience. <i>Arquivos De Gastroenterologia</i> , 2016, 53, 169-174.	0.3	8
2412	Macrophage colony-stimulating factor expressed in non-cancer tissues provides predictive powers for recurrence in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 8779.	1.4	18
2413	Laparoscopic and robotic approach for hepatocellular carcinoma—state of the art. <i>Hepatobiliary Surgery and Nutrition</i> , 2016, 5, 478-484.	0.7	27
2414	Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation. <i>Translational Gastroenterology and Hepatology</i> , 2016, 1, 34-34.	1.5	20
2415	Severe Anemia with Hemoperitoneum as a First Presentation for Multinodular Hepatocellular Carcinoma: A Rare Event in Western Countries. <i>Case Reports in Hepatology</i> , 2016, 2016, 1-4.	0.4	2
2416	Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-11.	0.8	20
2417	A Comparison between Three-Dimensional Visualization Guided Hepatectomy and Ultrasonography Guided Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma within the Milan Criteria. <i>BioMed Research International</i> , 2016, 2016, 1-10.	0.9	4
2418	Liquid Biopsy of Hepatocellular Carcinoma: Circulating Tumor-Derived Biomarkers. <i>Disease Markers</i> , 2016, 2016, 1-11.	0.6	48
2419	Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-9.	0.7	22
2420	Simple models based on gamma-glutamyl transpeptidase and platelets for predicting survival in hepatitis B-associated hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2016, 9, 2099.	1.0	21

#	ARTICLE	IF	CITATIONS
2421	Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. <i>Oncotargets and Therapy</i> , 2016, 9, 773.	1.0	21
2422	The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1618.	1.8	4
2423	MicroRNAs in the Evaluation and Potential Treatment of Liver Diseases. <i>Journal of Clinical Medicine</i> , 2016, 5, 52.	1.0	20
2424	Adenovirus encoding XAF-1 and TNF- $\alpha$ in the same open reading frame efficiently inhibits hepatocellular cancer cells. <i>Molecular Medicine Reports</i> , 2016, 13, 5169-5176.	1.1	1
2425	Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0148493.	1.1	19
2426	Comprehensive Comparison of Multiple-Detector Computed Tomography and Dynamic Magnetic Resonance Imaging in the Diagnosis of Hepatocellular Carcinoma with Varying Degrees of Fibrosis. <i>PLoS ONE</i> , 2016, 11, e0166157.	1.1	13
2427	National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2016, 5, 97-106.	4.2	47
2428	Chinese herbal medicine, Jianpi Ligan decoction, improves prognosis of unresectable hepatocellular carcinoma after transarterial chemoembolization: a retrospective study. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2461-2466.	2.0	19
2429	Combination of three-dimensional conformal radiotherapy and transcatheter arterial chemoembolisation versus transcatheter arterial chemoembolisation for primary hepatocellular carcinoma. <i>The Cochrane Library</i> , 2016, , .	1.5	2
2430	Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 4034.	1.4	40
2431	Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein. <i>Oncotarget</i> , 2016, 7, 8850-8865.	0.8	32
2432	Differences in Physician Referral Drive Disparities in Surgical Intervention for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2016, 263, 362-368.	2.1	11
2433	Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis. <i>Tumor Biology</i> , 2016, 37, 5951-5961.	0.8	12
2434	MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection. <i>Molecular Medicine Reports</i> , 2016, 14, 1617-1623.	1.1	5
2435	Comparative Efficacy of Interventional Therapies for Early-stage Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2016, 95, e3185.	0.4	32
2436	Anti-cancer effect of N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2,3-dihydronaphtho[1,2- <i>b</i> ]furan-2-carboxamide, a novel synthetic compound. <i>Molecular Carcinogenesis</i> , 2016, 55, 659-670.	1.3	8
2437	Improved Detection of Recurrent Hepatocellular Carcinomas in Arterial Phase With CAIPIRINHA-Dixon-TWIST-Volumetric Interpolated Breath-Hold Examination. <i>Investigative Radiology</i> , 2016, 51, 602-608.	3.5	12
2438	Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429. <i>Journal of Molecular Medicine</i> , 2016, 94, 1281-1296.	1.7	85

#	ARTICLE	IF	CITATIONS
2439	BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 467-474.	1.4	47
2440	Activated mutant forms of p3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade. <i>Liver International</i> , 2016, 36, 1176-1186.	1.9	26
2441	Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy. <i>International Journal of Cancer</i> , 2016, 138, 1601-1608.	2.3	26
2442	Biodistribution of TAT-LHRH conjugated chitosan/DNA nanoparticles in the mice bearing hepatoma xenografts. <i>Journal of Biomedical Materials Research - Part A</i> , 2016, 104, 2394-2400.	2.1	6
2443	NLRC5 promotes cell proliferation via regulating the AKT/VEGF-A signaling pathway in hepatocellular carcinoma. <i>Toxicology</i> , 2016, 359-360, 47-57.	2.0	30
2444	Multiparametric human hepatocellular carcinoma characterization and therapy response evaluation by hyperpolarized <sup>13</sup> C MRSI. <i>NMR in Biomedicine</i> , 2016, 29, 952-960.	1.6	28
2445	Prediction of postoperative liver failure using gadoxetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1349-1356.	1.4	10
2446	Prevalence of hepatocellular carcinoma in chronic hepatitis C patients in Mid Delta, Egypt: A single center study. <i>Journal of the Egyptian National Cancer Institute</i> , 2016, 28, 257-262.	0.6	57
2447	A Novel and Validated Inflammation-Based Score (IBS) Predicts Survival in Patients With Hepatocellular Carcinoma Following Curative Surgical Resection. <i>Medicine (United States)</i> , 2016, 95, e2784.	0.4	30
2448	Percutaneous thermal ablation for primary hepatocellular carcinoma: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 294-301.	1.4	86
2449	Short-term Outcomes of Laparoscopic Versus Open Right Hemihepatectomy for Hepatocellular Carcinoma. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2016, 26, e157-e160.	0.4	16
2450	Bibliometric analysis of the top-cited gastroenterology and hepatology articles. <i>BMJ Open</i> , 2016, 6, e009889.	0.8	42
2451	c-Jun N-terminal kinase inhibitor favors transforming growth factor- $\beta$ 2 to antagonize hepatitis B virus X protein-induced cell growth promotion in hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2016, 13, 1345-1352.	1.1	10
2452	An HBV-tolerant immunocompetent model that effectively simulates chronic hepatitis B virus infection in mice. <i>Experimental Animals</i> , 2016, 65, 373-382.	0.7	4
2453	Obesity and Risk of Cancer: An Introductory Overview. <i>Recent Results in Cancer Research</i> , 2016, 208, 1-15.	1.8	68
2454	Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. <i>Oncology Letters</i> , 2016, 12, 3662-3668.	0.8	14
2455	Surgical Resection for Hepatocellular Carcinoma with Cardiac Cirrhosis after the Fontan Procedure. <i>Internal Medicine</i> , 2016, 55, 3265-3272.	0.3	28
2456	Prognostic factors affecting postoperative survival of patients with solitary small hepatocellular carcinoma. <i>Chinese Journal of Cancer</i> , 2016, 35, 80.	4.9	18

#	ARTICLE	IF	CITATIONS
2457	Mitogen-activated protein kinase kinase 3 induces cell cycle arrest via p38 activation mediated Bmi-1 downregulation in hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2016, 13, 243-248.	1.1	9
2458	Recurrent Hepatocellular Carcinoma After Liver Transplantation: Analysis of Risk Factors. <i>Transplantation Proceedings</i> , 2016, 48, 2990-2993.	0.3	10
2460	Sonic hedgehog signaling in hepatocellular carcinoma: A pilot study. <i>Molecular and Clinical Oncology</i> , 2016, 4, 369-374.	0.4	21
2461	A review of prognostic scores after liver resection in hepatocellular carcinoma: the MSKCC, SLICER and SSCLIP scores. <i>Japanese Journal of Clinical Oncology</i> , 2016, 47, 287-293.	0.6	8
2462	Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma. <i>Oncology Reports</i> , 2016, 36, 3456-3464.	1.2	29
2463	Down-Regulation of LncRNA DGCR5 Correlates with Poor Prognosis in Hepatocellular Carcinoma. <i>Cellular Physiology and Biochemistry</i> , 2016, 40, 707-715.	1.1	84
2464	Percutaneous radiofrequency ablation of tumor feeding artery before target tumor ablation may reduce local tumor progression in hepatocellular carcinoma. <i>Biomedical Journal</i> , 2016, 39, 400-406.	1.4	9
2465	Consideraciones perioperatorias en el paciente oncológico sometido a hepatectomía. <i>Gaceta Mexicana De Oncología</i> , 2016, 15, 358-365.	0.0	0
2466	Development and Applicability of the A-P 200 Criteria for Liver Transplantation for Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2016, 48, 3317-3322.	0.3	5
2467	Distinct set of chromosomal aberrations in childhood hepatocellular carcinoma is correlated to hepatitis B virus infection. <i>Cancer Genetics</i> , 2016, 209, 87-96.	0.2	6
2469	Identification of allelic expression imbalance genes in human hepatocellular carcinoma through massively parallel DNA and RNA sequencing. <i>Medical Oncology</i> , 2016, 33, 38.	1.2	5
2470	Multifunctional microbeads for drug delivery in TACE. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1289-1300.	2.4	25
2471	Protective effects of Celastrol on diethylnitrosamine-induced hepatocellular carcinoma in rats and its mechanisms. <i>European Journal of Pharmacology</i> , 2016, 784, 173-180.	1.7	50
2472	Safflower yellow B suppresses HepG2 cell injury induced by oxidative stress through the AKT/Nrf2 pathway. <i>International Journal of Molecular Medicine</i> , 2016, 37, 603-612.	1.8	50
2473	ANXA2 enhances the progression of hepatocellular carcinoma via remodeling the cell motility associated structures. <i>Micron</i> , 2016, 85, 26-33.	1.1	18
2474	Iron depletion enhances the effect of sorafenib in hepatocarcinoma. <i>Cancer Biology and Therapy</i> , 2016, 17, 648-656.	1.5	21
2475	Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling. <i>Cell Death and Disease</i> , 2016, 7, e2201-e2201.	2.7	182
2476	Overexpression of hepatocyte nuclear factor 4 $\beta$ in human mesenchymal stem cells suppresses hepatocellular carcinoma development through Wnt/ $\beta$ -catenin signaling pathway downregulation. <i>Cancer Biology and Therapy</i> , 2016, 17, 558-565.	1.5	43

#	ARTICLE	IF	CITATIONS
2477	A double suicide gene system driven by vascular endothelial growth factor promoter selectively kills human hepatocellular carcinoma cells. <i>Oncology Letters</i> , 2016, 11, 3152-3160.	0.8	7
2478	Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. <i>Journal of Gastroenterology</i> , 2016, 51, 1150-1160.	2.3	44
2479	Reliability, Validity, and Reader Acceptance of LI-RADS—An In-depth Analysis. <i>Academic Radiology</i> , 2016, 23, 1145-1153.	1.3	39
2480	Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments. <i>World Journal of Surgical Oncology</i> , 2016, 14, 151.	0.8	66
2481	Copper chelation by trientine dihydrochloride inhibits liver RFA-induced inflammatory responses in vivo. <i>Inflammation Research</i> , 2016, 65, 1009-1020.	1.6	15
2482	Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells by elevated ROS production. <i>Cancer Letters</i> , 2016, 382, 157-165.	3.2	33
2483	Pre-treatment estimation of future remnant liver function using gadoxetic acid MRI in patients with HCC. <i>Journal of Hepatology</i> , 2016, 65, 1155-1162.	1.8	41
2484	Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon?. <i>Personalized Medicine</i> , 2016, 13, 455-467.	0.8	11
2485	Long noncoding RNA CCHE1 indicates a poor prognosis of hepatocellular carcinoma and promotes carcinogenesis via activation of the ERK/MAPK pathway. <i>Biomedicine and Pharmacotherapy</i> , 2016, 83, 450-455.	2.5	68
2486	Arsenite inhibits the function of CD133+ CD13+ liver cancer stem cells by reducing PML and Oct4 protein expression. <i>Tumor Biology</i> , 2016, 37, 14103-14115.	0.8	21
2487	Generation of a Scaffold-Free Three-Dimensional Liver Tissue via a Rapid Cell-to-Cell Click Assembly Process. <i>Bioconjugate Chemistry</i> , 2016, 27, 1991-1998.	1.8	15
2488	Dynamic Interplay between the Transcriptome and Methylome in Response to Oxidative and Alkylating Stress. <i>Chemical Research in Toxicology</i> , 2016, 29, 1428-1438.	1.7	8
2489	Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014). <i>Journal of Hepatology</i> , 2016, 65, 1086-1093.	1.8	36
2490	Identification of a novel oxidative stress induced cell death by Sorafenib and oleanolic acid in human hepatocellular carcinoma cells. <i>Biochemical Pharmacology</i> , 2016, 118, 9-17.	2.0	32
2492	Response to Ablation and resection for hepatocellular carcinoma within the Milan criteria and high alpha-fetoprotein levels. <i>Liver International</i> , 2016, 36, 1878-1878.	1.9	0
2493	Prospective cohort study of laparoscopic and open hepatectomy for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2016, 103, 1895-1901.	0.1	46
2494	PRDX2 protects hepatocellular carcinoma SMMC-7721 cells from oxidative stress. <i>Oncology Letters</i> , 2016, 12, 2217-2221.	0.8	21
2495	PIN1 in hepatocellular carcinoma is associated with TP53 gene status. <i>Oncology Reports</i> , 2016, 36, 2405-2411.	1.2	8

#	ARTICLE	IF	CITATIONS
2496	Roles of long noncoding RNAs in hepatocellular carcinoma. <i>Virus Research</i> , 2016, 223, 131-139.	1.1	50
2497	Synergistic effects of CD44 and TGF- $\beta$ 1 through AKT/GSK-3 $\beta$ / $\beta$ -catenin signaling during epithelial-mesenchymal transition in liver cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2016, 477, 568-574.	1.0	65
2498	Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple hepatocellular carcinoma. <i>Surgery</i> , 2016, 160, 1227-1235.	1.0	67
2499	TACE Combined with Implantation of Irradiation Stent Versus TACE Combine with Bare Stent for HCC Complicated by IVCTT. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 1280-1288.	0.9	8
2500	In Vitro Antihepatoma Activity of Novel 3D-Copper Cyanide Supramolecular Coordination Polymers. <i>Journal of AOAC INTERNATIONAL</i> , 2016, 99, 1240-1246.	0.7	1
2501	Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization. <i>Oncology Letters</i> , 2016, 11, 2987-2994.	0.8	30
2502	Weight loss following diet-induced obesity does not alter colon tumorigenesis in the AOM mouse model. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G699-G712.	1.6	14
2503	Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic review. <i>World Journal of Surgical Oncology</i> , 2016, 14, 159.	0.8	13
2504	“Hepatocellular carcinoma: A life-threatening disease”. <i>Biomedicine and Pharmacotherapy</i> , 2016, 84, 1679-1688.	2.5	68
2505	The herbal medicine <i>Cyperus amuricus</i> inhibits proliferation of human hepatocellular carcinoma Hep3B cells by inducing apoptosis and arrest at the G0/G1 cell cycle phase. <i>International Journal of Oncology</i> , 2016, 49, 2046-2054.	1.4	7
2506	Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma. <i>Translational Oncology</i> , 2016, 9, 466-471.	1.7	13
2507	Hepatocellular Carcinoma “ Liver Transplantation, Hepatic Resection, and Regional Treatment Options. , 2016, , 391-421.		0
2508	KLHL21, a novel gene that contributes to the progression of hepatocellular carcinoma. <i>BMC Cancer</i> , 2016, 16, 815.	1.1	44
2509	Umbilical cord-derived mesenchymal stem cells inhibit growth and promote apoptosis of HepG2 cells. <i>Molecular Medicine Reports</i> , 2016, 14, 2717-2724.	1.1	23
2510	Impact of Branched-Chain Amino Acid-Enriched Nutrient on liver Cirrhosis with Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization in Barcelona Clinic Liver Cancer Stage B: A Prospective Study. <i>Journal of Nippon Medical School</i> , 2016, 83, 248-256.	0.3	14
2511	Conditional disease-free survival after liver transplantation for hepatocellular carcinoma. <i>Medicine (United States)</i> , 2016, 95, e4383.	0.4	8
2513	Dysregulated fatty acid metabolism in hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2016, 3, 241-251.	4.2	56
2515	Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. <i>Medicine (United States)</i> , 2016, 95, e4602.	0.4	6

#	ARTICLE	IF	CITATIONS
2516	Adenovirus-mediated artificial microRNA against human fibrinogen like protein 2 inhibits hepatocellular carcinoma growth. <i>Journal of Gene Medicine</i> , 2016, 18, 102-111.	1.4	14
2517	Cirrhosis is under-recognized in patients subsequently diagnosed with hepatocellular cancer. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 621-630.	1.9	73
2518	Hepatic resection of hepatocellular carcinoma after proton beam therapy: A case report. <i>Hepatology Research</i> , 2016, 46, 483-488.	1.8	5
2519	A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation. <i>Transplant International</i> , 2016, 29, 369-380.	0.8	26
2520	Surgical outcomes of hepatocellular carcinoma with biliary tumor thrombus: a systematic review. <i>BMC Gastroenterology</i> , 2016, 16, 11.	0.8	17
2521	CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy. <i>BMC Cancer</i> , 2016, 16, 15.	1.1	37
2522	Percutaneous radio-frequency ablation of hepatocellular carcinoma adjacent to the gastrointestinal tract. <i>International Journal of Hyperthermia</i> , 2016, 32, 600-606.	1.1	4
2523	Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs. <i>Oncology</i> , 2016, 91, 90-100.	0.9	25
2524	Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3-5cm: A propensity score matching study. <i>Digestive and Liver Disease</i> , 2016, 48, 1082-1087.	0.4	16
2525	Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan. <i>Liver Cancer</i> , 2016, 5, 190-197.	4.2	122
2526	Validation and reappraisal of the assessment for retreatment with transarterial chemoembolization score for unresectable non-metastatic hepatocellular carcinoma in a hepatitis b virus-endemic region. <i>European Radiology</i> , 2016, 26, 3510-3518.	2.3	7
2527	Cancer stem cell marker expression alone and in combination with microvascular invasion predicts poor prognosis in patients undergoing transplantation for hepatocellular carcinoma. <i>American Journal of Surgery</i> , 2016, 212, 238-245.	0.9	18
2528	A case of miriplatin-induced lung injury. <i>Journal of Infection and Chemotherapy</i> , 2016, 22, 486-489.	0.8	4
2529	Silencing of ST6GalNAc I suppresses the proliferation, migration and invasion of hepatocarcinoma cells through PI3K/AKT/NF- $\kappa$ B pathway. <i>Tumor Biology</i> , 2016, 37, 12213-12221.	0.8	20
2530	Value of the 8-oxodG/dG ratio in chronic liver inflammation of patients with hepatocellular carcinoma. <i>Redox Biology</i> , 2016, 8, 259-270.	3.9	8
2531	Laparoscopic left lateral sectionectomy in patients with histologically confirmed cirrhosis. <i>Surgical Oncology</i> , 2016, 25, 132-138.	0.8	16
2532	Comparison of Salvage Living Donor Liver Transplantation and Local Regional Therapy for Recurrent Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2016, 40, 2472-2480.	0.8	13
2533	Percutaneous radiofrequency ablation for patients with malignant lung tumors: a phase II prospective multicenter study (JIVROSG-0702). <i>Japanese Journal of Radiology</i> , 2016, 34, 556-563.	1.0	13



#	ARTICLE	IF	CITATIONS
2534	Changes in Doppler parameters of portal pressure after interventional management of hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2016, 41, 1532-1538.	1.0	5
2535	Adjuvant $^{131}\text{I}$ -Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2016, 40, 1941-1950.	0.8	3
2536	Anti-hepatoma activity of the stiff branched $\beta$ -D-glucan and effects of molecular weight. <i>Journal of Materials Chemistry B</i> , 2016, 4, 4565-4573.	2.9	44
2537	Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. <i>Hepatology</i> , 2016, 64, 774-784.	3.6	77
2538	Role of intratumoral infiltrating macrophages after transarterial immunoembolization for hepatocellular carcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2016, 23, 298-304.	1.4	2
2539	Transcriptome Analysis of WHV/c-myc Transgenic Mice Implicates Cytochrome P450 Enzyme 17A1 as a Promising Biomarker for Hepatocellular Carcinoma. <i>Cancer Prevention Research</i> , 2016, 9, 739-749.	0.7	7
2540	The antibacterial peptide from <i>Bombyx mori</i> cecropinXJ induced growth arrest and apoptosis in human hepatocellular carcinoma cells. <i>Oncology Letters</i> , 2016, 12, 57-62.	0.8	22
2541	The Liver in Systemic Diseases. , 2016, , .		2
2542	Heterogeneity of Hepatocellular Carcinoma. <i>Translational Bioinformatics</i> , 2016, , 371-398.	0.0	0
2543	Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation. <i>Cut</i> , 2016, 65, 134-143.	6.1	53
2544	Spontaneous ruptured hepatocellular carcinoma. <i>Hepatology Research</i> , 2016, 46, 13-21.	1.8	94
2545	The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation. <i>Oncogene</i> , 2016, 35, 1314-1323.	2.6	52
2546	Improving the Anticancer Efficacy of Laminin Receptor-Specific Therapeutic Ruthenium Nanoparticles (RuBB-Loaded EGCG-RuNPs) via ROS-Dependent Apoptosis in SMMC-7721 Cells. <i>ACS Applied Materials &amp; Interfaces</i> , 2016, 8, 15000-15012.	4.0	49
2547	Microtubule targeted therapeutics loaded polymeric assembled nanospheres for potentiation of antineoplastic activity. <i>Faraday Discussions</i> , 2016, 186, 45-59.	1.6	2
2548	Hepatocellular carcinoma: modern image-guided therapies. <i>Postgraduate Medical Journal</i> , 2016, 92, 165-171.	0.9	10
2549	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016, 150, 835-853.	0.6	1,365
2550	The Clinicopathologic Significance of BAF250a (ARID1A) Expression in Hepatocellular Carcinoma. <i>Pathology and Oncology Research</i> , 2016, 22, 453-459.	0.9	31
2551	When Should We Propose Liver Transplant After Resection of Hepatocellular Carcinoma? A Comparison of Salvage and De Principe Strategies. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 66-76.	0.9	28

#	ARTICLE	IF	CITATIONS
2552	Failure recovery of circulating NKG2D <sup>+</sup> CD56 <sup>dim</sup> NK cells in HBV-associated hepatocellular carcinoma after hepatectomy predicts early recurrence. <i>Oncolmmunology</i> , 2016, 5, e1048061.	2.1	16
2553	Combination of miR-125b and miR-27a enhances sensitivity and specificity of AFP-based diagnosis of hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 6539-6549.	0.8	36
2554	Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma. <i>Transplantation</i> , 2016, 100, 116-125.	0.5	339
2555	Quantitative Assessment of the Portal Pressure for the Liver Surgery Using Serological Tests. <i>Annals of Surgery</i> , 2016, 264, 330-338.	2.1	12
2556	A 2015 survey of established or potential epigenetic biomarkers for the accurate detection of human cancers. <i>Biomarkers</i> , 2016, 21, 387-403.	0.9	4
2557	Formylpeptide receptor 1 mediates the tumorigenicity of human hepatocellular carcinoma cells. <i>Oncolmmunology</i> , 2016, 5, e1078055.	2.1	13
2558	Interleukin-12 inhibits the hepatocellular carcinoma growth by inducing macrophage polarization to the M1-like phenotype through downregulation of Stat-3. <i>Molecular and Cellular Biochemistry</i> , 2016, 415, 157-168.	1.4	46
2559	Long noncoding RNA SNHG1 predicts a poor prognosis and promotes hepatocellular carcinoma tumorigenesis. <i>Biomedicine and Pharmacotherapy</i> , 2016, 80, 73-79.	2.5	137
2560	Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. <i>British Journal of Cancer</i> , 2016, 114, 767-776.	2.9	60
2561	A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1288-1297.	0.2	6
2562	Recognizing Focal Liver Lesions in CEUS With Dynamically Trained Latent Structured Models. <i>IEEE Transactions on Medical Imaging</i> , 2016, 35, 713-727.	5.4	20
2563	Morbidity of hepatic resection for intermediate and advanced hepatocellular carcinoma. <i>Langenbeck's Archives of Surgery</i> , 2016, 401, 43-53.	0.8	6
2564	Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study. <i>Future Oncology</i> , 2016, 12, 183-198.	1.1	8
2565	Autologous adipose tissue-derived mesenchymal stem cells are involved in rat liver regeneration following repeat partial hepatectomy. <i>Molecular Medicine Reports</i> , 2016, 13, 2053-2059.	1.1	20
2566	Melittin suppresses cathepsin S-induced invasion and angiogenesis via blocking of the VEGF-A/VEGFR-2/MEK1/ERK1/2 pathway in human hepatocellular carcinoma. <i>Oncology Letters</i> , 2016, 11, 610-618.	0.8	43
2567	Radiopharmaceuticals for Therapy. , 2016, , .		42
2568	Microvascular invasion patterns affect survival in hepatocellular carcinoma patients after second hepatectomy. <i>Journal of Surgical Research</i> , 2016, 200, 82-90.	0.8	14
2569	Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Hepatic Cancer. , 2016, , 209-222.		0

#	ARTICLE	IF	CITATIONS
2570	Tumor-targeted docetaxel-loaded hyaluronic acid-quercetin polymeric micelles with p-gp inhibitory property for hepatic cancer therapy. <i>RSC Advances</i> , 2016, 6, 27542-27556.	1.7	24
2571	MicroRNA-379-5p inhibits tumor invasion and metastasis by targeting FAK/AKT signaling in hepatocellular carcinoma. <i>Cancer Letters</i> , 2016, 375, 73-83.	3.2	95
2572	Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. <i>Journal of Gastroenterology</i> , 2016, 51, 1011-1021.	2.3	29
2573	Pathobiologic Characteristics of Small Hepatocellular Carcinoma. , 2016, , 11-24.		0
2574	Dysregulated YAP1/TAZ and TGF- $\beta$ 2 signaling mediate hepatocarcinogenesis in <i>Mob1a/1b</i> -deficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E71-80.	3.3	158
2575	Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. <i>International Journal of Clinical Oncology</i> , 2016, 21, 676-683.	1.0	4
2576	Clinical Impact of Anatomical Liver Resection for Hepatocellular Carcinoma with Pathologically Proven Portal Vein Invasion. <i>World Journal of Surgery</i> , 2016, 40, 402-411.	0.8	24
2577	Abnormal miRNAs Targeting Chromosome Open Reading Frame Genes were Enriched in Microvesicles Derived from the Circulation of HCC. <i>Biochemical Genetics</i> , 2016, 54, 120-133.	0.8	7
2578	Radiofrequency Ablation for Small Hepatocellular Carcinoma. , 2016, , .		4
2579	Sustained protein release from hydrogel microparticles using layer-by-layer (LbL) technology. <i>Drug Delivery</i> , 2016, 23, 2747-2755.	2.5	15
2580	Morphologic severity of cirrhosis determines the extent of liver resection in patients with hepatocellular carcinoma and Child-Pugh grade AA cirrhosis. <i>Journal of Surgical Research</i> , 2016, 200, 444-451.	0.8	18
2581	Glucose-regulated protein 94 mediates cancer progression via AKT and eNOS in hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 4295-4304.	0.8	25
2582	Low-level expression of microRNA-375 predicts poor prognosis in hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 2145-2152.	0.8	12
2583	ML-7 amplifies the quinocetone-induced cell death through akt and MAPK-mediated apoptosis on HepG2 cell line. <i>Toxicology Mechanisms and Methods</i> , 2016, 26, 11-21.	1.3	4
2584	Demystifying Interventional Radiology. , 2016, , .		2
2585	Management strategies for hepatocellular carcinoma: old certainties and new realities. <i>Clinical and Experimental Medicine</i> , 2016, 16, 243-256.	1.9	27
2586	Heterogeneity of liver cancer and personalized therapy. <i>Cancer Letters</i> , 2016, 379, 191-197.	3.2	202
2587	Laparoscopic versus open major hepatectomy for hepatocellular carcinoma: a matched pair analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2016, 30, 1965-1974.	1.3	104

#	ARTICLE	IF	CITATIONS
2588	Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis. <i>Journal of Proteome Research</i> , 2016, 15, 1126-1134.	1.8	78
2589	Significance of viral status on prognosis of hepatitis B-related hepatocellular carcinoma after curative resection in East Asia. <i>Hepatology Research</i> , 2016, 46, 40-49.	1.8	7
2590	Fast semi-automatic segmentation of focal liver lesions in contrast-enhanced ultrasound, based on a probabilistic model. <i>Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization</i> , 2017, 5, 329-338.	1.3	14
2591	Acute exacerbation of hepatitis C in hepatocellular carcinoma patients receiving chemotherapy. <i>Journal of Medical Virology</i> , 2017, 89, 153-160.	2.5	6
2592	The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy. <i>International Journal of Oncology</i> , 2017, 50, 381-386.	1.4	26
2593	HBx promotes cell proliferation by disturbing the cross-talk between miR-181a and PTEN. <i>Scientific Reports</i> , 2017, 7, 40089.	1.6	25
2594	Intra-arterial therapies for liver cancer: assessing tumor response. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 119-127.	1.1	11
2595	Aqueous extract of <i>Polygonum bistorta</i> modulates proteostasis by ROS-induced ER stress in human hepatoma cells. <i>Scientific Reports</i> , 2017, 7, 41437.	1.6	18
2596	Macrolide antibiotics differentially influence human HepG2 cytotoxicity and modulate intrinsic/extrinsic apoptotic pathways in rat hepatocellular carcinoma model. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 379-395.	1.4	15
2597	Loss of N-Acetylgalactosaminyltransferase-4 Orchestrates Oncogenic MicroRNA-9 in Hepatocellular Carcinoma. <i>Journal of Biological Chemistry</i> , 2017, 292, 3186-3200.	1.6	27
2598	Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function. <i>Digestive and Liver Disease</i> , 2017, 49, 697-704.	0.4	23
2599	Management of people with intermediate-stage hepatocellular carcinoma. <i>The Cochrane Library</i> , 2017, 3, CD011649.	1.5	16
2600	MicroRNA-185 induces potent autophagy via AKT signaling in hepatocellular carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831769431.	0.8	28
2601	Development of Semiautomated Module for Preparation of <sup>131</sup> I Labeled Lipiodol for Liver Cancer Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 33-37.	0.7	6
2602	The apoptotic inducible effects of salicylic acid on hepatoma cell line: relationship with nitric oxide signaling. <i>Journal of Cell Communication and Signaling</i> , 2017, 11, 245-253.	1.8	6
2603	Cirrhose et carcinome hépatocellulaire : diagnostic et suivi biologique. <i>Revue Francophone Des Laboratoires</i> , 2017, 2017, 64-71.	0.0	0
2604	On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multicentre, prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1146-1155.	1.9	47
2605	microRNA-23b suppresses epithelial-mesenchymal transition (EMT) and metastasis in hepatocellular carcinoma via targeting Pyk2. <i>Biomedicine and Pharmacotherapy</i> , 2017, 89, 642-650.	2.5	36

#	ARTICLE	IF	CITATIONS
2606	Microwave ablation is as effective as radiofrequency ablation for very-early-stage hepatocellular carcinoma. <i>Chinese Journal of Cancer</i> , 2017, 36, 14.	4.9	61
2607	MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation. <i>Oncogenesis</i> , 2017, 6, e312-e312.	2.1	91
2608	Cytotoxic effect of a mannogalactoglucan extracted from <i>Agaricus bisporus</i> on HepG2 cells. <i>Carbohydrate Polymers</i> , 2017, 170, 33-42.	5.1	24
2609	Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. <i>Medicine (United States)</i> , 2017, 96, e5811.	0.4	111
2610	Three-way decision support for diagnosis on focal liver lesions. <i>Knowledge-Based Systems</i> , 2017, 127, 85-99.	4.0	81
2611	Pure Laparoscopic Versus Open Right Hepatectomy for Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Annals of Surgery</i> , 2017, 265, 856-863.	2.1	165
2612	Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Treated with Initial Transarterial Chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1559-1566.	0.9	24
2613	Induced MiR-1249 expression by aberrant activation of Hedgehog signaling pathway in hepatocellular carcinoma. <i>Experimental Cell Research</i> , 2017, 355, 9-17.	1.2	18
2614	The Hippo pathway in hepatocellular carcinoma: Non-coding RNAs in action. <i>Cancer Letters</i> , 2017, 400, 175-182.	3.2	32
2615	Target-specific delivery of siRNA into hepatoma cellsâ€™ cytoplasm by bifunctional carrier peptide. <i>Drug Delivery and Translational Research</i> , 2017, 7, 147-155.	3.0	3
2616	HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. <i>Hepatology International</i> , 2017, 11, 199-208.	1.9	13
2617	Better prognosis of hepatic resection combined with antiviral therapy for HBV-related hepatocellular carcinoma with ABCLC Stage B/C. <i>Asian Journal of Surgery</i> , 2017, 40, 453-462.	0.2	10
2618	Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. <i>Hepatology</i> , 2017, 66, 1556-1569.	3.6	92
2620	Iodine-125 Brachytherapy Prophylaxis after Radiofrequency Ablation Cannot Benefit Patients in High Risk of Locoregional Hepatocellular Carcinoma Recurrence. <i>Scientific Reports</i> , 2017, 7, 3689.	1.6	4
2621	Risk factors and long-term outcome for postoperative intra-abdominal infection after hepatectomy for hepatocellular carcinoma. <i>Medicine (United States)</i> , 2017, 96, e6795.	0.4	20
2622	The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2017, 5, 944-953.	1.6	55
2623	New idea for treatment strategies for Barcelona Clinic Liver Cancer stages based on a network meta-analysis. <i>Medicine (United States)</i> , 2017, 96, e6950.	0.4	11
2624	A pumpkin polysaccharide induces apoptosis by inhibiting the JAK2/STAT3 pathway in human hepatoma HepG2 cells. <i>International Journal of Biological Macromolecules</i> , 2017, 104, 681-686.	3.6	30

#	ARTICLE	IF	CITATIONS
2625	GPX2 overexpression indicates poor prognosis in patients with hepatocellular carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831770041.	0.8	30
2626	Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1791-1799.	2.4	76
2627	Report from European Association for the Study of the Liver: HCC Summit, Geneva, Switzerland, 2â€“5 February 2017. <i>Future Oncology</i> , 2017, 13, 1297-1300.	1.1	1
2628	Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2017, 12, 449-462.	1.7	16
2629	Role of S100A3 in human hepatocellular carcinoma and the anticancer effect of sodium cantharidinate. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 2812-2818.	0.8	19
2630	Anti-angiogenics in Hepatocellular Cancer Therapy. , 2017, , 1-12.		0
2631	Laparoscopic Management of Hepatocellular Carcinoma: A Critical Reappraisal. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2017, 27, 203-205.	0.4	4
2632	Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells. <i>International Journal of Oncology</i> , 2017, 51, 128-144.	1.4	18
2633	Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 175-190.	1.0	30
2634	Management of people with early- or very early-stage hepatocellular carcinoma. <i>The Cochrane Library</i> , 2017, 3, CD011650.	1.5	59
2635	Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 38.	3.5	52
2636	Acoustic and hybrid 3D-printed electrochemical biosensors for the real-time immunodetection of liver cancer cells (HepG2). <i>Biosensors and Bioelectronics</i> , 2017, 94, 500-506.	5.3	64
2637	The mitochondrial hinge protein, <sc>UQCRH</sc>, is a novel prognostic factor for hepatocellular carcinoma. <i>Cancer Medicine</i> , 2017, 6, 749-760.	1.3	36
2638	The chemo-prophylactic efficacy of an ethanol <i>Moringa oleifera</i> leaf extract against hepatocellular carcinoma in rats. <i>Pharmaceutical Biology</i> , 2017, 55, 1458-1466.	1.3	54
2639	Laparoscopic Anatomic Segment 6 Liver Resection Using the Glissonian Approach. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2017, 27, e22-e25.	0.4	8
2640	Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma. <i>Journal of Controlled Release</i> , 2017, 263, 18-28.	4.8	51
2641	Obesity-associated digestive cancers: A review of mechanisms and interventions. <i>Tumor Biology</i> , 2017, 39, 101042831769502.	0.8	26
2642	Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal metaâ€“analysis. <i>Liver Transplantation</i> , 2017, 23, 836-844.	1.3	84

#	ARTICLE	IF	CITATIONS
2643	Antitumor and immunomodulatory effects of ginsenoside Rh2 and its octyl ester derivative in H22 tumor-bearing mice. <i>Journal of Functional Foods</i> , 2017, 32, 382-390.	1.6	51
2644	The optimal cut-off value of the preoperative prognostic nutritional index for the survival differs according to the TNM stage in hepatocellular carcinoma. <i>Surgery Today</i> , 2017, 47, 986-993.	0.7	16
2645	Laparoscopic hepatectomy for HCC in elderly patients: risks and feasibility. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 179-183.	1.4	22
2646	Indocyanine green fluorescence imaging in hepatobiliary surgery. <i>Photodiagnosis and Photodynamic Therapy</i> , 2017, 17, 208-215.	1.3	91
2647	CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma. <i>Cancer Letters</i> , 2017, 389, 1-10.	3.2	76
2648	Antiviral Therapy Inhibits Viral Reactivation and Improves Survival after Repeat Hepatectomy for Hepatitis B Virus-Related Recurrent Hepatocellular Carcinoma. <i>Journal of the American College of Surgeons</i> , 2017, 224, 283-293e4.	0.2	21
2649	Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 969-978.	3.3	9
2650	Well-Defined Multivalent Ligands for Hepatocytes Targeting via Asialoglycoprotein Receptor. <i>Bioconjugate Chemistry</i> , 2017, 28, 283-295.	1.8	77
2651	Sodium cantharidinate induces HepG2 cell apoptosis through LC3 autophagy pathway. <i>Oncology Reports</i> , 2017, 38, 1233-1239.	1.2	17
2652	Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma. <i>Current Treatment Options in Oncology</i> , 2017, 18, 67.	1.3	4
2653	Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1503-1511.e2.	0.2	37
2654	Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1061-1069.	1.9	35
2655	Prevalence of occult hepatitis B virus infection and Torque teno virus infection and their association with hepatocellular carcinoma in chronic hepatitis C patients. <i>Virus Research</i> , 2017, 242, 166-172.	1.1	19
2656	Decreased expression of long non-coding RNA LOC728290 in human hepatocellular carcinoma. <i>Oncology Letters</i> , 2017, 14, 4551-4556.	0.8	2
2657	A new plasma biomarker enhance the clinical prediction of postoperative acute kidney injury in patients with hepatocellular carcinoma. <i>Clinica Chimica Acta</i> , 2017, 475, 128-136.	0.5	5
2658	Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831772086.	0.8	30
2659	Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2. <i>Digestive Diseases</i> , 2017, 35, 583-588.	0.8	7
2660	A phase I study on stereotactic body radiotherapy of liver metastases based on functional treatment planning using positron emission tomography with <sup>18</sup> F-fluoro-2-deoxy-D-glucose. <i>Acta Oncologica</i> , 2017, 56, 1614-1620.	0.8	7

#	ARTICLE	IF	CITATIONS
2661	Camptothecin suppresses NRF2â€‘ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs. <i>British Journal of Cancer</i> , 2017, 117, 1495-1506.	2.9	54
2662	Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 945-954.	1.1	18
2663	Radionuclides in oncology clinical practice â€‘ review of the literature. <i>Dalton Transactions</i> , 2017, 46, 14475-14487.	1.6	4
2664	High expression of GP73 in primary hepatocellular carcinoma and its function in the assessment of transcatheter arterial chemoembolization. <i>Oncology Letters</i> , 2017, 14, 3953-3958.	0.8	15
2665	NEDD4 promotes cell growth and migration via PTEN/PI3K/AKT signaling in hepatocellular carcinoma. <i>Oncology Letters</i> , 2017, 14, 2649-2656.	0.8	29
2666	Metabolomic and transcriptomic profiling of hepatocellular carcinomas in Hras12V transgenic mice. <i>Cancer Medicine</i> , 2017, 6, 2370-2384.	1.3	14
2667	<i>HRAS</i> , <i>EGFR</i> , <i>MET</i> , and <i>RON</i> Genes Are Recurrently Activated by Provirus Insertion in Liver Tumors Induced by the Retrovirus Myeloblastosis-Associated Virus 2. <i>Journal of Virology</i> , 2017, 91, .	1.5	5
2668	Diagnostic value of long noncoding RNAs for hepatocellular carcinoma. <i>Medicine (United States)</i> , 2017, 96, e7496.	0.4	13
2669	Transarterial chemoembolization combined with Huaier granule for the treatment of primary hepatic carcinoma. <i>Medicine (United States)</i> , 2017, 96, e7589.	0.4	31
2670	A Meta-analysis comparing the effect of anatomical resection vs. non-anatomical resection on the long-term outcomes for patients undergoing hepatic resection for hepatocellular carcinoma. <i>Hpb</i> , 2017, 19, 843-849.	0.1	32
2671	S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 407-417.	3.7	51
2672	Prognostic nomogram for patients with non-B non-C hepatocellular carcinoma after curative liver resection. <i>International Journal of Surgery</i> , 2017, 44, 160-165.	1.1	7
2673	Downregulation of USP18 inhibits growth and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma cells by suppressing BCL2L1. <i>Experimental Cell Research</i> , 2017, 358, 315-322.	1.2	21
2674	Association between relative liver enhancement on gadoteric acid enhanced magnetic resonance images and histologic grade of hepatocellular carcinoma. <i>Medicine (United States)</i> , 2017, 96, e7580.	0.4	8
2675	Treatment of hepatocellular carcinoma using transarterial chemoembolization. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 225-230.	0.8	2
2676	<sc>WWC</sc>2 is an independent prognostic factor and prevents invasion <i>via</i> Hippo signalling in hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 3718-3729.	1.6	28
2677	HBx represses RIZ1 expression by DNA methyltransferase 1 involvement in decreased miR-152 in hepatocellular carcinoma. <i>Oncology Reports</i> , 2017, 37, 2811-2818.	1.2	25
2678	Peripheral blood neutrophil count as a prognostic factor for patients with hepatocellular carcinoma treated with sorafenib. <i>Molecular and Clinical Oncology</i> , 2017, 7, 837-842.	0.4	18



#	ARTICLE	IF	CITATIONS
2679	Long-term follow-up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report. <i>Oncology Letters</i> , 2017, 14, 4853-4856.	0.8	6
2680	Liver Imaging Reporting and Data System Classification of Hepatocellular Carcinoma: Implications for Clinical Management. <i>Digestive Disease Interventions</i> , 2017, 01, 083-093.	0.3	0
2681	Pre-S deletions of hepatitis B virus predict recurrence of hepatocellular carcinoma after curative resection. <i>Medicine (United States)</i> , 2017, 96, e8311.	0.4	6
2682	Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2931-2952.	1.4	14
2683	Over Expression of Long Non-Coding RNA PANDA Promotes Hepatocellular Carcinoma by Inhibiting Senescence Associated Inflammatory Factor IL8. <i>Scientific Reports</i> , 2017, 7, 4186.	1.6	25
2684	Automatic Identification of the Optimal Reference Frame for Segmentation and Quantification of Focal Liver Lesions in Contrast-Enhanced Ultrasound. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 2438-2451.	0.7	6
2685	Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Cell Transplantation</i> , 2017, 26, 429-438.	1.2	23
2686	A novel approach for Hepatocellular Carcinoma detection and classification based on triphasic CT Protocol. , 2017, , .		23
2687	Histone deacetylase 5 promotes the migration and invasion of hepatocellular carcinoma via increasing the transcription of hypoxia-inducible factor-1 $\alpha$ under hypoxia condition. <i>Tumor Biology</i> , 2017, 39, 101042831770503.	0.8	18
2688	Progressive hypofractionated carbon-13 radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials. <i>Cancer</i> , 2017, 123, 3955-3965.	2.0	66
2689	Diagnostic efficacy of the Liver Imaging-Reporting and Data System (LI-RADS) with CT imaging in categorising small nodules (10-20mm) detected in the cirrhotic liver at screening ultrasound. <i>Clinical Radiology</i> , 2017, 72, 901.e1-901.e11.	0.5	32
2690	PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. <i>Medicine (United States)</i> , 2017, 96, e7266.	0.4	29
2691	The antitumor activity of a lactosaminated albumin conjugate of doxorubicin in a chemically induced hepatocellular carcinoma rat model compared to sorafenib. <i>Digestive and Liver Disease</i> , 2017, 49, 213-222.	0.4	25
2692	A tumour-promoting role of Th9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 213-221.	0.9	50
2693	Microwave ablation versus hepatic resection for the treatment of hepatocellular carcinoma and oesophageal variceal bleeding in cirrhotic patients. <i>International Journal of Hyperthermia</i> , 2017, 33, 255-262.	1.1	12
2694	Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse <sup>®</sup> G600 analyzer. <i>Journal of Viral Hepatitis</i> , 2017, 24, 80-85.	1.0	19
2695	BCL2L10 inhibits growth and metastasis of hepatocellular carcinoma both in vitro and in vivo. <i>Molecular Carcinogenesis</i> , 2017, 56, 1137-1149.	1.3	16
2696	Increased interreader agreement in diagnosis of hepatocellular carcinoma using an adapted LI-RADS algorithm. <i>European Journal of Radiology</i> , 2017, 86, 33-40.	1.2	29

#	ARTICLE	IF	CITATIONS
2697	Hepatocellular Carcinoma (Ordinary Hepatocellular Carcinoma). , 2017, , 27-64.		0
2698	Hepatocellular Carcinoma: Prognostic Factors. , 2017, , 151-165.		1
2699	Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 273-281.e1.	2.4	106
2700	KrÄppelâ€like factor 8 promotes cancer stem cellâ€like traits in hepatocellular carcinoma through Wnt/Î²â€catenin signaling. <i>Molecular Carcinogenesis</i> , 2017, 56, 751-760.	1.3	21
2701	Liver-infiltrating CD11b~CD27~ NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression. <i>Cellular and Molecular Immunology</i> , 2017, 14, 819-829.	4.8	103
2702	Sorafenib with ASC-J9<sup>Â®</sup> synergistically suppresses the HCC progression <i>via</i> altering the pSTAT3-CCL2/Bcl2 signals. <i>International Journal of Cancer</i> , 2017, 140, 705-717.	2.3	25
2703	Inhibition of Orailâ€mediated Ca<sup>2+</sup> entry enhances chemosensitivity of HepG2 hepatocarcinoma cells to 5â€fluorouracil. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 904-915.	1.6	66
2704	Evaluation of the risk factors and prognostic factors of hepatectomy for hepatocellular carcinoma in patients aged 80 years or more. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2017, 24, 58-64.	1.4	20
2705	The role of regulatory B cells in digestive system diseases. <i>Inflammation Research</i> , 2017, 66, 303-309.	1.6	1
2706	Thermal Injuryâ€induced Hepatic Parenchymal Hypoperfusion: Risk of Hepatocellular Carcinoma Recurrence after Radiofrequency Ablation. <i>Radiology</i> , 2017, 282, 880-891.	3.6	16
2707	Preclinical evaluation of cisplatin-incorporated bio-nanocapsules as chemo-radiotherapy for human hepatocellular carcinoma. <i>Oncology Reports</i> , 2017, 38, 2259-2266.	1.2	5
2709	Targeted sequencing of cancerâ€associated genes in hepatocellular carcinoma using nextâ€generation sequencing. <i>Oncology Letters</i> , 2018, 15, 528-532.	0.8	6
2710	2017 Version of LI-RADS for CT and MR Imaging: An Update. <i>Radiographics</i> , 2017, 37, 1994-2017.	1.4	185
2711	Aflatoxin M 1 Contamination in Milk and Dairy Products. , 2017, , 237-250.		4
2712	Role of diffusion-weighted magnetic resonance imaging in the evaluation of hepatocellular carcinoma response to transcatheter arterial chemoembolization using drug eluting beads; correlation with dynamic MRI. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2017, 48, 817-824.	0.3	6
2713	The Role of E-Cadherin/Î²-Catenin in Hydroxysafflor Yellow A Inhibiting Adhesion, Invasion, Migration and Lung Metastasis of Hepatoma Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2017, 40, 1706-1715.	0.6	18
2714	Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000â€2014). <i>Hepatology Communications</i> , 2017, 1, 736-747.	2.0	8
2715	Malignancy characterization of hepatocellular carcinoma using hybrid texture and deep features. , 2017, , .		9

#	ARTICLE	IF	CITATIONS
2716	Lymphoepithelioma-like hepatocellular carcinoma. <i>Medicine (United States)</i> , 2017, 96, e9416.	0.4	22
2717	Practical Considerations of Real Life of Hepatocellular Carcinoma in a Tertiary Center of Brazil. <i>Annals of Hepatology</i> , 2017, 16, 255-262.	0.6	10
2718	Risk Factors for Prognosis of Hepatocellular Carcinoma After Curative Resection In Patients with Low Hepatitis B Viral Load. <i>Annals of Hepatology</i> , 2017, 16, 412-420.	0.6	5
2719	Surgical Outcomes in Hepatitis C Virus-Related Hepatocellular Carcinoma: Special Reference to Sustained Virological Responses to Interferon Therapy. <i>American Surgeon</i> , 2017, 83, 1246-1255.	0.4	8
2720	Liver Imaging Reporting and Data System: an expert consensus statement. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 29-39.	1.8	46
2721	Down-Regulation of TGF- $\beta$ 2 Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib. <i>Yonsei Medical Journal</i> , 2017, 58, 899.	0.9	18
2722	Lower Education and Household Income Contribute to Advanced Disease, Less Treatment Received and Poorer Prognosis in Patients with Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2017, 8, 3070-3077.	1.2	17
2723	TRAF4 Regulates Migration, Invasion, and Epithelial-Mesenchymal Transition via PI3K/AKT Signaling in Hepatocellular Carcinoma. <i>Oncology Research</i> , 2017, 25, 1329-1340.	0.6	35
2724	A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma. <i>Journal of Cancer</i> , 2017, 8, 2079-2087.	1.2	33
2725	Increasing AR by HIF-2 $\alpha$ inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals. <i>Cell Death and Disease</i> , 2017, 8, e3095-e3095.	2.7	53
2726	The Clinical Values of Serum Markers in the Early Prediction of Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2017, 2017, 1-11.	0.9	12
2727	Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma. <i>Disease Markers</i> , 2017, 2017, 1-8.	0.6	8
2728	<i>Glycyrrhiza glabra</i> (Licorice). , 2017, , 231-250.		10
2729	Increased ERp57 Expression in HBV-Related Hepatocellular Carcinoma: Possible Correlation and Prognosis. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	8
2730	Prognostic signatures from hepatocellular carcinoma biopsy. <i>Hepatic Oncology</i> , 2017, 4, 65-68.	4.2	0
2731	Detection of MicroRNA in Hepatic Cirrhosis and Hepatocellular Carcinoma in Hepatitis C Genotype-4 in Egyptian Patients. <i>BioMed Research International</i> , 2017, 2017, 1-10.	0.9	25
2732	Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 131-138.	1.8	45
2733	Magnetic resonance imaging of the cirrhotic liver: diagnosis of hepatocellular carcinoma and evaluation of response to treatment - Part 1. <i>Radiologia Brasileira</i> , 2017, 50, 38-47.	0.3	19

#	ARTICLE	IF	CITATIONS
2734	From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. <i>World Journal of Gastroenterology</i> , 2017, 23, 5282.	1.4	232
2735	Upregulation of RASAL2 promotes proliferation and metastasis, and is targeted by miR-203 in hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2017, 15, 2720-2726.	1.1	19
2736	Expression quantitative trait loci for PAX8 contributes to the prognosis of hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0173700.	1.1	11
2737	The value of Gd-EOB-DTPA-enhanced MR imaging in characterizing cirrhotic nodules with atypical enhancement on Gd-DTPA-enhanced MR images. <i>PLoS ONE</i> , 2017, 12, e0174594.	1.1	9
2738	Heat shock exerts anticancer effects on liver cancer via autophagic degradation of aquaporin 5. <i>International Journal of Oncology</i> , 2017, 50, 1857-1867.	1.4	7
2739	The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. <i>BMC Cancer</i> , 2017, 17, 645.	1.1	41
2740	Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study. <i>Chinese Journal of Cancer</i> , 2017, 36, 59.	4.9	24
2741	Prognostic Value of Long Non-Coding RNA HULC and MALAT1 Following the Curative Resection of Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2017, 7, 16142.	1.6	24
2742	Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study. <i>Oncotarget</i> , 2017, 8, 408-417.	0.8	10
2743	The Role of Novel 3d-Copper Cyanide Supramolecular Coordination Polymer in Epithelial Mesenchymal Transition Inhibition in Hepatocellular Carcinoma. <i>Biochemistry &amp; Pharmacology: Open Access</i> , 2017, 06, .	0.2	0
2744	Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafenib in HCC cells. <i>Oncotarget</i> , 2017, 8, 19354-19364.	0.8	56
2745	Hypoxia induces the expression of TET enzymes in HepG2 cells. <i>Oncology Letters</i> , 2017, 14, 6457-6462.	0.8	20
2746	Clinical Impact of Vitamin K Dosing on Sorafenib Treatment for Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2017, 8, 1988-1994.	1.2	12
2747	Partial hepatectomy for spontaneous tumor rupture in patients with hepatocellular carcinoma: a retrospective cohort study. <i>Cancer Management and Research</i> , 2017, Volume 9, 525-537.	0.9	13
2748	How admissions to various medical specialty divisions determines the outcome of patients with hepatocellular carcinoma: results from a retrospective study in a large hospital of northwest China. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 545-553.	0.9	2
2749	Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 417-428.	1.0	17
2750	Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study. <i>Oncotarget</i> , 2017, 8, 100734-100745.	0.8	23
2751	Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy. <i>Oncotarget</i> , 2017, 8, 32450-32460.	0.8	38

#	ARTICLE	IF	CITATIONS
2752	Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of $\alpha$ -fetoprotein, $\alpha$ -fetoprotein-L3, des- $\gamma$ -carboxy prothrombin, and Golgi protein 73. <i>Oncotarget</i> , 2017, 8, 80521-80530.	0.8	17
2753	<i>Plasmodium</i> parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector. <i>Oncotarget</i> , 2017, 8, 24785-24796.	0.8	24
2754	Overexpression of Aristaless-Like Homeobox-4 Inhibits Proliferation, Invasion, and EMT in Hepatocellular Carcinoma Cells. <i>Oncology Research</i> , 2017, 25, 11-18.	0.6	16
2755	Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 314-323.	0.6	5
2756	Reply to: "Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: Novel concerns" <i>Journal of Hepatology</i> , 2018, 68, 1316-1318.	1.8	0
2757	Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. <i>Future Oncology</i> , 2018, 14, 553-566.	1.1	22
2758	Intra-arterial locoregional therapy in the management of hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2018, 11, 6-10.	1.0	2
2759	Angiogenesis for tumor vascular normalization of Endostar on hepatoma 22 tumor-bearing mice is involved in the immune response. <i>Oncology Letters</i> , 2018, 15, 3437-3446.	0.8	17
2760	Emerging roles of hsa_circ_0005075 targeting miR-431 in the progress of HCC. <i>Biomedicine and Pharmacotherapy</i> , 2018, 99, 848-858.	2.5	43
2761	Experimental study of the anti-tumour activity and pharmacokinetics of arctigenin and its valine ester derivative. <i>Scientific Reports</i> , 2018, 8, 3307.	1.6	16
2762	Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels. <i>Annals of Surgery</i> , 2018, 268, 943-954.	2.1	97
2763	Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation. <i>Hepatology International</i> , 2018, 12, 149-157.	1.9	11
2764	Liver Transplantation for Intermediate-Stage Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 179-189.	4.2	12
2765	Emerging facets in the treatment of patients with hepatopancreaticobiliary malignancies. <i>Current Problems in Cancer</i> , 2018, 42, 8-11.	1.0	0
2766	The effects of polysaccharides from <i>Auricularia auricula</i> (Huaier) in adjuvant anti-gastrointestinal cancer therapy: A systematic review and network meta-analysis. <i>Pharmacological Research</i> , 2018, 132, 80-89.	3.1	39
2767	Chelerythrine Inhibits Human Hepatocellular Carcinoma Metastasis <i>in Vitro</i> . <i>Biological and Pharmaceutical Bulletin</i> , 2018, 41, 36-46.	0.6	30
2768	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 182-236.	1.8	6,153
2769	Cationic and Neutral $N$ -Heterocyclic Carbene Gold(I) Complexes: Cytotoxicity, NCI60 Screening, Cellular Uptake, Inhibition of Mammalian Thioredoxin Reductase, and Reactive Oxygen Species Formation. <i>ChemMedChem</i> , 2018, 13, 1218-1229.	1.6	24

#	ARTICLE	IF	CITATIONS
2770	Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study. <i>Cancer</i> , 2018, 124, 1964-1972.	2.0	46
2771	MicroRNA-214-5p Inhibits the Invasion and Migration of Hepatocellular Carcinoma Cells by Targeting Wiskott-Aldrich Syndrome Like. <i>Cellular Physiology and Biochemistry</i> , 2018, 46, 757-764.	1.1	30
2772	New nomogram predicts the recurrence of hepatocellular carcinoma in patients with negative preoperative serum AFP subjected to curative resection. <i>Journal of Surgical Oncology</i> , 2018, 117, 1540-1547.	0.8	40
2773	MiR-29a suppresses cell proliferation by targeting SIRT1 in hepatocellular carcinoma. <i>Cancer Biomarkers</i> , 2018, 22, 151-159.	0.8	27
2774	The expression of HtrA2 and its diagnostic value in patients with hepatocellular carcinoma. <i>Medicine (United States)</i> , 2018, 97, e0128.	0.4	8
2775	TR4 nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression. <i>Cell Death and Disease</i> , 2018, 9, 283.	2.7	18
2776	Association of processed food, synergistic effect of alcohol and HBV with Hepatocellular Carcinoma in a high incidence region of India. <i>Cancer Epidemiology</i> , 2018, 53, 35-41.	0.8	15
2777	Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions. <i>Scientific Reports</i> , 2018, 8, 2233.	1.6	15
2778	Surgery for Hepatocellular Carcinoma in Patients with Childâ€™s Pugh B Cirrhosis: Hepatic Resection Versus Living Donor Liver Transplantation. <i>World Journal of Surgery</i> , 2018, 42, 2606-2616.	0.8	17
2779	HEPATOCELLULAR CARCINOMA WITH CARDIAC CIRRHOSIS AFTER THE FONTAN PROCEDURE. <i>Gastroenterology Nursing</i> , 2018, 41, 68-71.	0.2	2
2780	Contrastâ€Enhanced Ultrasonography Versus Contrastâ€Enhanced Computed Tomography for Assessment of Residual Tumor From Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: A Metaâ€Analysis. <i>Journal of Ultrasound in Medicine</i> , 2018, 37, 1881-1890.	0.8	8
2781	Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2018, 27, 69-80.	0.6	19
2782	Histone deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells. <i>Cancer Letters</i> , 2018, 420, 1-13.	3.2	36
2783	Laparoscopic vs open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: A meta-analysis of the long-term survival outcomes. <i>International Journal of Surgery</i> , 2018, 50, 35-42.	1.1	43
2784	Patterns of Discordance Between Pretransplant Imaging Stage of Hepatocellular Carcinoma and Posttransplant Pathologic Stage. <i>Transplantation</i> , 2018, 102, 648-655.	0.5	26
2786	Genomics Studies in Hepatocellular Carcinoma via Next-Generation Sequencing. <i>Molecular Pathology Library</i> , 2018, , 49-68.	0.1	1
2787	LINCO0261 suppresses cell proliferation, invasion and Notch signaling pathway in hepatocellular carcinoma. <i>Cancer Biomarkers</i> , 2018, 21, 575-582.	0.8	53
2788	Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis. <i>International Journal of Hyperthermia</i> , 2018, 34, 1351-1358.	1.1	30

#	ARTICLE	IF	CITATIONS
2789	Matrix Metalloproteinase 1 as a Novel Biomarker for Monitoring Hepatocellular Carcinoma in Liver Transplant Patients. <i>Transplantation Proceedings</i> , 2018, 50, 623-627.	0.3	8
2790	Germline Duplication of SNORA18L5 Increases Risk for HBV-related Hepatocellular Carcinoma by Altering Localization of Ribosomal Proteins and Decreasing Levels of p53. <i>Gastroenterology</i> , 2018, 155, 542-556.	0.6	75
2791	Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins. <i>Molecular Medicine Reports</i> , 2018, 17, 8101-8110.	1.1	7
2792	Genetic correction of serum <sc>AFP</sc> level improves risk prediction of primary hepatocellular carcinoma in the Dongfengâ€‘Tongji cohort study. <i>Cancer Medicine</i> , 2018, 7, 2691-2698.	1.3	3
2793	Survival following liver transplantation for liver-only colorectal metastases compared with hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2018, 105, 736-742.	0.1	55
2794	Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study. <i>European Radiology</i> , 2018, 28, 3522-3531.	2.3	40
2795	A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy. <i>Oncology Letters</i> , 2018, 15, 4411-4422.	0.8	24
2796	Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepatocellular carcinoma patients: A propensity-matching cohort study. <i>International Journal of Surgery</i> , 2018, 54, 259-264.	1.1	12
2797	Oncogene RPA1 promotes proliferation of hepatocellular carcinoma via CDK4/Cyclin-D pathway. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 424-430.	1.0	21
2798	Preoperative Examination and Intraoperative Identification of Hepatocellular Carcinoma Using a Targeted Bimodal Imaging Probe. <i>Bioconjugate Chemistry</i> , 2018, 29, 1475-1484.	1.8	25
2799	Microvascular invasion and positive HB e antigen are associated with poorer survival after hepatectomy of early hepatocellular carcinoma: A retrospective cohort study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 330-338.	0.7	20
2800	Synthetic Dibenzoanthene Derivatives Induce Apoptosis Through Mitochondrial Pathway in Human Hepatocellular Cancer Cells. <i>Applied Biochemistry and Biotechnology</i> , 2018, 186, 145-160.	1.4	9
2801	Peroxiredoxin 1, restraining cell migration and invasion, is involved in hepatocellular carcinoma recurrence. <i>Journal of Digestive Diseases</i> , 2018, 19, 155-169.	0.7	12
2802	Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy. <i>Liver International</i> , 2018, 38, 136-143.	1.9	58
2803	Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery: a multi-center analysis. <i>Surgery Today</i> , 2018, 48, 73-79.	0.7	45
2804	A randomized placeboâ€‘controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. <i>Hepatology</i> , 2018, 67, 575-585.	3.6	57
2805	Precision diagnosis and treatment of liver cancer in China. <i>Cancer Letters</i> , 2018, 412, 283-288.	3.2	226
2806	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 381-403.	0.8	92

#	ARTICLE	IF	CITATIONS
2807	Chronic liver injury alters driver mutation profiles in hepatocellular carcinoma in mice. <i>Hepatology</i> , 2018, 67, 924-939.	3.6	36
2808	ITIH4: Effective Serum Marker, Early Warning and Diagnosis, Hepatocellular Carcinoma. <i>Pathology and Oncology Research</i> , 2018, 24, 663-670.	0.9	27
2809	Imaging Features of Gadoteric Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study. <i>Radiology</i> , 2018, 286, 897-908.	3.6	102
2810	Surgical resection versus transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis. <i>Hpb</i> , 2018, 20, 110-119.	0.1	35
2811	Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma. <i>International Journal of Infectious Diseases</i> , 2018, 67, 92-97.	1.5	66
2812	Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 2345-2354.	1.3	28
2813	lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G559-G565.	1.6	88
2814	Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: A systematic review. <i>Journal of Surgical Oncology</i> , 2018, 117, 341-353.	0.8	61
2815	New insights into the role of vitamin D in hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 287-294.	1.4	21
2816	Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of <i>PEG10</i> and Blocks Hepatocellular Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 26-38.	1.9	40
2817	Novel decellularized liver matrix-alginate hybrid gel beads for the 3D culture of hepatocellular carcinoma cells. <i>International Journal of Biological Macromolecules</i> , 2018, 109, 1154-1163.	3.6	30
2818	The Impact of Serosal Invasion on Prognosis after Curative Hepatectomy for Hepatocellular Carcinoma: Invasion to Adjacent Organs and Rupture of Tumor Were Crucial Tumor-Related Prognostic Factors Needed for Survival. <i>Digestive Surgery</i> , 2018, 35, 155-163.	0.6	6
2819	Gold nanoparticle labeling with tyramide signal amplification for highly sensitive detection of alpha fetoprotein in human serum by ICP-MS. <i>Talanta</i> , 2018, 176, 40-46.	2.9	31
2820	Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. <i>World Journal of Gastroenterology</i> , 2018, 24, 3626-3636.	1.4	38
2821	Postlaparoscopic hepatic resection of hepatocellular carcinoma: Portal site metastasis. <i>Surgical Practice</i> , 2018, 22, 182-184.	0.1	0
2822	A new tumor-associated antigen prognostic scoring system for spontaneous ruptured hepatocellular carcinoma after partial hepatectomy. <i>Cancer Biology and Medicine</i> , 2018, 15, 415.	1.4	4
2823	Efficacy and safety of megestrol in the management of hepatocellular carcinoma: a systematic review of the literature. <i>Wspolczesna Onkologia</i> , 2018, 22, 209-214.	0.7	3
2824	<sup>11</sup> C-acetate and <sup>18</sup> F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization. <i>Medicine (United States)</i> , 2018, 97, e12311.	0.4	16



#	ARTICLE	IF	CITATIONS
2825	Efficacy of sequential sorafenib plus hepatic arterial infusion chemotherapy in patients with Barcelona Clinic Liver Cancer stage B and C hepatocellular carcinoma: a retrospective single-institution study. <i>Wspolczesna Onkologia</i> , 2018, 22, 165-171.	0.7	8
2826	Evaluation and Surgical Management of Hepatocellular Carcinoma. , 2018, , .		1
2827	Trends and the Current Status of Living Donor Liver Transplant. , 2018, , .		2
2828	Ruptured HCC and Variables in Management-Case Series and Literature Review. <i>Jurnalul De Chirurgie</i> , 2018, 14, .	0.0	0
2829	XB130 Knockdown Inhibits the Proliferation, Invasiveness, and Metastasis of Hepatocellular Carcinoma Cells and Sensitizes them to TRAIL-Induced Apoptosis. <i>Chinese Medical Journal</i> , 2018, 131, 2320-2331.	0.9	6
2830	Racial and Geographic Disparities in Hepatocellular Carcinoma Outcomes. <i>American Journal of Preventive Medicine</i> , 2018, 55, S40-S48.	1.6	35
2831	ALBI Score as a Predictor of Survival in Patients with Compensated Cirrhosis Resected for Hepatocellular Carcinoma: Exploratory Evaluation in Relationship to PALBI and MELD Liver Function Scores. <i>Acta Clinica Croatica</i> , 2018, 57, 292-300.	0.1	5
2832	Evaluation of the prognostic value of paraoxonase 1 in the recurrence and metastasis of hepatocellular carcinoma and establishment of a liver-specific predictive model of survival. <i>Journal of Translational Medicine</i> , 2018, 16, 327.	1.8	20
2833	Novel Techniques in the Surgical Management of Hepatocellular Carcinoma. , 0, , .		2
2834	Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 1131.	1.1	36
2835	Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. <i>The Open Virology Journal</i> , 2018, 12, 26-32.	1.8	157
2836	Preoperative predictors of early recurrence/mortality including the role of inflammatory indices in patients undergoing partial hepatectomy for spontaneously ruptured hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2018, 118, 1227-1236.	0.8	9
2837	Staging systems of hepatocellular carcinoma: A review. <i>Indian Journal of Gastroenterology</i> , 2018, 37, 481-491.	0.7	88
2838	SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis. <i>Scientific Reports</i> , 2018, 8, 17905.	1.6	30
2839	HO-1 is a favorable prognostic factor for HBV-HCC patients who underwent hepatectomy. <i>Cancer Management and Research</i> , 2018, Volume 10, 6049-6059.	0.9	11
2840	Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis. <i>Journal of Cancer</i> , 2018, 9, 1745-1753.	1.2	14
2841	Comparison of gene expression in liver regeneration and hepatocellular carcinoma formation. <i>Cancer Management and Research</i> , 2018, Volume 10, 5691-5708.	0.9	12
2842	Gamma linolic acid regulates PHD2 mediated hypoxia and mitochondrial apoptosis in DEN induced Hepatocellular carcinoma. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 4241-4252.	2.0	17

#	ARTICLE	IF	CITATIONS
2843	The Epigenetic Regulation of HCC Metastasis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3978.	1.8	80
2844	23 Yttrium-90 Radioembolization of Malignant Liver Tumors. , 2018, , .		0
2845	CHAF1B knockdown blocks migration in a hepatocellular carcinoma model. <i>Oncology Reports</i> , 2018, 40, 405-413.	1.2	18
2846	MRI texture analysis for differentiation of malignant and benign hepatocellular tumors in the non-cirrhotic liver. <i>Heliyon</i> , 2018, 4, e00987.	1.4	32
2847	LI-RADS Version 2018 Ancillary Features at MRI. <i>Radiographics</i> , 2018, 38, 1973-2001.	1.4	83
2848	Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 487-495.	0.6	36
2849	Prognostic factors of disease-free and overall survival in patients with hepatocellular carcinoma undergoing partial hepatectomy in curative intent. <i>Langenbeck's Archives of Surgery</i> , 2018, 403, 851-861.	0.8	23
2850	Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma. <i>Cancer Biology and Therapy</i> , 2018, 19, 1057-1064.	1.5	15
2851	Surgically Diagnosed Primary Hepatic Angiosarcoma. <i>Internal Medicine</i> , 2018, 57, 687-691.	0.3	11
2852	Utilizing ethacrynic acid and ciclopirox olamine in liver cancer. <i>Oncology Letters</i> , 2018, 16, 6854-6860.	0.8	13
2853	Single nucleotide polymorphisms of XRCC3 gene in hepatocellular carcinoma " relationship with clinicopathological features. <i>Polish Journal of Pathology</i> , 2018, 69, 73-81.	0.1	9
2854	Health education helps to relieve postembolization pain during hepatic arterial chemoembolization therapy. <i>Journal of Pain Research</i> , 2018, Volume 11, 2115-2121.	0.8	3
2855	Perivascular Tumor-Infiltrating Leukocyte Scoring for Prognosis of Resected Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2018, 10, 389.	1.7	27
2856	The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study. <i>Internal Medicine</i> , 2018, 57, 1345-1353.	0.3	29
2857	ZFAS1: a novel tumor-related long non-coding RNA. <i>Cancer Cell International</i> , 2018, 18, 125.	1.8	62
2858	Spontaneous Regression of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>Case Reports in Gastroenterology</i> , 2018, 12, 411-419.	0.3	4
2859	Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK. <i>International Journal of Molecular Medicine</i> , 2018, 42, 2551-2559.	1.8	12
2860	Targeting hepatocarcinogenesis model in C56BL6 mice with pan-aurora kinase inhibitor Danusertib. <i>Journal of Cancer</i> , 2018, 9, 914-922.	1.2	4

#	ARTICLE	IF	CITATIONS
2861	High level of serum Cripto-1 in hepatocellular carcinoma, especially with hepatitis B virus infection. <i>Medicine (United States)</i> , 2018, 97, e11781.	0.4	10
2862	Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2018, 50, 100-112.	0.3	15
2863	Substitutions in interferon sensitivityâ€ determining region and hepatocarcinogenesis after hepatitis C virus eradication. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1904-1911.	1.4	3
2864	Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGIâ€110) in Hepatocellular Carcinoma. <i>Hepatology</i> , 2018, 68, 1412-1428.	3.6	48
2865	Transcatheter arterial chemoembolization (TACE) combined with Î³-knife compared to TACE or Î³-knife alone for hepatocellular carcinoma. <i>Medicine (United States)</i> , 2018, 97, e10890.	0.4	2
2866	Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1487-1501.	1.2	19
2867	Long-term prognostic impact of osteopontin and Dickkopf-related protein 1 in patients with hepatocellular carcinoma after hepatectomy. <i>Pathology Research and Practice</i> , 2018, 214, 814-820.	1.0	13
2868	Surgical management of children and adolescents with upfront completely resected hepatocellular carcinoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27293.	0.8	17
2869	The Nogoâ€B receptor promotes human hepatocellular carcinoma cell growth via the Akt signal pathway. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 7738-7746.	1.2	5
2870	Clinical outcomes of brain metastases from hepatocellular carcinoma: a multicenter retrospective study and a literature review. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1095-1100.	1.0	7
2871	Studying the frequency of aberrant DNA methylation of APC, P14, and E-cadherin genes in HCV-related hepatocarcinogenesis. <i>Cancer Biomarkers</i> , 2018, 22, 503-509.	0.8	8
2872	Highly Sensitive Diagnosis of Small Hepatocellular Carcinoma Using pH-Responsive Iron Oxide Nanocluster Assemblies. <i>Journal of the American Chemical Society</i> , 2018, 140, 10071-10074.	6.6	182
2873	Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2018, 8, 269.	1.3	106
2874	Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virusâ€Related Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2018, 153, e182721.	2.2	74
2875	The preliminary application of liver imaging reporting and data system (LI-RADS) with contrast-enhanced ultrasound (CEUS) on small hepatic nodules (â‰‰2cm). <i>Journal of Cancer</i> , 2018, 9, 2946-2952.	1.2	29
2876	Hypofractionated and Stereotactic Radiation Therapy. , 2018, , .		2
2877	Propensity scoreâ€matched comparison of nonâ€anatomical resection and radiofrequency ablation for hepatocellular carcinoma in patients with up to three tumours, each measuring up to 3 cm in diameter. <i>BJS Open</i> , 2018, 2, 213-219.	0.7	3
2878	The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 571.	1.1	8

#	ARTICLE	IF	CITATIONS
2879	miR-342-3p suppresses hepatocellular carcinoma proliferation through inhibition of IGF-1R-mediated Warburg effect. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 1643-1653.	1.0	62
2880	Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma: A Multi-institutional Study. <i>Annals of Surgical Oncology</i> , 2018, 25, 3316-3323.	0.7	85
2881	Tex10 is upregulated and promotes cancer stem cell properties and chemoresistance in hepatocellular carcinoma. <i>Cell Cycle</i> , 2018, 17, 1310-1318.	1.3	18
2882	HIF-1 $\alpha$ promotes the migration and invasion of hepatocellular carcinoma cells via the IL-8 $\alpha$ -NF- $\kappa$ B axis. <i>Cellular and Molecular Biology Letters</i> , 2018, 23, 26.	2.7	37
2883	Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-8.	0.8	84
2884	Role of Imaging in Surveillance and Diagnosis of Hepatocellular Carcinoma. <i>Gastroenterology Clinics of North America</i> , 2018, 47, 585-602.	1.0	20
2885	Microwave-Assisted Ablation Improves the Prognosis of Patients With Hepatocellular Carcinoma Undergoing Liver Resection. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381878598.	0.8	8
2886	Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness. <i>Molecules</i> , 2018, 23, 777.	1.7	18
2887	Xenogeneic cell therapy provides a novel potential therapeutic option for cancers by restoring tissue function, repairing cancer wound and reviving anti-tumor immune responses. <i>Cancer Cell International</i> , 2018, 18, 9.	1.8	16
2888	EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 3.	3.5	61
2889	The plant alkaloid tetrandrine inhibits metastasis via autophagy-dependent Wnt/ $\beta$ 2-catenin and metastatic tumor antigen 1 signaling in human liver cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 7.	3.5	51
2890	Comparison of overall survival between antiviral $\alpha$ -induced viral suppression and inactive phase chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1161-1171.	1.0	18
2891	Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study. <i>Future Oncology</i> , 2018, 14, 3049-3058.	1.1	6
2892	Lymphocyte-Specific Protein-1 Controls Sorafenib Sensitivity and Hepatocellular Proliferation through Extracellular Signal-Regulated Kinase $\alpha$ 1/2 Activation. <i>American Journal of Pathology</i> , 2018, 188, 2074-2086.	1.9	2
2893	Liver Resection for Hepatocellular Carcinoma in Patients with Renal Dysfunction. <i>World Journal of Surgery</i> , 2018, 42, 4054-4062.	0.8	11
2894	Prognostic importance of bile duct invasion in surgical resection with curative intent for hepatocellular carcinoma using PSM analysis. <i>Oncology Letters</i> , 2018, 16, 3593-3602.	0.8	8
2896	Transarterial chemoembolization for unresectable hepatocellular carcinoma. <i>Medicine (United States)</i> , 2018, 97, 1311-1316.	0.4	3
2897	High expression of TACC2 in hepatocellular carcinoma is associated with poor prognosis. <i>Cancer Biomarkers</i> , 2018, 22, 611-619.	0.8	9

#	ARTICLE	IF	CITATIONS
2898	Comparison of Models for Predicting Quality of Life After Surgical Resection of Hepatocellular Carcinoma: a Prospective Study. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 1724-1731.	0.9	12
2899	Liver Resection for Solitary Transplantable Hepatocellular Carcinoma: The Role of AFP Score. <i>World Journal of Surgery</i> , 2019, 43, 221-229.	0.8	5
2900	Gallstones and cholecystectomy in relation to risk of liver cancer. <i>European Journal of Cancer Prevention</i> , 2019, 28, 61-67.	0.6	10
2901	Analysis of Hepatocellular Carcinoma Tissue for Biomarker Discovery. <i>Molecular and Translational Medicine</i> , 2019, , 93-107.	0.4	6
2902	Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 789.	1.1	12
2903	Study of serum microRNA19a and microRNA223 as potential biomarkers for early diagnosis of hepatitis C virus-related hepatocellular carcinoma. <i>Gene Reports</i> , 2019, 15, 100398.	0.4	6
2904	Overexpression of miRNA-125a-5p inhibits the growth and angiogenesis of hepatocellular carcinoma by regulating the expression of VEGF-A. <i>Biotechnology and Biotechnological Equipment</i> , 2019, 33, 1116-1125.	0.5	5
2905	Structural characterization of a low molecular weight polysaccharide from <i>Grifola frondosa</i> and its antitumor activity in H22 tumor-bearing mice. <i>Journal of Functional Foods</i> , 2019, 61, 103472.	1.6	39
2906	Epigenetic regulation of histone H3 in the process of hepatocellular tumorigenesis. <i>Bioscience Reports</i> , 2019, 39, .	1.1	12
2907	LHX3 is an advanced-stage prognostic biomarker and metastatic oncogene in hepatocellular carcinoma. <i>Cancer Biomarkers</i> , 2019, 26, 31-39.	0.8	9
2908	A lncRNA risk score system for predicting the prognosis of patients with hepatitis B virus-positive hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2019, 20, 573-583.	1.1	5
2909	Aberrant histone deacetylase 1 expression upregulates vimentin expression via an NF- $\kappa$ B-dependent pathway in hepatocellular carcinoma. <i>Oncology Letters</i> , 2019, 18, 339-347.	0.8	6
2910	High GCLC level in tumor tissues is associated with poor prognosis of hepatocellular carcinoma after curative resection. <i>Journal of Cancer</i> , 2019, 10, 3333-3343.	1.2	28
2911	Mesenchymal Stem Cell-Mediated Delivery of an Oncolytic Adenovirus Enhances Antitumor Efficacy in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019, 79, 4503-4514.	0.4	62
2912	Hepatic resection versus operative microwave ablation for single hepatocellular carcinoma $\leq$ 5 cm: A propensity score-matched analysis. <i>Surgery</i> , 2019, 166, 254-262.	1.0	26
2913	SIRT5 Promotes Hepatocellular Carcinoma Progression by Regulating Mitochondrial Apoptosis. <i>Journal of Cancer</i> , 2019, 10, 3871-3882.	1.2	37
2914	The expression level and clinical significance of lncRNA X91348 in hepatocellular carcinoma. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 3067-3071.	1.9	13
2915	Actual 10-Year Survival After Surgical Microwave Ablation for Hepatocellular Carcinoma: A Single-Center Experience in Japan. <i>Annals of Surgical Oncology</i> , 2019, 26, 4126-4133.	0.7	21

#	ARTICLE	IF	CITATIONS
2916	Comprehensive DNA methylation analysis of tissue of origin of plasma cell-free DNA by methylated CpG tandem amplification and sequencing (MCTA-Seq). <i>Clinical Epigenetics</i> , 2019, 11, 93.	1.8	47
2917	Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence. <i>Cancers</i> , 2019, 11, 873.	1.7	19
2918	Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 705-715.	2.1	18
2919	A novel $\alpha$ -ESIPT near-infrared nanoprobe for the imaging of $\hat{I}^3$ -glutamyl transpeptidase in living cells and the application in precision medicine. <i>Analyst, The</i> , 2019, 144, 5136-5142.	1.7	31
2920	Downregulation of B7-H4 suppresses tumor progression of hepatocellular carcinoma. <i>Scientific Reports</i> , 2019, 9, 14854.	1.6	7
2921	The risk factors for long-term survival outcome in solitary hepatocellular carcinoma up to 2 cm: Propensity score matching analysis in a population cohort with a high rate of HBV infection. <i>International Journal of Surgery</i> , 2019, 72, 1-6.	1.1	5
2922	Proteomic Profile of Sorafenib Resistance in Hepatocellular Carcinoma; GRP78 Expression Is Associated With Inferior Response to Sorafenib. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 569-576.	1.0	13
2923	Preparation and In Vitro Evaluation of Neutron-Activated, Theranostic Samarium-153-Labeled Microspheres for Transarterial Radioembolization of Hepatocellular Carcinoma and Liver Metastasis. <i>Pharmaceutics</i> , 2019, 11, 596.	2.0	8
2924	Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1237, 97-119.	0.8	5
2925	Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. <i>PLoS ONE</i> , 2019, 14, e0223678.	1.1	14
2927	Biodegradable Samarium-153-labelled microspheres for hepatic radioembolization: preparation, characterization and radiolabelling evaluation after neutron activation. <i>Journal of Physics: Conference Series</i> , 2019, 1248, 012066.	0.3	1
2928	Relationship between the rs2596542 polymorphism in the MICA gene promoter and HBV/HCV infection-induced hepatocellular carcinoma: a meta-analysis. <i>BMC Medical Genetics</i> , 2019, 20, 142.	2.1	11
2929	Prognostic role of serial alpha-fetoprotein levels in hepatocellular carcinoma treated with locoregional therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1132-1137.	0.6	6
2930	Dynamic liver function is an independent predictor of recurrence-free survival after curative liver resection for HCC - A retrospective cohort study. <i>International Journal of Surgery</i> , 2019, 71, 56-65.	1.1	13
2931	<p>&lt;p>Thalassemia and hepatocellular carcinoma: links and risks</p>. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 323-334.	0.7	12
2932	Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 968-976.	0.4	14
2933	MicroRNA-101 modulates cisplatin chemoresistance in liver cancer cells via the DNA-PKcs signaling pathway. <i>Oncology Letters</i> , 2019, 18, 3655-3663.	0.8	12
2934	Utility of scoring systems combining the product of tumor number and size with liver function for predicting the prognosis of patients with hepatocellular carcinoma after hepatectomy. <i>Oncology Letters</i> , 2019, 18, 3903-3913.	0.8	4

#	ARTICLE	IF	CITATIONS
2935	JNK Signaling Pathway Mediates Acetaminophen-Induced Hepatotoxicity Accompanied by Changes of Glutathione S-Transferase A1 Content and Expression. <i>Frontiers in Pharmacology</i> , 2019, 10, 1092.	1.6	17
2936	Laparoscopic Versus Open Hepatectomy in Short- and Long-Term Outcomes of the Hepatocellular Carcinoma Patients with Cirrhosis: A Systematic Review and Meta-Analysis. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2019, 29, 643-654.	0.5	17
2937	PEGylated trimethylchitosan emulsomes conjugated to octreotide for targeted delivery of sorafenib to hepatocellular carcinoma cells of HepG2. <i>Journal of Liposome Research</i> , 2019, 29, 383-398.	1.5	17
2938	Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 83-89.	1.9	29
2939	Minimally Invasive Primary Liver Cancer Surgery. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 215-227.	0.6	14
2940	Recurrent hepatocellular carcinoma in pregnancy: A case report and literature review. <i>Obstetric Medicine</i> , 2019, 12, 202-204.	0.5	5
2941	Killing Effects of IFN $\gamma$ Mouse NK Cells Activated by HN Protein of NDV on Mouse Hepatoma Cells and Possible Mechanism with Syk and NF $\kappa$ B. <i>Anatomical Record</i> , 2019, 302, 1718-1725.	0.8	0
2942	Viral integration drives multifocal HCC during the occult HBV infection. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 261.	3.5	27
2943	Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response. <i>Liver International</i> , 2019, 39, 2174-2183.	1.9	17
2944	Residual cancerous lesion and vein tumour thrombus identified intraoperatively using a fluorescence navigation system in liver surgery. <i>ANZ Journal of Surgery</i> , 2019, 89, E308-E314.	0.3	9
2945	Ultrasonic Cavitation Ameliorates Antitumor Efficacy of Residual Cancer After Incomplete Radiofrequency Ablation in Rabbit VX2 Liver Tumor Model. <i>Translational Oncology</i> , 2019, 12, 1113-1121.	1.7	6
2946	Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma. <i>Radiology</i> , 2019, 292, 237-247.	3.6	53
2947	Open versus laparoscopic hepatic resection for hepatocellular carcinoma: a systematic review and meta-analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 2396-2418.	1.3	42
2948	The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. <i>BMC Cancer</i> , 2019, 19, 511.	1.1	53
2949	Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival. <i>PLoS ONE</i> , 2019, 14, e0216935.	1.1	31
2950	Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models. <i>Bioengineered</i> , 2019, 10, 190-196.	1.4	5
2951	Bio-responsive smart polymers and biomedical applications. <i>JPhys Materials</i> , 2019, 2, 032004.	1.8	52
2952	Circular RNA circTRIM33 $\Delta$ 12 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression. <i>Molecular Cancer</i> , 2019, 18, 105.	7.9	172

#	ARTICLE	IF	CITATIONS
2953	Î2-ionone inhibits nonalcoholic fatty liver disease and its association with hepatocarcinogenesis in male Wistar rats. <i>Chemico-Biological Interactions</i> , 2019, 308, 377-384.	1.7	5
2954	An InÂVitro Evaluation of Four Types of Drug-Eluting Embolics Loaded with Idarubicin. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1303-1309.	0.2	9
2955	Analyses of a Panel of Transcripts Identified From a Small Sample Size and Construction of RNA Networks in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2019, 10, 431.	1.1	14
2956	Role of US LI-RADS in the LI-RADS Algorithm. <i>Radiographics</i> , 2019, 39, 690-708.	1.4	45
2957	A combined treatment of curcumin, piperine, and taurine alters the circulating levels of IL-10 and miR-21 in hepatocellular carcinoma patients: a pilot study. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 766-776.	0.6	37
2958	The Pro-Apoptotic Activity of Tamarixetin on Liver Cancer Cells Via Regulation Mitochondrial Apoptotic Pathway. <i>Applied Biochemistry and Biotechnology</i> , 2019, 189, 647-660.	1.4	8
2959	Safety margin of radiofrequency ablation for hepatocellular carcinoma: a prospective study using magnetic resonance imaging with superparamagnetic iron oxide. <i>Japanese Journal of Radiology</i> , 2019, 37, 555-563.	1.0	11
2960	Yttrium-90 Radioembolization: Current Clinical Practice and Review of the Recent Literature. <i>Journal of Radiology Nursing</i> , 2019, 38, 86-91.	0.2	2
2961	Impact of spontaneous rupture on the survival outcomes after liver resection for hepatocellular carcinoma: A propensity matched analysis comparing ruptured versus non-ruptured tumors. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1652-1659.	0.5	30
2962	A 17 years retrospective study on multiple metal stents for complex malignant hilar biliary strictures: Survival, stents patency and outcomes of re-interventions for occluded metal stents. <i>Digestive and Liver Disease</i> , 2019, 51, 1287-1293.	0.4	9
2963	<p>Efficacy of on-demand intrahepatic arterial therapy in combination with sorafenib for advanced hepatocellular carcinoma</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2205-2214.	1.0	3
2964	Genomeâ€wide CRISPR knockout screens identify NCAPG as an essential oncogene for hepatocellular carcinoma tumor growth. <i>FASEB Journal</i> , 2019, 33, 8759-8770.	0.2	54
2965	Bloodâ€Bile Barrier: Morphology, Regulation, and Pathophysiology. <i>Gene Expression</i> , 2019, 19, 69-87.	0.5	32
2966	Molecular Diagnostics in Liver Cancer. , 2019, , 293-303.		3
2967	Cost Effectiveness of Hepatocellular Carcinoma SurveillanceÂAfter a Sustained Virologic Response to TherapyÂin Patients With Hepatitis C Virus Infection and Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1840-1849.e16.	2.4	82
2968	Transient increases in serum Î± fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma. <i>Oncology Letters</i> , 2019, 17, 3026-3034.	0.8	6
2969	RACK1 Promotes Self-Renewal and Chemoresistance of Cancer Stem Cells in Human Hepatocellular Carcinoma through Stabilizing Nanog. <i>Theranostics</i> , 2019, 9, 811-828.	4.6	53
2970	Nomogram and Artificial Neural Network for Prognostic Performance on the Albumin-Bilirubin Grade for Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 330-338.	0.2	24



#	ARTICLE	IF	CITATIONS
2971	Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging. <i>Cancer Letters</i> , 2019, 453, 74-83.	3.2	19
2972	Hepatocellular carcinoma after direct-acting antivirals: an unresolved problem. Review of five cases. <i>Clinical and Experimental Hepatology</i> , 2019, 5, 88-92.	0.6	1
2973	Advanced Hepatocellular Carcinoma with Bone Metastases: Prevalence, Associated Factors, and Survival Estimation. <i>Medical Science Monitor</i> , 2019, 25, 1105-1112.	0.5	18
2974	Endoplasmic Reticulum Stress Causes Liver Cancer Cells to Release Exosomal miR-23a-3p and Up-regulate Programmed Death Ligand 1 Expression in Macrophages. <i>Hepatology</i> , 2019, 70, 241-258.	3.6	304
2975	Hyaluronic acid inhibition by 4-methylumbelliferone reduces the expression of cancer stem cells markers during hepatocarcinogenesis. <i>Scientific Reports</i> , 2019, 9, 4026.	1.6	25
2976	Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 228-236.	0.6	2
2977	<p><The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1391-1400.	0.9	27
2978	Diagnosis of hepatocellular carcinoma using a novel anti-glycocholic acid monoclonal antibody-based method. <i>Oncology Letters</i> , 2019, 17, 3103-3112.	0.8	1
2979	Long term outcomes of patients transplanted for hepatocellular carcinoma with human immunodeficiency virus infection. <i>Hpb</i> , 2019, 21, 1009-1016.	0.1	2
2980	Surgical and oncological outcomes of hepatic resection for BCLC-B hepatocellular carcinoma: a retrospective multicenter analysis among 474 consecutive cases. <i>Updates in Surgery</i> , 2019, 71, 285-293.	0.9	25
2981	Ellagic acid synergistically potentiates inhibitory activities of chemotherapeutic agents to human hepatocellular carcinoma. <i>Phytomedicine</i> , 2019, 59, 152921.	2.3	38
2982	Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 1474-1493.	0.7	255
2983	Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1239-1246.	0.8	4
2984	Orthotopic hepatocellular carcinoma: molecular imaging-monitored intratumoral hyperthermia-enhanced direct oncolytic virotherapy. <i>International Journal of Hyperthermia</i> , 2019, 36, 343-349.	1.1	15
2985	Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 133, 54-61.	0.3	37
2986	Achieving Complete Remission of Hepatocellular Carcinoma: A Significant Predictor for Recurrence-Free Survival after Liver Transplantation. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-7.	0.8	4
2988	Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in advanced chronic liver disease. <i>The Cochrane Library</i> , 2019, , .	1.5	5
2990	Computed tomography for the diagnosis of hepatocellular carcinoma in chronic advanced liver disease. <i>The Cochrane Library</i> , 0, , .	1.5	7

#	ARTICLE	IF	CITATIONS
2991	7. Maligne Erkrankungen Des Gastrointestinaltrakts. , 2019, , 145-192.		0
2992	Abdominal ultrasound and alpha-fetoprotein for the diagnosis of hepatocellular carcinoma. The Cochrane Library, 0, , .	1.5	3
2993	Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis. BMC Gastroenterology, 2019, 19, 231.	0.8	32
2994	Liver Disease Among Renal Transplant Recipients. , 2019, , 539-565.		0
2996	An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis. Journal of Visualized Experiments, 2019, , .	0.2	4
2998	Cotreatment with sorafenib and oleanolic acid induces reactive oxygen species-dependent and mitochondrial-mediated apoptotic cell death in hepatocellular carcinoma cells. Anti-Cancer Drugs, 2019, 30, 209-217.	0.7	16
2999	Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 661-668.	3.3	7
3000	Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceasedâ€Donor Liver Transplantation?. Hepatology, 2019, 69, 1324-1336.	3.6	35
3001	Impact of pretreatments on outcomes after living donor liver transplantation for hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2019, 26, 73-81.	1.4	8
3002	Mycotoxins and Human Disease. , 2019, , 213-225.		14
3004	Identification of genes and pathways, including the CXCL2 axis, altered by DNA methylation in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 675-684.	1.2	23
3005	Quantification of Hemodynamic Changes in Chronic Liver Disease: Correlation of Perfusion-CT Data with Histopathologic Staging of Fibrosis. Academic Radiology, 2019, 26, 1174-1180.	1.3	13
3006	Cost-effectiveness of Sorafenib for Treatment of Advanced Hepatocellular Carcinoma in India. Journal of Clinical and Experimental Hepatology, 2019, 9, 468-475.	0.4	18
3007	Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2019, 28, 7-18.	1.9	18
3008	Exosomal miR-155 Derived from Hepatocellular Carcinoma Cells Under Hypoxia Promotes Angiogenesis in Endothelial Cells. Digestive Diseases and Sciences, 2019, 64, 792-802.	1.1	88
3009	A retrospective pilot study to examine the potential of aspartate aminotransferase to alanine aminotransferase ratio as a predictor of postoperative acute kidney injury in patients with hepatocellular carcinoma. Annals of Clinical Biochemistry, 2019, 56, 357-366.	0.8	9
3010	NUF2 is a valuable prognostic biomarker to predict early recurrence of hepatocellular carcinoma after surgical resection. International Journal of Cancer, 2019, 145, 662-670.	2.3	26
3011	Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. Future Oncology, 2019, 15, 439-449.	1.1	2

#	ARTICLE	IF	CITATIONS
3012	Stereotactic Body Radiation Therapy: A New Strategy for Local Regional Treatment for Hepatocellular Carcinoma While Awaiting Liver Transplantation. <i>World Journal of Surgery</i> , 2019, 43, 886-893.	0.8	15
3013	The enrichment of cancer stem cells using composite alginate/polycaprolactone nanofibers. <i>Carbohydrate Polymers</i> , 2019, 206, 70-79.	5.1	30
3014	Perioperative and prognostic implication of albumin-bilirubin-TNM score in Child-Pugh class A hepatocellular carcinoma. <i>Annals of Gastroenterological Surgery</i> , 2019, 3, 65-74.	1.2	12
3015	Hepatocellular carcinoma in acute hepatic porphyrias: A Damocles Sword. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 236-241.	0.5	32
3016	Extending 2-D Convolutional Neural Networks to 3-D for Advancing Deep Learning Cancer Classification With Application to MRI Liver Tumor Differentiation. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2019, 23, 923-930.	3.9	94
3017	Overexpression of heat shock protein HSP90AA1 and translocase of the outer mitochondrial membrane TOM34 in HCV-induced hepatocellular carcinoma: A pilot study. <i>Clinical Biochemistry</i> , 2019, 63, 10-17.	0.8	22
3018	Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: The impact of pre-existing diabetes mellitus. <i>Liver International</i> , 2019, 39, 361-370.	1.9	7
3019	Evaluating the Ability of the New Subclassification to Prognosticate Outcomes Following Hepatectomy for Patients with HBV-Related HCC. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 400-407.	0.6	1
3020	Thiamin Regresses the Anticancer Efficacy of Methotrexate in the Amelioration of Diethyl Nitrosamine-Induced Hepatocellular Carcinoma in Wistar Strain Rats. <i>Nutrition and Cancer</i> , 2020, 72, 170-181.	0.9	13
3021	Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes after Resection of Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 50-57.	0.9	26
3022	Overexpression of Pyruvate Kinase M2 in Tumor Tissues Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 853-860.	0.9	12
3023	Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/ $\beta$ -catenin-driven hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 104-118.	1.8	88
3025	A retrospective analysis of 1,717 paranasal sinus fungus ball cases from 2008 to 2017. <i>Laryngoscope</i> , 2020, 130, 75-79.	1.1	22
3026	NO and hepatocellular cancer. <i>British Journal of Pharmacology</i> , 2020, 177, 5459-5466.	2.7	18
3027	Identification of TAF1, SAT1, and ARHGEF9 as DNA methylation biomarkers for hepatocellular carcinoma. <i>Journal of Cellular Physiology</i> , 2020, 235, 611-618.	2.0	17
3028	Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting. <i>JGH Open</i> , 2020, 4, 54-60.	0.7	36
3029	Radiofrequency ablation versus laparoscopic hepatectomy for hepatocellular carcinoma: A real world single center study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 548-559.	0.5	23
3030	Feasibility of 4D CT simulation with synchronized intravenous contrast injection in hepatocellular carcinoma. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 293-298.	0.3	10

#	ARTICLE	IF	CITATIONS
3031	Cell-free DNA in hepatocellular carcinoma. , 2020, , 199-209.		1
3032	Emergency laparoscopic resection of spontaneous rupture of hepatocellular carcinoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2020, 66, 104-106.	0.2	2
3033	Role of microRNA-210-3p in hepatitis B virus-related hepatocellular carcinoma. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G401-G409.	1.6	26
3034	Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation. <i>Journal of Viral Hepatitis</i> , 2020, 27, 387-396.	1.0	10
3035	Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 255.	3.4	120
3036	Microvascular Invasion and a Size Cutoff Value of 2 cm Predict Long-Term Oncological Outcome in Multiple Hepatocellular Carcinoma: Reappraisal of the American Joint Committee on Cancer Staging System and Validation Using the Surveillance, Epidemiology, and End-Results Database. <i>Liver Cancer</i> , 2020, 9, 156-166.	4.2	32
3037	Platelet-to-lymphocyte ratio predicts therapy outcomes of transarterial chemoembolization plus apatinib in the treatment of advanced hepatocellular carcinoma. <i>Anti-Cancer Drugs</i> , 2020, 31, 966-972.	0.7	6
3038	mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. <i>Annals of Surgery</i> , 2020, 272, 855-862.	2.1	85
3039	Expression of Notch-Hif-1 signaling pathway in liver regeneration of rats. <i>Journal of International Medical Research</i> , 2020, 48, 030006052094379.	0.4	5
3040	Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382096558.	0.8	13
3041	Thymoquinone Selectively Induces Hepatocellular Carcinoma Cell Apoptosis in Synergism With Clinical Therapeutics and Dependence of p53 Status. <i>Frontiers in Pharmacology</i> , 2020, 11, 555283.	1.6	29
3042	A zinc finger family protein, ZNF263, promotes hepatocellular carcinoma resistance to apoptosis via activation of ER stress-dependent autophagy. <i>Translational Oncology</i> , 2020, 13, 100851.	1.7	20
3043	Sensing the scent of death: Modulation of microRNAs by Curcumin in gastrointestinal cancers. <i>Pharmacological Research</i> , 2020, 160, 105199.	3.1	61
3044	A nationwide cross-sectional survey on hepatitis B and C screening among workers in Japan. <i>Scientific Reports</i> , 2020, 10, 11435.	1.6	8
3045	Design, synthesis, and biological evaluation of 5-((8-methoxy-2-methylquinolin-4-yl)amino)-1H-indole-2-carbohydrazide derivatives as novel Nur77 modulators. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112608.	2.6	16
3046	Circular RNA circ_0008305 aggravates hepatocellular carcinoma growth through binding to miR-186 and inducing TMED2. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1742-1753.	1.6	7
3047	Hepatitis B-related hepatocellular carcinoma in a 36-year-old pregnant woman: prognosis and management dilemma. <i>Pan African Medical Journal</i> , 2020, 36, 298.	0.3	0
3048	Feasibility of High-Intensity Focused Ultrasound for Hepatocellular Carcinoma after Stereotactic Body Radiation Therapy: Initial Experience. <i>Ultrasound in Medicine and Biology</i> , 2020, 46, 2744-2751.	0.7	3

#	ARTICLE	IF	CITATIONS
3049	&lt;p&gt;A Novel Pathological Scoring System for Hepatic Cirrhosis with Hepatocellular Carcinoma&lt;/p&gt;. Cancer Management and Research, 2020, Volume 12, 5537-5547.	0.9	2
3050	Prospects and Therapeutic Applications of Cardiac Glycosides in Cancer Remediation. ACS Combinatorial Science, 2020, 22, 543-553.	3.8	18
3051	Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma?. Tumori, 2021, 107, 292-303.	0.6	5
3052	<i>Ex</i>-<i>Vivo</i> Identification of Tumor From Parenchyma in Human Liver Using Electrochemical Impedance Spectroscopy on a Needle. IEEE Sensors Journal, 2020, 20, 14042-14049.	2.4	3
3053	Expression of MMP-2 in residual VX2 liver tumor after transcatheter arterial embolization combined with portal venous embolization in an animal model. Journal of Interventional Medicine, 2020, 3, 167-173.	0.2	0
3054	Radiofrequency ablation versus microwave ablation for early stage hepatocellular carcinoma. Medicine (United States), 2020, 99, e22703.	0.4	25
3055	Influence of interapplicator distance on multibipolar radiofrequency ablation during physiological and interrupted liver perfusion in an in vivo porcine model. Scientific Reports, 2020, 10, 16210.	1.6	3
3056	Malatya and Other Criteria for Liver Transplantation in Hepatocellular Carcinoma. Journal of Gastrointestinal Cancer, 2020, 51, 1118-1121.	0.6	3
3057	Health related quality of life in chronic liver diseases. Liver International, 2020, 40, 2630-2642.	1.9	15
3058	Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis. Journal of International Medical Research, 2020, 48, 030006052094687.	0.4	8
3059	Tumor Diameter for Hepatocellular Carcinoma: Why Should Size Matter?. Journal of Gastrointestinal Cancer, 2020, 51, 1114-1117.	0.6	6
3060	Hepatitis B Virus Pre-S Mutants as Biomarkers and Targets for the Development and Recurrence of Hepatocellular Carcinoma. Viruses, 2020, 12, 945.	1.5	19
3061	A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma. Current Hepatology Reports, 2020, 19, 478-485.	0.4	4
3062	Combined use of murine double minute-2 promoter methylation and serum AFP improves diagnostic efficiency in hepatitis B virus-related hepatocellular carcinoma. International Journal of Medical Sciences, 2020, 17, 3190-3199.	1.1	0
3063	&lt;p&gt;Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging&lt;/p&gt;. Journal of Hepatocellular Carcinoma, 2020, Volume 7, 77-89.	1.8	44
3064	Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials. Clinical Cancer Research, 2020, 26, 3979-3989.	3.2	184
3065	The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization. European Radiology, 2020, 30, 5650-5662.	2.3	9
3066	Effect of epigenetic modulation on cancer sphere. Journal of Medical Investigation, 2020, 67, 70-74.	0.2	0

#	ARTICLE	IF	CITATIONS
3067	Procyanidin B1, a novel and specific inhibitor of Kv10.1 channel, suppresses the evolution of hepatoma. <i>Biochemical Pharmacology</i> , 2020, 178, 114089.	2.0	33
3068	An international expert consensus of management of recurrent hepatocellular carcinoma: a viewpoint. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 394-396.	0.7	0
3069	Treatment of solitary hepatocellular carcinoma up to 2 cm. <i>Medicine (United States)</i> , 2020, 99, e20321.	0.4	5
3070	Detection of hepatitis B virus pre-S mutants in plasma by a next-generation sequencing-based platform determines their patterns in liver tissues. <i>PLoS ONE</i> , 2020, 15, e0234773.	1.1	12
3071	Prognostic Significance of Elevated Preoperative Serum CA125 Levels After Curative Hepatectomy for Hepatocellular Carcinoma. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4559-4567.	1.0	9
3072	Serum expression and diagnostic potential of long non-coding RNAs NEAT1 and TUG1 in viral hepatitis C and viral hepatitis C-associated hepatocellular carcinoma. <i>Clinical Biochemistry</i> , 2020, 84, 38-44.	0.8	12
3073	A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 902-906.	0.4	2
3074	Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. <i>Hepatology Research</i> , 2020, 50, 966-977.	1.8	35
3075	AR420626, a selective agonist of GPR41/FFA3, suppresses growth of hepatocellular carcinoma cells by inducing apoptosis via HDAC inhibition. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091343.	1.4	15
3076	Combined Chubby and $\beta$ -Catenin Predicts Clinical Outcomes in Patients with Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2060.	1.8	5
3077	Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells. <i>Experimental and Molecular Medicine</i> , 2020, 52, 497-513.	3.2	15
3078	Prognostic significance of inflammatory indices in hepatocellular carcinoma treated with transarterial chemoembolization: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0230879.	1.1	15
3079	Hepatocellular carcinoma: Gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450. <i>Biochemical Pharmacology</i> , 2020, 177, 113912.	2.0	24
3080	Tumor necrosis as a poor prognostic predictor on postoperative survival of patients with solitary small hepatocellular carcinoma. <i>BMC Cancer</i> , 2020, 20, 607.	1.1	33
3081	Evodiamine and rutaecarpine from <i>Tetradium ruticarpum</i> in the treatment of liver diseases. <i>Phytomedicine</i> , 2020, 68, 153180.	2.3	45
3082	Proteomic Analysis Reveals that EPHX1 Contributes to 5-Fluorouracil Resistance in a Human Hepatocellular Carcinoma Cell Line. <i>Proteomics - Clinical Applications</i> , 2020, 14, e1900080.	0.8	8
3083	Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE). <i>European Radiology</i> , 2020, 30, 3782-3792.	2.3	9
3084	Identification of Hub Genes and Analysis of Prognostic Values in Hepatocellular Carcinoma by Bioinformatics Analysis. <i>American Journal of the Medical Sciences</i> , 2020, 359, 226-234.	0.4	6

#	ARTICLE	IF	CITATIONS
3085	Investigation of possible effects of apigenin, sorafenib and combined applications on apoptosis and cell cycle in hepatocellular cancer cells. <i>Gene</i> , 2020, 737, 144428.	1.0	22
3086	Relation of fibroblast growth factor receptor 2 expression to hepatocellular carcinoma recurrence after liver resection. <i>PLoS ONE</i> , 2020, 15, e0227440.	1.1	4
3087	LINC00662 promotes hepatocellular carcinoma progression via altering genomic methylation profiles. <i>Cell Death and Differentiation</i> , 2020, 27, 2191-2205.	5.0	44
3088	The Antiproliferative Activity of Oxypeucedanin via Induction of G2/M Phase Cell Cycle Arrest and p53-Dependent MDM2/p21 Expression in Human Hepatoma Cells. <i>Molecules</i> , 2020, 25, 501.	1.7	9
3089	Clinical implications of cancer stem cells in digestive cancers: acquisition of stemness and prognostic impact. <i>Surgery Today</i> , 2020, 50, 1560-1577.	0.7	20
3090	Intraoperative fluorescence imaging with indocyanine green in hepatic resection for malignancy: a systematic review and meta-analysis of diagnostic test accuracy studies. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 2891-2903.	1.3	30
3091	Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. <i>JGH Open</i> , 2020, 4, 880-888.	0.7	13
3092	Increased Survival Benefit of Adjuvant Intra-arterial Infusion Chemotherapy in HCC Patients with Portal Vein Infiltration after Hepatectomy. <i>World Journal of Surgery</i> , 2020, 44, 2770-2776.	0.8	9
3093	The suppressing effects of VEGF-mediated angiogenesis at different administration sequences of apatinib and transarterial embolization in vivo. <i>Translational Cancer Research</i> , 2020, 9, 1133-1143.	0.4	0
3094	Intraoperative Transfusion of Fresh Frozen Plasma Predicts Morbidity Following Partial Liver Resection for Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1212-1223.	0.9	11
3095	Combined hepatectomy and microwave ablation for multifocal hepatocellular carcinoma: Long-term outcomes and prognostic factors. <i>Asian Journal of Surgery</i> , 2021, 44, 186-191.	0.2	4
3096	Fibrolamellar Hepatocellular Carcinoma: A Population-Based Observational Study. <i>Digestive Diseases and Sciences</i> , 2021, 66, 308-314.	1.1	25
3097	Transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma: response analysis with mRECIST. <i>Diagnostic and Interventional Radiology</i> , 2021, 27, 85-93.	0.7	3
3098	Combining cellular immunotherapy was an optional choice for unresectable advanced HCC: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101440.	0.7	0
3099	Transcriptome Profiling Identifies TIGIT as a Marker of T Cell Exhaustion in Liver Cancer. <i>Hepatology</i> , 2021, 73, 1399-1418.	3.6	61
3100	Systematic review of outcomes and meta-analysis of risk factors for prognosis after liver resection for hepatocellular carcinoma without cirrhosis. <i>Asian Journal of Surgery</i> , 2021, 44, 36-45.	0.2	15
3101	Prediction of tumor recurrence by Î±-fetoprotein model after curative resection for hepatocellular carcinoma. <i>European Journal of Surgical Oncology</i> , 2021, 47, 660-666.	0.5	20
3102	Actual 10-year survivors and 10-year recurrence free survivors after primary liver resection for hepatocellular carcinoma in the 21st century: A single institution contemporary experience. <i>Journal of Surgical Oncology</i> , 2021, 123, 214-221.	0.8	12

#	ARTICLE	IF	CITATIONS
3103	Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma. Clinics in Liver Disease, 2021, 25, 19-33.	1.0	4
3105	Diagnostic Accuracy of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS) Tj ETQq1 1 0.784314 rgBT /Ov High-Risk Patients: A Meta-Analysis. Ultraschall in Der Medizin, 2021, 42, 187-193.	0.8	8
3106	Advanced analytics and artificial intelligence in gastrointestinal cancer: a systematic review of radiomics predicting response to treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1785-1794.	3.3	32
3107	Prognostic evaluation of HCC patients undergoing surgical resection: an analysis of 8 different staging systems. Langenbeck's Archives of Surgery, 2021, 406, 75-86.	0.8	18
3108	Magnetic immunoassay for tumor clinical diagnosis based on rolling circular amplification (RCA) coupled with ICP-MS. Microchemical Journal, 2021, 160, 105541.	2.3	6
3109	Prediction of the prognosis of advanced hepatocellular carcinoma by <i>TERT</i> promoter mutations in circulating tumor DNA. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1118-1125.	1.4	21
3110	HuR Protein in Hepatocellular Carcinoma: Implications in Development, Prognosis and Treatment. Biomedicines, 2021, 9, 119.	1.4	14
3111	Therapeutic efficacy of dendritic cell vaccine combined with programmed death 1 inhibitor for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1988-1996.	1.4	18
3112	Influence of omega-3 fatty acids and monounsaturated fats in liver diseases. , 2021, , 161-174.		0
3113	Amygdalin promotes the activity of T cells to suppress the progression of HBV-related hepatocellular carcinoma via the JAK2/STAT3 signaling pathway. BMC Infectious Diseases, 2021, 21, 56.	1.3	13
3114	HCC subtypes based on the activity changes of immunologic and hallmark gene sets in tumor and nontumor tissues. Briefings in Bioinformatics, 2021, 22, .	3.2	33
3115	Hepatitis C-Induced Hepatocellular Carcinoma in the Middle East. , 2021, , 259-297.		0
3116	Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis. Cancers, 2021, 13, 521.	1.7	5
3117	MCCC2 promotes HCC development by supporting leucine oncogenic function. Cancer Cell International, 2021, 21, 22.	1.8	12
3118	A deep survival interpretable radiomics model of hepatocellular carcinoma patients. Physica Medica, 2021, 82, 295-305.	0.4	27
3119	A novel hypoxia gene signature indicates prognosis and immune microenvironments characters in patients with hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2021, 25, 3772-3784.	1.6	15
3120	Hepatocellular Carcinoma in India. Indian Journal of Surgery, 0, , 1.	0.2	6
3121	TKP, a Serine Protease from <i>Trichosanthes kirilowii</i>, Inhibits Cell Proliferation by Blocking Aerobic Glycolysis in Hepatocellular Carcinoma Cells. Nutrition and Cancer, 2022, 74, 333-345.	0.9	6



#	ARTICLE	IF	CITATIONS
3122	If at First You Donâ€™t Succeed, TACE and TACE Again. <i>Radiology</i> , 2021, 298, 693-694.	3.6	0
3123	LIMK1 nuclear translocation promotes hepatocellular carcinoma progression by increasing p-ERK nuclear shuttling and by activating c-Myc signalling upon EGF stimulation. <i>Oncogene</i> , 2021, 40, 2581-2595.	2.6	8
3124	Efficacy of microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score analysis. <i>Abdominal Radiology</i> , 2021, 46, 3790-3797.	1.0	11
3125	Realâ€world hospital mortality of liver cirrhosis inpatients in Japan: a largeâ€scale cohort study using a medical claims database. <i>Hepatology Research</i> , 2021, 51, 682-693.	1.8	8
3126	Differentiation of Hepatocellular Carcinoma from Hepatic Hemangioma and Focal Nodular Hyperplasia using Computed Tomographic Spectral Imaging. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	3
3127	Using Integrated Bioinformatics Analysis to Identify Abnormally Methylated Differentially Expressed Genes in Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 805-823.	0.8	3
3128	JNK signaling as a target for anticancer therapy. <i>Pharmacological Reports</i> , 2021, 73, 405-434.	1.5	19
3129	Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. <i>PLoS ONE</i> , 2021, 16, e0247728.	1.1	3
3130	Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. <i>Biomarker Research</i> , 2021, 9, 19.	2.8	43
3131	Recurrence of Hepatocellular Carcinoma After Liver Transplantation is Associated with Episodes of Acute Rejections. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 133-143.	1.8	10
3132	Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1048-1059.	0.9	14
3133	Nâ€glycan fingerprint predicts alphaâ€fetoprotein negative hepatocellular carcinoma: A largeâ€scale multicenter study. <i>International Journal of Cancer</i> , 2021, 149, 717-727.	2.3	13
3134	Peripheral Blood Genetic Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 583714.	1.3	9
3135	Ras Mitogen-activated Protein Kinase Signaling and Kinase Suppressor of Ras as Therapeutic Targets for Hepatocellular Carcinoma. <i>Journal of Liver Cancer</i> , 2021, 21, 1-11.	0.3	4
3136	The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 5303.	1.6	20
3137	Correlation Between Portal Pressure and Indocyanine Green Retention Rate is Unaffected by the Cause of Cirrhosis: A Prospective Study. <i>World Journal of Surgery</i> , 2021, 45, 2546-2555.	0.8	3
3138	Serum deprivation-response protein induces apoptosis in hepatocellular carcinoma through ASK1-JNK/p38 MAPK pathways. <i>Cell Death and Disease</i> , 2021, 12, 425.	2.7	22
3139	Congenital heart disease-associated liver disease: a narrative review. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 577-590.	0.7	4

#	ARTICLE	IF	CITATIONS
3140	CDC20 promotes the progression of hepatocellular carcinoma by regulating epithelial-mesenchymal transition. <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	11
3141	Interaction of Hepatitis B Virus X Protein with the Pregnane X Receptor Enhances the Synergistic Effects of Aflatoxin B1 and Hepatitis B Virus on Promoting Hepatocarcinogenesis. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	4
3142	Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. <i>The Cochrane Library</i> , 2021, 2021, CD013346.	1.5	24
3143	LncRNA SUMO1P3 acts as a prognostic biomarker and promotes hepatocellular carcinoma growth and metastasis. <i>Aging</i> , 2021, 13, 12479-12492.	1.4	7
3144	Very-early-stage Hepatocellular Carcinoma, Are We at Long Last on Route for Achieving Better Patient Outcomes?. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	1
3145	Growing Human Hepatocellular Tumors Undergo a Global Metabolic Reprogramming. <i>Cancers</i> , 2021, 13, 1980.	1.7	9
3146	Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 7663-7672.	0.7	48
3147	Transarterial Radioembolization (TARE) with <sup>131</sup> Iodine-Lipiodol for Unresectable Primary Hepatocellular Carcinoma: Experience from a Tertiary Care Center in India. <i>South Asian Journal of Cancer</i> , 2021, 10, 81-86.	0.2	5
3148	Hepatitis B Virus Pre-S Gene Deletions and Pre-S Deleted Proteins: Clinical and Molecular Implications in Hepatocellular Carcinoma. <i>Viruses</i> , 2021, 13, 862.	1.5	11
3149	Spontaneous Rupture of Hepatocellular Carcinoma: New Insights. <i>Journal of Clinical and Experimental Hepatology</i> , 2021, 12, 483-491.	0.4	5
3150	Antitumor Effects of Triterpenes in Hepatocellular Carcinoma. <i>Current Medicinal Chemistry</i> , 2021, 28, 2465-2484.	1.2	7
3151	Prognostic Model for the Risk Stratification of Early and Late Recurrence in Hepatitis B Virus-Related Small Hepatocellular Carcinoma Patients with Global Histone Modifications. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 493-505.	1.8	3
3152	Predictive impact of prognostic nutritional index in early-stage hepatocellular carcinoma after operative microwave ablation. <i>Asian Journal of Surgery</i> , 2021, 45, 202-202.	0.2	2
3153	Omics-Based Identification of Shared and Gender Disparity Routes in Hras <sup>12V</sup> -Induced Hepatocarcinogenesis: An Important Role for Dlk1-Dio3 Genomic Imprinting Region. <i>Frontiers in Genetics</i> , 2021, 12, 620594.	1.1	3
3154	Genomic landscape of hepatocarcinogenesis. <i>Journal of Human Genetics</i> , 2021, 66, 845-851.	1.1	20
3155	Charge-reversal nanocomplexes-based CRISPR/Cas9 delivery system for loss-of-function oncogene editing in hepatocellular carcinoma. <i>Journal of Controlled Release</i> , 2021, 333, 362-373.	4.8	16
3156	Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. <i>The Cochrane Library</i> , 0, , .	1.5	2
3157	Repeat hepatectomy versus radiofrequency ablation in management of recurrent hepatocellular carcinoma: an average treatment effect analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 7731-7740.	0.7	8

#	ARTICLE	IF	CITATIONS
3158	Management of early hepatocellular carcinoma: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association. <i>Hpb</i> , 2021, 23, 753-761.	0.1	3
3159	ZSCAN16-AS1 expedites hepatocellular carcinoma progression via modulating the miR-181c-5p/SPAG9 axis to activate the JNK pathway. <i>Cell Cycle</i> , 2021, 20, 1134-1146.	1.3	6
3160	Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	10
3161	p53 Mutation at Serine 249 and Its Gain of Function Are Highly Related to Hepatocellular Carcinoma after Smoking Exposure. <i>Public Health Genomics</i> , 2021, 24, 171-181.	0.6	7
3162	Factors Associated with Recurrence of Hepatocellular Carcinoma in 197 Patients Following Transarterial Chemoembolization: A Retrospective Study from a Single Center. <i>Medical Science Monitor</i> , 2021, 27, e929879.	0.5	0
3163	PiRNAs and PIWI proteins as new biomarkers for diagnosis and treatment of liver cancer. <i>Gene Reports</i> , 2021, 23, 101103.	0.4	0
3164	Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 2837-2860.	1.1	4
3165	Surgical treatment of hepatocellular carcinoma. <i>BioScience Trends</i> , 2021, 15, 138-141.	1.1	63
3166	Neutrophil-to-Lymphocyte Ratio as a Biomarker Predicting Overall Survival after Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2830.	1.7	16
3167	Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 606-613.	0.6	10
3168	Hepatoma upregulated protein and Ki-67 expression in resectable hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 623-632.	0.6	4
3169	Pathophysiological role of prostaglandin E synthases in liver diseases. <i>Prostaglandins and Other Lipid Mediators</i> , 2021, 154, 106552.	1.0	4
3170	Screening, clinical features and prognostic analysis of liver cirrhosis-related hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 948-954.	0.6	1
3171	The Multidisciplinary Management of Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2021, 17, 405-408.	1.0	10
3172	Preoperative nomogram for microvascular invasion prediction based on clinical database in hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 13999.	1.6	9
3173	Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. <i>Hepatology Research</i> , 2021, 51, 979-989.	1.8	20
3174	The clinical value of kinesin superfamily protein 2A in hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101527.	0.7	6
3175	Fifteen-year-long journey with hepatocellular carcinoma from diagnosis during pregnancy to recurrence after liver transplantation: A case report of intractable tumor recurrence. <i>Annals of Liver Transplantation</i> , 2021, , .	0.4	1

#	ARTICLE	IF	CITATIONS
3176	Long-Term Survival of Combined Hepatocellular-Cholangiocarcinoma: A Nationwide Study. <i>Oncologist</i> , 2021, 26, e1774-e1785.	1.9	4
3177	Circular noncoding RNA hsa_circ_0005986 as a prognostic biomarker for hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 14930.	1.6	5
3178	Perivascular vital cells in the ablation center after multibipolar radiofrequency ablation in an in vivo porcine model. <i>Scientific Reports</i> , 2021, 11, 13886.	1.6	1
3179	Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2021, 29, 389-403.	0.6	3
3180	Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2021, 46, 5162-5179.	1.0	9
3181	Xenograft Zebrafish Models for the Development of Novel Anti-Hepatocellular Carcinoma Molecules. <i>Pharmaceuticals</i> , 2021, 14, 803.	1.7	3
3182	AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 299.	7.1	44
3183	Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1362-1372.	1.0	4
3184	Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 190-199.	1.4	3
3185	Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. <i>JHEP Reports</i> , 2021, 3, 100305.	2.6	83
3186	Adjuvant transarterial chemotherapy for margin-positive resection of hepatocellular carcinoma: a propensity score-matched analysis. <i>Langenbeck's Archives of Surgery</i> , 2021, , 1.	0.8	1
3187	Drug-eluting bead trans-arterial chemoembolization combined with microwave ablation therapy vs. microwave ablation alone for early stage hepatocellular carcinoma: a preliminary investigation of clinical value. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1781-1788.	1.2	6
3188	Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101587.	0.7	6
3189	Navigated liver surgery: State of the art and future perspectives. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 226-233.	0.6	16
3190	Long Noncoding RNA NTT Context-Dependently Regulates MYB by Interacting With Activated Complex in Hepatocellular Carcinoma Cells. <i>Frontiers in Oncology</i> , 2021, 11, 592045.	1.3	2
3191	iRGD Peptide-Mediated Liposomal Nanoparticles with Photoacoustic/Ultrasound Dual-Modality Imaging for Precision Theranostics Against Hepatocellular Carcinoma. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 6455-6475.	3.3	17
3192	Saussurea lappa Exhibits Anti-Oncogenic Effect in Hepatocellular Carcinoma, HepG2 Cancer Cell Line by Bcl-2 Mediated Apoptotic Pathway and Mitochondrial Cytochrome C Release. <i>Current Issues in Molecular Biology</i> , 2021, 43, 1114-1132.	1.0	17
3193	Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2021, 41, 4555-4562.	0.5	7

#	ARTICLE	IF	CITATIONS
3194	Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection?. <i>European Journal of Internal Medicine</i> , 2021, 94, 6-14.	1.0	5
3195	Prognostic significance of preoperative hyaluronic acid level in patients with hepatocellular carcinoma. <i>Hpb</i> , 2021, , .	0.1	1
3196	Comparison of short-term outcomes and invasiveness of microwave versus radiofrequency ablation for the treatment of hepatic tumors. <i>Tenri Medical Bulletin</i> , 2021, 24, 27-36.	0.1	0
3197	Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells. <i>Anticancer Research</i> , 2021, 41, 645-660.	0.5	2
3198	Identification of hepatocellular carcinoma-related genes associated with macrophage differentiation based on bioinformatics analyses. <i>Bioengineered</i> , 2021, 12, 296-309.	1.4	15
3199	<i>In vitro</i> and <i>in vivo</i> antitumor effects of lupeol-loaded galactosylated liposomes. <i>Drug Delivery</i> , 2021, 28, 709-718.	2.5	13
3200	Early experience with laparoscopic treatment of liver tumors using a separable cluster electrode with a no-touch technique. <i>Wideochirurgia I Inne Techniki Maloinwazyjne</i> , 2021, 16, 76-82.	0.3	2
3207	Percutaneous Ablation of Hepatocellular Carcinoma. <i>Recent Results in Cancer Research</i> , 2006, 167, 91-105.	1.8	9
3208	Percutaneous Alcohol Instillation. , 2008, , 123-127.		1
3209	Hepatic Ablation: Hepatocellular Carcinoma and Metastases. , 2013, , 115-137.		2
3210	The Liver in Type 2 Diabetes Mellitus. , 2008, , 351-364.		2
3211	Preclinical Testing of Virotherapeutics for Primary and Secondary Tumors of the Liver. <i>Methods in Molecular Biology</i> , 2012, 806, 121-136.	0.4	4
3212	Hepatocellular Carcinoma: Etiology and Natural History. , 2012, , 1-16.		2
3213	Multidisciplinary Management of Hepatocellular Carcinoma. <i>Recent Results in Cancer Research</i> , 2013, 190, 247-259.	1.8	12
3214	Locoregional Therapy. , 2011, , 2072-2073.		2
3215	Locoregional Therapy. , 2015, , 1-3.		1
3216	Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease. <i>Biomarkers in Disease</i> , 2017, , 321-348.	0.0	1
3217	Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease. <i>Biomarkers in Disease</i> , 2016, , 1-28.	0.0	2

#	ARTICLE	IF	CITATIONS
3218	Imaging of HCC. , 2012, 37, 215.		1
3219	Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2669-2680.	1.2	16
3220	Liver and Bile Duct Cancer. , 2008, , 1569-1594.		1
3222	Transplantation for Primary Hepatic Malignancy. , 2005, , 211-231.		1
3223	HP1s modulate the S-Adenosyl Methionine synthesis pathway in liver cancer cells. <i>Biochemical Journal</i> , 2020, 477, 1033-1047.	1.7	5
3224	Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature. <i>Bioscience Reports</i> , 2020, 40, .	1.1	14
3225	Liver Cancer. , 2006, , 763-786.		63
3226	Clinical Outcomes of Sorafenib Treatment in Patients With Metastatic Hepatocellular Carcinoma Who Had Been Previously Treated With Fluoropyrimidine Plus Platinum-based Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 125-129.	0.6	10
3227	Hepatocellular carcinoma in a low-endemic area. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1.	0.8	24
3228	Empirical 188Re-HDD/lipiodol intra-arterial therapy based on tumor volume, in patients with solitary inoperable hepatocellular carcinoma. <i>Nuclear Medicine Communications</i> , 2021, 42, 43-50.	0.5	4
3229	Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020, 104, 1136-1142.	0.5	105
3230	Genomic Progression in Mouse Models for Liver Tumors. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2005, 70, 217-224.	2.0	13
3231	Generation and Analysis of Genetically Defined Liver Carcinomas Derived from Bipotential Liver Progenitors. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2005, 70, 251-261.	2.0	58
3232	Combination of neutrophilâ€toâ€lymphocyte ratio and early desâ€³â€carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2017, 47, 533-541.	1.8	13
3233	Sorafenib inhibits liver regeneration in rats. <i>Hpb</i> , 2013, 15, 944-950.	0.1	7
3234	Chemoembolisation combined with percutaneous radiofrequency ablation in the treatment of primary angiosarcoma of the liver. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013009511-bcr2013009511.	0.2	3
3235	Serum Levels of Interleukin-6 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients. <i>ISRN Hepatology</i> , 2013, 2013, 1-9.	0.9	26
3236	Construction and Comprehensive Analyses of a Competing Endogenous RNA Network in Tumor-Node-Metastasis Stage I Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2020, 2020, 1-14.	0.9	8

#	ARTICLE	IF	CITATIONS
3237	Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 2509-2526.	3.9	29
3238	Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. <i>Journal of Clinical Investigation</i> , 2010, 120, 924-930.	3.9	305
3239	Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma. <i>Journal of Clinical Investigation</i> , 2012, 122, 2554-2566.	3.9	113
3240	HCC screening: assessment of an abbreviated non-contrast MRI protocol. <i>European Radiology Experimental</i> , 2019, 3, 49.	1.7	37
3241	HCV Infection and Mitochondria Proteomics. , 2013, , 219-236.		1
3242	Somatostatin analogues in advanced hepatocellular carcinoma: An updated systematic review and meta-analysis of randomized controlled trials. <i>Medical Science Monitor</i> , 2011, 17, RA169-RA176.	0.5	21
3243	IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma. <i>Medical Science Monitor</i> , 2014, 20, 247-254.	0.5	10
3244	Improving the Surgical Effect for Primary Liver Cancer with Intraoperative Fluorescence Navigation Compared with Intraoperative Ultrasound. <i>Medical Science Monitor</i> , 2019, 25, 3406-3416.	0.5	12
3245	Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new?. <i>World Journal of Clinical Cases</i> , 2018, 6, 259-273.	0.3	12
3246	The Effect of Gamisoyo-san Intravenous Pharmacopuncture on Restoration of Liver Function after Partial Hepatectomy in SD Rat. <i>Journal of Korean Medicine</i> , 2015, 36, 22-32.	0.1	7
3247	Transgenic CHD1L Expression in Mouse Induces Spontaneous Tumors. <i>PLoS ONE</i> , 2009, 4, e6727.	1.1	47
3248	Recombinant VP1, an Akt Inhibitor, Suppresses Progression of Hepatocellular Carcinoma by Inducing Apoptosis and Modulation of CCL2 Production. <i>PLoS ONE</i> , 2011, 6, e23317.	1.1	31
3249	Associations of HLA-DP Variants with Hepatitis B Virus Infection in Southern and Northern Han Chinese Populations: A Multicenter Case-Control Study. <i>PLoS ONE</i> , 2011, 6, e24221.	1.1	60
3250	Extract of <i>Pleurotus pulmonarius</i> Suppresses Liver Cancer Development and Progression through Inhibition of VEGF-Induced PI3K/AKT Signaling Pathway. <i>PLoS ONE</i> , 2012, 7, e34406.	1.1	53
3251	Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2012, 7, e37563.	1.1	252
3252	Upregulator of Cell Proliferation Predicts Poor Prognosis in Hepatocellular Carcinoma and Contributes to Hepatocarcinogenesis by Downregulating FOXO3a. <i>PLoS ONE</i> , 2012, 7, e40607.	1.1	35
3253	Excess Body Mass Index and Risk of Liver Cancer: A Nonlinear Dose-Response Meta-Analysis of Prospective Studies. <i>PLoS ONE</i> , 2012, 7, e44522.	1.1	29
3254	Synthesized Multiple Antigenic Polypeptide Vaccine Based on B-Cell Epitopes of Human Heparanase Could Elicit a Potent Antimetastatic Effect on Human Hepatocellular Carcinoma In Vivo. <i>PLoS ONE</i> , 2013, 8, e52940.	1.1	15

#	ARTICLE	IF	CITATIONS
3255	Direct Transformation of Lung Microenvironment by Interferon- $\beta$ Treatment Counteracts Growth of Lung Metastasis of Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e58913.	1.1	14
3256	Pre-S Deletion and Complex Mutations of Hepatitis B Virus Related to Young Age Hepatocellular Carcinoma in Qidong, China. PLoS ONE, 2013, 8, e59583.	1.1	23
3257	A Human Anti-c-Met Fab Fragment Conjugated with Doxorubicin as Targeted Chemotherapy for Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e63093.	1.1	32
3258	Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging for the Detection of Hepatocellular Carcinoma: A Meta-Analysis. PLoS ONE, 2013, 8, e70896.	1.1	46
3259	Case Report Evidence of Relationships between Hepatocellular Carcinoma and Ochratoxicosis. PLoS ONE, 2013, 8, e71423.	1.1	10
3260	Hepatic Stellate Cells Secreted Hepatocyte Growth Factor Contributes to the Chemoresistance of Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e73312.	1.1	54
3261	Radiofrequency Ablation Is Superior to Ethanol Injection in Early-Stage Hepatocellular Carcinoma Irrespective of Tumor Size. PLoS ONE, 2013, 8, e80276.	1.1	23
3262	Fish Intake and Risk of Liver Cancer: A Meta-Analysis. PLoS ONE, 2015, 10, e0096102.	1.1	32
3263	Association of Adjuvant Antiviral Therapy with Risk of Cancer Progression and Deaths in Patients with Hepatitis-B-Virus-Related Hepatocellular Carcinoma following Curative Treatment: A Nationwide Cohort Study. PLoS ONE, 2014, 9, e102051.	1.1	13
3264	The Histone Deacetylase Inhibitor, Vorinostat, Represses Hypoxia Inducible Factor 1 Alpha Expression through Translational Inhibition. PLoS ONE, 2014, 9, e106224.	1.1	83
3265	Design and Development of a Robotized System Coupled to $\mu$ CT Imaging for Intratumoral Drug Evaluation in a HCC Mouse Model. PLoS ONE, 2014, 9, e106675.	1.1	11
3266	Comparison of the Effects of Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma between Patients with and without Extrahepatic Metastases. PLoS ONE, 2014, 9, e113926.	1.1	17
3267	Incomplete Radiofrequency Ablation Enhances Invasiveness and Metastasis of Residual Cancer of Hepatocellular Carcinoma Cell HCCLM3 via Activating $\beta$ -Catenin Signaling. PLoS ONE, 2014, 9, e115949.	1.1	58
3268	The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma. PLoS ONE, 2015, 10, e0118658.	1.1	46
3269	Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)? PLoS ONE, 2015, 10, e0129573.	1.1	8
3270	Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS ONE, 2015, 10, e0133488.	1.1	110
3271	Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients. PLoS ONE, 2015, 10, e0137706.	1.1	68
3272	The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0146456.	1.1	12



#	ARTICLE	IF	CITATIONS
3273	RASSF1A and DOK1 Promoter Methylation Levels in Hepatocellular Carcinoma, Cirrhotic and Non-Cirrhotic Liver, and Correlation with Liver Cancer in Brazilian Patients. PLoS ONE, 2016, 11, e0153796.	1.1	19
3274	Overrepresentation of IL-10-Expressing B Cells Suppresses Cytotoxic CD4+ T Cell Activity in HBV-Induced Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0154815.	1.1	48
3275	Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy. PLoS ONE, 2016, 11, e0155588.	1.1	37
3276	Higher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin Levels. PLoS ONE, 2016, 11, e0161825.	1.1	33
3277	Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients. PLoS ONE, 2016, 11, e0168798.	1.1	20
3278	Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization. PLoS ONE, 2017, 12, e0170750.	1.1	9
3279	Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101. PLoS ONE, 2017, 12, e0174769.	1.1	43
3280	Hepatitis B virus pre-S2 deletion (nucleotide 1 to 54) in plasma predicts recurrence of hepatocellular carcinoma after curative surgical resection. PLoS ONE, 2020, 15, e0242748.	1.1	10
3281	Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. Journal of Clinical and Translational Hepatology, 2017, XX, 1-14.	0.7	16
3282	Efficacy and safety of transarterial chemoembolization combined to conformal radiotherapy for uninodular hepatocellular carcinoma. International Journal of Cancer Therapy and Oncology, 2014, 2, 020410.	0.2	4
3283	Novel Therapeutics in Hepatocellular Carcinoma: How Can We Make Progress?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e137-e142.	1.8	7
3284	Plant polyphenolic extracts as potential anti-human hepatocarcinoma agents. Plant Science Today, 2014, 1, 213-218.	0.4	2
3285	Downstaging of hepatocellular carcinoma with radiofrequency ablation on the Hungarian liver transplantation waiting list – Early results and learned lessons. Interventional Medicine & Applied Science, 2009, 1, 41-45.	0.2	4
3288	Association of MDR1 gene polymorphisms with the risk of hepatocellular carcinoma in the Chinese Han population. Brazilian Journal of Medical and Biological Research, 2013, 46, 311-317.	0.7	12
3289	BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arquivos De Gastroenterologia, 2020, 57, 1-20.	0.3	22
3290	Liver transplantation and expanded Milan criteria: does it really work?. Arquivos De Gastroenterologia, 2012, 49, 189-194.	0.3	1
3291	Liver transplantation in hemophilia A and von Willebrand disease type 3: perioperative management and post-transplant outcome. Revista Espanola De Enfermedades Digestivas, 2018, 110, 522-526.	0.1	6
3292	Reduced SOD2 expression is associated with mortality of hepatocellular carcinoma patients in a mutant p53-dependent manner. Aging, 2016, 8, 1184-1200.	1.4	34

#	ARTICLE	IF	CITATIONS
3293	TPGS-1000 exhibits potent anticancer activity for hepatocellular carcinoma in vitro and in vivo. <i>Aging</i> , 2020, 12, 1624-1642.	1.4	12
3294	The association between KLF4 as a tumor suppressor and the prognosis of hepatocellular carcinoma after curative resection. <i>Aging</i> , 2020, 12, 15566-15580.	1.4	6
3295	Combination treatment including targeted therapy for advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 71036-71051.	0.8	44
3296	Microarray analysis on the lncRNA expression profile in male hepatocellular carcinoma patients with chronic hepatitis B virus infection. <i>Oncotarget</i> , 2016, 7, 76169-76180.	0.8	16
3297	Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. <i>Oncotarget</i> , 2016, 7, 75482-75491.	0.8	18
3298	Prognostic nutritional index predicts short-term outcomes after liver resection for hepatocellular carcinoma within the Milan criteria. <i>Oncotarget</i> , 2016, 7, 81611-81620.	0.8	32
3299	Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF- $\kappa$ B pathway in human hepatocellular carcinoma-bearing mouse model. <i>Oncotarget</i> , 2016, 7, 85450-85463.	0.8	28
3300	Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 37835-37844.	0.8	23
3301	Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC. <i>Oncotarget</i> , 2017, 8, 11950-11962.	0.8	29
3302	The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 15846-15857.	0.8	40
3303	Long noncoding RNA PCAT-14 induces proliferation and invasion by hepatocellular carcinoma cells by inducing methylation of miR-372. <i>Oncotarget</i> , 2017, 8, 34429-34441.	0.8	37
3304	MiR-106b inhibitors sensitize TRAIL-induced apoptosis in hepatocellular carcinoma through increase of death receptor 4. <i>Oncotarget</i> , 2017, 8, 41921-41931.	0.8	20
3305	Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 45234-45241.	0.8	7
3306	Genetic polymorphisms in human UDP-glucuronosyltransferases 1A7 and the risk of gastrointestinal carcinomas: A systematic review and network meta-analysis. <i>Oncotarget</i> , 2017, 8, 66371-66381.	0.8	12
3307	IGFBP2 plays an important role in heat shock protein 27-mediated cancer progression and metastasis. <i>Oncotarget</i> , 2017, 8, 54978-54992.	0.8	24
3308	Transcatheter hepatic arterial chemoembolization and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials. <i>Oncotarget</i> , 2017, 8, 59601-59608.	0.8	10
3309	Meta-analysis reveals gender difference in the association of liver cancer incidence and excess BMI. <i>Oncotarget</i> , 2017, 8, 72959-72971.	0.8	12
3310	Clinical significance of lncRNA-ATB expression in human hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 78588-78597.	0.8	34

#	ARTICLE	IF	CITATIONS
3311	Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib. <i>Oncotarget</i> , 2017, 8, 103077-103086.	0.8	41
3312	Curcumin downregulates the expression of Snail via suppressing Smad2 pathway to inhibit TGF- $\beta$ 1-induced epithelial-mesenchymal transitions in hepatoma cells. <i>Oncotarget</i> , 2017, 8, 108498-108508.	0.8	25
3313	Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC. <i>Oncotarget</i> , 2017, 8, 115444-115455.	0.8	25
3314	Determination of candidate metabolite biomarkers associated with recurrence of HCV-related hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 6245-6258.	0.8	8
3315	Novel roles of TMEM100: inhibition metastasis and proliferation of hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 17379-17390.	0.8	23
3316	C12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4 $\beta$ inactivation, which causes c-Met induction. <i>Oncotarget</i> , 2015, 6, 19055-19069.	0.8	35
3317	MicroRNA-424 inhibits Akt3/E2F3 axis and tumor growth in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 27736-27750.	0.8	62
3318	A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway. <i>Oncotarget</i> , 2015, 6, 31927-31943.	0.8	98
3319	Long non-coding RNA expression profiles of hepatitis C virus-related dysplasia and hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 43770-43778.	0.8	79
3320	pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 2646-2659.	0.8	47
3321	HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. <i>Oncotarget</i> , 2016, 7, 473-489.	0.8	20
3322	Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. <i>Oncotarget</i> , 2016, 7, 6639-6648.	0.8	18
3323	Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. <i>Oncotarget</i> , 2016, 7, 7241-7252.	0.8	33
3324	RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation. <i>Oncotarget</i> , 2016, 7, 9832-9843.	0.8	12
3325	Generation of functional hepatocytes from human spermatogonial stem cells. <i>Oncotarget</i> , 2016, 7, 8879-8895.	0.8	23
3326	CWP232228 targets liver cancer stem cells through Wnt/ $\beta$ -catenin signaling: a novel therapeutic approach for liver cancer treatment. <i>Oncotarget</i> , 2016, 7, 20395-20409.	0.8	66
3327	MicroRNA-452 promotes stem-like cells of hepatocellular carcinoma by inhibiting Sox7 involving Wnt/ $\beta$ -catenin signaling pathway. <i>Oncotarget</i> , 2016, 7, 28000-28012.	0.8	62
3328	Glypican-3 and Alphafetoprotein as Diagnostic Tests for Hepatocellular Carcinoma. , 2004, 8, 207.		13

#	ARTICLE	IF	CITATIONS
3329	1, 25(OH)D <sub>3</sub> ; Inhibits Hepatocellular Carcinoma Development Through Reducing Secretion of Inflammatory Cytokines from Immunocytes. <i>Current Medicinal Chemistry</i> , 2013, 20, 4131-4141.	1.2	40
3330	Recent Findings on Nanotechnology-based Therapeutic Strategies Against Hepatocellular Carcinoma. <i>Current Drug Metabolism</i> , 2019, 20, 283-291.	0.7	4
3331	Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment?. <i>Current Cancer Drug Targets</i> , 2018, 19, 26-40.	0.8	31
3332	Serum Vascular Endothelial Growth Factor in Patients with Hepatocellular Carcinoma and its Validity as a Tumor Biomarker. <i>Open Biomarkers Journal</i> , 2019, 9, 84-94.	0.1	1
3333	Correlation Between Poor Prognosis and Lower TPPP Gene Expression in Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2016, 36, 4639-4646.	0.5	7
3334	Prognostic Nomogram for Advanced Hepatocellular Carcinoma Treated with FOLFOX 4. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 1225-1232.	0.5	10
3335	Prevention of Hepatocellular Carcinoma. , 2009, , 36-61.		2
3336	Structural features of synthetic glycoconjugates and efficiency of their interaction with glycoprotein receptors on the surface of hepatocytes. <i>Fine Chemical Technologies</i> , 2019, 14, 7-20.	0.1	1
3337	Techniques of Interventional Tumor Therapy. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2008, 105, 646-53.	0.6	14
3338	Sorafenib for the treatment of advanced hepatocellular carcinoma. <i>Health Technology Assessment</i> , 2010, 14, 17-21.	1.3	10
3339	Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 288.	4.5	15
3340	Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 60.	4.5	23
3341	Recent advances in the imaging of hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 95.	4.5	8
3342	The mutational landscape of hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 220.	4.5	108
3343	Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 287.	4.5	30
3344	Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 250-258.	4.5	42
3345	A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 128-137.	4.5	24
3346	Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 335-343.	4.5	42

#	ARTICLE	IF	CITATIONS
3347	Molecular targeting for treatment of advanced hepatocellular carcinoma. <i>The Korean Journal of Hepatology</i> , 2009, 15, 299.	1.5	8
3349	Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinoma. <i>The Korean Journal of Hepatology</i> , 2010, 16, 383.	1.5	23
3350	Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center. <i>The Korean Journal of Hepatology</i> , 2011, 17, 113.	1.5	27
3351	A case of isolated metastatic hepatocellular carcinoma arising from the pelvic bone. <i>The Korean Journal of Hepatology</i> , 2012, 18, 89.	1.5	8
3352	Fundamentals of microwave physics: application to hepatic ablation. <i>Journal of Microwave Surgery</i> , 2012, 30, 25-40.	0.3	8
3353	Thymoquinone exerts anti-tumor activities on human hepatocellular carcinoma cells: role of angiogenesis-related genes VCAN, Grb2 and EZH2. <i>European Journal of Cell Science</i> , 0, , 10-16.	0.2	3
3354	Non-Immunotherapy Options for the First-Line Management of Hepatocellular Carcinoma: Exploring the Evolving Role of Sorafenib and Lenvatinib in Advanced Disease. <i>Current Oncology</i> , 2020, 27, 165-172.	0.9	9
3355	Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. <i>World Journal of Gastroenterology</i> , 2008, 14, 1.	1.4	98
3356	Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. <i>World Journal of Gastroenterology</i> , 2008, 14, 1657.	1.4	64
3357	Troglitazone, a peroxisome proliferator-activated receptor $\beta$ ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells. <i>World Journal of Gastroenterology</i> , 2008, 14, 2168.	1.4	21
3358	Hepatocellular carcinoma: Defining the place of surgery in an era of organ shortage. <i>World Journal of Gastroenterology</i> , 2008, 14, 4445.	1.4	17
3359	Macro-regenerative nodules in biliary atresia: CT/MRI findings and their pathological relations. <i>World Journal of Gastroenterology</i> , 2008, 14, 4529.	1.4	22
3360	Complete hepatocellular carcinoma necrosis following sequential porto-arterial embolization. <i>World Journal of Gastroenterology</i> , 2008, 14, 6869.	1.4	8
3361	Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: A cohort study. <i>World Journal of Gastroenterology</i> , 2009, 15, 1843.	1.4	35
3362	Current management strategy of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2009, 15, 3210.	1.4	122
3363	Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: Case reports and literature review. <i>World Journal of Gastroenterology</i> , 2009, 15, 4726.	1.4	48
3364	Liver transplantation for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2009, 15, 5511.	1.4	20
3365	Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: A retrospective study. <i>World Journal of Gastroenterology</i> , 2009, 15, 713.	1.4	40

#	ARTICLE	IF	CITATIONS
3366	Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2005, 11, 2526.	1.4	14
3367	Diagnostic laparoscopy and laparoscopic ultrasonography with local anesthesia in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2005, 11, 4120.	1.4	2
3368	Rapid quantification of semen hepatitis B virus DNA by real-time polymerase chain reaction. <i>World Journal of Gastroenterology</i> , 2005, 11, 5385.	1.4	35
3369	Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2005, 11, 6104.	1.4	71
3370	Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis. <i>World Journal of Gastroenterology</i> , 2005, 11, 1215.	1.4	65
3371	Risk factors for immediate post-operative fatal recurrence after curative resection of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2006, 12, 99.	1.4	32
3372	Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2006, 12, 3275.	1.4	99
3373	Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells. <i>World Journal of Gastroenterology</i> , 2006, 12, 3977.	1.4	22
3374	Low utility of plasma Nociceptin/orphanin FQ in the diagnosis of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2006, 12, 4716.	1.4	12
3375	Inhibition of hepatic tumor cell proliferation <i>in vitro</i> and tumor growth <i>in vivo</i> by taltobulin, a synthetic analogue of the tripeptide hemiasterlin. <i>World Journal of Gastroenterology</i> , 2006, 12, 6771.	1.4	5
3376	Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2006, 12, 6955.	1.4	19
3377	Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. <i>World Journal of Gastroenterology</i> , 2006, 12, 7239.	1.4	74
3378	Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: A multivariate analysis of pre-treatment findings. <i>World Journal of Gastroenterology</i> , 2007, 13, 6022.	1.4	16
3379	Hepatitis B virus-induced oncogenesis. <i>World Journal of Gastroenterology</i> , 2007, 13, 74.	1.4	233
3380	Chinese medicinal compound delisheng has satisfactory anti-tumor activity, and is associated with up-regulation of endostatin in human hepatocellular carcinoma cell line HepG2 in three-dimensional culture. <i>World Journal of Gastroenterology</i> , 2007, 13, 5432.	1.4	15
3381	Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. <i>World Journal of Gastroenterology</i> , 2010, 16, 264.	1.4	46
3382	Present and future possibilities for early diagnosis of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2010, 16, 418.	1.4	161
3383	Local recurrence of hepatocellular carcinoma after radiofrequency ablation. <i>World Journal of Gastroenterology</i> , 2010, 16, 5135.	1.4	4

#	ARTICLE	IF	CITATIONS
3384	Staging systems for predicting survival of patients with hepatocellular carcinoma after surgery. <i>World Journal of Gastroenterology</i> , 2010, 16, 5257.	1.4	17
3385	Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report. <i>World Journal of Gastroenterology</i> , 2010, 16, 5518.	1.4	24
3386	β-catenin accumulation in nuclei of hepatocellular carcinoma cells up-regulates glutathione-s-transferase M3 mRNA. <i>World Journal of Gastroenterology</i> , 2011, 17, 1772.	1.4	15
3387	P16 gene hypermethylation and hepatocellular carcinoma: A systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2011, 17, 3043.	1.4	53
3388	Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm. <i>World Journal of Gastroenterology</i> , 2011, 17, 3126-32.	1.4	5
3389	Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2011, 17, 4206.	1.4	35
3390	A potential oncogenic role of the commonly observed E2F5 overexpression in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2011, 17, 470.	1.4	44
3391	Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization?. <i>World Journal of Gastroenterology</i> , 2012, 18, 1933.	1.4	11
3392	Hepatocellular carcinoma and macrophage interaction induced tumor immunosuppression via Treg requires TLR4 signaling. <i>World Journal of Gastroenterology</i> , 2012, 18, 2938.	1.4	46
3393	Surveillance for gastrointestinal malignancies. <i>World Journal of Gastroenterology</i> , 2012, 18, 4507.	1.4	7
3394	Tumour seeding after percutaneous cryoablation for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2012, 18, 6587.	1.4	12
3395	Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: A retrospective analysis. <i>World Journal of Gastroenterology</i> , 2012, 18, 466.	1.4	8
3396	Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2013, 19, 1811.	1.4	101
3397	Sorafenib and entecavir: The dioscure of treatment for advanced hepatocellular carcinoma?. <i>World Journal of Gastroenterology</i> , 2013, 19, 2141.	1.4	4
3398	Value of circulating cell-free DNA in diagnosis of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2013, 19, 3143.	1.4	48
3399	Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. <i>World Journal of Gastroenterology</i> , 2013, 19, 3207.	1.4	16
3400	Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations. <i>World Journal of Gastroenterology</i> , 2013, 19, 3861.	1.4	18
3401	Survival outcome of patients with spontaneously ruptured hepatocellular carcinoma treated surgically or by transarterial embolization. <i>World Journal of Gastroenterology</i> , 2013, 19, 4537.	1.4	49

#	ARTICLE	IF	CITATIONS
3402	Molecular targeted therapy for hepatocellular carcinoma: Current and future. World Journal of Gastroenterology, 2013, 19, 6144.	1.4	75
3403	Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World Journal of Gastroenterology, 2013, 19, 7515.	1.4	102
3404	Management of small hepatocellular carcinoma in cirrhosis: Focus on portal hypertension. World Journal of Gastroenterology, 2013, 19, 1193.	1.4	34
3405	Hepatitis B virus infection and intrahepatic cholangiocarcinoma. World Journal of Gastroenterology, 2014, 20, 5721.	1.4	35
3406	Significance of viral status on occurrence of hepatitis B-related hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 5999.	1.4	11
3407	Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia. World Journal of Gastroenterology, 2014, 20, 6244.	1.4	24
3408	Laparoscopic vs open approach to resection of hepatocellular carcinoma in patients with known cirrhosis: Systematic review and meta-analysis. World Journal of Gastroenterology, 2014, 20, 8274.	1.4	94
3409	Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?. World Journal of Gastroenterology, 2014, 20, 9217-28.	1.4	59
3410	Clinical outcome of small hepatocellular carcinoma after different treatments: A meta-analysis. World Journal of Gastroenterology, 2014, 20, 10174.	1.4	47
3411	Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 745.	1.4	17
3412	Current management of hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 10223.	1.4	61
3413	Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World Journal of Gastroenterology, 2014, 20, 11384.	1.4	55
3414	Resection of hepatitis B virus-related hepatocellular carcinoma: Evolving strategies and emerging therapies to improve outcome. World Journal of Gastroenterology, 2014, 20, 12473.	1.4	21
3415	Recent advances in the surgical treatment of hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 14381.	1.4	81
3416	C-arm Lipiodol CT in transcatheter arterial chemoembolization for small hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 3035.	1.4	14
3417	Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition. World Journal of Gastroenterology, 2015, 21, 475.	1.4	35
3418	Prognostic factors of spontaneously ruptured hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 7488.	1.4	25
3419	Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 10584.	1.4	66



#	ARTICLE	IF	CITATIONS
3420	Sub-classification of intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas. <i>World Journal of Gastroenterology</i> , 2015, 21, 10604.	1.4	18
3421	Comparison of percutaneous radiofrequency ablation and CyberKnife <sup>®</sup> for initial solitary hepatocellular carcinoma: A pilot study. <i>World Journal of Gastroenterology</i> , 2015, 21, 13490.	1.4	39
3422	Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment. <i>World Journal of Gastroenterology</i> , 2016, 22, 2993.	1.4	56
3423	Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. <i>World Journal of Gastroenterology</i> , 2016, 22, 5384.	1.4	40
3424	Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study. <i>World Journal of Gastroenterology</i> , 2016, 22, 10219.	1.4	18
3425	Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization. <i>World Journal of Gastroenterology</i> , 2016, 22, 10406.	1.4	18
3427	Prognostic value of pretreatment <sup>&gt;18&lt;/sup&gt;F-FDG PET-CT in radiotherapy for patients with hepatocellular carcinoma. <i>Radiation Oncology Journal</i>, 2015, 33, 179.</sup>	0.7	13
3428	Efficacy and safety of drug <sup>®</sup> eluting beads for transarterial chemoembolization in patients with advanced hepatocellular carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 4625-4630.	0.8	5
3429	CLEC4M overexpression inhibits progression and is associated with a favorable prognosis in hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2020, 22, 2245-2252.	1.1	5
3430	Newer treatments for advanced hepatocellular carcinoma. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 149.	0.7	28
3431	Effect of <i>Catha edulis</i> on the Activities of Enzyme Markers of Carcinogenicity in Chemically-induced Hepatocellular Carcinoma in Rabbits. <i>International Journal of Cancer Research</i> , 2014, 10, 1-13.	0.2	2
3432	Regulation of Cancer Stem Cell Marker (CD133) by Transforming Growth Factor Beta in Hepatocellular Carcinoma. <i>International Journal of Cancer Research</i> , 2014, 10, 65-73.	0.2	7
3433	Activation of sonic hedgehog signaling pathway is an independent potential prognosis predictor in human hepatocellular carcinoma patients. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2012, 24, 323-31.	0.7	28
3434	Perspectives on using des- <sup>1</sup> -carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China. <i>Hepatobiliary Surgery and Nutrition</i> , 2013, 2, 227-31.	0.7	20
3435	Laparoscopic liver resection for hepatocellular carcinoma in cirrhotic patients: single center experience of 90 cases. <i>Hepatobiliary Surgery and Nutrition</i> , 2015, 4, 320-4.	0.7	9
3436	Laparoscopic right hepatectomy for hepatocellular carcinoma in cirrhotic patient. <i>Hepatobiliary Surgery and Nutrition</i> , 2015, 4, 436-8.	0.7	4
3437	Vitamin D and GI cancers: shedding some light on dark diseases. <i>Annals of Translational Medicine</i> , 2014, 2, 9.	0.7	20
3438	Quantitative Platelet Abnormalities in Patients With Hepatitis B Virus-Related Liver Disease. <i>Gastroenterology Research</i> , 2009, 2, 344-349.	0.4	8

#	ARTICLE	IF	CITATIONS
3439	Human U Three Protein 14a Expression is Increased in Hepatocellular Carcinoma and Associated with Poor Prognosis. Chinese Medical Journal, 2017, 130, 470-476.	0.9	8
3440	Digital contrast enhancement of 18Fluorine-fluorodeoxyglucose positron emission tomography images in hepatocellular carcinoma. Indian Journal of Nuclear Medicine, 2016, 31, 20.	0.1	1
3441	Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. Indian Journal of Medical Research, 2019, 149, 9.	0.4	74
3442	Outcome of conventional transarterial chemoembolization (cTACE) in the management of spontaneously ruptured hepatocellular carcinoma. Indian Journal of Radiology and Imaging, 2019, 29, 177-181.	0.3	5
3443	A comparison between radiofrequency ablation combined with transarterial chemoembolization and surgical resection in hepatic carcinoma: A meta-analysis. Journal of Cancer Research and Therapeutics, 2019, 15, 1617.	0.3	24
3444	Guanabenz Acetate Induces Endoplasmic Reticulum Stress-Related Cell Death in Hepatocellular Carcinoma Cells. Journal of Pathology and Translational Medicine, 2019, 53, 94-103.	0.4	9
3445	Systems Biology Approaches to Decoding the Genome of Liver Cancer. Cancer Research and Treatment, 2011, 43, 205-211.	1.3	4
3447	Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. Annals of Surgical Treatment and Research, 2020, 99, 238.	0.4	20
3448	Hepatocellular Carcinoma: The Final Moments of Life. Journal of Cancer Therapy, 2013, 04, 377-383.	0.1	3
3449	Cancer and Infectious Causes. Open Journal of Medical Microbiology, 2014, 04, 161-177.	0.1	2
3450	Concurrent and subsequent radiofrequency ablation combined with hepatectomy for hepatocellular carcinomas. World Journal of Gastrointestinal Surgery, 2010, 2, 137.	0.8	8
3451	Proteomics approaches for early detection and targeted therapy of hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2017, 9, 1.	0.8	2
3452	Identification of circulating CD90 <sup>+</sup> CD73 <sup>+</sup> cells in cirrhosis of liver. World Journal of Stem Cells, 2011, 3, 63.	1.3	3
3453	Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. World Journal of Hepatology, 2018, 10, 485-495.	0.8	31
3454	Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World Journal of Hepatology, 2010, 2, 114.	0.8	42
3455	Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. World Journal of Hepatology, 2014, 6, 716.	0.8	55
3456	Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World Journal of Hepatology, 2014, 6, 818.	0.8	62
3457	Surgical approach for hepatitis C virus-related hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 70.	0.8	5

#	ARTICLE	IF	CITATIONS
3458	Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients. <i>World Journal of Hepatology</i> , 2015, 7, 1312.	0.8	20
3459	Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. <i>World Journal of Hepatology</i> , 2015, 7, 1460.	0.8	16
3460	Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 1581.	0.8	28
3461	Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 1875.	0.8	26
3462	Strategies to increase the resectability of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 2147.	0.8	28
3463	Surgical management of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2014, 7, 245.	0.8	70
3464	Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. <i>World Journal of Hepatology</i> , 2015, 7, 2245.	0.8	8
3465	Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system?. <i>World Journal of Hepatology</i> , 2015, 7, 521.	0.8	8
3466	Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. <i>World Journal of Hepatology</i> , 2015, 7, 1157.	0.8	71
3467	Magnetic resonance imaging ancillary features used in Liver Imaging Reporting and Data System: An illustrative review. <i>World Journal of Radiology</i> , 2018, 10, 9-23.	0.5	4
3468	Resection vs thermal ablation of small hepatocellular carcinoma: What's the first choice?. <i>World Journal of Radiology</i> , 2013, 5, 1.	0.5	33
3469	Transarterial chemoembolization using 40 $\mu$ m drug eluting beads for hepatocellular carcinoma. <i>World Journal of Radiology</i> , 2017, 9, 245.	0.5	25
3470	Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2015, 5, 19-25.	0.1	4
3471	Treatment of Hepatocellular Carcinoma with Portal Vein Thrombosis by Sorafenib Combined with Hepatic Arterial Infusion Chemotherapy. <i>Gut and Liver</i> , 2010, 4, 423-427.	1.4	12
3472	Clinical and Virological Responses to Clevudine Therapy of Hepatocellular Carcinoma Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2011, 5, 82-87.	1.4	1
3473	The Optimal Selection of Radiotherapy Treatment for Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2012, 6, 139-148.	1.4	23
3474	DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarterial Chemoembolization: A Pilot Study. <i>Gut and Liver</i> , 2013, 7, 89-95.	1.4	20
3475	Management of Hepatocellular Carcinoma: Current Status and Future Directions. <i>Gut and Liver</i> , 2015, 9, 437.	1.4	49

#	ARTICLE	IF	CITATIONS
3476	Hepatocellular carcinoma's 100 most influential manuscripts: A bibliometric analysis. <i>International Journal of Hepatobiliary and Pancreatic Diseases</i> , 2019, 9, 1.	0.2	6
3477	The Objective Image Analysis for HCC and HH with a Axial Image of Liver CT Scan. <i>The Journal of the Korea Contents Association</i> , 2015, 15, 411-417.	0.0	1
3478	Molecular approach to treatment of hepatocellular carcinoma: new hope for therapeutic targets. <i>Journal of Experimental and Integrative Medicine</i> , 2011, 1, 83.	0.1	3
3479	MiR-371 promotes proliferation and metastasis in hepatocellular carcinoma by targeting PTEN. <i>BMB Reports</i> , 2019, 52, 312-317.	1.1	12
3480	Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. <i>World Journal of Virology</i> , 2012, 1, 174.	1.3	28
3481	A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2015, 14, 869-880.	0.6	21
3482	The expression and functions of microRNAs in pancreatic adenocarcinoma and hepatocellular carcinoma. <i>Chinese Journal of Cancer</i> , 2011, 30, 540-550.	4.9	18
3483	Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma. <i>Chinese Journal of Cancer</i> , 2013, 32, 141-148.	4.9	31
3484	Genomic Profiling of Liver Cancer. <i>Genomics and Informatics</i> , 2013, 11, 180.	0.4	8
3485	Local Ablation for Hepatocellular Carcinoma. <i>Experimental and Clinical Transplantation</i> , 2014, 12, 55-59.	0.2	3
3486	Association of MDR1 Gene Polymorphisms with Susceptibility to Hepatocellular Carcinoma in the Chinese Population. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 5451-5454.	0.5	19
3487	Prospective Study on the Survival of HCC Patients Treated with Transcatheter Arterial Lipiodol Chemoembolization. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 1039-1042.	0.5	10
3488	Recurrence after Anatomic Resection Versus Nonanatomic Resection for Hepatocellular Carcinoma: A Meta-analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 1771-1777.	0.5	29
3489	Genistein Reinforces the Inhibitory Effect of Cisplatin on Liver Cancer Recurrence and Metastasis after Curative Hepatectomy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 759-764.	0.5	21
3490	Experiences of Family of Patient with Newly Diagnosed Advanced Terminal Stage Hepatocellular Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 4655-4660.	0.5	7
3491	Inpatients' Knowledge about Primary Liver Cancer and Hepatitis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 4913-4918.	0.5	9
3492	Association Between the c.3751G>A Genetic Variant of MDR1 and Hepatocellular Carcinoma Risk in a Chinese Han Population. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 5361-5365.	0.5	6
3493	Diagnostic and Prognostic Roles of Serum Osteopontin and Osteopontin Promoter Polymorphisms in Hepatitis B-related Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 7211-7217.	0.5	15

#	ARTICLE	IF	CITATIONS
3494	Exogenous p53 Upregulated Modulator of Apoptosis (PUMA) Decreases Growth of Lung Cancer A549 Cells. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 741-746.	0.5	9
3495	Identification of four prognostic lncRNAs for survival prediction of patients with hepatocellular carcinoma. <i>PeerJ</i> , 2017, 5, e3575.	0.9	46
3496	Relationship between CDH17 and Tumor Progression. <i>World Journal of Cancer Research</i> , 2021, 11, 131-136.	0.1	1
3497	Circulating Tumor Cell-Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue-Based Messenger RNA Profiling Into a Noninvasive Setting. <i>Liver Transplantation</i> , 2022, 28, 200-214.	1.3	8
3498	A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion. <i>Liver Cancer</i> , 2021, 10, 539-544.	4.2	46
3499	Operative Microwave Ablation for Hepatocellular Carcinoma Within 3 cm and 3 Nodules: Experience in 559 Patients. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 615-622.	0.9	5
3500	Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. <i>The Cochrane Library</i> , 2021, 2021, CD013362.	1.5	12
3501	Problems inherent to antiviral therapy. , 2004, , 203-238.		0
3502	Staging system for hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2005, 46, 53-63.	0.0	1
3504	Management of Recurrent Viral Hepatitis B and C. , 2006, , 975-993.		0
3505	Lokoregionäre Therapie von primären Lebertumoren. , 2006, , 937-957.		0
3506	Molecular Pathogenesis of Hepatocellular Carcinoma. , 2006, , 165-175.		0
3507	Impact of European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Guidelines on the Use of Contrast Agents in Liver Ultrasound. , 2006, , 1-14.		0
3508	Hepatozelluläres Karzinom (HCC). , 2006, , 4045-4070.		0
3509	Carcinoma hepatoelular. , 2006, , 795-798.		0
3510	Liver Tumors. , 2006, , 502-514.		1
3511	Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization. <i>World Journal of Gastroenterology</i> , 2007, 13, 6593.	1.4	14
3512	Embolization of Liver Tumors. , 2007, , 1218-1245.		1

#	ARTICLE	IF	CITATIONS
3513	Ablation of Liver Tumors. , 2007, , 1269-1297.		1
3514	Tumors of the Liverâ€™Pathologic Aspects. , 2007, , 1085-1130.		1
3515	Interferon-alpha restrains growth and invasive potential of hepatocellular carcinoma induced by hepatitis B virus X protein. World Journal of Gastroenterology, 2008, 14, 5564.	1.4	3
3516	Liver Disease in Renal Transplant Recipients. , 2008, , 508-533.		0
3517	Regulatory T Cells in Hepatitis and Hepatocellular Carcinoma. , 2008, , 393-405.		0
3518	Living-Donor Liver Transplantation for Hepatocellular Carcinoma. , 2008, , 227-233.		0
3519	Percutaneous Ethanol Injection. , 2009, , 407-420.		2
3520	Hepatocellular Cancer in Cirrhotic Patients: Radiological Imaging. , 2009, , 261-273.		0
3521	NHG-Standaard Virushepatitis en andere leveraandoeningen. , 2009, , 1409-1433.		0
3523	Recombinant vascular basement-membrane-derived multifunctional peptide inhibits angiogenesis and growth of hepatocellular carcinoma. World Journal of Gastroenterology, 2009, 15, 1744.	1.4	2
3524	MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009021.	0.5	3
3525	Targeted therapy in hepatocellular carcinoma. , 2009, , 58-60.		0
3526	16 Levertumoren. , 2009, , 160-171.		0
3527	Staging. , 2009, , 94-103.		0
3528	Local Ablation Therapy. , 2009, , 104-113.		0
3529	Imaging of Hepatocellular Carcinoma. , 2009, , 82-93.		1
3530	Molecular Events on Metastasis of Hepatocellular Carcinoma. , 2010, , 349-371.		0
3531	Chemotherapie bei primÄren Lebertumoren. , 2010, , 368-374.		0

#	ARTICLE	IF	CITATIONS
3532	Epidemiologie, Ätiologie und Pathogenese. , 2010, , 14-37.		0
3533	Biology of Hepatocellular Carcinoma: Past, Present and Beyond. , 2010, , 3-17.		0
3535	Comparison of Surgical Outcomes and Long-term Survival between Limited and Major Hepatic Resection for Hepatocellular Carcinoma Less than 5 cm. [Chapchi] Journal Taehan Oekwa Hakhoe, 2010, 78, 29.	1.1	2
3536	Cancer Stem Cells and Liver Cancer. , 2010, , 279-299.		0
3537	Treatment outcome of hepatocellular carcinoma patients with high-risk vascular invasion: a retrospective analysis. Asian Biomedicine, 2010, 4, 491-496.	0.2	0
3538	Vascular Resection for Hepatocellular Carcinoma. , 2011, , 239-259.		0
3539	Complete Response of Hepatocellular Carcinoma with Sorafenib and 90y Radioembolization. Current Oncology, 2010, 17, 67-69.	0.9	15
3540	Preoperative Imaging of Liver Cancers: Hepatocellular Carcinoma. , 2011, , 51-59.		0
3543	NHG-Standaard Virushepatitis en andere leveraandoeningen. , 2011, , 179-203.		0
3544	Chronic Hypoxia Emerging as One of the Driving Forces behind Gene Expression and Prognosis of Hepatocellular Carcinoma. ISRN Pathology, 2011, 2011, 1-10.	0.4	0
3545	Clinical Indications for Carbon Ion Radiotherapy and Radiation Therapy with Other Heavier Ions. Biological and Medical Physics Series, 2012, , 179-192.	0.3	0
3549	Immunotherapy of Hepatocellular Carcinoma. , 2012, , 299-337.		0
3551	Bipolar Radiofrequency Ablation Using Dual Internally Cooled Wet Electrodes: Experimental Study in Ex Vivo Bovine Liver. Journal of the Korean Society of Radiology, 2012, 67, 425.	0.1	1
3552	Differential Diagnosis of Focal Hepatic Lesions. , 2012, , 79-126.		1
3553	Factors Associated with Psychological Characteristics in Patients with Hepatic Malignancy before Interventional Procedures. Asian Pacific Journal of Cancer Prevention, 2012, 13, 309-314.	0.5	2
3554	Surveillance for Hepatocellular Carcinoma. , 2012, , 17-43.		0
3555	Laparoscopic Radiofrequency Thermal Ablation of Hepatocellular Carcinoma in Liver Cirrhosis Patients. Gastroenterology Research, 2012, 5, 232-235.	0.4	2
3556	Liver transplantation for hepatocellular carcinoma. , 2012, , 1702-1711.e3.		0

#	ARTICLE	IF	CITATIONS
3557	Midkine Is a Potential Therapeutic Target of Hepatocellular Carcinoma. , 2012, , 273-282.		0
3558	Current Status of Hepatocellular Carcinoma Treatment in Japan. Clinical Drug Investigation, 2012, 32, 37-51.	1.1	5
3559	Current Status of Hepatocellular Carcinoma Treatment in Japan. Clinical Drug Investigation, 2012, 32, 15-23.	1.1	3
3560	Interventional Oncology. , 2013, , 205-362.		0
3561	Hepatobiliäre Tumoren und Lebermetastasen. , 2013, , 639-662.		0
3562	Early Hepatocellular Carcinoma: Diagnosing the Difficult Nodule. Journal of Cancer Therapy, 2013, 04, 651-661.	0.1	1
3563	Use of ultrasound as the initial screening exam for hepatocellular carcinoma in high risk populations. Open Journal of Gastroenterology, 2013, 03, 148-154.	0.1	1
3564	Elite portuguese soccer playersâ€™ use of psychological techniques: where, when and why. Journal of Human Sport and Exercise, 2013, 8, 847-860.	0.2	2
3565	Diagnostic accuracy of color Doppler in diagnosis of Hepatocellular carcinoma taking histopathology as gold standard. Journal of Biomedical Science and Engineering, 2013, 06, 609-614.	0.2	0
3570	Chemoembolizations and Hepatic Intra-arterial Chemotherapies. , 2014, , 115-133.		0
3571	Molecular-Genetic Testing in Hepatocellular Carcinoma and Its Premalignant Conditions. , 2014, , 211-258.		0
3572	Early Chronic Inflammation and Subsequent Somatic Mutations Shift Phospho-Smad3 Signaling from Tumor- Suppression to Fibro-Carcinogenesis in Human Chronic Liver Diseases. , 0, , .		0
3573	Innate Immunity and Disorders of the Liver. , 2014, , 65-77.		0
3574	CT Imaging Characteristics of Hepatocellular Carcinoma. , 2014, , 317-346.		0
3575	MR Imaging of Hepatocellular Carcinoma. , 2014, , 169-207.		0
3578	Advances in Traditional Chinese Medical Treatment Research in Liver Cancer Postoperation. Traditional Chinese Medicine, 2014, 03, 38-46.	0.1	1
3579	Liver Disease among Renal Transplant Recipients. , 2014, , 511-536.		0
3583	Effectiveness and Safety of Splenic Micro-wave Ablation Combined with Hepatic Ar-terial Chemoembolization for Hepatocellular Carcinoma Associated with Hypersplenism: A Prospective Study in 5 Patients. Open Journal of Radiology, 2015, 05, 72-79.	0.1	0



#	ARTICLE	IF	CITATIONS
3584	Cirrhosis and Hepatocellular Carcinoma. , 2015, , 77-96.		0
3585	Development of a High-Throughput Molecular Imaging-Based Orthotopic Hepatocellular Carcinoma Model. Cureus, 2015, 7, e281.	0.2	1
3586	Significance of hepatocyte growth factor concentrations in serum of patients with liver cirrhosis and patients with hepatocellular carcinoma. The Egyptian Journal of Internal Medicine, 2015, 27, 92-101.	0.3	1
3587	Combined Therapies of RFA. , 2016, , 61-73.		0
3588	Biomarkers of the Antioxidant Response: A Focus on Liver Carcinogenesis. Exposure and Health, 2016, , 1-24.	2.8	0
3589	Hepatocellular Carcinoma (Ordinary Hepatocellular Carcinoma). , 2016, , 1-38.		0
3590	Hepatocellular Carcinoma: Prognostic Factors. , 2016, , 1-16.		0
3592	Resection of Hepatocellular Carcinoma. , 2016, , 467-475.		0
3593	Endocrine Disease and Liver. , 2016, , 251-270.		0
3594	Contrast-Induced Nephropathy in Patients with Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization. Open Journal of Radiology, 2016, 06, 243-249.	0.1	0
3595	Current HCC Staging Systems: Their Uses and Limitations. , 2016, , 425-442.		4
3596	The Role of the Diffusion Sequence in Magnetic Resonance Imaging for the Differential Diagnosis between Hepatocellular Carcinoma and Benign Liver Lesions. Medicine and Pharmacy Reports, 2016, 89, 241-249.	0.2	5
3597	Added Value of Contrast-Enhanced Ultrasonography as a Planning Modality for Radiofrequency Ablation of Hepatocellular Carcinoma: Comparison with Gray-Scale Ultrasonography. Iranian Journal of Radiology, 2016, Inpress, .	0.1	0
3598	Assessment of health-related quality of life after hepatocellular carcinoma management (radiofrequency ablation or transarterial chemoembolization). Egyptian Liver Journal, 2017, 7, 51-57.	0.3	1
3599	Synthesis of a Neural Network Classifier for Hepatocellular Carcinoma Grading Based on Triphasic CT Images. Communications in Computer and Information Science, 2017, , 356-368.	0.4	5
3601	Biomarkers of the Antioxidant Response: A Focus on Liver Carcinogenesis. Biomarkers in Disease, 2017, , 785-808.	0.0	0
3602	Liver transplantation for hepatocellular carcinoma. , 2017, , 1781-1790.e4.		0
3603	Locoregional Therapy. , 2017, , 2535-2537.		0

#	ARTICLE	IF	CITATIONS
3604	Stereotactic body radiation therapy for hepatocellular carcinoma: Experience from a tertiary cancer care center in India. <i>Indian Journal of Cancer</i> , 2017, 54, 316.	0.2	1
3605	Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. <i>Oncotarget</i> , 2017, 8, 47555-47564.	0.8	1
3606	SERUM SOLUBLE CD25 IN HEPATOCELLULAR CARCINOMA, SHALL WE BE ABLE TO CHANGE THE NATURAL HISTORY?. <i>International Journal of Medicine and Medical Research</i> , 2017, , .	0.0	1
3607	The Roles of miR-25 and Its Targeted Genes in Human Cancer. , 2018, , 129-139.		0
3608	Surgical Approach in Hepatocellular Carcinoma: Resection Versus Transplantation. , 2018, , 45-55.		0
3609	Midterm Outcomes and Prognostic Factors of Patients Treated Using Microballoon-Occluded Transarterial Chemoembolization with Miriplatin: A Retrospective Study of 37 Cases. <i>Interventional Radiology</i> , 2018, 3, 97-109.	0.2	0
3610	Hepatobiliary Malignancies. , 2018, , 265-284.		0
3611	Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 21560-21568.	0.8	6
3612	Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma in Hong Kong. <i>Journal of Clinical and Translational Hepatology</i> , 2018, x, 1-6.	0.7	4
3613	Radiofrequency and Microwave Ablation in the Treatment of Hepatocellular Carcinoma. <i>Iranian Journal of Radiology</i> , 2018, In Press, .	0.1	1
3615	Anti-angiogenics in Hepatocellular Cancer Therapy. , 2019, , 435-446.		0
3616	Prevention of Hepatocarcinogenesis in Liver Cirrhosis. , 2019, , 159-166.		0
3617	CARM1 Regulates the Growth of Hepatocellular Carcinoma Cells via Regulation of Bax/Bcl-2 Level and Caspase-3 Activity. <i>World Journal of Cancer Research</i> , 2019, 09, 90-97.	0.1	0
3619	Ablation for Liver Tumors. <i>Juntendo Medical Journal</i> , 2019, 65, 433-443.	0.1	0
3620	A Case of Spontaneous Rupture of Hepatocellular Carcinoma Supplied by the Right Renal Capsular Artery Treated by Transcatheter Arterial Embolization. <i>Journal of Liver Cancer</i> , 2019, 19, 59-63.	0.3	0
3621	Polyethylenimine (PEI)-Mediated E1A Increases the Sensitivity of Hepatocellular Carcinoma Cells to Chemotherapy. <i>Medical Science Monitor Basic Research</i> , 2019, 25, 113-120.	2.6	0
3622	MicroRNA-373 exerts anti-tumor functions in human liver cancer by targeting Rab22a. <i>Molecular Medicine Reports</i> , 2019, 20, 3874-3882.	1.1	4
3623	The Management of Hepatocellular Carcinoma. , 2020, , 237-271.		1

#	ARTICLE	IF	CITATIONS
3624	Actual Problems and Perspectives of the Application of Nuclear Medicine Techniques in the Diagnostic and Treatment of Hepatocellular Carcinoma: Analytical Review. <i>Medical Radiology and Radiation Safety</i> , 2019, 64, 58-68.	0.0	0
3626	FIB-4 Is a Potential Tool for Hepatocellular Carcinoma Risk Stratification in Ethnically Diverse Chronic Hepatitis B Patients When Using Specific Cutoff Values. <i>Hepatitis Monthly</i> , 2019, In Press, .	0.1	0
3627	A Rare Colonic Metastasis Case from Hepatocellular Carcinoma. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2019, 7, 4368-4371.	0.1	5
3629	Cordyceps militaris fraction inhibits angiogenesis of hepatocellular carcinoma in vitro and in vivo. <i>Pharmacognosy Magazine</i> , 2020, 16, 169.	0.3	2
3630	Antitumor mechanism of MAP30 in bladder cancer T24 cells, and its potential toxic effects in mice. <i>Cellular and Molecular Biology</i> , 2020, 66, 42-48.	0.3	5
3632	Multimodality Imaging of Hepatocellular Carcinoma: From Diagnosis to Treatment Response Assessment in Everyday Clinical Practice. <i>Canadian Association of Radiologists Journal</i> , 2021, 72, 714-727.	1.1	2
3634	Screening for hepatocellular carcinoma in chronic liver disease: a systematic review and meta-analysis of randomized controlled trials comparing screening methodologies. <i>Journal of Global Health Reports</i> , 0, 4, .	1.0	0
3635	Effectiveness of combined therapy radiofrequency ablation/transarterial chemoembolization versus transarterial chemoembolization/radiofrequency ablation on management of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1573-1577.	0.8	3
3636	Preoperative predictors of early recurrence of AJCC T4 hepatocellular carcinoma. <i>Surgical Oncology</i> , 2021, 39, 101671.	0.8	1
3637	EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 21396.	1.6	17
3638	Hepatocellular Carcinoma: First Manifestation as Solitary Humeral Bone Metastasis. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-6.	0.2	4
3639	Locoregional Therapy: Cancer Interventions with and Without Radionuclides. , 2021, , 89-109.		0
3640	Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein. <i>BMC Medical Genomics</i> , 2020, 13, 194.	0.7	5
3641	Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus. <i>Annals of Hepatology</i> , 2022, 27, 100552.	0.6	8
3642	Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients. , 2020, 38, 89-91.		1
3643	Biphenotypic Tumors. , 2020, , 63-78.		0
3646	Multimodal approach to portal hypertension and gastric varices before hepatic resection for hepatocellular carcinoma: a case report. <i>Surgical Case Reports</i> , 2020, 6, 190.	0.2	1
3648	Imaging modalities in hepatic tumours. , 0, , 137-150.		0

#	ARTICLE	IF	CITATIONS
3649	Gene expression profiling of hepatocellular carcinoma: past, present and future. , 0, , 233-237.		0
3650	New therapeutic approaches: anti-angiogenesis, immunotherapy. , 0, , 247-253.		0
3651	Guidance and Assessment of Interventional Therapy in Liver. , 2005, , 187-203.		0
3652	Effects of Combined IFN-Alpha/Ribavirin Treatment in HCV Disease-Related Progression. , 2008, , 215-236.		0
3653	Algorithms of diagnosis and options of hepatocellular carcinoma therapy. , 2008, , 252-265.		0
3654	Hepatic Chemoembolization. , 2006, , 397-407.		1
3655	HepatozellulÄres Karzinom. , 0, , 734-739.		0
3656	Percutaneous Alcohol Instillation. , 2008, , 123-127.		1
3660	Transarterial Chemoembolization (TACE) in Primary and Secondary Liver Tumors. , 2008, , 47-62.		0
3661	CT-Guided HDR Brachytherapy: Challenging the Limits of Thermal Ablation. , 2008, , 63-71.		0
3662	Medical Oncology. , 2008, , 528-780.		0
3663	DPM1 expression as a potential prognostic tumor marker in hepatocellular carcinoma. PeerJ, 2020, 8, e10307.	0.9	7
3665	Viruses and human cancer. Yale Journal of Biology and Medicine, 2006, 79, 115-22.	0.2	75
3666	Aldo-keto reductase 1 family B7 is the gene induced in response to oxidative stress in the livers of Long-Evans Cinnamon rats. International Journal of Oncology, 2006, 29, 829-38.	1.4	6
3667	Decoding human liver cancer signatures. Gastrointestinal Cancer Research: GCR, 2008, 2, S31-4.	0.8	0
3668	Accomplishments in 2008 in the management of hepatobiliary cancers. Gastrointestinal Cancer Research: GCR, 2009, 3, S28-36.	0.8	3
3669	Emerging agents for the medical therapy of hepatocellular carcinoma. Gastroenterology and Hepatology, 2007, 3, 600-2.	0.2	0
3670	PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Research, 2010, 30, 4951-8.	0.5	124

#	ARTICLE	IF	CITATIONS
3671	Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives. <i>World Journal of Gastroenterology</i> , 2011, 17, 3075-81.	1.4	18
3672	Genotypes, mutations, and viral load of hepatitis B virus and the risk of hepatocellular carcinoma: HBV properties and hepatocarcinogenesis. <i>Hepatitis Monthly</i> , 2011, 11, 86-91.	0.1	30
3673	HCC, diet and metabolic factors: Diet and HCC. <i>Hepatitis Monthly</i> , 2011, 11, 159-62.	0.1	35
3674	Spontaneous regression of hepatocellular cancer: case report and review of literature. <i>Gastrointestinal Cancer Research: GCR</i> , 2011, 4, 141-3.	0.8	7
3675	The transcription factor LSF: a novel oncogene for hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2012, 2, 269-85.	1.4	23
3676	Mast cells, disease and gastrointestinal cancer: A comprehensive review of recent findings. <i>Translational Gastrointestinal Cancer</i> , 2012, 1, 138-150.	3.0	22
3677	Proton therapy for hepatocellular carcinoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2012, 24, 361-7.	0.7	4
3678	Decreased apoptosis in advanced-stage/high-grade hepatocellular carcinoma complicating chronic hepatitis C is mediated through the downregulation of p21 ras. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2013, 25, 281-8.	0.7	5
3679	Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. <i>Current Cancer Drug Targets</i> , 2012, 12, 1129-59.	0.8	55
3680	Antiproliferative Activity of the Chinese Medicinal Compound, Delisheng, Compared With Rg3 and Gemcitabine in HepG2 Cells. <i>Indian Journal of Pharmaceutical Sciences</i> , 2013, 75, 578-84.	1.0	5
3681	Valproic acid overcomes transforming growth factor- $\beta$ -mediated sorafenib resistance in hepatocellular carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 1299-313.	0.5	13
3682	Hepatitis B virus X stimulates redox signaling through activation of ataxia telangiectasia mutated kinase. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 2032-43.	0.5	8
3683	Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. <i>World Journal of Gastroenterology</i> , 2006, 12, 5160-7.	1.4	26
3685	Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. <i>American Journal of Translational Research (discontinued)</i> , 2014, 6, 340-52.	0.0	48
3686	A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, E121-4.	0.6	2
3687	Longitudinal analysis of meta-analysis literatures in the database of ISI Web of Science. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 3559-65.	1.3	3
3689	Disturbance of redox status enhances radiosensitivity of hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2015, 5, 1368-81.	1.4	8
3690	Down-regulation of Rab17 promotes tumorigenic properties of hepatocellular carcinoma cells via Erk pathway. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 4963-71.	0.5	9

#	ARTICLE	IF	CITATIONS
3691	Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 10388-400.	1.3	15
3692	Highly expressed UNC119 promotes hepatocellular carcinoma cell proliferation through Wnt/ $\beta^2$ -catenin signaling and predicts a poor prognosis. <i>American Journal of Cancer Research</i> , 2015, 5, 3123-34.	1.4	10
3693	A novel treatment strategy in hepatocellular carcinoma by down-regulation of histone deacetylase 1 expression using a shRNA lentiviral system. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 17721-9.	1.3	6
3694	The safety and efficacy of laparoscopic and open hepatectomy in hepatocellular carcinoma patients with liver cirrhosis: a systematic review. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 20679-89.	1.3	21
3695	Human lung cancer-derived microparticles enhanced angiogenesis and growth of hepatoma cells in rodent lung parenchyma. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 1302-18.	0.0	0
3696	Follicular helper T cell exhaustion induced by PD-L1 expression in hepatocellular carcinoma results in impaired cytokine expression and B cell help, and is associated with advanced tumor stages. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 2926-36.	0.0	21
3697	Sorting and biological characteristics analysis for side population cells in human primary hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2016, 6, 1890-1905.	1.4	13
3698	Gpr110 deficiency decelerates carcinogen-induced hepatocarcinogenesis via activation of the IL-6/STAT3 pathway. <i>American Journal of Cancer Research</i> , 2017, 7, 433-447.	1.4	6
3699	Expression Levels of the Uridine-Cytidine Kinase Like-1 Protein As a Novel Prognostic Factor for Hepatitis C Virus-Associated Hepatocellular Carcinomas. <i>Acta Naturae</i> , 2017, 9, 108-114.	1.7	1
3700	Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/ $\beta^2$ -catenin pathways. <i>Anticancer Research</i> , 2014, 34, 1709-13.	0.5	56
3701	Current and Future Systemic Therapies for Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2019, 15, 266-272.	0.2	9
3702	IL-9 promotes proliferation and metastasis of hepatocellular cancer cells by activating JAK2/STAT3 pathway. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 7940-7946.	0.5	2
3703	Construction of a prognostic model based on nine immune-related genes and identification of small molecule drugs for hepatocellular carcinoma (HCC). <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 5108-5130.	0.0	5
3704	Peroxisome proliferator-activated receptor gamma coactivator 1 $\alpha$ protects a fibrotic liver from partial hepatectomy-induced advanced liver injury through regulating cell cycle arrest. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 254-267.	1.2	3
3705	Quantification of Tc-99m macroaggregated albumin liver perfusion as a predictor of tumor response to intra-arterial therapy with yttrium 90 spheres. <i>American Journal of Interventional Radiology</i> , 0, 5, 20.	0.0	1
3706	Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial. <i>Hepatology International</i> , 2021, 15, 1402-1412.	1.9	33
3707	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	1.8	1,495
3708	Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3831-3841.	1.1	3

#	ARTICLE	IF	CITATIONS
3709	The characteristics of patients with macrovascular invasion in hepatocellular carcinoma: when East meets West. <i>Langenbeck's Archives of Surgery</i> , 2021, , 1.	0.8	1
3710	Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Caseâ€Control Study. <i>Hepatology Communications</i> , 2022, 6, 679-691.	2.0	28
3711	New insights into dietary management of polar bears ( <i>Ursus maritimus</i> ) and brown bears ( <i>U. Tj ETQq0 0.0,rgBT /Oyerglock 10</i> )	0.5	8
3712	Leukocytes infiltration correlates intratumoral microvessel density and influence overall and late-phase disease-free survival in hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e28135.	0.4	2
3713	Clinical Features and Risk Factors of Extrahepatic Metastases from Primary Liver Cancer. <i>Advances in Clinical Medicine</i> , 2021, 11, 6024-6030.	0.0	0
3714	The Face of Hepatocellular Carcinoma ( HCC ) is Changing: Analysis of the temporal trends in aetiology and clinical patterns of HCC in South Australia. <i>Internal Medicine Journal</i> , 0, , .	0.5	2
3715	The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022, 20, 4.	1.5	1
3716	Sorafenib resistance and autophagy in hepatocellular carcinoma: A concealed threat. <i>Journal of Cancer Research and Practice</i> , 2019, 6, 107.	0.2	5
3717	A nomogram for predicting the risk of postoperative recurrence of hepatitis B virus-related hepatocellular carcinoma in patients with high preoperative serum glutamyl transpeptidase. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 298-310.	0.6	4
3718	Medical Treatment for Hepatocellular Carcinoma in Japan. <i>Journal of Nippon Medical School</i> , 2022, , .	0.3	1
3719	Oncological Outcomes of Operative Microwave Ablation for Intermediate Stage Hepatocellular Carcinoma: Experience in 246 Consecutive Patients. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1178-1186.	0.9	1
3720	Endovascular treatment of common hepatocellular carcinoma: the experience of one center. <i>Ukrainska ĀntervencĀjna NejroradĀologĀĀ Ta HĀ-rurgĀĀĀ</i> , 2022, 37, 57-61.	0.1	0
3721	N-Acetyltransferase 2, glutathione S-transferase gene polymorphisms and susceptibility to hepatocellular carcinoma in an Algerian population. <i>Xenobiotica</i> , 2022, 52, 99-104.	0.5	1
3722	Acute-Phase Serum Amyloid A May Predict Microvascular Invasion andĀEarly Tumor Recurrence in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Undergoing Liver Resection. <i>Journal of Investigative Surgery</i> , 2022, , 1-9.	0.6	1
3724	Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 810251.	1.6	2
3725	Balloon-Occluded Radiofrequency Ablation as Bridge to TACE in the Treatment of Advanced HCC with Arteriportal Shunt. <i>Current Radiopharmaceuticals</i> , 2022, 15, .	0.3	0
3726	Barcelona Clinic Liver Cancer 2022 update: Linking prognosis prediction and evidenceâ€based treatment recommendation with multidisciplinary clinical decisionâ€making. <i>Liver International</i> , 2022, 42, 488-491.	1.9	8
3727	Concurrent transarterial radioembolization and combination atezolizumab/ bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report. <i>Journal of Liver Cancer</i> , 2022, 22, 69-74.	0.3	4

#	ARTICLE	IF	CITATIONS
3728	Advances in artificial intelligence techniques drive the application of radiomics in the clinical research of hepatocellular carcinoma. , 2022, 1, 49-54.		1
3729	Elevated expression of RAB3B plays important roles in chemoresistance and metastatic potential of hepatoma cells. BMC Cancer, 2022, 22, 260.	1.1	10
3730	siRNA-mediated silencing of Nanog reduces stemness properties and increases the sensitivity of HepG2 cells to cisplatin. Gene, 2022, 821, 146333.	1.0	6
3731	A novel machine learning derived RNA-binding protein gene-based score system predicts prognosis of hepatocellular carcinoma patients. PeerJ, 2021, 9, e12572.	0.9	6
3732	Demystifying Lysosomal $\alpha$ -Fucosidase in Liver Cancer-Bearing Mice by Specific Two-Photon Fluorescence Imaging. ACS Sensors, 2022, 7, 71-81.	4.0	11
3733	Mac-2 Binding Protein Glycosylation Isomer as a Prognostic Marker for Hepatocellular Carcinoma With Sustained Virological Response. Anticancer Research, 2022, 42, 245-251.	0.5	1
3734	hsa_circ_0003410 promotes hepatocellular carcinoma progression by increasing the ratio of M2/M1 macrophages through the miR-139a-3p/CCL5 axis. Cancer Science, 2022, 113, 634-647.	1.7	26
3735	Approaches for Detection of Hepatitis B Virus Pre-S Gene Deletions and Pre-S Deleted Proteins and Their Application in Prediction of Higher Risk of Hepatocellular Carcinoma Development and Recurrence. Viruses, 2022, 14, 428.	1.5	4
3736	Single-Cell Sequencing Identifies the Heterogeneity of CD8+ T Cells and Novel Biomarker Genes in Hepatocellular Carcinoma. Journal of Healthcare Engineering, 2022, 2022, 1-16.	1.1	7
3737	Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation. Cancers, 2022, 14, 2056.	1.7	24
3738	Polysaccharide-Rich Fractions from Ganoderma resinaceum (Ganodermataceae) as Chemopreventive Agents in N-Diethylnitrosamine-Induced Hepatocellular Carcinoma in Wistar Rats. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-15.	0.5	4
3739	Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors. EMBO Reports, 2022, , e54275.	2.0	5
3740	Safety and Long-Term Survival Outcome in Patients With Unresectable Barcelona Clinic Liver Cancer (BCLC) Stages C and D Advanced Hepatocellular Carcinoma Treated With 40 $\mu$ m Drug-Eluting Bead Transcatheter Arterial Chemoembolization. Cureus, 2022, 14, e24047.	0.2	1
3741	Comparing Radiomics features of tumour and healthy liver tissue in a limited CT dataset: A machine learning study. Radiography, 2022, 28, 718-724.	1.1	5
3742	Radiofrequency Ablation (RFA). , 2008, , 129-138.		0
3743	Hepatocellular Carcinoma (HCC). , 2008, , 235-242.		0
3745	Transarterial Chemoembolization (TACE) in Primary and Secondary Liver Tumors. , 2008, , 47-62.		0
3746	CT-Guided HDR Brachytherapy: Challenging the Limits of Thermal Ablation. , 2008, , 63-71.		0



#	ARTICLE	IF	CITATIONS
3749	Liver Transplantation: Indications, Contraindications and Results. , 0 , 1984-1995.		1
3750	Decoding the Liver Cancer Genome. , 0 , 991-997.		0
3751	Hepatoma. , 0 , 119-138.		0
3752	Natural History and Experimental Models. , 0 , 439-467.		1
3753	Management of Hepatocellular Cancer. , 0 , 740-754.		0
3754	Cancer of the Liver, Biliary Tract and Pancreas. , 0 , 253-269.		0
3764	The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	1
3765	Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. <i>The Cochrane Library</i> , 2022, 2022, CD014798.	1.5	10
3766	New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1110-1119.	1.0	19
3767	Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review. <i>Cancers</i> , 2022, 14, 2357.	1.7	18
3768	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. <i>Nature Cancer</i> , 2022, 3, 386-401.	5.7	126
3769	NO-dependent vasodilation and deep tumor penetration for cascade-amplified antitumor performance. <i>Journal of Controlled Release</i> , 2022, 347, 389-399.	4.8	14
3770	Effects of Berberine on Liver Cancer. <i>Natural Product Communications</i> , 2022, 17, 1934578X2211020.	0.2	1
3771	The Outcome of Conversion Liver Resection Surgery by Lenvatinib Treatment: A Single Center Experience. <i>Anticancer Research</i> , 2022, 42, 3049-3054.	0.5	4
3772	Survival characteristics of fibrolamellar hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results database study. <i>World Journal of Clinical Oncology</i> , 2022, 13, 352-365.	0.9	5
3773	Selection and Role of Polymers for Designing of a Drug Carrier. , 0 , , .		5
3774	Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?. <i>World Journal of Hepatology</i> , 2022, 14, 1074-1086.	0.8	1
3775	Cellular Prion Protein Is Closely Associated with Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma. <i>Diagnostics</i> , 2022, 12, 1635.	1.3	2

#	ARTICLE	IF	CITATIONS
3776	RBM47 inhibits hepatocellular carcinoma progression by targeting UPF1 as a DNA/RNA regulator. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	8
3777	Transarterial Chemoembolization Combined With Radiofrequency Ablation Versus Hepatectomy for Hepatocellular Carcinoma: A Meta-Analysis. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	1
3778	Debelactone Prevents Hepatic Cancer via Diminishing the Inflammatory Response and Oxidative Stress on Male Wistar Rats. <i>Molecules</i> , 2022, 27, 4499.	1.7	1
3779	Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 1049-1060.	3.7	3
3780	CTNNB1 polymorphism (rs121913407) in circulating tumor DNA (ctDNA) in Egyptian hepatocellular carcinoma patients. <i>Egyptian Liver Journal</i> , 2022, 12, .	0.3	0
3781	Computer-aided hepatocellular carcinoma detection on the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging using a convolutional neural network: Feasibility evaluation with multi-sequence data. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 225, 107032.	2.6	5
3782	Risk factors and predictive nomograms for early death of patients with advanced hepatocellular carcinoma: a large retrospective study based on the SEER database. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	7
3783	Probing Iron-Mediated Synergistic Change of Cl <sup>+</sup> and HClO in Liver Cancer Cells with a Dual-Color Fluorescence Reporter. <i>Analytical Chemistry</i> , 2022, 94, 10659-10668.	3.2	10
3784	Alternative mRNA Splicing of Liver Intestine-Cadherin in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2005, 11, 483-489.	3.2	70
3785	Transarterial Infusion Chemotherapy With and Without Embolisation in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis. <i>Annals of the Academy of Medicine, Singapore</i> , 2017, 46, 174-184.	0.2	2
3786	Identification of Brain-Derived Neurotrophic Factor as a Novel Functional Protein in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2005, 65, 219-225.	0.4	76
3787	Comprehensive analysis of a TPX2-related TRHDE-AS1/PKIA ceRNA network involving prognostic signatures in Hepatitis B virus-infected hepatocellular carcinoma. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	3
3788	DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma. <i>Cancer Letters</i> , 2022, 548, 215899.	3.2	18
3789	A miRNA-mediated attenuation of hepatocarcinogenesis in both hepatocytes and Kupffer cells. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 30, 1-12.	2.3	10
3790	Zytostatikabeschichtete Beads. <i>Springer Reference Medizin</i> , 2022, , 1-8.	0.0	0
3791	Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization and its Impact on Overall Survival. <i>In Vivo</i> , 2022, 36, 2332-2341.	0.6	1
3792	Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	6
3793	Circulating tumour cell counts and ultrasomics signature-based nomogram for preoperative prediction of early recurrence of hepatocellular carcinoma after radical treatment. <i>British Journal of Radiology</i> , 2022, 95, .	1.0	0

#	ARTICLE	IF	CITATIONS
3794	Comparison of Anatomic and Non-Anatomic Liver Resection for Hepatocellular Carcinoma: A Retrospective Cohort Study. <i>Medicina (Lithuania)</i> , 2022, 58, 1305.	0.8	2
3796	Impact and the delivery of loco-regional treatment for hepatocellular carcinoma during COVID-19 pandemic. <i>Journal of Interventional Medicine</i> , 2022, , .	0.2	0
3797	Hepatobiliary and Pancreatic Interventions. , 2022, , 125-133.		0
3798	Association between the risk of hepatitis virus-related hepatocellular carcinoma and EGF polymorphism: A PRISMA-compliant updated meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e31280.	0.4	1
3799	PRR34-AS1 promotes exosome secretion of VEGF and TGF- $\beta$ 2 via recruiting DDX3X to stabilize Rab27a mRNA in hepatocellular carcinoma. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
3800	Does hypointense HCC in the Hepatobiliary Phase at Gadobutrol-Enhanced MRI Predict Recurrence After Surgery? A Systematic Review and Meta-analysis. <i>Academic Radiology</i> , 2023, 30, 1298-1305.	1.3	4
3802	Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2022, 42, 5479-5486.	0.5	2
3803	Impact of WTAP in small HCC and paired adjacent non-neoplastic liver tissue on recurrence: A cohort study with external extension analysis. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2
3804	Elevated intramuscular adipose tissue content with a high Ishak fibrosis stage (>3) had a negative effect on liver regeneration in cirrhotic patients undergoing portal vein embolization. <i>Kaohsiung Journal of Medical Sciences</i> , 0, , .	0.8	0
3805	Intra-operative indocyanine green fluorescence imaging in hepatobiliary surgery: a narrative review of the literature as a useful guide for the surgeon. <i>Updates in Surgery</i> , 2023, 75, 23-29.	0.9	6
3806	Towards refining the utility of dual (18F-FDG / 18F-Choline) PET/CT for the management of hepatocellular carcinoma: a tertiary center study. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	0.4	0
3807	Transarterial chemoembolization combined with radiofrequency ablation in the treatment of large hepatocellular carcinoma with stage C. <i>World Journal of Clinical Cases</i> , 0, 10, 12156-12163.	0.3	0
3810	Appraisal of the Antioxidant Activity, Polyphenolic Content, and Characterization of Selected Himalayan Herbs: Anti-Proliferative Potential in HepG2 Cells. <i>Molecules</i> , 2022, 27, 8629.	1.7	4
3811	Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact. <i>Cancers</i> , 2022, 14, 6245.	1.7	0
3812	Thymoquinone Suppresses Angiogenesis in DEN-Induced Hepatocellular Carcinoma by Targeting miR-1-3p. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15904.	1.8	5
3813	Liver Cancer: Interdisciplinary Approach. , 2022, , 41-83.		0
3814	METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression. <i>Cancer Communications</i> , 2023, 43, 338-364.	3.7	18
3815	Percutaneous ethanol injection is an acceptable bridging therapy to hepatocellular carcinoma prior to liver transplantation. <i>Langenbeck's Archives of Surgery</i> , 2023, 408, .	0.8	3

#	ARTICLE	IF	CITATIONS
3816	Surgical Strategies for Recurrent Hepatocellular Carcinoma after Resection: A Review of Current Evidence. <i>Cancers</i> , 2023, 15, 508.	1.7	3
3817	Nanomicelles for GLUT1-targeting hepatocellular carcinoma therapy based on NADPH depletion. <i>Drug Delivery</i> , 2023, 30, .	2.5	3
3818	Geriatric nutritional risk index as a prognostic factor in patients with hepatocellular carcinoma following transarterial chemoembolization: A retrospective study. <i>Medicine (United States)</i> , 2022, 101, e32322.	0.4	7
3819	Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France. <i>PLoS ONE</i> , 2023, 18, e0280442.	1.1	3
3820	Image-guided Radiofrequency Ablation of Liver Malignancies: Experience at Singapore General Hospital. <i>Annals of the Academy of Medicine, Singapore</i> , 2006, 35, 851-857.	0.2	5
3821	Exploring Palmitoylated Arabinogalactan in Solid Lipid Nanoparticles: Formulation Design and in vitro Assessment for Hepatospecific Targeting. <i>Drug Delivery Letters</i> , 2023, 13, 92-102.	0.2	0
3822	Development and Validation of an $\hat{I}\pm$ -Fetoprotein Tumor Burden Score Model to Predict Postrecurrence Survival among Patients with Hepatocellular Carcinoma. <i>Journal of the American College of Surgeons</i> , 2023, 236, 982-992.	0.2	8
3823	Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study. <i>Liver Cancer</i> , 2023, 12, 321-338.	4.2	9
3824	Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview. <i>Cancers</i> , 2023, 15, 1310.	1.7	4
3825	Artificial intelligence in liver cancers: Decoding the impact of machine learning models in clinical diagnosis of primary liver cancers and liver cancer metastases. <i>Pharmacological Research</i> , 2023, 189, 106706.	3.1	13
3826	Role of textural analysis parameters derived from FDG PET/CT in differentiating hepatocellular carcinoma and hepatic metastases. <i>Nuclear Medicine Communications</i> , 2023, 44, 381-389.	0.5	2
3827	Effect of HBsAg expression in liver tissue on prognosis of hepatocellular carcinoma after minimally invasive interventional therapy. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
3828	EVALUATION OF DIAGNOSTIC VALIDITY OF PIVKA-II FOR DIAGNOSIS OF HEPATOCELLULAR CARCINOMA IN PATIENTS OF CIRRHOSIS WITH LIVER NODULES PRESENTED IN A TERTIARY CARE HOSPITAL OF LAHORE. , 2023, 20, .		0
3829	Systemic treatment for unresectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 29, 1407-1424.	1.4	0
3830	Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy. <i>Livers</i> , 2023, 3, 121-160.	0.8	2
3831	Systemic treatment for unresectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 29, 1551-1568.	1.4	5
3832	CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	3
3833	Effects of hypersplenism on the outcome of hepatectomy in hepatocellular carcinoma with hepatitis B virus related portal hypertension. <i>Frontiers in Surgery</i> , 0, 10, .	0.6	0

#	ARTICLE	IF	CITATIONS
3834	Mortality Evaluation and Life Expectancy Prediction of Patients with Hepatocellular Carcinoma with Data Mining. Healthcare (Switzerland), 2023, 11, 925.	1.0	4
3835	Non-invasive imaging in the diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma. Abdominal Radiology, 0, , .	1.0	0
3836	Development of a sorafenib-loaded solid self-nanoemulsifying drug delivery system: Formulation optimization and characterization of enhanced properties. Journal of Drug Delivery Science and Technology, 2023, 82, 104374.	1.4	2
3837	Hepatic Cancer: Present Scenario, Treatment Options and Nursing Management. Biomedical and Pharmacology Journal, 2023, 16, 419-428.	0.2	0
3838	Does adjuvant hepatic artery infusion chemotherapy improve patient outcomes for hepatocellular carcinoma following liver resection? A meta-analysis. World Journal of Surgical Oncology, 2023, 21, .	0.8	3
3839	Transarterial Chemoembolization With Drug-Eluting Beads Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Outcomes From a Multicenter, Randomized, Phase 2 Trial (the Tj ETQq1 1 06784314 mgBT /Overl	0.8	1
3840	Evaluation of the Clinical Efficacy of Intensity-Modulated Radiotherapy Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Extrahepatic Oligometastasis and Prognostic Factors for Patient Survival. International Journal of General Medicine, 0, Volume 16, 1271-1278.	0.8	1
3841	Deep Learning Radiomics Model of Dynamic <scp>Contrastâ€Enhanced MRI</scp> for Evaluating Vessels Encapsulating Tumor Clusters and Prognosis in Hepatocellular Carcinoma. Journal of Magnetic Resonance Imaging, 2024, 59, 108-119.	1.9	5
3842	Sample forms and templates. , 2023, , 533-555.		0
3845	Pathophysiology of Gastrointestinal Tract Cancers and Therapeutic Status. , 2023, , 1-32.		0
3851	Thermoresponsive hydrogel for transcatheter arterial chemoembolization of hepatocellular carcinoma. Chemical Communications, 2023, 59, 9352-9355.	2.2	0
3865	Systemic Onco-Spheres: Viruses in Cancer. , 2023, , 579-606.		0